
<html lang="en"     class="pb-page"  data-request-id="1f33c79d-9329-41c6-95c9-cfc6d14157a4"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.9b01916;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-10"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase" /></meta><meta name="dc.Creator" content="Daniela  Angst" /></meta><meta name="dc.Creator" content="François  Gessier" /></meta><meta name="dc.Creator" content="Philipp  Janser" /></meta><meta name="dc.Creator" content="Anna  Vulpetti" /></meta><meta name="dc.Creator" content="Rudolf  Wälchli" /></meta><meta name="dc.Creator" content="Christian  Beerli" /></meta><meta name="dc.Creator" content="Amanda  Littlewood-Evans" /></meta><meta name="dc.Creator" content="Janet  Dawson" /></meta><meta name="dc.Creator" content="Barbara  Nuesslein-Hildesheim" /></meta><meta name="dc.Creator" content="Grazyna  Wieczorek" /></meta><meta name="dc.Creator" content="Sascha  Gutmann" /></meta><meta name="dc.Creator" content="Clemens  Scheufler" /></meta><meta name="dc.Creator" content="Alexandra  Hinniger" /></meta><meta name="dc.Creator" content="Alfred  Zimmerlin" /></meta><meta name="dc.Creator" content="Enrico G.  Funhoff" /></meta><meta name="dc.Creator" content="Robert  Pulz" /></meta><meta name="dc.Creator" content="Bruno  Cenni" /></meta><meta name="dc.Description" content="Bruton’s tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in immunity and is considered an attractive target for treating autoimmune diseases. The use of currently markete..." /></meta><meta name="Description" content="Bruton’s tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in immunity and is considered an attractive target for treating autoimmune diseases. The use of currently markete..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 21, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01916" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01916" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01916" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01916" /></link>
        
    
    

<title>Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01916" /></meta><meta property="og:title" content="Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0020.jpeg" /></meta><meta property="og:description" content="Bruton’s tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in immunity and is considered an attractive target for treating autoimmune diseases. The use of currently marketed covalent BTK inhibitors is limited to oncology indications based on their suboptimal kinase selectivity. We describe the discovery and preclinical profile of LOU064 (remibrutinib, 25), a potent, highly selective covalent BTK inhibitor. LOU064 exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for a best-in-class covalent BTK inhibitor for the treatment of autoimmune diseases. It demonstrates potent in vivo target occupancy with an EC90 of 1.6 mg/kg and dose-dependent efficacy in rat collagen-induced arthritis. LOU064 is currently being tested in phase 2 clinical studies for chronic spontaneous urticaria and Sjoegren’s syndrome." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01916"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01916">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01916&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01916&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01916&amp;href=/doi/10.1021/acs.jmedchem.9b01916" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 10</span><span class="cit-fg-pageRange">, 5102-5118</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/10" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00597" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Featured Article</span><a href="/doi/10.1021/acs.jmedchem.9b01924" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Daniela Angst</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniela Angst</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#dcb8bdb2b5b9b0bdf2bdb2bbafa89cb2b3aabdaea8b5aff2bfb3b1"><span class="__cf_email__" data-cfemail="fd999c939498919cd39c939a8e89bd93928b9c8f89948ed39e9290">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniela++Angst">Daniela Angst</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4212-2829" title="Orcid link">http://orcid.org/0000-0002-4212-2829</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">François Gessier</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">François Gessier</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fran%C3%A7ois++Gessier">François Gessier</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Philipp Janser</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Philipp Janser</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Philipp++Janser">Philipp Janser</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anna Vulpetti</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anna Vulpetti</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anna++Vulpetti">Anna Vulpetti</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3114-8679" title="Orcid link">http://orcid.org/0000-0002-3114-8679</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rudolf Wälchli</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rudolf Wälchli</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rudolf++W%C3%A4lchli">Rudolf Wälchli</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christian Beerli</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christian Beerli</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Autoimmunity, Transplantation & Inflammation, Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christian++Beerli">Christian Beerli</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Amanda Littlewood-Evans</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Amanda Littlewood-Evans</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Autoimmunity, Transplantation & Inflammation, Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Amanda++Littlewood-Evans">Amanda Littlewood-Evans</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Janet Dawson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Janet Dawson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Autoimmunity, Transplantation & Inflammation, Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Janet++Dawson">Janet Dawson</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4615-4091" title="Orcid link">http://orcid.org/0000-0003-4615-4091</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Barbara Nuesslein-Hildesheim</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Barbara Nuesslein-Hildesheim</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Autoimmunity, Transplantation & Inflammation, Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Barbara++Nuesslein-Hildesheim">Barbara Nuesslein-Hildesheim</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Grazyna Wieczorek</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Grazyna Wieczorek</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Autoimmunity, Transplantation & Inflammation, Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Grazyna++Wieczorek">Grazyna Wieczorek</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sascha Gutmann</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sascha Gutmann</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sascha++Gutmann">Sascha Gutmann</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4242-8510" title="Orcid link">http://orcid.org/0000-0002-4242-8510</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Clemens Scheufler</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Clemens Scheufler</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Clemens++Scheufler">Clemens Scheufler</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alexandra Hinniger</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alexandra Hinniger</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alexandra++Hinniger">Alexandra Hinniger</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alfred Zimmerlin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alfred Zimmerlin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">PK Sciences, Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alfred++Zimmerlin">Alfred Zimmerlin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Enrico G. Funhoff</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Enrico G. Funhoff</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Preclinical Safety, Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Enrico+G.++Funhoff">Enrico G. Funhoff</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Robert Pulz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Robert Pulz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Robert++Pulz">Robert Pulz</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8035-1008" title="Orcid link">http://orcid.org/0000-0002-8035-1008</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Bruno Cenni</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bruno Cenni</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Autoimmunity, Transplantation & Inflammation, Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bruno++Cenni">Bruno Cenni</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8603-2032" title="Orcid link">http://orcid.org/0000-0002-8603-2032</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01916&amp;href=/doi/10.1021%2Facs.jmedchem.9b01916" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 10</span><span class="cit-pageRange">, 5102–5118</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 21, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>19 November 2019</li><li><span class="item_label"><b>Published</b> online</span>21 February 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 May 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01916" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01916</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5102%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DDaniela%2BAngst%252C%2BFran%25C3%25A7ois%2BGessier%252C%2BPhilipp%2BJanser%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D10%26contentID%3Dacs.jmedchem.9b01916%26title%3DDiscovery%2Bof%2BLOU064%2B%2528Remibrutinib%2529%252C%2Ba%2BPotent%2Band%2BHighly%2BSelective%2BCovalent%2BInhibitor%2Bof%2BBruton%25E2%2580%2599s%2BTyrosine%2BKinase%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5118%26publicationDate%3DMay%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01916"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5953</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">22</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01916" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Daniela&quot;,&quot;last_name&quot;:&quot;Angst&quot;},{&quot;first_name&quot;:&quot;François&quot;,&quot;last_name&quot;:&quot;Gessier&quot;},{&quot;first_name&quot;:&quot;Philipp&quot;,&quot;last_name&quot;:&quot;Janser&quot;},{&quot;first_name&quot;:&quot;Anna&quot;,&quot;last_name&quot;:&quot;Vulpetti&quot;},{&quot;first_name&quot;:&quot;Rudolf&quot;,&quot;last_name&quot;:&quot;Wälchli&quot;},{&quot;first_name&quot;:&quot;Christian&quot;,&quot;last_name&quot;:&quot;Beerli&quot;},{&quot;first_name&quot;:&quot;Amanda&quot;,&quot;last_name&quot;:&quot;Littlewood-Evans&quot;},{&quot;first_name&quot;:&quot;Janet&quot;,&quot;last_name&quot;:&quot;Dawson&quot;},{&quot;first_name&quot;:&quot;Barbara&quot;,&quot;last_name&quot;:&quot;Nuesslein-Hildesheim&quot;},{&quot;first_name&quot;:&quot;Grazyna&quot;,&quot;last_name&quot;:&quot;Wieczorek&quot;},{&quot;first_name&quot;:&quot;Sascha&quot;,&quot;last_name&quot;:&quot;Gutmann&quot;},{&quot;first_name&quot;:&quot;Clemens&quot;,&quot;last_name&quot;:&quot;Scheufler&quot;},{&quot;first_name&quot;:&quot;Alexandra&quot;,&quot;last_name&quot;:&quot;Hinniger&quot;},{&quot;first_name&quot;:&quot;Alfred&quot;,&quot;last_name&quot;:&quot;Zimmerlin&quot;},{&quot;first_name&quot;:&quot;Enrico&quot;,&quot;last_name&quot;:&quot;G. Funhoff&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;Pulz&quot;},{&quot;first_name&quot;:&quot;Bruno&quot;,&quot;last_name&quot;:&quot;Cenni&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;21&quot;,&quot;issue&quot;:&quot;10&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;5102-5118&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01916&quot;},&quot;abstract&quot;:&quot;Bruton’s tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in immunity and is considered an attractive target for treating autoimmune diseases. The use of currently marketed covalent BTK inhibitors is limited to oncology indications based on their suboptimal kinase selectivity. We describe the discovery and preclinical profile of LOU064 (remibrutinib, 25), a potent, highly selective covalent BTK inhibitor. LOU064 exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for a best-in-class covalent BTK inhibitor for the treatment of autoimmune diseases. It demonstrates potent in vivo target occupancy with an EC90 of 1.6 mg/kg and dose-dependent efficacy in rat collagen-induced arthritis. LOU064 is currently being tested in phase 2 clinical studies for chronic spontaneous urticaria and Sjoegren’s syndrome.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01916&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01916" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01916&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01916" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01916&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01916" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01916&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01916&amp;href=/doi/10.1021/acs.jmedchem.9b01916" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01916" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01916" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (8 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01916%26sid%3Dliteratum%253Aachs%26pmid%3D32083858%26genre%3Darticle%26aulast%3DAngst%26date%3D2020%26atitle%3DDiscovery%2Bof%2BLOU064%2B%2528Remibrutinib%2529%252C%2Ba%2BPotent%2Band%2BHighly%2BSelective%2BCovalent%2BInhibitor%2Bof%2BBruton%25E2%2580%2599s%2BTyrosine%2BKinase%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D10%26spage%3D5102%26epage%3D5118%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/10" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/jmcmar.2020.63.issue-10/20200528/jmcmar.2020.63.issue-10.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01916&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Bruton’s tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in immunity and is considered an attractive target for treating autoimmune diseases. The use of currently marketed covalent BTK inhibitors is limited to oncology indications based on their suboptimal kinase selectivity. We describe the discovery and preclinical profile of LOU064 (remibrutinib, <b>25</b>), a potent, highly selective covalent BTK inhibitor. LOU064 exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for a best-in-class covalent BTK inhibitor for the treatment of autoimmune diseases. It demonstrates potent <i>in vivo</i> target occupancy with an EC<sub>90</sub> of 1.6 mg/kg and dose-dependent efficacy in rat collagen-induced arthritis. LOU064 is currently being tested in phase 2 clinical studies for chronic spontaneous urticaria and Sjoegren’s syndrome.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11042" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11042" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Bruton’s tyrosine kinase (BTK) is a cytoplasmic tyrosine kinase selectively expressed in a subset of immune cells, including macrophages, mast cells, basophils, platelets and B cells, but not in mature plasma cells and T cells.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> BTK is activated by membrane recruitment via its pleckstrin homology domain and phosphorylation of the activation loop Tyr551 by SYK and SRC family kinases, resulting in autophosphorylation of Tyr223 in the SH3 domain.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> BTK is an essential node and rheostat for the signaling of the antigen receptor in B cells (BCR) and of activating Fc receptors for IgG and IgE (FcγR, FcεR) in macrophages and mast cells.<a onclick="showRef(event, 'ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5">(3−5)</a> While inborn BTK deficiency does not affect the development of many immune cells, it results in severely impaired B cell development and antibody production.<a onclick="showRef(event, 'ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8">(6−8)</a> In humans BTK deficiency is the most frequent cause of the primary immunodeficiency X-linked agammaglobulinemia (XLA), a condition that if untreated is associated with an increased bacterial infection risk.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Today XLA is treated by immunoglobulin replacement therapy, suggesting that the main risk factor for infections is the absence of protective immunoglobulins rather than the deficiency in cellular BTK function.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The role of BTK appears not to be critical for B cell survival once the B cells have developed, suggesting that BTK inhibition after infancy may not lead to acute B cell and antibody depletion.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_p">The potential role of BTK in autoimmunity, allergy, and chronic inflammatory conditions is supported by genetic validation in many rodent models for arthritis, systemic lupus erythematosus, and anaphylaxis.<a onclick="showRef(event, 'ref3 ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref3 ref11 ref12 ref13">(3,11−13)</a> More recently, the functional relevance of BTK has also been validated by pharmacological inhibition in various clinical trials and is testament for the activities across many pharmaceutical companies to identify and develop BTK inhibitors, both covalent and reversible.<a onclick="showRef(event, 'ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22">(14−22)</a></div><div class="NLM_p">The kinase domain of BTK contains Cys481 in a position conserved in a group of 11 kinases including the closely related TEC family kinases BMX, TEC, ITK and TXK, as well as in EGFR, ERBB2, ERBB4, JAK3, BLK and MKK7.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a> These conserved cysteines have been targeted in the development of covalent inhibitors of BTK, EGFR, JAK3 and MKK7. The concept of selective targeted covalent kinase inhibitors has received more attention due its potential for sustained target inhibition, uncoupled from sustained and high systemic drug exposure. This special pharmacologic feature of covalent inhibitors may lead to high efficacy and an improved safety profile.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a></div><div class="NLM_p">The covalent BTK inhibitors ibrutinib (<b>1</b>) and acalabrutinib (<b>2</b>) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>a) have shown efficacy and an attractive risk–benefit profile leading to their approval in several B cell malignancies including chronic lymphocytic leukemia and mantle cell lymphoma.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> However, ibrutinib (<b>1</b>) not only potently inhibits BTK but irreversibly inhibits all kinases that carry a Cys at the same position as BTK and in addition inhibits reversibly several other kinases.<a onclick="showRef(event, 'ref14 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref14 ref28 ref29">(14,28,29)</a> While the clinical efficacy of <b>1</b> is of significant benefit in difficult to treat oncologic indications, its side effect profile precludes its use in rheumatologic indications.<a onclick="showRef(event, 'ref30 ref31 ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32 ref33 ref34">(30−34)</a> It is likely that its off-target activity is associated with the clinical risk for skin rash and diarrhea (well established for EGFR inhibitors<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a>) or platelet disfunction (shown for TEC and SRC kinases<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a>). Second generation clinical-stage covalent inhibitors such as acalabrutinib (<b>2</b>), tirabrutinib (<b>3</b>), evobrutinib (<b>4</b>), and branebrutinib (<b>5</b>) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>a) retain a similar binding mode to BTK as <b>1</b> and therefore, despite offering an overall improved kinase selectivity profile, still inhibit several Cys-containing kinases.<a onclick="showRef(event, 'ref18 ref22 ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref18 ref22 ref38 ref39 ref40">(18,22,38−40)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) Selected examples of covalent BTK inhibitors (<b>1</b>–<b>5</b>). (b) Structure of CGI-1746 (<b>6</b>), the first reported compound binding to an inactive BTK conformation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01916&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Reversible BTK inhibitors with high kinase selectivity have been described,<a onclick="showRef(event, 'ref15 ref16 ref21 ref41'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref21 ref41">(15,16,21,41)</a> and CGI-1746 (<b>6</b>) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>b) was the first compound reported to bind to an inactive conformation of BTK resulting in an excellent kinase selectivity. This binding mode prevents the phosphorylation of Tyr551 in the activation loop of BTK by upstream kinases and possibly contributes to higher cellular potency.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> In contrast to covalent inhibitors, reversible inhibitors require continuous systemic drug exposure over the entire dosing interval in order to maintain a high degree of target inhibition. In order to achieve this, intensive efforts were necessary to optimize the profile of <b>6</b>, including ADME properties, potency, and safety, while maintaining the specific binding mode, finally leading to GDC-0853 (fenebrutinib), a selective reversible BTK inhibitor currently in phase 2 clinical trials.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><div class="NLM_p last">We were attracted by the concept of covalent BTK inhibition as it allows the optimization of compounds for a potent and sustained pharmacodynamic effect without the need for extended and high systemic compound exposure.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> At the same time, we wanted to differentiate from competitor molecules by aiming for a very high selectivity to minimize kinase off-target reversible and covalent binding. Therefore, we selected the strategy of combining the advantages of the covalent MoA with targeting the inactive conformation of BTK.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10717" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10717" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The concept of combining a reversible BTK inhibitor binding to an inactive conformation of BTK with a warhead leading to highly selective, covalent BTK inhibitors has been recently published by us and others.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> We disclosed the discovery of a series of pyrrolopyrimidines. Using compound <b>7</b> (BTK enzyme IC<sub>50</sub> of 0.013 ± 0.0078 μM, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) as starting point, a reversible BTK inhibitor binding to the same inactive BTK conformation as <b>6</b>, we designed inhibitors forming a covalent bond with Cys481. The compounds of this series, represented by <b>8</b> (BTK enzyme IC<sub>50</sub> of 0.0009 ± 0.0005 μM, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), are potent inhibitors of BTK <i>in vitro</i>, and we were able to demonstrate BTK occupancy after oral dosing in a PK/PD model. However, the pyrrolopyrimidine series suffered from very high <i>in vivo</i> clearance, making it challenging to achieve <i>in vivo</i> efficacy at low doses. Thorough investigation of the pyrrolopyrimidine SAR did not lead to a significantly improved PK profile. Therefore, we decided to explore alternative hinge binders with the aim of improving the ADME properties while keeping the key interactions with BTK, as displayed in the X-ray cocrystal structure of <b>7</b> in complex with BTK (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Replacing the pyrrolopyrimidine moiety by 6-aminopyrimidine as hinge binder motif provided <b>9</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) as a reversible prototype. <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> shows the model of the aminopyrimidine <b>9</b> bound to the inactive conformation of BTK based on the solved crystal structure with <b>7</b>. In the model, the aminopyrimidine scaffold forms the same key interactions with BTK as the pyrrolopyrimidine <b>7</b> with the exception of the contacts at the entrance of the ATP binding pocket. The phenyl group at position 6 of compound <b>7</b> is sandwiched between the side chains of Leu408 and Gly480 and contributes to binding affinity. For that reason, for compound <b>9</b> some loss of affinity was expected.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Morphing of the pyrrolopyrimidine scaffold to an aminopyrimidine scaffold, BTK enzyme inhibition in Caliper assay with IC<sub>50</sub> shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01916&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Crystal structure of <b>7</b> in complex with human BTK (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S90">6S90</a>; in cyan) overlaid with the binding model of compound <b>9</b> (in purple). H-bonds of the pyrrolopyrimidine and 6-aminopyrimidine scaffold to Met477 and a water molecule (red sphere) are highlighted (black dashed lines), as well as the hydrogen bond between the carbonyl of the amide of the ligand and Lys430 side chain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01916&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Indeed, compound <b>9</b> inhibited BTK in an enzymatic assay with an IC<sub>50</sub> of 7.3 ± 0.35 μM, confirming our morphing idea. Similar to what we described for the pyrrolopyrimidine scaffold,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> we envisaged generating potent and selective covalent inhibitors by introducing a linker with a warhead at position 5 of the pyrimidine moiety to reach Cys481. We started with acrylamide warheads, as they have been used successfully in covalent BTK inhibitors such as <b>1</b> and <b>4</b>.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> SAR: Optimizing <i>in Vivo</i> BTK Occupancy</h3><div class="NLM_p">We first investigated alkene based linkers between the pyrimidine core and the warhead providing a somewhat rigidified exit vector. Introducing a three carbon linker (<b>10</b>) and a four carbon linker (<b>11</b>) led to moderately potent compounds in the BCR/CD69 assay in blood (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). However, <b>10</b> and <b>11</b> suffered from very high clearance in rat liver microsomes (CL<sub>int</sub> of 924 and 815 μL min<sup>–1</sup> mg<sup>–1</sup>, respectively). Replacing the carbon linkers with 3-oxypyrrolidine (<b>12</b>) was not tolerated with respect to BTK inhibition, but the metabolic stability significantly increased (CL<sub>int</sub> = 135 μL min<sup>–1</sup> mg<sup>–1</sup>). Switching to a 3-oxyazetidine linker (<b>13</b>) led to an improvement of blood BCR/CD69 potency and good metabolic stability (CL<sub>int</sub> = 25 μL min<sup>–1</sup> mg<sup>–1</sup>). Having successfully combined these two properties, we sought to assess the <i>in vivo</i> PD effect of <b>13</b> by measuring BTK occupancy in rat spleen after a single oral dose (<a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>). Administration of <b>13</b> (10 mg/kg po) provided 36% BTK occupancy and blood levels of 13 nM 5 h postdose. A rat PK of <b>13</b> revealed a bioavailability of only 5%, likely limited by the low permeability. Therefore, we set out to optimize the permeability, since improved oral absorption should subsequently increase target occupancy. We envisioned that introducing a fluoro substituent ortho to the amide on the phenyl ring occupying the H3 pocket could form an internal hydrogen bond in solution, masking the amide NH and leading to improved permeability.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> The fluoro substituent was tolerated with respect to potency, and <b>14</b> indeed displayed improved permeability by more than one log unit compared to <b>13</b>. This led to a higher bioavailability of 51% in a rat PK study and resulted in 96% target occupancy after a 10 mg/kg po dose. Lowering the dose of <b>14</b> to 3 mg/kg po and 1 mg/kg po still provided BTK occupancy of 79% and 44%, respectively. In an effort to further improve the potency we investigated two alternative moieties in the H3 pocket, which in previous studies on a related reversible series (not shown) had provided a positive effect on the potency. Surprisingly, replacing the cyclopropyl substituent in <b>14</b> with 2-hydroxypropanyl (<b>15</b>) led to a decreased potency in the blood BCR/CD69 assay. Introducing a second fluoro substituent (<b>16</b>) recovered the blood potency; however the permeability of <b>16</b> was poor, translating into a modest target occupancy of only 32% after a dose of 3 mg/kg po. On the basis of the promising results of <b>14</b> in the BTK occupancy assay, we profiled the compound more broadly. However, the stability of <b>14</b> in human plasma turned out to be low (<i>t</i><sub>1/2</sub> = 35 min). Plasma instability could be an indication of an undesired covalent binding to plasma proteins or enzymatic cleavage; therefore we used this assay to optimize our scaffold.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Linker and Tail Modifications</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0014.gif" alt="" id="GRAPHIC-d7e719-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0015.gif" alt="" id="gr14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">BTK enzyme inhibition in Caliper assay, with IC<sub>50</sub> shown as the mean ± SD (<i>n</i> ≥ 2).</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">FcγR induced IL8, with IC<sub>50</sub> shown as the mean ± SD (<i>n</i> ≥ 2).</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Anti-IgM/IL-4 induced CD69 expression on human blood B cells, with IC<sub>50</sub> shown as the mean ± SD (<i>n</i> ≥ 2).</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">PAMPA permeability, log <i>P</i><sub>e</sub> at pH 6.8.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">BTK occupancy in rat spleen homogenate 5 h after po dose of compounds compared to vehicle control, determined as the mean (<i>n</i> = 3).</p></div><div class="footnote" id="t1fn6"><sup><sup>f</sup></sup><p class="last"><i>n</i> = 1. n.t.: not tested.</p></div></div><div></div></div><div class="NLM_p">We sought to investigate the linker to the warhead more broadly with the goal to increase the plasma stability and in addition to further improve blood potency and <i>in vivo</i> PD. We combined various linkers with the most attractive H3 pocket moiety, the fluorinated cyclopropylphenyl tail. The propenyl linker (<b>17</b>) led to a 2-fold increase in potency in the blood BCR/CD69 assay compared to <b>14</b> and good plasma stability (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). However, the increased blood potency did not translate into an improved PD effect; <b>17</b> performed similarly to <b>14</b><i>in vivo</i>, providing 77% BTK occupancy, probably due to the high rat <i>in vivo</i> clearance (307 mL min<sup>–1</sup> kg<sup>–1</sup>). The oxygen linked open-chain analog <b>18</b> was in the same potency range as <b>14</b> and gave high target occupancy of 84% despite its only moderate permeability. Replacing the linker oxygen by a nitrogen (<b>19</b>) was not tolerated leading to a roughly 10-fold loss of potency in the human blood assay. Despite a more than 2-fold reduced blood potency compared to <b>14</b>, introduction of a piperidine linker (<b>20</b>) gave similar target occupancy, due to high exposure (207 nM 5 h postdose). Whereas the (<i>R</i>)-pyrrolidine linker (<b>21</b>) was not tolerated with respect to BTK inhibition, the (<i>S</i>)-derivative <b>22</b> potently inhibited the blood BCR/CD69 assay, and BTK occupancy of 90% was achieved. However, <b>22</b> suffered from a strong hERG flag (hERG dofetilide binding IC<sub>50</sub> = 49 ± 12 nM (<i>n</i> = 2)). Replacing the pyrrolidine moiety by an azetidine provided <b>23</b>, which achieved 80% BTK occupancy. However, as in the case of azetidine <b>14</b>, plasma stability of <b>23</b> was low. An enhanced reactivity of <i>N</i>-acryloyl azetidines toward cysteines has been reported and might explain the low plasma stability of compounds <b>14</b> and <b>23</b>.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> The corresponding (<i>R</i>)-azetidine <b>24</b> was less potent than <b>23</b> in the blood assay. The N-methylated analogue of <b>18</b> (<b>25</b>) was nearly 5-fold more potent than <b>14</b> in the blood BCR/CD69 assay and displayed 94% BTK occupancy. Increasing the length of the open chain linker to three carbons led to <b>26</b> which was significantly less potent than <b>25</b> in the blood assay. Modifying the <i>N</i>-methyl substituent on the acrylamide to an ethyl group provided <b>27</b>, which was comparable to <b>25</b> with respect to blood potency and target occupancy. However, <b>27</b> had a higher log <i>P</i> compared to <b>25</b> (3.6 vs 2.9) and interestingly inhibited CYP2D6 with an IC<sub>50</sub> of 1.26 μM. Overall, <b>27</b> did not seem to offer any advantage over <b>25</b>. With the exception of azetidine acrylamide <b>23</b> all compounds from <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> tested for stability in human plasma showed plasma half-lives of >120 min.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Linker Modifications</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0016.gif" alt="" id="GRAPHIC-d7e941-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0017.gif" alt="" id="gr15" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">BTK enzyme inhibition in Caliper assay, with IC<sub>50</sub> shown as the mean ± SD (<i>n</i> ≥ 2).</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">FcγR induced IL8, with IC<sub>50</sub> shown as the mean ± SD (<i>n</i> ≥ 2).</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Anti-IgM/IL-4 induced CD69 expression on human blood B cells, with IC<sub>50</sub> shown as the mean ± SD (<i>n</i> ≥ 2).</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">PAMPA permeability, log <i>P</i><sub>e</sub> at pH 6.8.</p></div><div class="footnote" id="t2fn5"><sup><sup>e</sup></sup><p class="last">BTK occupancy in rat spleen homogenate 5 h after po dose of compounds compared to vehicle control, determined as the mean (<i>n</i> = 3).</p></div><div class="footnote" id="t2fn6"><sup><sup>f</sup></sup><p class="last"><i>n</i> = 1. n.t.: not tested.</p></div></div><div></div></div><div class="NLM_p">Having identified the highly potent acrylamide <b>25</b>, we wanted to assess if an alternative warhead could provide an overall advantage. Generally, a highly reactive moiety could lead to increased binding to off-targets, whereas too low intrinsic reactivity could lower the reaction rate to the Cys of interest. To probe the intrinsic reactivity of different warheads, we investigated the stability of the compounds toward an excess of glutathione (GSH) as a surrogate for Cys-containing nucleophiles and proteins (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). In the presence of GSH, <b>25</b> showed a slow decrease with 68.5% remaining parent after 24 h. For the sterically hindered methyl substituted acrylamide <b>28</b>, a significantly decreased reactivity toward GSH was observed. However, <b>28</b> was also significantly less active in the blood BCR/CD69 assay. The 4-(dimethylamino)but-2-enamide <b>29</b> showed a slow decrease in the presence of GSH over 24 h, similar to <b>25</b>. However, the permeability of <b>29</b> was very low (log <i>P</i><sub>e</sub> pH 6.8 <−6.5), and together with the reduced blood BCR/CD69 potency compared to <b>25</b> we did not pursue this compound further. The propynamide <b>30</b> was highly unstable in the presence of GSH with complete disappearance of the parent within 24 h. In addition, only limited stability (<i>t</i><sub>1/2</sub> = 96 min) in human plasma was observed. For the but-2-yneamide <b>31</b>, decrease of parent was slow, but due to the decreased blood BCR/CD69 assay potency, this compound was also not considered further. In summary, compound <b>25</b> (LOU064, remibrutinib) exhibited the best overall profile and was selected for further characterization.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Warhead Modifications</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0018.gif" alt="" id="GRAPHIC-d7e1059-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0019.gif" alt="" id="gr16" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">BTK enzyme inhibition in Caliper assay, with IC<sub>50</sub> shown as the mean ± SD (<i>n</i> ≥ 2).</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">FcγR induced IL8, with IC<sub>50</sub> shown as the mean ± SD (<i>n</i> ≥ 2).</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Anti-IgM/IL-4 induced CD69 expression on human blood B cells, with IC<sub>50</sub> shown as the mean ± SD (<i>n</i> ≥ 2).</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">The stability in the presence of GSH is given as ratio area (analyte/internal standard) in %. n.t.: not tested.</p></div></div><div></div></div><div class="NLM_p last">The melting point of crystalline LOU064 is 194 °C. It has a low thermodynamic solubility of <0.003 g/L at pH 6.8, but solubility increases to >1.5 g/L at pH 1. The permeability is high (PAMPA: log Pe pH 6.8−4.3; Caco <i>P</i><sub>app</sub>(A–B) = 15.9, <i>P</i><sub>app</sub>(B–A) = 10.2) suggesting good absorption. The half-maximum inhibition of the CYP enzymes 3A4, 2C9, and 2D6 was ≥5 μM (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01916/suppl_file/jm9b01916_si_001.pdf" class="ext-link">Supporting Information</a>). LOU064 showed some activity in an <i>in vitro</i> PXR reporter gene assay (EC<sub>50</sub> > 5.48 μM and <i>E</i><sub>max</sub> = 94.7%) indicating a risk for CYP induction and drug–drug interactions.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> LOU064 Binds Covalently to BTK</h3><div class="NLM_p">The covalent character of BTK inhibition by LOU064 was confirmed in a series of studies. First, the kinetics of BTK inhibition were assessed in an enzyme dilution experiment.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> The biochemical BTK enzyme assay (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01916/suppl_file/jm9b01916_si_001.pdf" class="ext-link">Supporting Information</a>) was modified to include a 1 h preincubation of BTK protein at a concentration of 4.7 μM with a 10% molar excess of compound. The compound/enzyme mixture was then diluted into kinase assay buffer containing ATP and peptide substrate to reach a final concentration of 1 nM BTK and 1.1 nM compound, and enzyme activity was monitored by measuring substrate phosphorylation (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). The increase in phosphorylated substrate peptide over time indicated recovery of BTK kinase activity by the dilution step for the DMSO solvent control, the reversible BTK inhibitor staurosporine, as well as the inactive noncovalent ethylamide analog <b>32</b> (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). In line with expectations for a covalent binder, LOU064 showed no recovery of BTK activity after the dilution step.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Rescue of BTK enzymatic activity by dilution. The increase of phosphorylated substrate peptide over time after the dilution step is indicated for the DMSO solvent control (black dash and triangles), for the reversible BTK inhibitor staurosporine (blue dash and triangles), for the noncovalent ethylamide analog <b>32</b> (red dash and empty circles), and for LOU064 (red line and filled circles).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01916&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Second, we assessed covalent binding of LOU064 to the BTK kinase domain by analysis with LC/MS (for experimental details see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01916/suppl_file/jm9b01916_si_001.pdf" class="ext-link">Supporting Information</a>), which revealed the presence of a main peak with 32 222.3 Da mass, closely corresponding to the predicted BTK/LOU064 1:1 adduct (based on the masses of 507.5 and 31 714.5 Da, respectively, for LOU064 and the kinase domain construct). This provided further evidence for a specific and single covalent modification of BTK by LOU064 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Deconvoluted mass spectrum of covalent BTK kinase domain (encompassing amino acids 386–659) adduct with LOU064. The peak with a corresponding mass of 32 222.3 Da is indicative of the presence of one covalent adduct of LOU064 (507.5 Da) to the BTK kinase domain (31 714.5 Da).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01916&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Third, solving the X-ray complex structure revealed the atomic details of LOU064 binding to BTK and confirmed the design hypothesis. As expected, the inhibitor is covalently attached to Cys481 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>), with the carbonyl of the acrylamide making a hydrogen bond with the NH of the backbone of Cys481. The aminopyrimidine moiety forms a bidentate hydrogen bonding interaction with the backbone of Met477 of the kinase hinge region. The phenyl group of LOU064 at position 4 of the 6-aminopyrimidine scaffold makes hydrophobic contacts with the Val416 side chain, while the fluorine makes a multipolar interaction with the carbonyl of Gly409 of the Gly-rich loop (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01916/suppl_file/jm9b01916_si_001.pdf" class="ext-link">Figure S-1, Supporting Information</a>).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The fluorophenylcyclopropyl group occupies the H3 pocket and stabilizes BTK in an inactive conformation. The H3 pocket<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> is formed by the side chains of Gln412, Phe413 (both Gly-rich loop), Asp521, Asn526 (both part of the catalytic loop), Asp539 (DFG), Leu542, Ser543, Val546, and Tyr551 (belonging to the activation loop) (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01916/suppl_file/jm9b01916_si_001.pdf" class="ext-link">Figure S-1</a>). The fluorine in this pocket points toward the cavity instead of toward the NH of the amide of the ligand, most likely to avoid the unfavorable vicinity to the carbonyl of Asn526 (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01916/suppl_file/jm9b01916_si_001.pdf" class="ext-link">Figure S-1</a>).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. X-ray complex structure of BTK kinase domain bound to LOU064 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TFP">6TFP</a>, protein chain A with ligand chain L). The molecular surface of LOU064 is colored in orange, and key residues lining up the binding site are shown as labeled stick model. The main polar interactions between protein and inhibitor are indicated with dotted green lines. For improved clarity water molecules are omitted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01916&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Selectivity of LOU064</h3><div class="NLM_p">Our aim was to combine covalent BTK binding and the high selectivity associated with binding to the inactive BTK conformation. The selectivity of LOU064 was assessed not only in a selected panel of enzymatic kinase assays but also in a competition binding assay<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> against 395 human nonmutant kinases and 61 atypical, mutant, or pathogen kinases. In this screen (KINOMEscan, DiscoverX), LOU064 at a concentration of 1 μM showed full inhibition of probe binding to BTK (0.25% remaining probe binding) and partial inhibition of TEC (24% remaining probe binding) and BMX (53% remaining probe binding), indicating an excellent kinase selectivity profile (TREE<i>spot</i> kinase dendogram of LOU064 (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01916/suppl_file/jm9b01916_si_001.pdf" class="ext-link">Figure S-2</a>) and KINOMEscan data in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01916/suppl_file/jm9b01916_si_001.pdf" class="ext-link">Supporting Information</a>).</div><div class="NLM_p">On the basis of this kinome-wide screen, the selectivity of LOU064 was further assessed and compared to clinical covalent BTK inhibitors. As the determination of IC<sub>50</sub> values in biochemical enzyme assays for covalent inhibitors suffers from time-dependent effects,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> we determined the binding constants (<i>K</i><sub>d</sub>) in a competition binding assay<a onclick="showRef(event, 'ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref50 ref51">(50,51)</a> for a set of Cys-containing kinases (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). LOU064 showed very potent affinity to BTK with a subnanomolar <i>K</i><sub>d</sub> of 0.63 nM and with a selectivity of 175-fold against TEC (<i>K</i><sub>d</sub> of 110 nM) and 857 fold against BMX (<i>K</i><sub>d</sub> of 540 nM). LOU064 did not show binding to ITK, EGFR, ERBB2, ERBB4, and JAK3 up to 10 μM. By contrast, ibrutinib (<b>1</b>) showed similar high affinity for BTK but poor selectivity against BMX, TEC, EGFR, ERBB2, and ERBB4. Of note, acalabrutinib (<b>2</b>), tirabrutinib (<b>3</b>), and evobrutinib (<b>4</b>) are significantly less potent than LOU064 on BTK and less selective. Branebrutinib (<b>5</b>) displayed high affinity for BTK, comparable to LOU064 and ibrutinib, with an improved selectivity profile compared to ibrutinib but inferior to LOU064, potently inhibiting BMX and TEC. These binding data are in line with recent publications in other assay systems<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> and our data in biochemical enzyme assays (not shown). Overall, in addition to being among the most potent inhibitors for BTK, LOU064 differentiates with its excellent, best-in-class kinase selectivity from other clinical-stage covalent inhibitors.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Binding Constants (<i>K</i><sub>d</sub> in nM) of Covalent BTK Inhibitors for Selected Kinases Containing a Conserved Cysteine and Selectivity vs Off-Target Kinases (<i>K</i><sub>d,off-target</sub>/<i>K</i><sub>d,BTK</sub>)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">BTK</th><th class="colsep0 rowsep0" align="center">BMX</th><th class="colsep0 rowsep0" align="center">TEC</th><th class="colsep0 rowsep0" align="center">ITK</th><th class="colsep0 rowsep0" align="center">EGFR</th><th class="colsep0 rowsep0" align="center">ERBB2</th><th class="colsep0 rowsep0" align="center">ERBB4</th><th class="colsep0 rowsep0" align="center">JAK3</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left"><b>25</b> (LOU064)</td><td class="colsep0 rowsep0" align="left"><i>K</i><sub>d</sub></td><td class="colsep0 rowsep0" align="left">0.63</td><td class="colsep0 rowsep0" align="left">540</td><td class="colsep0 rowsep0" align="left">110</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">fold</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">857</td><td class="colsep0 rowsep0" align="left">175</td><td class="colsep0 rowsep0" align="left">>15873</td><td class="colsep0 rowsep0" align="left">>15873</td><td class="colsep0 rowsep0" align="left">>15873</td><td class="colsep0 rowsep0" align="left">>15873</td><td class="colsep0 rowsep0" align="left">>15873</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left"><b>1</b> (ibrutinib)</td><td class="colsep0 rowsep0" align="left"><i>K</i><sub>d</sub></td><td class="colsep0 rowsep0" align="left">1.9</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">57</td><td class="colsep0 rowsep0" align="left">6.9</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left">37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">fold</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">0.6</td><td class="colsep0 rowsep0" align="left">0.9</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">3.6</td><td class="colsep0 rowsep0" align="left">0.6</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left"><b>2</b> (acalabrutinib)</td><td class="colsep0 rowsep0" align="left"><i>K</i><sub>d</sub></td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">610</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">5600</td><td class="colsep0 rowsep0" align="left">7.4</td><td class="colsep0 rowsep0" align="left">140</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">fold</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">29</td><td class="colsep0 rowsep0" align="left">0.7</td><td class="colsep0 rowsep0" align="left">>476</td><td class="colsep0 rowsep0" align="left">267</td><td class="colsep0 rowsep0" align="left">0.4</td><td class="colsep0 rowsep0" align="left">6.7</td><td class="colsep0 rowsep0" align="left">>476</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left"><b>3</b> (tirabrutinib)</td><td class="colsep0 rowsep0" align="left"><i>K</i><sub>d</sub></td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">47</td><td class="colsep0 rowsep0" align="left">6.2</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">610</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">fold</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">3.4</td><td class="colsep0 rowsep0" align="left">0.4</td><td class="colsep0 rowsep0" align="left">>714</td><td class="colsep0 rowsep0" align="left">>714</td><td class="colsep0 rowsep0" align="left">44</td><td class="colsep0 rowsep0" align="left">>714</td><td class="colsep0 rowsep0" align="left">>714</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left"><b>4</b> (evobrutinib)</td><td class="colsep0 rowsep0" align="left"><i>K</i><sub>d</sub></td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="left">4.5</td><td class="colsep0 rowsep0" align="left">3700</td><td class="colsep0 rowsep0" align="left">7100</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">5600</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">fold</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1.9</td><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left">231</td><td class="colsep0 rowsep0" align="left">443</td><td class="colsep0 rowsep0" align="left">>625</td><td class="colsep0 rowsep0" align="left">350</td><td class="colsep0 rowsep0" align="left">>625</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left"><b>5</b> (branebrutinib)</td><td class="colsep0 rowsep0" align="left"><i>K</i><sub>d</sub></td><td class="colsep0 rowsep0" align="left">0.56</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">0.99</td><td class="colsep0 rowsep0" align="left">320</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">2500</td><td class="colsep0 rowsep0" align="left">1300</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">fold</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">39</td><td class="colsep0 rowsep0" align="left">1.8</td><td class="colsep0 rowsep0" align="left">571</td><td class="colsep0 rowsep0" align="left">>17857</td><td class="colsep0 rowsep0" align="left">>17853</td><td class="colsep0 rowsep0" align="left">4464</td><td class="colsep0 rowsep0" align="left">2321</td></tr></tbody></table></div></div><div class="NLM_p">We evaluated the cellular selectivity of LOU064 in a panel of culture systems with primary human cells representative for several tissues, including fibroblasts, epithelial cells, keratinocytes, and immune cells (BioMAP Diversity plus panel, DiscoverX).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> LOU064 was tested at concentrations of 270, 900, 3000, and 10000 nM, all concentrations well above its cellular BTK inhibition in cell culture conditions (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01916/suppl_file/jm9b01916_si_001.pdf" class="ext-link">Figure S-3, Supporting Information</a>). The main activity detected was in the BT panel and represents the intended inhibition of cellular BTK function in B cells stimulated via the B cell receptor and in the presence of T cell co-stimulatory pathways, resulting in the inhibition of several inflammatory readouts such as TNF-α, IL-17A, IL-6, and IL-2, as well as inhibition of B cell proliferation (indicated by the gray arrow in the BT panel). The response was not concentration dependent as all concentrations tested were well above maximal cellular BTK inhibition. Of note is the absence of a peak in the EGFR signal in the HDF3CGF panel, clearly indicating the lack of any activity of LOU064 in the dermal fibroblast system, an effect that has been shown for BTK inhibitors with off-target effects on EGFR, such as ibrutinib (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01916/suppl_file/jm9b01916_si_001.pdf" class="ext-link">Figure S-4, Supporting Information</a>).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Across all these cellular systems, LOU064 showed no cytotoxicity. In addition to the expected effects on B cell proliferation, LOU064 exerted effects on fibroblast proliferation at concentrations of 270 and 10 000 nM (gray arrow in the HDF3CGF panel).</div><div class="NLM_p last">Furthermore, the high selectivity of LOU064 was confirmed by testing against a broad panel of <i>in vitro</i> assays (in binding or in functional mode) comprising 85 G-protein-coupled receptors, transporters, nuclear receptors, enzymes, and ion channels (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01916/suppl_file/jm9b01916_si_001.pdf" class="ext-link">Supporting Information</a>). LOU064 did not show binding, inhibition, or activation in any of these assays at concentrations up to 10 μM, with the exception of PIK4CB (IC<sub>50</sub> = 3.1 μM) and bile salt export pump (BSEP, IC<sub>50</sub> = 6.6 μM), thus establishing a more than 2000-fold selectivity for BTK over these off-targets. In the <i>in vitro</i> hERG patch clamp assay an IC<sub>50</sub> of 1.4 μM was measured. In preclinical invasive and noninvasive dog telemetry studies after single and long-term dosing, no effect on any cardiovascular parameter was detected. As the noncovalent analog <b>32</b> showed very similar activity on BSEP (IC<sub>50</sub> = 3.7 μM) and hERG (IC<sub>50</sub> = 2.9 μM in Qpatch assay), it is likely that the interaction of LOU064 with these off-target proteins is noncovalent. No significant inhibition of other cardiac ion channels (Nav1.5, Cav1.2, KCNQ1) was observed, and LOU064 was found negative in genotoxicity and mutagenicity assays (<i>in vitro</i> Ames, <i>in vitro</i> and <i>in vivo</i> micronucleus tests). Similarly, LOU064 was negative in the 3T3 NRU phototoxicity assay.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Preclinical PK Profile of LOU064</h3><div class="NLM_p">The <i>in vitro</i> clearance of LOU064 in microsomes was moderate in rat and high in mouse and dog (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). The <i>in vivo</i> pharmacokinetic properties of LOU064 were assessed in rat, mouse, and dog (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). In rats, the compound displayed a moderate clearance, a low volume of distribution, a short half-life, and a moderate bioavailability. LOU064 was mainly cleared via oxidative metabolism, and elimination of unchanged LOU064 was not a major pathway in rat. In mice, LOU064 displayed a similar PK profile as for rats with high CL, a low volume of distribution, and a short half-life. In dogs, the clearance was high, in the range of the hepatic blood flow, the volume of distribution was low, the half-life was short, and the bioavailability was low. Formulations were developed that enabled preclinical toxicology studies (not shown).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. <i>In Vitro</i> and <i>in Vivo</i> Pharmacokinetic Parameters of LOU064 in Rat, Mouse, and Dog</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><i>in vitro</i></th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">mouse</th><th class="colsep0 rowsep0" align="center">dog</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL int (μL min<sup>–1</sup> mg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">33</td><td class="colsep0 rowsep0" align="left">325</td><td class="colsep0 rowsep0" align="left">146</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hepatic extraction (%)</td><td class="colsep0 rowsep0" align="left">52</td><td class="colsep0 rowsep0" align="left">93</td><td class="colsep0 rowsep0" align="left">87</td></tr></tbody></table><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><i>in vivo</i></th><th class="colsep0 rowsep0" align="center">female Lewis</th><th class="colsep0 rowsep0" align="center">female C57BL/6</th><th class="colsep0 rowsep0" align="center">male beagle</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dose</td><td class="colsep0 rowsep0" align="left">1 mg/kg iv</td><td class="colsep0 rowsep0" align="left">1 mg/kg iv</td><td class="colsep0 rowsep0" align="left">1 mg/kg iv</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">3 mg/kg po</td><td class="colsep0 rowsep0" align="left">3 mg/kg po</td><td class="colsep0 rowsep0" align="left">3 mg/kg po</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (mL min<sup>–1</sup> kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">44 ± 12</td><td class="colsep0 rowsep0" align="left">97 ± 11</td><td class="colsep0 rowsep0" align="left">29 ± 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg)</td><td class="colsep0 rowsep0" align="left">1.4 ± 0.3</td><td class="colsep0 rowsep0" align="left">1.0 ± 0.1</td><td class="colsep0 rowsep0" align="left">1.0 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.5 ± 0.03</td><td class="colsep0 rowsep0" align="left">1.0 ± 0.1</td><td class="colsep0 rowsep0" align="left">0.9 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">C<sub>max</sub> d.n. (nM)</td><td class="colsep0 rowsep0" align="left">148 ± 33</td><td class="colsep0 rowsep0" align="left">53 ± 14</td><td class="colsep0 rowsep0" align="left">19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left">0.3 ± 0.1</td><td class="colsep0 rowsep0" align="left">0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">29 ± 3</td><td class="colsep0 rowsep0" align="left">16 ± 4</td><td class="colsep0 rowsep0" align="left">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC po d.n. (nM·h)</td><td class="colsep0 rowsep0" align="left">225 ± 27</td><td class="colsep0 rowsep0" align="left">54 ± 15</td><td class="colsep0 rowsep0" align="left">55</td></tr></tbody></table></div></div><div class="NLM_p last">In essence, the preclinical ADME properties of LOU064 are characterized by excellent permeability, high clearance, and fast elimination.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> <i>In Vitro</i> BTK Inhibition Kinetics</h3><div class="NLM_p">To further characterize the mechanism of BTK inhibition by LOU064, we tested the kinetics of enzymatic inhibition. In biochemical assays of enzymatic activity with recombinant full-length human BTK, LOU064 showed very fast inhibition of BTK (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01916/suppl_file/jm9b01916_si_001.pdf" class="ext-link">Figure S-5, Supporting Information</a>). LOU064 showed potent BTK inhibition starting from the earliest time-point and no indication of a time-dependent shift in IC<sub>50</sub> over the time frame that allowed reliable detection of BTK activity or inhibition. The very fast binding kinetics of LOU064 to purified BTK prevented the determination of accurate and meaningful biochemical reaction parameters.</div><div class="NLM_p">We therefore assessed the engagement of cellular BTK in a clinically relevant matrix: human blood. Blood from healthy volunteers was mixed with serial dilutions of LOU064, incubated at room temperature to allow binding to cellular BTK and at given time points aliquots of blood were sampled and analyzed for covalent binding of LOU064 to BTK with immunoassays for free BTK (i.e., not covalently occupied by compound) and total BTK protein (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01916/suppl_file/jm9b01916_si_001.pdf" class="ext-link">Supporting Information</a>). LOU064 showed very rapid covalent binding to cellular BTK in human blood at concentrations as low as 300 nM (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, left panel).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Time- and concentration-dependent <i>in vitro</i> engagement of cellular BTK by LOU064 and related inhibitors in human blood. Left panel shows data for LOU064 from two independent experiments with different blood donors (solid lines show nonlinear one-phase association curve fits). Right panel shows the association kinetics for a concentration of 300 nM for each compound (solid lines show nonlinear one-phase association curve fits). Individual data are from two independent experiments with different blood donors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01916&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We compared the binding characteristics of LOU064 to related covalent BTK inhibitors in the same type of assay at a concentration of 300 nM (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, right panel). In contrast to the rapid and complete BTK binding of LOU064, the other covalent BTK inhibitors, with exception of branebrutinib, showed slower binding kinetics. A comparison of the enzymatic and cellular potency of LOU064 to these covalent BTK inhibitors across several assays confirmed the very high potency of LOU064 (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). These data suggest that LOU064 has very fast reaction kinetics and rapidly reaches full BTK inhibition in relevant matrices such as human blood.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Comparative Potency of LOU064 and Covalent BTK inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">BTK</th><th class="colsep0 rowsep0" align="center">FcγR/IL8</th><th class="colsep0 rowsep0" align="center">BCR/CD69</th><th class="colsep0 rowsep0" align="center">FcεR/CD63</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LOU064 (<b>25</b>)</td><td class="colsep0 rowsep0" align="left">1.3 ± 0.9</td><td class="colsep0 rowsep0" align="left">2.5 ± 0.7</td><td class="colsep0 rowsep0" align="left">18 ± 5</td><td class="colsep0 rowsep0" align="left">67 ± 54</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ibrutinib (<b>1</b>)</td><td class="colsep0 rowsep0" align="left">2.3 ± 2</td><td class="colsep0 rowsep0" align="left">16 ± 14</td><td class="colsep0 rowsep0" align="left">66 ± 57</td><td class="colsep0 rowsep0" align="left">230 ± 210</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">acalabrutinib (<b>2</b>)</td><td class="colsep0 rowsep0" align="left">19 ± 22</td><td class="colsep0 rowsep0" align="left">24 ± 24</td><td class="colsep0 rowsep0" align="left">203 ± 77</td><td class="colsep0 rowsep0" align="left">747 ± 75</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tirabrutinib (<b>3</b>)</td><td class="colsep0 rowsep0" align="left">5.2 ± 5</td><td class="colsep0 rowsep0" align="left">26 ± 16</td><td class="colsep0 rowsep0" align="left">132 ± 46</td><td class="colsep0 rowsep0" align="left">363 ± 200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">evobrutinib (<b>4</b>)</td><td class="colsep0 rowsep0" align="left">62 ± 4</td><td class="colsep0 rowsep0" align="left">61 ± 37</td><td class="colsep0 rowsep0" align="left">320 ± 74</td><td class="colsep0 rowsep0" align="left">1182 ± 819</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">branebrutinib (<b>5</b>)</td><td class="colsep0 rowsep0" align="left">0.1 ± 0.05<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></td><td class="colsep0 rowsep0" align="left">6.0 (<i>n</i> = 1)</td><td class="colsep0 rowsep0" align="left">18 ± 4</td><td class="colsep0 rowsep0" align="left">40 ± 10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">BTK enzyme inhibition in Caliper assay, with IC<sub>50</sub> shown as the mean ± SD (<i>n</i> ≥ 2).</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">FcγR induced IL8, with IC<sub>50</sub> shown as the mean ± SD (<i>n</i> ≥ 2).</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">Anti-IgM/IL-4 induced CD69 expression on human blood B cells, with IC<sub>50</sub> shown as the mean ± SD (<i>n</i> ≥ 2).</p></div><div class="footnote" id="t6fn4"><sup><sup>d</sup></sup><p class="last">Anti-IgE-induced degranulation and CD63 expression on human blood basophils, with IC<sub>50</sub> shown as the mean ± SD (<i>n</i> ≥ 2).</p></div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> <i>In Vivo</i> BTK Engagement</h3><div class="NLM_p">For a covalent inhibitor of BTK, the PD effects are determined by the extent and duration of BTK target occupancy. The initial inactivation of BTK by LOU064 binding is primarily determined by the systemic exposure of the drug. Once the drug is eliminated from systemic circulation, the duration of BTK inhibition becomes independent from drug exposure and is determined by the turnover of the inactive drug/protein complex by synthesis of new BTK protein.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> For BTK, the turnover of inactivated protein by newly synthesized protein has been described in preclinical models and ranges from 20% to 40% of BTK protein being resynthesized after 24 h.<a onclick="showRef(event, 'ref18 ref22 ref54'); return false;" href="javascript:void(0);" class="ref ref18 ref22 ref54">(18,22,54)</a></div><div class="NLM_p">We set out to determine the detailed PK/PD relationship of LOU064 in rats by using BTK occupancy as the primary PD readout. A series of studies were performed in rats to determine the dose range leading to varying degrees of BTK occupancy in spleen (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). To minimize the impact of circulating LOU064, the animals were sacrificed 5 h after oral dosing and tissues were sampled. BTK occupancy in spleen homogenates was measured relative to vehicle controls. A dose–response curve fit indicates an EC<sub>50</sub> of 0.6 mg/kg (EC<sub>90</sub> = 1.6 mg/kg). The analysis of LOU064 in blood from these animals showed that for the 1 mg/kg dose, resulting in an average of 78% BTK occupancy, the systemic exposure was 49.1 nM at 0.5 h postdose (5.6 nM at 5 h). This suggests that very low and transient systemic exposures of LOU064 are sufficient for BTK inhibition.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Spleen BTK occupancy relative to vehicle controls was measured 5 h after oral dosing in female rats combined from two separate studies (with 3 animals per each dose group). Open triangles show the BTK occupancy levels in the combined vehicle dosed animals. Filled circles show the BTK occupancy of LOU064 treated animals. The dotted line shows a dose–response curve fit.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01916&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Preclinical Efficacy in SRBC and CIA Models</h3><div class="NLM_p">To extend the preclinical PK/PD relationship to repeated dosing regimen, we examined the efficacy of LOU064 in a model of B cell dependent antibody formation following immunization with sheep red blood cells (SRBC).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Female rats were immunized with SRBC and treated for 4 days with one daily oral dose of LOU064 starting on the day of immunization. On day 5, SRBC antibody formation was assessed <i>ex vivo</i> on splenocytes (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>, left panel), as well as BTK occupancy in the same tissue (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>, right panel). The IgM antibody response was maximally inhibited (by 96%) at a dose of 3 mg/kg q.d. This level of IgM response inhibition was correlated to a spleen BTK occupancy at the 24 h trough of 71.5 %. Doses as low as 0.3 mg/kg demonstrated a partial but significant inhibitory effect on SRBC specific antibody response (with a trough BTK occupancy in spleen of 31%).</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. IgM response inhibition by LOU064 in the rat model of B cell response to SRBC immunization. Left panel: inhibition of anti-IgM response. Open triangles show vehicle (V), open circles cyclosporine A (CsA), and closed circles LOU064 treated animals. The group mean values are shown as the central bars, and the standard deviations are shown as whisker error bars. Statistical significance (ANOVA, followed by Dunnett’s test) is shown as ∗∗∗ for <i>p</i> < 0.001. Right panel: BTK occupancy in spleen 24 h after the last dose of LOU064. Open triangles show vehicle (V), open circles cyclosporine A (CsA), and closed circles LOU064 treated animals relative to the average of the vehicle group. Group mean values are shown as central bars and standard deviations as whisker error bars. Statistical significance (ANOVA, followed by Dunnett’s test) is shown as ∗∗∗ for <i>p</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01916&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next we assessed the effects of LOU064 in the inflammatory model of collagen-induced arthritis (CIA) in rats.<a onclick="showRef(event, 'ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref56 ref57">(56,57)</a> Collagen-specific B- and T-lymphocytes are important in the pathogenesis of CIA, with the peak of the T-cell response occurring around the time of disease onset.<a onclick="showRef(event, 'ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref57 ref58">(57,58)</a> Female Lewis rats were immunized with porcine collagen, and LOU064 oral dosing, once daily, was started after the onset of arthritis, continuing until day 26 after immunization. The animals treated with LOU064 showed a fast onset of action, and within a few days paw swelling was fully reduced (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, left panel). This was evident in the three highest doses of 3, 10, and 30 mg/kg, whereas the 0.3 mg/kg dose was largely inactive (no 1 mg/kg dose group was included in the study).</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Efficacy of LOU064 in the rat model of collagen-induced arthritis. Left panel: Paw swelling scores are shown as the mean ± SEM. LOU064 treatment is once daily with doses of 0.3, 3, 10, and 30 mg/kg from day 12 to 25 postimmunization. Statistical significance (ANOVA, followed by Dunnett’s test) is shown as ∗∗ for <i>p</i> < 0.01. Right panel: BTK occupancy in spleen 24 h after the last dose of LOU064. Triangles show vehicle (V), and circles represent LOU064 treated animals relative to the average of the vehicle group. Group mean values are shown as central bars and standard deviations as whiskers. Statistical significance (ANOVA, followed by Dunnett’s test) is shown as ∗∗∗ for <i>p</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01916&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Histopathological analysis of the 3 and 10 mg/kg groups showed that bone and cartilage erosion, as well as inflammatory cell infiltration, were all significantly inhibited by LOU064 (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). Dose proportional levels of BTK occupancy in spleen were found on day 26 at trough, 24 h after the last dose (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, right panel). Occupancy levels of 80% (for the 3 mg/kg dose) and higher were associated with significant inhibition of paw swelling.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Histopathological analysis of arthritis in rat CIA model. Left panel: Histology scores combined for the hind paws of each animal show inflammatory cell infiltrate, joint damage, and proteoglycan loss (average ± SEM of 6 animals per group, ANOVA, followed by Dunnett’s test with ∗∗ for <i>p</i> < 0.01). Right panel: Photomicrographs of paw sections stained with Giemsa (left column) and Safranin O (right column) illustrate joint tissue inflammation and preservation of joint cartilage, respectively. LOU064 significantly reduced joint inflammation and damage as well as proteoglycan loss at 3 and 10 mg/kg q.d. po.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01916&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">This study shows that LOU064 potently inhibits a chronic arthritic inflammation <i>in vivo</i> in a therapeutic treatment setting with a fast onset of action. Since we timed the treatment to start after the immunization phase, the fast onset of action suggests that the anti-inflammatory effect is due to the inhibition of inflammatory macrophages and of immune complexes in the paws.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Synthesis of LOU064 (<b>25</b>)</h3><div class="NLM_p">The synthesis of <b>25</b> is outlined in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> shows the synthesis of the upper portion of the molecule, intermediate <b>38</b>. Borylation of 1-bromo-5-fluoro-2-methyl-3-nitrobenzene (<b>33</b>) with bis(pinacolato)diboron in the presence of Pd(dppf)Cl<sub>2</sub>·DCM and potassium acetate gave boronic ester <b>34</b> which upon catalytic hydrogenation provided aniline <b>35</b>. Suzuki reaction of methyl 4-bromo-2-fluorobenzoate (<b>36</b>) and cyclopropylboronic acid gave cyclopropyl intermediate <b>37</b>. Boronic ester <b>38</b> was then accessed via a NaHMDS mediated amide formation of aniline <b>35</b> and ester <b>37</b>. The synthesis of LOU064 was completed as outlined in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. The lower portion of the molecule was assembled starting from 2,4-dichloro-3-methoxypyrimidine (<b>39</b>). Treatment with ammonia in a pressure reactor resulted in aminopyrimidine <b>40</b>, which was subjected to boron tribromide treatment to give aminopyrimidinol <b>41</b>. The linker moiety was introduced via a Mitsunobu reaction with <i>N</i>-Boc-<i>N</i>-methyl-2-hydroxyethylamine in the presence of DIAD and Smopex-301, a convenient polymer supported version of triphenylphosphine, to obtain <b>42</b>. Boc protected intermediate <b>43</b> was assembled via Suzuki coupling of <b>42</b> and <b>38</b>. Finally, Boc deprotection of <b>43</b> followed by amide coupling with acrylic acid in the presence of propylphosphonic anhydride (T3P) provided LOU064 (<b>25</b>).</div><figure id="sch1" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Boronic Ester <b>38</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01916&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BISPIN, Pd(dppf)Cl<sub>2</sub>·DCM, KOAc, dioxane, 100 °C, 3.5 h, 92%; (b) H<sub>2</sub>, Pd/C, MeOH, RT, 7 h, 93%; (c) cyclopropylboronic acid, Pd(OAc)<sub>2</sub>, tricyclohexylphosphine, K<sub>3</sub>PO<sub>4</sub>, water, toluene, 100 °C, overnight, 99%; (d) <b>35</b>, NaHMDS (1 M in THF), THF, RT, 4 h, 76%.</p></p></figure><figure id="sch2" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of LOU064<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01916&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NH<sub>4</sub>OH, 2-propanol, 70 °C, 48 h, 94%; (b) BBr<sub>3</sub>, DCM, 40 °C, 3 h, 59%; (c) <i>N</i>-Boc-<i>N</i>-methyl-2-hydroxyethylamine, DIAD, Smopex-301, THF, 60 °C, 2 h, 53%; (d) <b>38</b>, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, aq Na<sub>2</sub>CO<sub>3</sub>, DME, water, microwave, 110 °C, 25 min, 74%; (e) TFA, DCM, RT, 12 h; (f) acrylic acid, DIPEA, T3P (50% in DMF), DMF, RT, 2 h, 45% over 2 steps.</p></p></figure><div class="NLM_p last">The experimental details are provided in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. For the synthesis of analogues the schemes and synthetic details are provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01916/suppl_file/jm9b01916_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47701" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47701" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In summary, we have discovered a covalent BTK inhibitor, LOU064 (remibrutinib, <b>25</b>), that shows excellent selectivity and potency with potential for best-in-class <i>in vivo</i> profile. By a structure-based approach, starting from a selective, reversible BTK binder, we successfully morphed the hinge binder moiety and introduced a linker with a warhead leading to selective, covalent BTK inhibitors. The drug discovery efforts focused on the optimization of potency, ADME properties, and PK/PD using an <i>in vivo</i> target occupancy assay.</div><div class="NLM_p last">The preclinical pharmacokinetic data of LOU064 are favorable for a covalent inhibitor with the potential for once daily dosing. On the basis of the singular PK/PD profile of a covalent inhibitor, LOU064 showed potent BTK occupancy with an EC<sub>90</sub> of 1.6 mg/kg after single oral dose with transient low exposure. In addition, the <i>in vivo</i> efficacy on B cell response and the potent inhibition of rat arthritis with a fast onset of action suggest that the compound could have utility in treating autoimmune diseases. The compound displayed a good preclinical tolerability and safety profile in two species at different doses, and these findings encouraged us to progress LOU064 into clinical studies in autoimmune diseases. In phase 1 studies, healthy and atopic subjects have been exposed to LOU064 at doses ranging from 0.5 mg to 600 mg.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Administration of LOU064 in healthy subjects did not raise any safety signals in any of these studies. With favorable phase 1 results, LOU064 entered phase 2 clinical studies in several immune disorders including chronic spontaneous urticaria and Sjoegren’s syndrome. Further details and clinical results will be reported in due course.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27621" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27621" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Experimental Details</h3><div class="NLM_p last">All chemicals were used directly as received from commercial suppliers. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Bruker 400 or 600 spectrometer. Chemical shifts are expressed in δ ppm referenced to the residual solvent peak (DMSO-<i>d</i><sub>6</sub>, δ = 2.50 ppm; CDCl<sub>3</sub>, δ = 7.27 ppm; CD<sub>3</sub>OD, δ = 3.30 ppm). Abbreviations used in describing peak signals are br = broad signal, v = very, s = singlet, d = doublet, dd = doublet of doublets, t = triplet, q = quartet, m = multiplet. All final compounds were purified to >95% by reverse phase high performance liquid chromatography (HPLC), supercritical fluid chromatography (SFC), or normal phase silica gel column chromatography. The purity was assessed by reverse phase UPLC with a gradient of 5–98% acetonitrile in water (with either acid or base modifier) and monitored by UV absorption at 210–450 nm. Purity of all final compounds is ≥95%. Low-resolution mass spectra were recorded on liquid chromatography–mass spectrometer in electrospray positive (ES+) and negative (ES−) modes. The HR-MS analyses were performed by using electrospray ionization in positive ion mode after separation by liquid chromatography (Nexera from Shimadzu). The elemental composition was derived from the mass spectra acquired at a high resolution of about 30 000 on an LTQ Orbitrap XL mass spectrometer (Thermo Scientific). The high mass accuracy below 1 ppm was obtained by using a lock mass.</div></div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> <i>N</i>-(3-(6-Amino-5-(2-(<i>N</i>-methylacrylamido)ethoxypyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide (<b>25</b>, LOU064)</h3><div id="sec4_1_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Step 1</h4><div class="NLM_p last">To a solution of <b>43</b> (6.5 g, 11.74 mmol) in DCM (100 mL) was added TFA (9.05 mL, 117 mmol). The reaction mixture was stirred at RT for 12 h. The mixture was concentrated under reduced pressure. The residue was dried in vacuo to obtain the crude amine <b>44</b> as TFA salt. [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>26</sub>F<sub>2</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 454.2; found, 454.3.</div></div><div id="sec4_1_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Step 2</h4><div class="NLM_p last">To a solution of acrylic acid (1.10 g, 15.26 mmol) in DMF (50 mL) was added DIPEA (6.15 mL, 35.2 mmol) followed by T3P (50% in DMF, 7.54 mL, 12.91 mmol). The mixture was stirred at RT for 30 min to form the active ester. The mixture was added dropwise to a solution of crude <b>44</b> and DIPEA (6.15 mL, 35.2 mmol) in DMF (50 mL) at 0 °C. The reaction mixture was stirred at RT for 2 h. The mixture was diluted with EtOAc and washed with water (2×) and brine. The organic layer was dried over MgSO<sub>4</sub>, filtered, and concentrated. The residue was purified by column chromatography (SiO<sub>2</sub>; (DCM containing 2% NH<sub>3</sub>)/MeOH gradient) to afford 2.80 g of <b>25</b> as a white solid. Yield: 45% over 2 steps. [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>28</sub>F<sub>2</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 508.2; found, 508.3. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) rotamers δ 9.79 and 9.57 (2s, total 1H), 8.22 and 8.19 (2s, total 1H), 7.78–7.72 and 7.71–7.65 (2m, total 1H), 7.63–7.52 (m, 1H), 7.15–7.03 (m, 4H), 7.03–6.96 (m, 1H), 6.71–6.57 (m, 1H), 6.14–6.02 (m, 1H), 5.65–5.56 (m, 1H), 3.63–3.54 (m, 2H), 3.54–3.45 (m, 2H), 2.81 and 2.51 (overlapping with DMSO) (2s, total 3H), 2.10–2.00 (m, 1H), overlapping with 2.03 and 1.98 (2s, total 3H), 1.11–1.03 (m, 2H), 0.86–0.78 (m, 2H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) rotamers δ 165.58, 165.54, 162.65, 162.40, 160.66, 160.50, 160.16, 160.04, 159.01, 158.85, 158.72, 158.56, 158.44, 153.84, 153.44, 153.35, 152.93, 151.06, 151.01, 150.82, 150.77, 138.75, 138.69, 138.34, 138.28, 137.85, 137.78, 137.70, 136.08, 135.23, 130.55, 130.36, 128.35, 128.32, 127.10, 126.89, 126.20, 126.05, 121.65, 121.59, 120.43, 120.34, 119.99, 119.90, 112.83, 112.78, 112.72, 112.63, 112.57, 112.22, 112.06, 111.86, 70.23, 68.69, 48.25, 47.36, 35.41, 32.80, 15.16, 14.23, 14.19, 10.55, 10.52. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>28</sub>F<sub>2</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 508.21547; found, 508.21582.</div></div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 2-(5-Fluoro-2-methyl-3-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (<b>34</b>)</h3><div class="NLM_p last">To a solution of 1-bromo-5-fluoro-2-methyl-3-nitrobenzene (463 g, 1978 mmol) in dioxane (16 L) was added bis(pinacolato)diboron (755 g, 2973 mmol) followed by potassium acetate (681 g, 6939 mmol) and PdCl<sub>2</sub>(dppf)·DCM adduct (85 g, 104 mmol). The reaction mixture was refluxed at 110 °C for 3.5 h. After cooling to RT, the mixture was diluted with EtOAc and washed with saturated aqueous NaHCO<sub>3</sub> solution. The aqueous layer was back-extracted with EtOAc (2×). The combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated. The residue was purified by column chromatography (SiO<sub>2</sub>; heptane/EtOAc 9:1) to obtain 513 g of <b>34</b> as a beige solid. Yield: 92%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.93 (dd, 1H), 7.62 (dd, 1H), 2.50 (s, 3H, overlapping with DMSO), 1.32 (s, 12H).</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 5-Fluoro-2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (<b>35</b>)</h3><div class="NLM_p last">To a solution of <b>34</b> (509 g, 1811 mmol) in MeOH (4.6 L) in an autoclave was added Pd–C 10% (50 g). The mixture was evacuated and purged with hydrogen. The reaction mixture was stirred at RT under a hydrogen atmosphere for 7 h. The mixture was filtered through a suction filter, and the filter cake was washed with MeOH. The filtrate was concentrated. The residue was purified by column chromatography (SiO<sub>2</sub>; heptane/EtOAc gradient) to afford batch 1 (435 g) and batch 2 (5.4 g) of <b>35</b>. Batch 1 of <b>35</b> (435 g) was dissolved in hexane (1400 mL) under reflux and was allowed to cool to RT over 2 h while stirring. The precipitate was filtered off and washed with cold hexane, then dried in vacuo to afford 387 g of <b>35</b> as a white solid. The mother liquor was concentrated and combined with batch 2 of <b>35</b> (5.4 g). The residue was recrystallized from hexane (100 mL) as described above to afford 36 g of <b>35</b> as a white solid. The two batches were combined. Yield: 93%. [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>20</sub>BFNO<sub>2</sub> [M + H]<sup>+</sup>, 252.2; found, 252.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.52–6.45 (m, 2H), 5.09 (s, 2H), 2.17 (s, 3H), 1.28 (s, 12H).</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Methyl 4-Cyclopropyl-2-fluorobenzoate (<b>37</b>)</h3><div class="NLM_p last">A solution of methyl 4-bromo-2-fluorobenzoate (20.00 g, 84 mmol) and cyclopropylboronic acid (9.68 g, 109 mmol) in toluene (250 mL) was purged with argon for 5 min. Then, tricyclohexylphosphine (2.36 g, 8.41 mmol) and water (1.82 mL, 101 mmol) were added. The mixture was purged with argon for an additional 10 min. Pd(OAc)<sub>2</sub> (0.944 g, 4.21 mmol) was added, and the reaction mixture was stirred at 100 °C overnight. The mixture was partitioned between EtOAc and water. The black suspension was filtered over a pad of Celite. The layers of the now clear mixture were separated. The aqueous layer was back-extracted with EtOAc. The combined organic layers were washed with saturated aqueous NaHCO<sub>3</sub> solution and brine, dried over MgSO<sub>4</sub>, filtered, and concentrated. The residue was purified by column chromatography (SiO<sub>2</sub>; cyclohexane/EtOAc gradient) to obtain 17.00 g (purity 95%) of <b>37</b> as a brown oil. Yield: 99%. [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>12</sub>FO<sub>2</sub> [M + H]<sup>+</sup>, 195.1; found, 195.1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.79–7.69 (m, 1H), 7.04 (s, 1H), 7.03–6.99 (m, 1H), 3.81 (s, 3H), 2.06–1.95 (m, 1H), 1.10–1.00 (m, 2H), 0.85–0.73 (m, 2H).</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 4-Cyclopropyl-2-fluoro-<i>N</i>-(5-fluoro-2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzamide (<b>38</b>)</h3><div class="NLM_p last">To a suspension of <b>35</b> (17.00 g, 64.3 mmol) and <b>37</b> (16.24 g, 84.0 mmol) in THF (300 mL) at 0 °C was added NaHMDS (1 M in THF, 96 mL, 96.0 mmol) dropwise. The reaction mixture was stirred at RT for 1 h, then more NaHMDS (1 M in THF, 20 mL, 20.0 mmol) was added. The reaction mixture was stirred at RT for 1 h. Then, a third batch of NaHMDS (1.0 M in THF, 20 mL, 20.0 mmol) was added and the reaction mixture was stirred at RT for another 2 h. The mixture was diluted with EtOAc and washed with saturated aqueous NaHCO<sub>3</sub> solution. The aqueous layer was back-extracted with EtOAc. The combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated. The residue was suspended in EtOAc and stirred at RT for 20 min. The solid was filtered off, washed with EtOAc, and dried in vacuo to afford a first batch of <b>38</b> (17.8 g) as a beige solid. The filtrate was concentrated, and the residue was suspended in EtOAc. The suspension was stirred at RT for 20 min. The resulting solid was filtered off, washed with EtOAc, and dried in vacuo to afford a second batch of <b>38</b> (3.4 g) as a beige solid. The two batches were combined. Yield: 76%. [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>27</sub>BF<sub>2</sub>NO<sub>3</sub> [M + H]<sup>+</sup>, 414.2; found, 414.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.72 (d, <i>J</i> = 2.9 Hz, 1H), 7.67–7.59 (m, 1H), 7.52 (d, br, <i>J</i> = 9.9 Hz, 1H), 7.21 (dd, <i>J</i> = 8.7, 2.9 Hz, 1H), 7.10–7.03 (m, 2H), 2.38 (s, 3H), 2.08–1.97 (m, 1H), 1.32 (s, 12H), 1.10–1.01 (m, 2H), 0.83–0.75 (m, 2H).</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 6-Amino-4-chloro-5-methoxypyrimidine (<b>40</b>)</h3><div class="NLM_p last">To a solution of 4,6-dichloro-5-methoxypyrimidine (5.00 g, 27.9 mmol) in 2-propanol (40 mL) in an autoclave was added ammonium hydroxide (26% in water, 5.0 mL, 33.5 mmol). The autoclave was sealed, and the reaction mixture was stirred at 70 °C for 48 h. After the mixture was cooled, the precipitate was filtered off and washed with <i>n</i>-pentane and diethyl ether. The residue was dried in vacuo to obtain 4.40 g of <b>40</b> as a white solid. Yield: 94%. [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>5</sub>H<sub>7</sub>ClN<sub>3</sub>O [M + H]<sup>+</sup>, 160.0; found, 160.1. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.12 (s, 1H), 5.29 (s, 2H), 3.89 (s, 3H).</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 6-Amino-4-chloro-5-pyrimidinol (<b>41</b>)</h3><div class="NLM_p last">To a solution of <b>40</b> (2.30 g, 13.69 mmol) in DCM (100 mL) at RT was slowly added boron tribromide (6.5 mL, 68.5 mmol), and the reaction mixture was stirred at 40 °C for 3 h. The mixture was quenched by slowly adding MeOH (50 mL) at −10 °C, stirred at RT for 12 h, then concentrated under reduced pressure. The residue was taken up in water and EtOAc. The mixture was basified with aqueous sodium carbonate solution (2 M) to pH 9–10. The aqueous layer was washed with EtOAc (discarded), acidified to pH 5–6 with aqueous HCl solution (5 M), then extracted with EtOAc (1×) and DCM (1×). The combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated to afford 1.30 g (purity 90%) of <b>41</b> as a beige solid. Yield: 59%. [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>4</sub>H<sub>5</sub>ClN<sub>3</sub>O [M + H]<sup>+</sup>, 146.0; found, 146.0. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.57 (s, 1H), 7.78 (s, 1H), 6.89 (s, 2H).</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> <i>tert</i>-Butyl (2-((4-Amino-6-chloropyrimidin-5-yl)oxy)ethyl)(methyl)carbamate (<b>42</b>)</h3><div class="NLM_p last">To a solution of <b>41</b> (2.00 g, 13.7 mmol) in THF (120 mL) was added a solution of <i>N</i>-Boc-<i>N</i>-methyl-2-hydroxyethylamine (6.74 g, 38.5 mmol) in THF (5 mL) followed by Smopex-301 (1 mmol/g) (34.4 g, 34.4 mmol) and a solution of DIAD (6.68 mL, 34.4 mmol) in THF (15 mL). The reaction mixture was stirred at 60 °C for 2 h. The mixture was filtered through a pad of Celite. The filtrate was concentrated to afford a yellow oil. The residue was treated with EtOAc and sonicated to provide a suspension which was allowed to stand at RT for 1 h. The precipitate was filtered off and dried in vacuo to obtain 2.33 g (purity 95%) of <b>42</b> as a white solid. Yield: 53%. [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>20</sub>ClN<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 303.1; found, 303.0. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) rotamers δ 7.97 (s, 1H), 7.27 (s, br, 2H), 4.04–3.89 (m, 2H), 3.59–3.48 (m, 2H), 2.97–2.81 (m, 3H), 1.47–1.30 (m, 9H).</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> <i>tert</i>-Butyl (2-((4-Amino-6-(3-(4-cyclopropyl-2-fluorobenzamido)-5-fluoro-2-methyl-phenyl)pyrimidin-5-yl)oxy)ethyl)(methyl)carbamate (<b>43</b>)</h3><div class="NLM_p last">The reaction was carried out using a Masterwave BTR microwave reactor with a 1000 mL vial. DME and water were purged with argon. To a solution of <b>42</b> (17.0 g, 56.2 mmol) and <b>38</b> (25.5 g, 61.8 mmol) in DME (264 mL) and water (38 mL) was added PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (1.971 g, 2.81 mmol) followed by aqueous Na<sub>2</sub>CO<sub>3</sub> solution (1 M, 168 mL, 168 mmol). The reaction mixture was heated at 110 °C under microwave irradiation for 15 min. More <b>38</b> (1.4 g, 3.4 mmol) and PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (0.28 g, 0.40 mmol) were added. The reaction mixture was heated at 110 °C under microwave irradiation for an additional 10 min. The mixture was diluted with EtOAc (850 mL) and saturated aqueous NaHCO<sub>3</sub> solution (710 mL) and transferred into a separatory funnel. The layers were separated,and the aqueous layer was back-extracted with EtOAc (425 mL). The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was triturated with EtOAc, and the mixture was stirred at RT for 30 min. The precipitate was filtered off and washed with EtOAc to afford 24.13 g (purity 97%) of <b>43</b> as a light gray solid. Yield: 74%. [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>34</sub>F<sub>2</sub>N<sub>5</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 554.3; found, 554.3. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) rotamers δ 9.74 (s, br, 1H), 8.18 (s, 1H), 7.69–7.62 (m, 1H), 7.62–7.55 (m, 1H), 7.10–7.03 (m, 2H), 7.03–6.90 (m, 3H), 3.57–3.47 (m, 2H), 3.28–3.22 (m, 2H), 2.58 (s, 3H), 2.09–1.97 (m, 1H) overlapping with 2.04 (s, 3H), 1.33 and 1.29 (2s, br, total 9H), 1.10–1.01 (m, 2H), 0.84–0.75 (m, 2H).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Kinase Binding Assays</h3><div class="NLM_p">The kinase-binding assays in screening or <i>K</i><sub>d</sub> determination modes have been described<a onclick="showRef(event, 'ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref50 ref51">(50,51)</a> and were as follows: recombinant DNA-tagged kinase proteins were produced from kinase-tagged T7 phage strains or by producing the kinase protein in HEK-293 cells with subsequent tagging with DNA for qPCR detection. Streptavidin-coated magnetic beads were treated with biotinylated small molecule ligands for 30 min at room temperature to generate affinity resins for kinase assays. The liganded beads were blocked with excess biotin and washed with blocking buffer (SeaBlock (Pierce), 1% BSA, 0.05% Tween 20, 1 mM DTT) to remove unbound ligand and to reduce nonspecific binding. Binding reactions were assembled by combining kinases, liganded affinity beads, and test compounds in 1× binding buffer (20% SeaBlock, 0.17× PBS, 0.05% Tween 20, 6 mM DTT). Test compounds were prepared as 111× stocks in 100% DMSO. <i>K</i><sub>d</sub> values were determined using an 11-point 3-fold compound dilution series with three DMSO control points. All compounds for <i>K</i><sub>d</sub> measurements are distributed by acoustic transfer (noncontact dispensing) in 100% DMSO. The compounds were then diluted directly into the assays such that the final concentration of DMSO was 0.9%. All reactions were performed in polypropylene 384-well plates in a final volume of 0.02 mL. The assay plates were incubated at room temperature with shaking for 1 h, and the affinity beads were washed with wash buffer (1× PBS, 0.05% Tween 20). The beads were then resuspended in elution buffer (1× PBS, 0.05% Tween 20, 0.5 μM nonbiotinylated affinity ligand) and incubated at room temperature with shaking for 30 min. The kinase concentration in the eluates was measured by qPCR.</div><div class="NLM_p last">Binding constants (<i>K</i><sub>d</sub>) were calculated with a standard dose–response curve using the Hill equation:<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_m001.gif" alt="" id="_i35" /></img></span>The Hill Slope was set to −1, and curves were fitted using a nonlinear least-square fit with the Levenberg–Marquardt algorithm</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> BTK Occupancy</h3><div class="NLM_p last">Covalent binding of compounds to BTK was determined with immunoassays for free BTK (i.e., not covalently occupied by compound) and total BTK protein. For free BTK measurements, samples were incubated with a biotinylated covalent BTK probe,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> then samples were added to streptavidin ELISA plates to allow binding of probe-bound BTK. The binding of the probe to BTK is mutually exclusive with compound binding to BTK. Plate-bound BTK was detected with an anti-BTK antibody (D3H5, Cell Signaling Technology). For total BTK measurements, an ELISA plate was coated with D3H5 anti-BTK to capture total BTK. An anti-BTK antibody (no. 53, BD Biosciences) directed to a different epitope was then used to detect captured BTK. The respective free BTK levels for each sample were normalized to the total BTK level in the same sample, and these ratios were expressed as percentage of the vehicle control samples.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Animal Studies</h3><div class="NLM_p last">All animal studies described here were performed according to Swiss animal welfare laws and specifically according to animal licenses BS-1182, BS-1151, and BS-1244 issued by the Basel-Stadt Cantonal Veterinary Office.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> BTK Occupancy PK/PD Model</h3><div class="NLM_p last">To assess the PK/PD profile of the covalent BTK inhibitors, we measured BTK occupancy from tissue samples of animals treated with compounds. Female OFA-1 rats were dosed orally with compounds formulated at the indicated doses. Blood samples at 0.5, 2, and 5 h after compound dosing were taken into EDTA tubes under deep anesthesia for PK analysis. Five hours after dosing the animals were sacrificed and the spleen was removed to determine BTK target occupancy as described above (BTK occupancy assay).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i39"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01916" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71286" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71286" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b01916?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01916</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Synthesis of compounds <b>9</b>–<b>24</b> and <b>26</b>–<b>32</b>; structural biology data; <i>in vitro</i> ADME profile of LOU064; biology data; animal studies; references (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01916/suppl_file/jm9b01916_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01916/suppl_file/jm9b01916_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01916/suppl_file/jm9b01916_si_001.pdf">jm9b01916_si_001.pdf (1.3 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01916/suppl_file/jm9b01916_si_002.csv">jm9b01916_si_002.csv (2.65 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB accession codes are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S90">6S90</a> (BTK kinase domain bound to <b>7</b>) and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TFP">6TFP</a> (BTK kinase domain bound to LOU064). Authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.9b01916" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80137" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80137" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniela Angst</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , and , Novartis Institutes for BioMedical
Research, Novartis Campus, CH-4002 Basel, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4212-2829" title="Orcid link">http://orcid.org/0000-0002-4212-2829</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#670306090e020b06490609001413270908110615130e144904080a"><span class="__cf_email__" data-cfemail="e98d8887808c8588c788878e9a9da987869f889b9d809ac78a8684">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">François Gessier</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , and , Novartis Institutes for BioMedical
Research, Novartis Campus, CH-4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philipp Janser</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , and , Novartis Institutes for BioMedical
Research, Novartis Campus, CH-4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anna Vulpetti</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , and , Novartis Institutes for BioMedical
Research, Novartis Campus, CH-4002 Basel, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3114-8679" title="Orcid link">http://orcid.org/0000-0002-3114-8679</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rudolf Wälchli</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , and , Novartis Institutes for BioMedical
Research, Novartis Campus, CH-4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christian Beerli</span> - <span class="hlFld-Affiliation affiliation">Autoimmunity, Transplantation & Inflammation, , , , and , Novartis Institutes for BioMedical
Research, Novartis Campus, CH-4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amanda Littlewood-Evans</span> - <span class="hlFld-Affiliation affiliation">Autoimmunity, Transplantation & Inflammation, , , , and , Novartis Institutes for BioMedical
Research, Novartis Campus, CH-4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Janet Dawson</span> - <span class="hlFld-Affiliation affiliation">Autoimmunity, Transplantation & Inflammation, , , , and , Novartis Institutes for BioMedical
Research, Novartis Campus, CH-4002 Basel, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4615-4091" title="Orcid link">http://orcid.org/0000-0003-4615-4091</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Barbara Nuesslein-Hildesheim</span> - <span class="hlFld-Affiliation affiliation">Autoimmunity, Transplantation & Inflammation, , , , and , Novartis Institutes for BioMedical
Research, Novartis Campus, CH-4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Grazyna Wieczorek</span> - <span class="hlFld-Affiliation affiliation">Autoimmunity, Transplantation & Inflammation, , , , and , Novartis Institutes for BioMedical
Research, Novartis Campus, CH-4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sascha Gutmann</span> - <span class="hlFld-Affiliation affiliation">Chemical Biology & Therapeutics, , , , and , Novartis Institutes for BioMedical
Research, Novartis Campus, CH-4002 Basel, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4242-8510" title="Orcid link">http://orcid.org/0000-0002-4242-8510</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Clemens Scheufler</span> - <span class="hlFld-Affiliation affiliation">Chemical Biology & Therapeutics, , , , and , Novartis Institutes for BioMedical
Research, Novartis Campus, CH-4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexandra Hinniger</span> - <span class="hlFld-Affiliation affiliation">Chemical Biology & Therapeutics, , , , and , Novartis Institutes for BioMedical
Research, Novartis Campus, CH-4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alfred Zimmerlin</span> - <span class="hlFld-Affiliation affiliation">PK Sciences, , , , and , Novartis Institutes for BioMedical
Research, Novartis Campus, CH-4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Enrico G. Funhoff</span> - <span class="hlFld-Affiliation affiliation">Preclinical
Safety, , , , and , Novartis Institutes for BioMedical
Research, Novartis Campus, CH-4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert Pulz</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , and , Novartis Institutes for BioMedical
Research, Novartis Campus, CH-4002 Basel, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8035-1008" title="Orcid link">http://orcid.org/0000-0002-8035-1008</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bruno Cenni</span> - <span class="hlFld-Affiliation affiliation">Autoimmunity, Transplantation & Inflammation, , , , and , Novartis Institutes for BioMedical
Research, Novartis Campus, CH-4002 Basel, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8603-2032" title="Orcid link">http://orcid.org/0000-0002-8603-2032</a></span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): All authors are employees of Novartis.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i41">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33565" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33565" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank G. Rosé, J. Karrer, E. Blum, E. Buccheri, O. Decoret, N. Fur, S. Ilic, M.-L. Goude, B. Niepold, F. Ossola, G. Schwalm, S. Wildpreth, and D. Wiss for their synthesis support, P. Drueckes, D. Eichlisberger, S. Gaveriaux, and A.-S. Mangold for their efforts toward developing and performing biochemical and cellular assays, R. Keller, P. Ramseier, and M. Vogelsanger for <i>in</i><i>vivo</i> pharmacology, C. Marx and R. Denay for analytical data, and A. Lingel for GSH stability data. We are grateful to the MX beamline team at the Swiss Light Source (PSI Villigen, Switzerland) for outstanding support at the beamline and Expose GmbH (Switzerland) for diffraction data collection.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term">BCR</td><td class="NLM_def"><p class="first last">B-cell receptor</p></td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">CIA</td><td class="NLM_def"><p class="first last">collagen-induced arthritis</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">CsA</td><td class="NLM_def"><p class="first last">cyclosporin</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">IgM</td><td class="NLM_def"><p class="first last">immunoglobulin M</p></td></tr><tr><td class="NLM_term">IL-4</td><td class="NLM_def"><p class="first last">interleukin-4</p></td></tr><tr><td class="NLM_term">IL-8</td><td class="NLM_def"><p class="first last">interleukin-8</p></td></tr><tr><td class="NLM_term">PAMPA</td><td class="NLM_def"><p class="first last">parallel artificial membrane permeability assay</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamic</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SRBC</td><td class="NLM_def"><p class="first last">sheep red blood cell</p></td></tr><tr><td class="NLM_term">XLA</td><td class="NLM_def"><p class="first last">X-linked agammaglobulinemia</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i43">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65423" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65423" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 59 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Islam, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattsson, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohamed, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nore, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vihinen, M.</span></span> <span> </span><span class="NLM_article-title">The Tec Family of Cytoplasmic Tyrosine Kinases: Mammalian Btk, Bmx, Itk, Tec, Txk and Homologs in Other Species</span>. <i>BioEssays</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">436</span>– <span class="NLM_lpage">446</span>, <span class="refDoi"> DOI: 10.1002/bies.1062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1002%2Fbies.1062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=11340625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptVOjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2001&pages=436-446&author=C.+I.+E.+Smithauthor=T.+C.+Islamauthor=P.+T.+Mattssonauthor=A.+J.+Mohamedauthor=B.+F.+Noreauthor=M.+Vihinen&title=The+Tec+Family+of+Cytoplasmic+Tyrosine+Kinases%3A+Mammalian+Btk%2C+Bmx%2C+Itk%2C+Tec%2C+Txk+and+Homologs+in+Other+Species&doi=10.1002%2Fbies.1062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Tec family of cytoplasmic tyrosine kinases: Mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species</span></div><div class="casAuthors">Smith, C. I. Edvard; Islam, Tahmina C.; Mattsson, Pekka T.; Mohamed, Abdalla J.; Nore, Beston F.; Vihinen, Mauno</div><div class="citationInfo"><span class="NLM_cas:title">BioEssays</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">436-446</span>CODEN:
                <span class="NLM_cas:coden">BIOEEJ</span>;
        ISSN:<span class="NLM_cas:issn">0265-9247</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Cytoplasmic protein-tyrosine kinases (PTKs) are enzymes involved in transducing a vast no. of signals in metazoans.  The importance of the Tec family of kinases was immediately recognized when, in 1993, mutations in the gene encoding Bruton's tyrosine kinase (Btk) were reported to cause the human disease X-linked agammaglobulinemia (XLA).  Since then, addnl. kinases belonging to this family have been isolated, and the availability of full genome sequences allows identification of all members in selected species enabling phylogenetic considerations.  Tec kinases are endowed with Pleckstrin homol. (PH) and Tec homol. (TH) domains and are involved in diverse biol. processes related to the control of survival and differentiation fate.  Membrane translocation resulting in the activation of Tec kinases with subsequent Ca2+ release seems to be a general feature.  However, nuclear translocation may also be of importance.  The purpose of this essay is to characterize members of the Tec family and discuss their involvement in signaling.  The three-dimensional structure, expression pattern and evolutionary aspects will also be considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9ajt-jHfjH7Vg90H21EOLACvtfcHk0li4JnwukHmDAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptVOjtrc%253D&md5=1277b381019ee1e2e2371bb8a5282802</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fbies.1062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbies.1062%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26aulast%3DIslam%26aufirst%3DT.%2BC.%26aulast%3DMattsson%26aufirst%3DP.%2BT.%26aulast%3DMohamed%26aufirst%3DA.%2BJ.%26aulast%3DNore%26aufirst%3DB.%2BF.%26aulast%3DVihinen%26aufirst%3DM.%26atitle%3DThe%2520Tec%2520Family%2520of%2520Cytoplasmic%2520Tyrosine%2520Kinases%253A%2520Mammalian%2520Btk%252C%2520Bmx%252C%2520Itk%252C%2520Tec%252C%2520Txk%2520and%2520Homologs%2520in%2520Other%2520Species%26jtitle%3DBioEssays%26date%3D2001%26volume%3D23%26spage%3D436%26epage%3D446%26doi%3D10.1002%2Fbies.1062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, J. M.</span></span> <span> </span><span class="NLM_article-title">The Src, Syk, and Tec Family Kinases: Distinct Types of Molecular Switches</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1175</span>– <span class="NLM_lpage">1184</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2010.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1016%2Fj.cellsig.2010.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=20206686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtlyntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2010&pages=1175-1184&author=J.+M.+Bradshaw&title=The+Src%2C+Syk%2C+and+Tec+Family+Kinases%3A+Distinct+Types+of+Molecular+Switches&doi=10.1016%2Fj.cellsig.2010.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The Src, Syk, and Tec family kinases: Distinct types of molecular switches</span></div><div class="casAuthors">Bradshaw, J. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1175-1184</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The Src, Syk, and Tec family kinases are three of the most well characterized tyrosine kinase families found in the human genome.  Members of these kinase families function downstream of antigen and Fc receptors in hematopoietic cells and transduce signals leading to calcium mobilization, altered gene expression, cytokine prodn., and cell proliferation.  Over the last several years, structural and biochem. studies have begun to uncover the mol. mechanisms regulating activation of these kinases.  It appears that each kinase family functions as a distinct type of mol. switch.  This review discusses the activation of the Src, Syk, and Tec kinases from the perspective of structure, phosphorylation, allosteric regulation, and kinetics.  The multiple factors that regulate the Src, Syk, and Tec families illustrate the important role played by each of these kinases in immune cell signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_PA9QDCCGPLVg90H21EOLACvtfcHk0li4JnwukHmDAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtlyntbw%253D&md5=7f562f792a04682d05aa32dc09a7cb6e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2010.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2010.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520Src%252C%2520Syk%252C%2520and%2520Tec%2520Family%2520Kinases%253A%2520Distinct%2520Types%2520of%2520Molecular%2520Switches%26jtitle%3DCell.%2520Signalling%26date%3D2010%26volume%3D22%26spage%3D1175%26epage%3D1184%26doi%3D10.1016%2Fj.cellsig.2010.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span> <span> </span><span class="NLM_article-title">Btk Function in B Cell Development and Response</span>. <i>Semin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">316</span>, <span class="refDoi"> DOI: 10.1006/smim.1998.0123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1006%2Fsmim.1998.0123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=9695187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADyaK1cXltlCiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1998&pages=309-316&author=A.+B.+Satterthwaiteauthor=Z.+Liauthor=O.+N.+Witte&title=Btk+Function+in+B+Cell+Development+and+Response&doi=10.1006%2Fsmim.1998.0123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Btk function in B cell development and response</span></div><div class="casAuthors">Satterthwaite, Anne B.; Li, Zuomei; Witte, Owen N.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-316</span>CODEN:
                <span class="NLM_cas:coden">SEIME2</span>;
        ISSN:<span class="NLM_cas:issn">1044-5323</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review with 85 refs.  Mutations in Bruton's tyrosine kinase (Btk) result in the B cell immunodeficiencies XLA (X-linked agammaglobulinemia) in humans and Xid (X-linked immunodeficiency) in mice.  Both the maintenance of peripheral B cell nos. and their response to B cell antigen receptor (BCR) crosslinking depend on Btk.  Btk integrates signals from multiple cell surface receptors, including BCR and G-protein coupled receptors.  These Btk dependent signals control B cell proliferation and survival by mediating Ca2+ flux, activating JNK and p38 and inducing cell cycle regulatory genes.  (c) 1998 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVrVOyUeT25bVg90H21EOLACvtfcHk0li4JnwukHmDAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltlCiuro%253D&md5=f03605bc9f39d663d28794c7b7e40138</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1006%2Fsmim.1998.0123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fsmim.1998.0123%26sid%3Dliteratum%253Aachs%26aulast%3DSatterthwaite%26aufirst%3DA.%2BB.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DBtk%2520Function%2520in%2520B%2520Cell%2520Development%2520and%2520Response%26jtitle%3DSemin.%2520Immunol.%26date%3D1998%26volume%3D10%26spage%3D309%26epage%3D316%26doi%3D10.1006%2Fsmim.1998.0123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucheron, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellmeier, W.</span></span> <span> </span><span class="NLM_article-title">The Role of Tec Family Kinases in Myeloid Cells</span>. <i>Int. Arch. Allergy Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1159/000078339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1159%2F000078339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=15133303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktFKlsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2004&pages=65-78&author=U.+Schmidtauthor=N.+Boucheronauthor=B.+Ungerauthor=W.+Ellmeier&title=The+Role+of+Tec+Family+Kinases+in+Myeloid+Cells&doi=10.1159%2F000078339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Tec Family Kinases in Myeloid Cells</span></div><div class="casAuthors">Schmidt, Uwe; Boucheron, Nicole; Unger, Bernd; Ellmeier, Wilfried</div><div class="citationInfo"><span class="NLM_cas:title">International Archives of Allergy and Immunology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-78</span>CODEN:
                <span class="NLM_cas:coden">IAAIEG</span>;
        ISSN:<span class="NLM_cas:issn">1018-2438</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">A review.  Members of the Tec kinase family (Bmx, Btk, Itk, Rlk and Tec) are primarily expressed in the hematopoietic system and form, after the Src kinase family, the second largest class of non-receptor protein tyrosine kinases.  During lymphocyte development and activation Tec kinases have important functions in signaling pathways downstream of the antigen receptors.  Tec family kinases are also expressed in cells of the myeloid lineage.  However, with the exception of mast cells and platelets, their biol. role in the myeloid system is only poorly understood.  This review summarizes the current knowledge about the function of Tec family kinases in hematopoietic cells of the myeloid lineage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpewxKP7kBxe7Vg90H21EOLACvtfcHk0lgsbK_lqoCVWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktFKlsr8%253D&md5=e6e88b9b59049d9e55e95b6621a27453</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1159%2F000078339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000078339%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DU.%26aulast%3DBoucheron%26aufirst%3DN.%26aulast%3DUnger%26aufirst%3DB.%26aulast%3DEllmeier%26aufirst%3DW.%26atitle%3DThe%2520Role%2520of%2520Tec%2520Family%2520Kinases%2520in%2520Myeloid%2520Cells%26jtitle%3DInt.%2520Arch.%2520Allergy%2520Immunol.%26date%3D2004%26volume%3D134%26spage%3D65%26epage%3D78%26doi%3D10.1159%2F000078339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, T.</span></span> <span> </span><span class="NLM_article-title">Bruton’s Tyrosine Kinase Is Involved in Innate and Adaptive Immunity</span>. <i>Histol. Histopathol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">945</span>– <span class="NLM_lpage">955</span>, <span class="refDoi"> DOI: 10.14670/HH-20.945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.14670%2FHH-20.945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=15944945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsFKjtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2005&pages=945-955&author=C.+Brunnerauthor=B.+M%C3%BCllerauthor=T.+Wirth&title=Bruton%E2%80%99s+Tyrosine+Kinase+Is+Involved+in+Innate+and+Adaptive+Immunity&doi=10.14670%2FHH-20.945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's Tyrosine Kinase is involved in innate and adaptive immunity</span></div><div class="casAuthors">Brunner, C.; Mueller, B.; Wirth, T.</div><div class="citationInfo"><span class="NLM_cas:title">Histology and Histopathology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">945-955</span>CODEN:
                <span class="NLM_cas:coden">HIHIES</span>;
        ISSN:<span class="NLM_cas:issn">0213-3911</span>.
    
            (<span class="NLM_cas:orgname">Jimenez Godoy, S.A.</span>)
        </div><div class="casAbstract">A review.  Btk is a cytoplasmic tyrosine kinase, which is mainly involved in B cell receptor signaling.  Gene targeting expts. revealed that Btk is important for B cell development and function.  However, Btk is not only expressed in B cells, but also in most other hematopoietic lineages except for T cells and plasma cells.  Recently we found that Btk is involved in Toll-like receptor signaling.  Toll-like receptors play an important role in innate immunity.  They are highly expressed on mast cells, macrophages and dendritic cells, which are essential for the recognition and consequently for the elimination of microbial pathogens.  Therefore Btk might play an important role for the function of immunocompetent cells of innate as well as adaptive immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQA-9NFdeNr7Vg90H21EOLACvtfcHk0lgsbK_lqoCVWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsFKjtL4%253D&md5=97cbcc5df2704d4b58933085ab8ff929</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.14670%2FHH-20.945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14670%252FHH-20.945%26sid%3Dliteratum%253Aachs%26aulast%3DBrunner%26aufirst%3DC.%26aulast%3DM%25C3%25BCller%26aufirst%3DB.%26aulast%3DWirth%26aufirst%3DT.%26atitle%3DBruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Is%2520Involved%2520in%2520Innate%2520and%2520Adaptive%2520Immunity%26jtitle%3DHistol.%2520Histopathol.%26date%3D2005%26volume%3D20%26spage%3D945%26epage%3D955%26doi%3D10.14670%2FHH-20.945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nyhoff, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barron, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonami, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kendall, P. L.</span></span> <span> </span><span class="NLM_article-title">Bruton’s Tyrosine Kinase Is Not Essential for B Cell Survival beyond Early Developmental Stages</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>200</i></span>,  <span class="NLM_fpage">2352</span>– <span class="NLM_lpage">2361</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1701489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.4049%2Fjimmunol.1701489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=29483358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFSltbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=200&publication_year=2018&pages=2352-2361&author=L.+E.+Nyhoffauthor=E.+S.+Clarkauthor=B.+L.+Barronauthor=R.+H.+Bonamiauthor=W.+N.+Khanauthor=P.+L.+Kendall&title=Bruton%E2%80%99s+Tyrosine+Kinase+Is+Not+Essential+for+B+Cell+Survival+beyond+Early+Developmental+Stages&doi=10.4049%2Fjimmunol.1701489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's Tyrosine Kinase Is Not Essential for B Cell Survival beyond Early Developmental Stages</span></div><div class="casAuthors">Nyhoff, Lindsay E.; Clark, Emily S.; Barron, Bridgette L.; Bonami, Rachel H.; Khan, Wasif N.; Kendall, Peggy L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">200</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2352-2361</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a crucial regulator of B cell signaling and is a therapeutic target for lymphoma and autoimmune disease.  BTK-deficient patients suffer from humoral immunodeficiency, as their B cells fail to progress beyond the bone marrow.  However, the role of Btk in fully developed, mature peripheral B cells is not well understood.  Anal. using BTK inhibitors is complicated by suboptimal inhibition, off-target effects, or failure to eliminate BTK's adaptor function.  Therefore a Btkflox/Cre-ERT2 mouse model was developed and used to excise Btk after B cell populations were established.  Mice lacking Btk from birth are known to have reduced follicular (FO) compartments, with expanded transitional populations, suggesting a block in development.  In adult Btkflox/Cre-ERT2 mice, Btk excision did not reduce FO B cells, which persisted for weeks.  Autoimmune-prone B1 cells also survived conditional Btk excision, contrasting their near absence in global Btk-deficient mice.  Therefore, Btk supports BCR signaling during selection into the FO and B1 compartments, but is not needed to maintain these cell populations.  B1-related natural IgM levels remained normal, contrasting global Btk deficiency, but B cell proliferation and T-independent type II immunization responses were blunted.  Thus, B cells have nuanced signaling responses that are differentially regulated by Btk for development, survival, and function.  These findings raise the possibility that Btk may also be expendable for survival of mature human B cells, therefore requiring prolonged dosing to be effective, and that success of BTK inhibitors may depend in part on off-target effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP6akmBuHl2bVg90H21EOLACvtfcHk0lgsbK_lqoCVWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFSltbo%253D&md5=c1e633a39d298ce08a70906db3ad577c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1701489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1701489%26sid%3Dliteratum%253Aachs%26aulast%3DNyhoff%26aufirst%3DL.%2BE.%26aulast%3DClark%26aufirst%3DE.%2BS.%26aulast%3DBarron%26aufirst%3DB.%2BL.%26aulast%3DBonami%26aufirst%3DR.%2BH.%26aulast%3DKhan%26aufirst%3DW.%2BN.%26aulast%3DKendall%26aufirst%3DP.%2BL.%26atitle%3DBruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Is%2520Not%2520Essential%2520for%2520B%2520Cell%2520Survival%2520beyond%2520Early%2520Developmental%2520Stages%26jtitle%3DJ.%2520Immunol.%26date%3D2018%26volume%3D200%26spage%3D2352%26epage%3D2361%26doi%3D10.4049%2Fjimmunol.1701489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conley, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobbs, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farmer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paris, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigoriadou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coustan-Smith, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campana, D.</span></span> <span> </span><span class="NLM_article-title">Primary B Cell Immunodeficiencies: Comparisons and Contrasts</span>. <i>Annu. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1146/annurev.immunol.021908.132649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1146%2Fannurev.immunol.021908.132649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=19302039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFSlsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=199-227&author=M.+E.+Conleyauthor=A.+K.+Dobbsauthor=D.+M.+Farmerauthor=S.+Kilicauthor=K.+Parisauthor=S.+Grigoriadouauthor=E.+Coustan-Smithauthor=V.+Howardauthor=D.+Campana&title=Primary+B+Cell+Immunodeficiencies%3A+Comparisons+and+Contrasts&doi=10.1146%2Fannurev.immunol.021908.132649"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Primary B cell immunodeficiencies: comparisons and contrasts</span></div><div class="casAuthors">Conley, Mary Ellen; Dobbs, A. Kerry; Farmer, Dana M.; Kilic, Sebnem; Paris, Kenneth; Grigoriadou, Sofia; Coustan-Smith, Elaine; Howard, Vanessa; Campana, Dario</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">199-227</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Sophisticated genetic tools have made possible the identification of the genes responsible for most well-described immunodeficiencies in the past 15 years.  Mutations in Btk, components of the pre-B cell and B cell receptor (λ5, Igα, Igβ), or the scaffold protein BLNK account for approx. 90% of patients with defects in early B cell development.  Hyper-IgM syndromes result from mutations in CD40 ligand, CD40, AID, or UNG in 70-80% of affected patients.  Rare defects in ICOS or CD19 can result in a clin. picture that is consistent with common variable immunodeficiency, and as many as 10% of patients with this disorder have heterozygous amino acid substitutions in TACI.  For all these disorders, there is considerable clin. heterogeneity in patients with the same mutation.  Identifying the genetic and environmental factors that influence the clin. phenotype may enhance patient care and the understanding of normal B cell development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_hgfd2bSrJ7Vg90H21EOLACvtfcHk0ljXwfhAcg9jyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFSlsbY%253D&md5=83216a7a297af38c2efdf9d3e79a1213</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1146%2Fannurev.immunol.021908.132649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.immunol.021908.132649%26sid%3Dliteratum%253Aachs%26aulast%3DConley%26aufirst%3DM.%2BE.%26aulast%3DDobbs%26aufirst%3DA.%2BK.%26aulast%3DFarmer%26aufirst%3DD.%2BM.%26aulast%3DKilic%26aufirst%3DS.%26aulast%3DParis%26aufirst%3DK.%26aulast%3DGrigoriadou%26aufirst%3DS.%26aulast%3DCoustan-Smith%26aufirst%3DE.%26aulast%3DHoward%26aufirst%3DV.%26aulast%3DCampana%26aufirst%3DD.%26atitle%3DPrimary%2520B%2520Cell%2520Immunodeficiencies%253A%2520Comparisons%2520and%2520Contrasts%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D2009%26volume%3D27%26spage%3D199%26epage%3D227%26doi%3D10.1146%2Fannurev.immunol.021908.132649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideras, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alt, F. W.</span></span> <span> </span><span class="NLM_article-title">The Role of Bruton’s Tyrosine Kinase in B-Cell Development and Function in Mice and Man</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>764</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.1995.tb55802.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1111%2Fj.1749-6632.1995.tb55802.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=7486535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADyaK28XkvFelsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=764&publication_year=1995&pages=27-38&author=W.+N.+Khanauthor=P.+Siderasauthor=F.+S.+Rosenauthor=F.+W.+Alt&title=The+Role+of+Bruton%E2%80%99s+Tyrosine+Kinase+in+B-Cell+Development+and+Function+in+Mice+and+Man&doi=10.1111%2Fj.1749-6632.1995.tb55802.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The role of Bruton's tyrosine kinase in B-cell development and function in mice and man</span></div><div class="casAuthors">Khan, Wasif N.; Sideras, Paschalis; Rosen, Fred S.; Alt, Frederick W.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">764</span>
        (<span class="NLM_cas:issue">Immunoglobulin Gene Expression in Development and Disease</span>),
    <span class="NLM_cas:pages">27-38</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">New York Academy of Sciences</span>)
        </div><div class="casAbstract">A review and discussion with 36 refs.  Both Btk (Bruton's tyrosine kinase) PH mutant chimeras and Btk kinase domain mutant mice lack expression of the btk protein.  The maturation and function of B cells are defective in both types of mutant mice and this defect is similar to that described for xid.  However, there appears to be a less stringent requirement for btk for early murine B cell development as compared to humans.  Possible explanations are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9njk8U5lZErVg90H21EOLACvtfcHk0ljXwfhAcg9jyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XkvFelsg%253D%253D&md5=73fe40ec20bad09a441ffac9556e7759</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.1995.tb55802.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.1995.tb55802.x%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DW.%2BN.%26aulast%3DSideras%26aufirst%3DP.%26aulast%3DRosen%26aufirst%3DF.%2BS.%26aulast%3DAlt%26aufirst%3DF.%2BW.%26atitle%3DThe%2520Role%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520in%2520B-Cell%2520Development%2520and%2520Function%2520in%2520Mice%2520and%2520Man%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D1995%26volume%3D764%26spage%3D27%26epage%3D38%26doi%3D10.1111%2Fj.1749-6632.1995.tb55802.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Howard, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pahwa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkelstein, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conley, M. E.</span></span> <span> </span><span class="NLM_article-title">The Health Status and Quality of Life of Adults with X-Linked Agammaglobulinemia</span>. <i>Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1016/j.clim.2005.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1016%2Fj.clim.2005.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=16377251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhtlars7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2006&pages=201-208&author=V.+Howardauthor=J.+M.+Greeneauthor=S.+Pahwaauthor=J.+A.+Winkelsteinauthor=J.+M.+Boyleauthor=M.+Kocakauthor=M.+E.+Conley&title=The+Health+Status+and+Quality+of+Life+of+Adults+with+X-Linked+Agammaglobulinemia&doi=10.1016%2Fj.clim.2005.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The health status and quality of life of adults with X-linked agammaglobulinemia</span></div><div class="casAuthors">Howard, Vanessa; Greene, Jeffrey M.; Pahwa, Savita; Winkelstein, Jerry A.; Boyle, John M.; Kocak, Mehmet; Conley, Mary Ellen</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Immunology (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">201-208</span>CODEN:
                <span class="NLM_cas:coden">CLIIFY</span>;
        ISSN:<span class="NLM_cas:issn">1521-6616</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Forty-one adults (mean age 33) with a definitive diagnosis of X-linked agammaglobulinemia (XLA) completed a questionnaire concerning current and past medical problems and quality of life.  Thirty-six of the 41 were working full time or were full time students; 18 had not missed any work or school due to infection in the previous year.  Their quality of life was equiv. to that of the general US male population.  Thirteen of the 41 reported that they had chronic lung disease, and 33 indicated that they had one or more episodes of sinusitis in the preceding year.  Arthritis, diarrhea and skin infections were common but not debilitating.  The 41 study subjects were more likely to have a prior family history of XLA, and they were more likely to have milder mutations in Btk, the gene responsible for XLA.  These results indicate that most adults with XLA are moderately healthy and lead productive lives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSok5lz2chVLVg90H21EOLACvtfcHk0ljXwfhAcg9jyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhtlars7w%253D&md5=838bd23e504efab6a7c16d660d966faf</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.clim.2005.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clim.2005.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DHoward%26aufirst%3DV.%26aulast%3DGreene%26aufirst%3DJ.%2BM.%26aulast%3DPahwa%26aufirst%3DS.%26aulast%3DWinkelstein%26aufirst%3DJ.%2BA.%26aulast%3DBoyle%26aufirst%3DJ.%2BM.%26aulast%3DKocak%26aufirst%3DM.%26aulast%3DConley%26aufirst%3DM.%2BE.%26atitle%3DThe%2520Health%2520Status%2520and%2520Quality%2520of%2520Life%2520of%2520Adults%2520with%2520X-Linked%2520Agammaglobulinemia%26jtitle%3DClin.%2520Immunol.%26date%3D2006%26volume%3D118%26spage%3D201%26epage%3D208%26doi%3D10.1016%2Fj.clim.2005.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shillitoe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gennery, A.</span></span> <span> </span><span class="NLM_article-title">X-Linked Agammaglobulinaemia: Outcomes in the Modern Era</span>. <i>Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1016/j.clim.2017.07.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1016%2Fj.clim.2017.07.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=28729230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Giu7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2017&pages=54-62&author=B.+Shillitoeauthor=A.+Gennery&title=X-Linked+Agammaglobulinaemia%3A+Outcomes+in+the+Modern+Era&doi=10.1016%2Fj.clim.2017.07.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">X-Linked Agammaglobulinaemia: Outcomes in the modern era</span></div><div class="casAuthors">Shillitoe, Ben; Gennery, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Immunology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">54-62</span>CODEN:
                <span class="NLM_cas:coden">CLIIFY</span>;
        ISSN:<span class="NLM_cas:issn">1521-6616</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Colonel Ogden Bruton reported X-Linked Agammaglobulinemia in 1952 and treated the child with replacement Ig therapy.  Over 60 years later, the treatment for XLA has largely remained unchanged.  Replacement Ig lacks the isotypes IgA and IgM, leading to concerns that patients continue to experience recurrent sinopulmonary tract infections and be at increased risk of bronchiectasis.  There is potential hope of earlier diagnosis with newborn screening, and a potential cure for these patients, in the form of gene therapy.  However, it is first necessary to evaluate current management and outcomes to aid decisions regarding further research and clin. trials.  This article reviews current management and outcomes of XLA, while identifying gaps in our knowledge base that may need answering before we proceed with novel diagnostic methods and treatment for XLA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUnHekSivzvbVg90H21EOLACvtfcHk0ljXwfhAcg9jyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Giu7fP&md5=5b02e84329c8ed351b680aa196e23ca4</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.clim.2017.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clim.2017.07.008%26sid%3Dliteratum%253Aachs%26aulast%3DShillitoe%26aufirst%3DB.%26aulast%3DGennery%26aufirst%3DA.%26atitle%3DX-Linked%2520Agammaglobulinaemia%253A%2520Outcomes%2520in%2520the%2520Modern%2520Era%26jtitle%3DClin.%2520Immunol.%26date%3D2017%26volume%3D183%26spage%3D54%26epage%3D62%26doi%3D10.1016%2Fj.clim.2017.07.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jansson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmdahl, R.</span></span> <span> </span><span class="NLM_article-title">Genes on the X Chromosome Affect Development of Collagen-Induced Arthritis in Mice</span>. <i>Clin. Exp. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">465</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2249.1993.tb08218.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1111%2Fj.1365-2249.1993.tb08218.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=8252807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADyaK2cXhtVCksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1993&pages=459-465&author=L.+Janssonauthor=R.+Holmdahl&title=Genes+on+the+X+Chromosome+Affect+Development+of+Collagen-Induced+Arthritis+in+Mice&doi=10.1111%2Fj.1365-2249.1993.tb08218.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Genes on the X chromosome affect development of collagen-induced arthritis in mice</span></div><div class="casAuthors">Jansson, Liselotte; Holmdahl, R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Immunology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">459-65</span>CODEN:
                <span class="NLM_cas:coden">CEXIAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    </div><div class="casAbstract">Susceptibility to collagen-induced arthritis (CIA) in mice is assocd. with a class II gene in MHC (Aq) but also with unknown genes outside MHC.  Investigated here is the influence of genes on the X chromosome as well as the role of the X-linked immunodeficiency (xid) mutation.  Reciprocal male F1 hybrids, bred to be heterozygous or homozygous for Aq, showed a genetic influence in their susceptibility to develop CIA.  Crosses were made between B10.G, B10.Q, DBA/1, SWR/J, C3H.Q and CBA/Ca, and all F1 mice were castrated to avoid sex hormone modulation of the susceptibility.  A differential timing of arthritis onset and severity were seen in the reciprocal F1 males.  An exception was the reciprocal F1 male offspring from SWR/J and DBA/1 crosses which differed only in disease severity late in the course of the disease.  The female F1 crosses did not show the same pattern of differential susceptibility to CIA as the F1 males.  To exclude the possible influence of the Y chromosome, F1 males of reciprocal crosses were back-crossed to the parental strains creating offspring with equal X chromosomes but divergent Y chromosomes.  No difference in development of arthritis was obsd. in these.  The influence of the xid mutation was investigated next.  The xid loci from the CBA/N mouse was bred into DBA/1 strain which is highly susceptible to CIA.  The resulting congenic DBA/1-xid strain was resistant to induction of CIA and did not develop an antibody response to type II collagen.  The authors concluded that polymorphic genes on the X chromosome modulate susceptibility to CIA.  The results from the expts. with mice carrying xid mutations confirm that such immune modulating genes exist on the sex chromosomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXuu6ocKN6h7Vg90H21EOLACvtfcHk0liKvqs4BbcXng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhtVCksL0%253D&md5=77777b6215fb6c1e839b5a68d555df3c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2249.1993.tb08218.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2249.1993.tb08218.x%26sid%3Dliteratum%253Aachs%26aulast%3DJansson%26aufirst%3DL.%26aulast%3DHolmdahl%26aufirst%3DR.%26atitle%3DGenes%2520on%2520the%2520X%2520Chromosome%2520Affect%2520Development%2520of%2520Collagen-Induced%2520Arthritis%2520in%2520Mice%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D1993%26volume%3D94%26spage%3D459%26epage%3D465%26doi%3D10.1111%2Fj.1365-2249.1993.tb08218.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smathers, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederiksen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, A. D.</span></span> <span> </span><span class="NLM_article-title">Ability of the Xid Gene to Prevent Autoimmunity in (NZB X NZW)F1 Mice during the Course of Their Natural History, after Polyclonal Stimulation, or Following Immunization with DNA</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">597</span>, <span class="refDoi"> DOI: 10.1172/JCI110651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1172%2FJCI110651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=6980900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A280%3ADyaL383ms1ejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1982&pages=587-597&author=B.+J.+Steinbergauthor=P.+A.+Smathersauthor=K.+Frederiksenauthor=A.+D.+Steinberg&title=Ability+of+the+Xid+Gene+to+Prevent+Autoimmunity+in+%28NZB+X+NZW%29F1+Mice+during+the+Course+of+Their+Natural+History%2C+after+Polyclonal+Stimulation%2C+or+Following+Immunization+with+DNA&doi=10.1172%2FJCI110651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Ability of the xid gene to prevent autoimmunity in (NZB X NZW)F1 mice during the course of their natural history, after polyclonal stimulation, or following immunization with DNA</span></div><div class="casAuthors">Steinberg B J; Smathers P A; Frederiksen K; Steinberg A D</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">587-97</span>
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    </div><div class="casAbstract">F1 hybrid offspring of New Zealand Black mothers and New Zealand White fathers [(NZB X NZW)F1] female mice develop antibodies to single-stranded (ss) and native DNA, immune complex glomerulonephritis, massive proteinuria, and premature death with renal failure.  By a series of matings, congenic (NZB X NZW)F1 . xid/xid mice were prepared.  These mice were different from (NZB X NZW)F1 mice in having the X chromosome-linked immune deficiency gene, xid, in homozygous form.  Such congenic (NZB X NZW)F1 . xid/xid females failed to develop antibodies to single-stranded or native DNA.  They also failed to develop fatal renal disease as measured by proteinuria, glomerular histology, glomerular immunofluorescence, and survival.  To control for unknown genetic factors, studies were performed with littermates that were derived by mating NZB . xid/+ females with NZW . xid/Y males such that the resulting offspring were either (NZB X NZW)F1 . xid/xid (and therefore "defective") or (NZB X NZW)F1 . xid/+ [phenotypically like (NZB X NZW)F1].  In these and in additional studies, mice were housed in the same cages and identified by ear tagging so as to avoid possible environmental variations from cage to cage.  In these studies, xid/xid mice failed to develop the characteristic signs of autoimmunity, whereas the controls did.  Similar results were also obtained with (NZW X NZB)F1 xid/xid mice compared with (NZW X NZB)F1 xid/+ mice.  The effect of xid/xid upon (NZB X NZW)F1 mice was further investigated by assessing responses to immunization and polyclonal B cell activation in vivo.  The xid/xid mice failed to produce anti-ssDNA following immunization with ssDNA complexed to a protein carrier in fluid form or even emulsified in adjuvant.  Finally, the xid/xid mice failed to produce antiDNA in response to multiple injections of the polyclonal activator, bacterial lipopolysaccharide (LPS), or the polyclonal activator, polyribose inosinic acid . polyribose cytidylic acid.  However, the xid/xid mice were neither generally hyporesponsive nor unable to recognize LPS because they made normal antibody responses following immunization with LPS to which multiple trinitrophenyl groups were chemically attached.  We conclude from these studies that xid/xid, which is known to cause the deletion of a B cell subset, has a profound affect upon (NZB X NZW)F1 mice, rendering them insusceptible to the naturally occurring autoimmune disease characteristic of (NZB X NZW)F1 mice, and preventing them from producing antibodies to DNA despite purposeful immunization and polyclonal B cell activation.  These results force a reevaluation of previous concepts regarding the mechanisms by which xid/xid might interfere with the development of autoimmunity, and a consideration of therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThDLn7032pYRBrI9DTGjC0fW6udTcc2eZW5efv53Nu87ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL383ms1ejtg%253D%253D&md5=8608a4617f65a1c46ef46a6e5388f7a6</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1172%2FJCI110651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI110651%26sid%3Dliteratum%253Aachs%26aulast%3DSteinberg%26aufirst%3DB.%2BJ.%26aulast%3DSmathers%26aufirst%3DP.%2BA.%26aulast%3DFrederiksen%26aufirst%3DK.%26aulast%3DSteinberg%26aufirst%3DA.%2BD.%26atitle%3DAbility%2520of%2520the%2520Xid%2520Gene%2520to%2520Prevent%2520Autoimmunity%2520in%2520%2528NZB%2520X%2520NZW%2529F1%2520Mice%2520during%2520the%2520Course%2520of%2520Their%2520Natural%2520History%252C%2520after%2520Polyclonal%2520Stimulation%252C%2520or%2520Following%2520Immunization%2520with%2520DNA%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1982%26volume%3D70%26spage%3D587%26epage%3D597%26doi%3D10.1172%2FJCI110651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hata, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lantz, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda-Yamamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldfeld, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alt, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galli, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, T.</span></span> <span> </span><span class="NLM_article-title">Involvement of Bruton’s Tyrosine Kinase in FcεRI-Dependent Mast Cell Degranulation and Cytokine Production</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">1235</span>– <span class="NLM_lpage">1247</span>, <span class="refDoi"> DOI: 10.1084/jem.187.8.1235</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1084%2Fjem.187.8.1235" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=9547335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADyaK1cXis1Cru7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=1998&pages=1235-1247&author=D.+Hataauthor=Y.+Kawakamiauthor=N.+Inagakiauthor=C.+S.+Lantzauthor=T.+Kitamuraauthor=W.+N.+Khanauthor=M.+Maeda-Yamamotoauthor=T.+Miuraauthor=W.+Hanauthor=S.+E.+Hartmanauthor=L.+Yaoauthor=H.+Nagaiauthor=A.+E.+Goldfeldauthor=F.+W.+Altauthor=S.+J.+Galliauthor=O.+N.+Witteauthor=T.+Kawakami&title=Involvement+of+Bruton%E2%80%99s+Tyrosine+Kinase+in+Fc%CE%B5RI-Dependent+Mast+Cell+Degranulation+and+Cytokine+Production&doi=10.1084%2Fjem.187.8.1235"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of Bruton's tyrosine kinase in FcεRI-dependent mast cell degranulation and cytokine production</span></div><div class="casAuthors">Hata, Daisuke; Kawakami, Yuko; Inagaki, Naoki; Lantz, Chris S.; Kitamura, Toshio; Khan, Wasif N.; Maeda-Yamamoto, Mari; Miura, Toru; Han, Wei; Hartman, Stephen E.; Yao, Libo; Nagai, Hiroichi; Goldfeld, Anne E.; Alt, Frederick W.; Galli, Stephen J.; Witte, Owen N.; Kawakami, Toshiaki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1235-1247</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">The role of Bruton's tyrosine kinase (Btk) in FcεRI-dependent activation of mouse mast cells was investigated, using xid and btk null mutant mice.  Unlike B cell development, mast cell development is apparently normal in these btk mutant mice.  However, mast cells derived from these mice exhibited significant abnormalities in FcεRI-dependent function.  Xid mice primed with anti-dinitrophenyl monoclonal IgE antibody exhibited mildly diminished early-phase and severely blunted late-phase anaphylactic reactions in response to antigen challenge in vivo.  Consistent with this finding, cultured mast cells derived from the bone marrow cells of xid or btk null mice exhibited mild impairments in degranulation, and more profound defects in the prodn. of several cytokines, upon FcεRI crosslinking.  Moreover, the transcriptional activities of these cytokine genes were severely reduced in FcεRI-stimulated btk mutant mast cells.  The specificity of these effects of btk mutations was confirmed by the improvement in the ability of btk mutant mast cells to degranulate and to secrete cytokines after the retroviral transfer of wild-type btk cDNA, but not of vector or kinase-dead btk cDNA.  Retroviral transfer of Emt (= Itk/Tsk), Btk's closest relative, also partially improved the ability of btk mutant mast cells to secrete mediators.  These results demonstrate an important role for Btk in the full expression of FcεRI signal transduction in mast cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ3R8NlYi0F7Vg90H21EOLACvtfcHk0liKvqs4BbcXng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXis1Cru7k%253D&md5=ca0908f7ddf320595c53c8ac7804bb1f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1084%2Fjem.187.8.1235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.187.8.1235%26sid%3Dliteratum%253Aachs%26aulast%3DHata%26aufirst%3DD.%26aulast%3DKawakami%26aufirst%3DY.%26aulast%3DInagaki%26aufirst%3DN.%26aulast%3DLantz%26aufirst%3DC.%2BS.%26aulast%3DKitamura%26aufirst%3DT.%26aulast%3DKhan%26aufirst%3DW.%2BN.%26aulast%3DMaeda-Yamamoto%26aufirst%3DM.%26aulast%3DMiura%26aufirst%3DT.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DHartman%26aufirst%3DS.%2BE.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DNagai%26aufirst%3DH.%26aulast%3DGoldfeld%26aufirst%3DA.%2BE.%26aulast%3DAlt%26aufirst%3DF.%2BW.%26aulast%3DGalli%26aufirst%3DS.%2BJ.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26aulast%3DKawakami%26aufirst%3DT.%26atitle%3DInvolvement%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520in%2520Fc%25CE%25B5RI-Dependent%2520Mast%2520Cell%2520Degranulation%2520and%2520Cytokine%2520Production%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1998%26volume%3D187%26spage%3D1235%26epage%3D1247%26doi%3D10.1084%2Fjem.187.8.1235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirisawad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loury, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thamm, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span> <span> </span><span class="NLM_article-title">The Bruton Tyrosine Kinase Inhibitor PCI-32765 Blocks B-Cell Activation and Is Efficacious in Models of Autoimmune Disease and B-Cell Malignancy</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">13075</span>– <span class="NLM_lpage">13080</span>, <span class="refDoi"> DOI: 10.1073/pnas.1004594107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1073%2Fpnas.1004594107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=20615965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=13075-13080&author=L.+A.+Honigbergauthor=A.+M.+Smithauthor=M.+Sirisawadauthor=E.+Vernerauthor=D.+Louryauthor=B.+Changauthor=S.+Liauthor=Z.+Panauthor=D.+H.+Thammauthor=R.+A.+Millerauthor=J.+J.+Buggy&title=The+Bruton+Tyrosine+Kinase+Inhibitor+PCI-32765+Blocks+B-Cell+Activation+and+Is+Efficacious+in+Models+of+Autoimmune+Disease+and+B-Cell+Malignancy&doi=10.1073%2Fpnas.1004594107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span></div><div class="casAuthors">Honigberg, Lee A.; Smith, Ashley M.; Sirisawad, Mint; Verner, Erik; Loury, David; Chang, Betty; Li, Shyr; Pan, Zhengying; Thamm, Douglas H.; Miller, Richard A.; Buggy, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">13075-13080, S13075/1-S13075/3</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Activation of the B-cell antigen receptor (BCR) signaling pathway contributes to the initiation and maintenance of B-cell malignancies and autoimmune diseases.  The Bruton tyrosine kinase (Btk) is specifically required for BCR signaling as demonstrated by human and mouse mutations that disrupt Btk function and prevent B-cell maturation at steps that require a functional BCR pathway.  Herein we describe a selective and irreversible Btk inhibitor, PCI-32765, that is currently under clin. development in patients with B-cell non-Hodgkin lymphoma.  We have used this inhibitor to investigate the biol. effects of Btk inhibition on mature B-cell function and the progression of B cell-assocd. diseases in vivo.  PCI-32765 blocked BCR signaling in human peripheral B cells at concns. that did not affect T cell receptor signaling.  In mice with collagen-induced arthritis, orally administered PCI-32765 reduced the level of circulating autoantibodies and completely suppressed disease.  PCI-32765 also inhibited autoantibody prodn. and the development of kidney disease in the MRL-Fas(lpr) lupus model.  Occupancy of the Btk active site by PCI-32765 was monitored in vitro and in vivo using a fluorescent affinity probe for Btk.  Active site occupancy of Btk was tightly correlated with the blockade of BCR signaling and in vivo efficacy.  Finally, PCI-32765 induced objective clin. responses in dogs with spontaneous B-cell non-Hodgkin lymphoma.  These findings support Btk inhibition as a therapeutic approach for the treatment of human diseases assocd. with activation of the BCR pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT4OQHme7oHLVg90H21EOLACvtfcHk0li6REbFS-iw0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D&md5=196ce4a05bb9c622c49cb7e908682e63</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1004594107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1004594107%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DLoury%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DThamm%26aufirst%3DD.%2BH.%26aulast%3DMiller%26aufirst%3DR.%2BA.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Bruton%2520Tyrosine%2520Kinase%2520Inhibitor%2520PCI-32765%2520Blocks%2520B-Cell%2520Activation%2520and%2520Is%2520Efficacious%2520in%2520Models%2520of%2520Autoimmune%2520Disease%2520and%2520B-Cell%2520Malignancy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D13075%26epage%3D13080%26doi%3D10.1073%2Fpnas.1004594107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postelnek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, D.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pashine, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Mahony, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narula, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMartino, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fine, J. S.</span></span> <span> </span><span class="NLM_article-title">RN486, a Selective Bruton’s Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.187740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1124%2Fjpet.111.187740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=22228807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVagt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2012&pages=90-103&author=D.+Xuauthor=Y.+Kimauthor=J.+Postelnekauthor=M.+D.+Vuauthor=D.-Q.+Huauthor=C.+Liaoauthor=M.+Bradshawauthor=J.+Hsuauthor=J.+Zhangauthor=A.+Pashineauthor=D.+Srinivasanauthor=J.+Woodsauthor=A.+Levinauthor=A.+O%E2%80%99Mahonyauthor=T.+D.+Owensauthor=Y.+Louauthor=R.+J.+Hillauthor=S.+Narulaauthor=J.+DeMartinoauthor=J.+S.+Fine&title=RN486%2C+a+Selective+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitor%2C+Abrogates+Immune+Hypersensitivity+Responses+and+Arthritis+in+Rodents&doi=10.1124%2Fjpet.111.187740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents</span></div><div class="casAuthors">Xu, Daigen; Kim, Yong; Postelnek, Jennifer; Vu, Minh Diem; Hu, Dong-Qing; Liao, Cheng; Bradshaw, Mike; Hsu, Jonathan; Zhang, Jun; Pashine, Achal; Srinivasan, Dinesh; Woods, John; Levin, Anita; O'Mahony, Alison; Owens, Timothy D.; Lou, Yan; Hill, Ronald J.; Narula, Satwant; DeMartino, Julie; Fine, Jay S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">90-103</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Genetic mutation and pharmacol. inhibition of Bruton's tyrosine kinase (Btk) both have been shown to prevent the development of collagen-induced arthritis (CIA) in mice, providing a rationale for the development of Btk inhibitors for treating rheumatoid arthritis (RA).  In the present study, we characterized a novel Btk inhibitor, 6-cyclopropyl-8-fluoro-2-(2-hydroxymethyl-3-{1-methyl-5-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-2H-isoquinolin-1-one (RN486), in vitro and in rodent models of immune hypersensitivity and arthritis.  We demonstrated that RN486 not only potently and selectively inhibited the Btk enzyme, but also displayed functional activities in human cell-based assays in multiple cell types, blocking Fcε receptor crosslinking-induced degranulation in mast cells (IC50 = 2.9 nM), Fcγ receptor engagement-mediated tumor necrosis factor α prodn. in monocytes (IC50 = 7.0 nM), and B cell antigen receptor-induced expression of an activation marker, CD69, in B cells in whole blood (IC50 = 21.0 nM).  RN486 displayed similar functional activities in rodent models, effectively preventing type I and type III hypersensitivity responses.  More importantly, RN486 produced robust anti-inflammatory and bone-protective effects in mouse CIA and rat adjuvant-induced arthritis (AIA) models.  In the AIA model, RN486 inhibited both joint and systemic inflammation either alone or in combination with methotrexate, reducing both paw swelling and inflammatory markers in the blood.  Together, our findings not only demonstrate that Btk plays an essential and conserved role in regulating immunoreceptor-mediated immune responses in both humans and rodents, but also provide evidence and mechanistic insights to support the development of selective Btk inhibitors as small-mol. disease-modifying drugs for RA and potentially other autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXBTQENfl5RbVg90H21EOLACvtfcHk0li6REbFS-iw0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVagt7g%253D&md5=06be56a47afd2eb09e0871710c1d2b47</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.187740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.187740%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DPostelnek%26aufirst%3DJ.%26aulast%3DVu%26aufirst%3DM.%2BD.%26aulast%3DHu%26aufirst%3DD.-Q.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DBradshaw%26aufirst%3DM.%26aulast%3DHsu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPashine%26aufirst%3DA.%26aulast%3DSrinivasan%26aufirst%3DD.%26aulast%3DWoods%26aufirst%3DJ.%26aulast%3DLevin%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DNarula%26aufirst%3DS.%26aulast%3DDeMartino%26aufirst%3DJ.%26aulast%3DFine%26aufirst%3DJ.%2BS.%26atitle%3DRN486%252C%2520a%2520Selective%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitor%252C%2520Abrogates%2520Immune%2520Hypersensitivity%2520Responses%2520and%2520Arthritis%2520in%2520Rodents%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D341%26spage%3D90%26epage%3D103%26doi%3D10.1124%2Fjpet.111.187740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barck, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carano, R. A. D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForge, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrando, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staker, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Specific Btk Inhibition Suppresses B Cell- and Myeloid Cell-Mediated Arthritis</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1038/nchembio.481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1038%2Fnchembio.481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=21113169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=41-50&author=J.+A.+Di+Paoloauthor=T.+Huangauthor=M.+Balazsauthor=J.+Barbosaauthor=K.+H.+Barckauthor=B.+J.+Bravoauthor=R.+A.+D.+D.+Caranoauthor=J.+Darrowauthor=D.+R.+Daviesauthor=L.+E.+DeForgeauthor=L.+Diehlauthor=R.+Ferrandoauthor=S.+L.+Gallionauthor=A.+M.+Giannettiauthor=P.+Griblingauthor=V.+Hurezauthor=S.+G.+Hymowitzauthor=R.+Jonesauthor=J.+E.+Kropfauthor=W.+P.+Leeauthor=P.+M.+Maciejewskiauthor=S.+A.+Mitchellauthor=H.+Rongauthor=B.+L.+Stakerauthor=J.+A.+Whitneyauthor=S.+Yehauthor=W.+B.+Youngauthor=C.+Yuauthor=J.+Zhangauthor=K.+Reifauthor=K.+S.+Currie&title=Specific+Btk+Inhibition+Suppresses+B+Cell-+and+Myeloid+Cell-Mediated+Arthritis&doi=10.1038%2Fnchembio.481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span></div><div class="casAuthors">Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai H.; Bravo, Brandon J.; Carano, Richard A. D.; Darrow, James; Davies, Douglas R.; DeForge, Laura E.; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven L.; Giannetti, Anthony M.; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah G.; Jones, Randall; Kropf, Jeffrey E.; Lee, Wyne P.; Maciejewski, Patricia M.; Mitchell, Scott A.; Rong, Hong; Staker, Bart L.; Whitney, J. Andrew; Yeh, Sherry; Young, Wendy B.; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and mol. mechanisms by which Btk mediates inflammation are poorly understood.  Here we describe the discovery of CGI1746, a small-mol. Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.  CGI1746 has exquisite selectivity for Btk and inhibits both auto- and transphosphorylation steps necessary for enzyme activation.  Using CGI1746, we demonstrate that Btk regulates inflammatory arthritis by two distinct mechanisms.  CGI1746 blocks B cell receptor-dependent B cell proliferation and in prophylactic regimens reduces autoantibody levels in collagen-induced arthritis.  In macrophages, Btk inhibition abolishes FcγRIII-induced TNFα, IL-1β and IL-6 prodn.  Accordingly, in myeloid- and FcγR-dependent autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and ameliorates disease.  These results provide new understanding of the function of Btk in both B cell- or myeloid cell-driven disease processes and provide a compelling rationale for targeting Btk in rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoegiZYoitP57Vg90H21EOLACvtfcHk0lgCqnn-NVbCtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP&md5=99d925c71bc1b201191ebde0f1c0b50f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.481%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBarck%26aufirst%3DK.%2BH.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%2BD.%2BD.%26aulast%3DDarrow%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DFerrando%26aufirst%3DR.%26aulast%3DGallion%26aufirst%3DS.%2BL.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHurez%26aufirst%3DV.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DMaciejewski%26aufirst%3DP.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DSpecific%2520Btk%2520Inhibition%2520Suppresses%2520B%2520Cell-%2520and%2520Myeloid%2520Cell-Mediated%2520Arthritis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D41%26epage%3D50%26doi%3D10.1038%2Fnchembio.481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rankin, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreyeva, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, T. a</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmonds, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathialagan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoit, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyashiro, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaiah, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messing, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homer, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunussi-Joannopoulos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickerson-Nutter, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnute, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douhan, J.,  3rd</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">4540</span>– <span class="NLM_lpage">4550</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1301553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.4049%2Fjimmunol.1301553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=24068666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1eqs7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=4540-4550&author=A.+L.+Rankinauthor=N.+Sethauthor=S.+Keeganauthor=T.+Andreyevaauthor=T.+a+Cookauthor=J.+Edmondsauthor=N.+Mathialaganauthor=M.+J.+Bensonauthor=J.+Syedauthor=Y.+Zhanauthor=S.+E.+Benoitauthor=J.+S.+Miyashiroauthor=N.+Woodauthor=S.+Mohanauthor=E.+Peevaauthor=S.+K.+Ramaiahauthor=D.+Messingauthor=B.+L.+Homerauthor=K.+Dunussi-Joannopoulosauthor=C.+L.+Nickerson-Nutterauthor=M.+E.+Schnuteauthor=J.+Douhan&title=Selective+Inhibition+of+BTK+Prevents+Murine+Lupus+and+Antibody-Mediated+Glomerulonephritis&doi=10.4049%2Fjimmunol.1301553"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis</span></div><div class="casAuthors">Rankin, Andrew L.; Seth, Nilufer; Keegan, Sean; Andreyeva, Tatyana; Cook, Tim A.; Edmonds, Jason; Mathialagan, Nagappan; Benson, Micah J.; Syed, Jameel; Zhan, Yutian; Benoit, Stephen E.; Miyashiro, Joy S.; Wood, Nancy; Mohan, Shashi; Peeva, Elena; Ramaiah, Shashi K.; Messing, Dean; Homer, Bruce L.; Dunussi-Joannopoulos, Kyri; Nickerson-Nutter, Cheryl L.; Schnute, Mark E.; Douhan, John, III</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4540-4550</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Autoantibody prodn. and immune complex deposition within the kidney promote renal disease in patients with lupus nephritis.  Thus, therapeutics that inhibit these pathways may be efficacious in the treatment of systemic lupus erythematosus.  Bruton's tyrosine kinase (BTK) is a crit. signaling component of both BCR and FcR signaling.  We sought to assess the efficacy of inhibiting BTK in the development of lupus-like disease, and in this article describe (R)-5-amino-1-(1-cyanopiperidin-3-yl)-3-(4-[2,4-difluorophenoxy]phenyl)-1H-pyrazole-4-carboxamide (PF-06250112), a novel highly selective and potent BTK inhibitor.  We demonstrate in vitro that PF-06250112 inhibits both BCR-mediated signaling and proliferation, as well as FcR-mediated activation.  To assess the therapeutic impact of BTK inhibition, we treated aged NZBxWF1 mice with PF-06250112 and demonstrate that PF-06250112 significantly limits the spontaneous accumulation of splenic germinal center B cells and plasma cells.  Correspondingly, anti-dsDNA and autoantibody levels were reduced in a dose-dependent manner.  Moreover, administration of PF-06250112 prevented the development of proteinuria and improved glomerular pathol. scores in all treatment groups.  Strikingly, this therapeutic effect could occur with only a modest redn. obsd. in anti-dsDNA titers, implying a crit. role for BTK signaling in disease pathogenesis beyond inhibition of autoantibody prodn.  We subsequently demonstrate that PF-06250112 prevents proteinuria in an FcR-dependent, Ab-mediated model of glomerulonephritis.  Importantly, these results highlight that BTK inhibition potently limits the development of glomerulonephritis by impacting both cell- and effector mol.-mediated pathways.  These data provide support for evaluating the efficacy of BTK inhibition in systemic lupus erythematosus patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBldekay4INLVg90H21EOLACvtfcHk0lgCqnn-NVbCtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1eqs7zE&md5=7abfb074bf422aa3fb63aa0bc3d8cf58</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1301553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1301553%26sid%3Dliteratum%253Aachs%26aulast%3DRankin%26aufirst%3DA.%2BL.%26aulast%3DSeth%26aufirst%3DN.%26aulast%3DKeegan%26aufirst%3DS.%26aulast%3DAndreyeva%26aufirst%3DT.%26aulast%3DCook%26aufirst%3DT.%2Ba%26aulast%3DEdmonds%26aufirst%3DJ.%26aulast%3DMathialagan%26aufirst%3DN.%26aulast%3DBenson%26aufirst%3DM.%2BJ.%26aulast%3DSyed%26aufirst%3DJ.%26aulast%3DZhan%26aufirst%3DY.%26aulast%3DBenoit%26aufirst%3DS.%2BE.%26aulast%3DMiyashiro%26aufirst%3DJ.%2BS.%26aulast%3DWood%26aufirst%3DN.%26aulast%3DMohan%26aufirst%3DS.%26aulast%3DPeeva%26aufirst%3DE.%26aulast%3DRamaiah%26aufirst%3DS.%2BK.%26aulast%3DMessing%26aufirst%3DD.%26aulast%3DHomer%26aufirst%3DB.%2BL.%26aulast%3DDunussi-Joannopoulos%26aufirst%3DK.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%2BL.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DDouhan%26aufirst%3DJ.%26atitle%3DSelective%2520Inhibition%2520of%2520BTK%2520Prevents%2520Murine%2520Lupus%2520and%2520Antibody-Mediated%2520Glomerulonephritis%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D4540%26epage%3D4550%26doi%3D10.4049%2Fjimmunol.1301553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin
Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elzinga, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westhouse, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catlett, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pokross, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allentoff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3228</span>– <span class="NLM_lpage">3250</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00167</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00167" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC1MXls1aks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3228-3250&author=S.+H.+Wattersonauthor=Q.+Liuauthor=M.+Beaudoin%0ABertrandauthor=D.+G.+Battauthor=L.+Liauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=L.+Chengauthor=M.+T.+Obermeierauthor=R.+Mooreauthor=Z.+Yangauthor=R.+Vickeryauthor=P.+A.+Elzingaauthor=L.+Discenzaauthor=C.+D%E2%80%99Arienzoauthor=K.+M.+Gilloolyauthor=T.+L.+Taylorauthor=C.+Pulicicchioauthor=Y.+Zhangauthor=E.+Heimrichauthor=K.+W.+McIntyreauthor=Q.+Ruanauthor=R.+A.+Westhouseauthor=I.+M.+Catlettauthor=N.+Zhengauthor=C.+Chaudhryauthor=J.+Daiauthor=M.+A.+Galellaauthor=A.+J.+Tebbenauthor=M.+Pokrossauthor=J.+Liauthor=R.+Zhaoauthor=D.+Smithauthor=R.+Rampullaauthor=A.+Allentoffauthor=M.+A.+Wallaceauthor=A.+Mathurauthor=L.+Salter-Cidauthor=J.+E.+Macorauthor=P.+H.+Carterauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+A.+Tino&title=Discovery+of+Branebrutinib+%28BMS-986195%29%3A+A+Strategy+for+Identifying+a+Highly+Potent+and+Selective+Covalent+Inhibitor+Providing+Rapid+in+Vivo+Inactivation+of+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29&doi=10.1021%2Facs.jmedchem.9b00167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK)</span></div><div class="casAuthors">Watterson, Scott H.; Liu, Qingjie; Beaudoin Bertrand, Myra; Batt, Douglas G.; Li, Ling; Pattoli, Mark A.; Skala, Stacey; Cheng, Lihong; Obermeier, Mary T.; Moore, Robin; Yang, Zheng; Vickery, Rodney; Elzinga, Paul A.; Discenza, Lorell; D'Arienzo, Celia; Gillooly, Kathleen M.; Taylor, Tracy L.; Pulicicchio, Claudine; Zhang, Yifan; Heimrich, Elizabeth; McIntyre, Kim W.; Ruan, Qian; Westhouse, Richard A.; Catlett, Ian M.; Zheng, Naiyu; Chaudhry, Charu; Dai, Jun; Galella, Michael A.; Tebben, Andrew J.; Pokross, Matt; Li, Jianqing; Zhao, Rulin; Smith, Daniel; Rampulla, Richard; Allentoff, Alban; Wallace, Michael A.; Mathur, Arvind; Salter-Cid, Luisa; Macor, John E.; Carter, Percy H.; Fura, Aberra; Burke, James R.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3228-3250</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a non-receptor tyrosine kinase, is a member of the Tec family of kinases and is essential for B cell receptor (BCR) mediated signaling.  BTK also plays a crit. role in the downstream signaling pathways for the Fcγ receptor in monocytes, the Fcε receptor in granulocytes, and the RANK receptor in osteoclasts.  As a result, pharmacol. inhibition of BTK is anticipated to provide an effective strategy for the clin. treatment of autoimmune diseases such as rheumatoid arthritis and lupus.  This article will outline the evolution of our strategy to identify a covalent, irreversible inhibitor of BTK that has the intrinsic potency, selectivity, and pharmacokinetic properties necessary to provide a rapid rate of inactivation systemically following a very low dose.  With excellent in vivo efficacy and a very desirable tolerability profile, 5a (branebrutinib, BMS-986195) has advanced into clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGr5oQEoebirVg90H21EOLACvtfcHk0lj59ObwoK5G3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXls1aks7w%253D&md5=2d521ec7c06d503f940cb44d381af58d</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00167%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBeaudoin%2BBertrand%26aufirst%3DM.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DMoore%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DElzinga%26aufirst%3DP.%2BA.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DRuan%26aufirst%3DQ.%26aulast%3DWesthouse%26aufirst%3DR.%2BA.%26aulast%3DCatlett%26aufirst%3DI.%2BM.%26aulast%3DZheng%26aufirst%3DN.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DPokross%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DAllentoff%26aufirst%3DA.%26aulast%3DWallace%26aufirst%3DM.%2BA.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%2520Branebrutinib%2520%2528BMS-986195%2529%253A%2520A%2520Strategy%2520for%2520Identifying%2520a%2520Highly%2520Potent%2520and%2520Selective%2520Covalent%2520Inhibitor%2520Providing%2520Rapid%2520in%2520Vivo%2520Inactivation%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3228%26epage%3D3250%26doi%3D10.1021%2Facs.jmedchem.9b00167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lucca, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langevine, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin
Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traeger, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-Fluoro-1-Methyl-2,4-Dioxo-1,2-Dihydroquinazolin-3(4H)-Yl)-2-Methylphenyl)-2-(S)-(2-Hydroxypropan-2-Yl)-2,3,4,9-Tetrahydro-1H-Carbazole-8-Carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine (BTK) Conformationally Constrained by Two Locked Atropisomers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9173</span>– <span class="NLM_lpage">9200</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01088</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01088" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKjsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9173-9200&author=S.+H.+Wattersonauthor=G.+V.+De+Luccaauthor=Q.+Shiauthor=C.+M.+Langevineauthor=Q.+Liuauthor=D.+G.+Battauthor=M.+Beaudoin%0ABertrandauthor=H.+Gongauthor=J.+Daiauthor=S.+Yipauthor=P.+Liauthor=D.+Sunauthor=D.-R.+Wuauthor=C.+Wangauthor=Y.+Zhangauthor=S.+C.+Traegerauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=L.+Chengauthor=M.+T.+Obermeierauthor=R.+Vickeryauthor=L.+N.+Discenzaauthor=C.+J.+D%E2%80%99Arienzoauthor=Y.+Zhangauthor=E.+Heimrichauthor=K.+M.+Gilloolyauthor=T.+L.+Taylorauthor=C.+Pulicicchioauthor=K.+W.+McIntyreauthor=M.+A.+Galellaauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=C.+Changauthor=R.+Rampullaauthor=A.+Mathurauthor=L.+Salter-Cidauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+A.+Tino&title=Discovery+of+6-Fluoro-5-%28R%29-%283-%28S%29-%288-Fluoro-1-Methyl-2%2C4-Dioxo-1%2C2-Dihydroquinazolin-3%284H%29-Yl%29-2-Methylphenyl%29-2-%28S%29-%282-Hydroxypropan-2-Yl%29-2%2C3%2C4%2C9-Tetrahydro-1H-Carbazole-8-Carboxamide+%28BMS-986142%29%3A+A+Reversible+Inhibitor+of+Bruton%E2%80%99s+Tyrosine+%28BTK%29+Conformationally+Constrained+by+Two+Locked+Atropisomers&doi=10.1021%2Facs.jmedchem.6b01088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers</span></div><div class="casAuthors">Watterson, Scott H.; De Lucca, George V.; Shi, Qing; Langevine, Charles M.; Liu, Qingjie; Batt, Douglas G.; Beaudoin Bertrand, Myra; Gong, Hua; Dai, Jun; Yip, Shiuhang; Li, Peng; Sun, Dawn; Wu, Dauh-Rurng; Wang, Chunlei; Zhang, Yingru; Traeger, Sarah C.; Pattoli, Mark A.; Skala, Stacey; Cheng, Lihong; Obermeier, Mary T.; Vickery, Rodney; Discenza, Lorell N.; D'Arienzo, Celia J.; Zhang, Yifan; Heimrich, Elizabeth; Gillooly, Kathleen M.; Taylor, Tracy L.; Pulicicchio, Claudine; McIntyre, Kim W.; Galella, Michael A.; Tebben, Andy J.; Muckelbauer, Jodi K.; Chang, ChiehYing; Rampulla, Richard; Mathur, Arvind; Salter-Cid, Luisa; Barrish, Joel C.; Carter, Percy H.; Fura, Aberra; Burke, James R.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9173-9200</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a member of the Tec family of kinases.  BTK plays an essential role in B cell receptor (BCR)-mediated signaling as well as Fcγ receptor signaling in monocytes and Fcε receptor signaling in mast cells and basophils, all of which have been implicated in the pathophysiol. of autoimmune disease.  As a result, inhibition of BTK is anticipated to provide an effective strategy for the clin. treatment of autoimmune diseases such as lupus and rheumatoid arthritis.  This article details the structure-activity relationships (SAR) leading to a novel series of highly potent and selective carbazole and tetrahydrocarbazole based, reversible inhibitors of BTK.  Of particular interest is that two atropisomeric centers were rotationally locked to provide a single, stable atropisomer, resulting in enhanced potency and selectivity as well as a redn. in safety liabilities.  With significantly enhanced potency and selectivity, excellent in vivo properties and efficacy, and a very desirable tolerability and safety profile, 14f (BMS-986142) was advanced into clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmpBAygRAsYrVg90H21EOLACvtfcHk0lj59ObwoK5G3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKjsrfF&md5=91098abc802521b9ad91563d20ac5893</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01088%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DLangevine%26aufirst%3DC.%2BM.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DBeaudoin%2BBertrand%26aufirst%3DM.%26aulast%3DGong%26aufirst%3DH.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DYip%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DD.-R.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTraeger%26aufirst%3DS.%2BC.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DDiscenza%26aufirst%3DL.%2BN.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25206-Fluoro-5-%2528R%2529-%25283-%2528S%2529-%25288-Fluoro-1-Methyl-2%252C4-Dioxo-1%252C2-Dihydroquinazolin-3%25284H%2529-Yl%2529-2-Methylphenyl%2529-2-%2528S%2529-%25282-Hydroxypropan-2-Yl%2529-2%252C3%252C4%252C9-Tetrahydro-1H-Carbazole-8-Carboxamide%2520%2528BMS-986142%2529%253A%2520A%2520Reversible%2520Inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520%2528BTK%2529%2520Conformationally%2520Constrained%2520by%2520Two%2520Locked%2520Atropisomers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9173%26epage%3D9200%26doi%3D10.1021%2Facs.jmedchem.6b01088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukral, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudhgaonkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span> <span> </span><span class="NLM_article-title">Bruton’s Tyrosine Kinase Inhibitor BMS-986142 in Experimental Models of Rheumatoid Arthritis Enhances Efficacy of Agents Representing Clinical Standard-of-Care</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e0181782</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0181782</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1371%2Fjournal.pone.0181782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=28742141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVSntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&author=K.+M.+Gilloolyauthor=C.+Pulicicchioauthor=M.+A.+Pattoliauthor=L.+Chengauthor=S.+Skalaauthor=E.+M.+Heimrichauthor=K.+W.+McIntyreauthor=T.+L.+Taylorauthor=D.+W.+Kukralauthor=S.+Dudhgaonkarauthor=J.+Nagarauthor=D.+Banasauthor=S.+H.+Wattersonauthor=J.+A.+Tinoauthor=A.+Furaauthor=J.+R.+Burke&title=Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitor+BMS-986142+in+Experimental+Models+of+Rheumatoid+Arthritis+Enhances+Efficacy+of+Agents+Representing+Clinical+Standard-of-Care&doi=10.1371%2Fjournal.pone.0181782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care</span></div><div class="casAuthors">Gillooly, Kathleen M.; Pulicicchio, Claudine; Pattoli, Mark A.; Cheng, Lihong; Skala, Stacey; Heimrich, Elizabeth M.; McIntyre, Kim W.; Taylor, Tracy L.; Kukral, Daniel W.; Dudhgaonkar, Shailesh; Nagar, Jignesh; Banas, Dana; Watterson, Scott H.; Tino, Joseph A.; Fura, Aberra; Burke, James R.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e0181782/1-e0181782/20</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) regulates crit. signal transduction pathways involved in the pathobiol. of rheumatoid arthritis (RA) and other autoimmune disorders.  BMS-986142 is a potent and highly selective reversible small mol. inhibitor of BTK currently being investigated in clin. trials for the treatment of both RA and primary Sj.ovrddot.ogren's syndrome.  In the present report, we detail the in vitro and in vivo pharmacol. of BMS-986142 and show this agent provides potent and selective inhibition of BTK (IC50 = 0.5 nM), blocks antigen receptor-dependent signaling and functional endpoints (cytokine prodn., co-stimulatory mol. expression, and proliferation) in human B cells (IC50 ≤ 5 nM), inhibits Fcγ receptor-dependent cytokine prodn. from peripheral blood mononuclear cells, and blocks RANK-L-induced osteoclastogenesis.  Through the benefits of impacting these important drivers of autoimmunity, BMS-986142 demonstrated robust efficacy in murine models of rheumatoid arthritis (RA), including collagen-induced arthritis (CIA) and collagen antibody-induced arthritis (CAIA).  In both models, robust efficacy was obsd. without continuous, complete inhibition of BTK.  When a suboptimal dose of BMS-986142 was combined with other agents representing the current std. of care for RA (e.g., methotrexate, the TNFα antagonist etanercept, or the murine form of CTLA4-Ig) in the CIA model, improved efficacy compared to either agent alone was obsd.  The results suggest BMS-986142 represents a potential therapeutic for clin. investigation in RA, as monotherapy or co-administered with agents with complementary mechanisms of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg22LhZ5lc9rVg90H21EOLACvtfcHk0liZnUNbWxy97A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVSntbs%253D&md5=144039a2425c898869da3d9c263d7321</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0181782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0181782%26sid%3Dliteratum%253Aachs%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DHeimrich%26aufirst%3DE.%2BM.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DKukral%26aufirst%3DD.%2BW.%26aulast%3DDudhgaonkar%26aufirst%3DS.%26aulast%3DNagar%26aufirst%3DJ.%26aulast%3DBanas%26aufirst%3DD.%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26atitle%3DBruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitor%2520BMS-986142%2520in%2520Experimental%2520Models%2520of%2520Rheumatoid%2520Arthritis%2520Enhances%2520Efficacy%2520of%2520Agents%2520Representing%2520Clinical%2520Standard-of-Care%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26doi%3D10.1371%2Fjournal.pone.0181782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmont, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coraggio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2227</span>– <span class="NLM_lpage">2245</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01712</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01712" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCnt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2227-2245&author=J.+J.+Crawfordauthor=A.+R.+Johnsonauthor=D.+L.+Misnerauthor=L.+D.+Belmontauthor=G.+Castanedoauthor=R.+Choyauthor=M.+Coraggioauthor=L.+Dongauthor=C.+Eigenbrotauthor=R.+Ericksonauthor=N.+Ghilardiauthor=J.+Hauauthor=A.+Katewaauthor=P.+B.+Kohliauthor=W.+Leeauthor=J.+W.+Lubachauthor=B.+S.+McKenzieauthor=D.+F.+Ortwineauthor=L.+Schuttauthor=S.+Tayauthor=B.+Weiauthor=K.+Reifauthor=L.+Liuauthor=H.+Wongauthor=W.+B.+Young&title=Discovery+of+GDC-0853%3A+A+Potent%2C+Selective%2C+and+Noncovalent+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitor+in+Early+Clinical+Development&doi=10.1021%2Facs.jmedchem.7b01712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development</span></div><div class="casAuthors">Crawford, James J.; Johnson, Adam R.; Misner, Dinah L.; Belmont, Lisa D.; Castanedo, Georgette; Choy, Regina; Coraggio, Melis; Dong, Liming; Eigenbrot, Charles; Erickson, Rebecca; Ghilardi, Nico; Hau, Jonathan; Katewa, Arna; Kohli, Pawan Bir; Lee, Wendy; Lubach, Joseph W.; McKenzie, Brent S.; Ortwine, Daniel F.; Schutt, Leah; Tay, Suzanne; Wei, BinQing; Reif, Karin; Liu, Lichuan; Wong, Harvey; Young, Wendy B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2227-2245</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a nonreceptor cytoplasmic tyrosine kinase involved in B-cell and myeloid cell activation, downstream of B-cell and Fcγ receptors, resp.  Preclin. studies have indicated that inhibition of Btk activity might offer a potential therapy in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.  Here we disclose the discovery and preclin. characterization of a potent, selective, and noncovalent Btk inhibitor currently in clin. development.  GDC-0853 (29) suppresses B cell- and myeloid cell-mediated components of disease and demonstrates dose-dependent activity in an in vivo rat model of inflammatory arthritis.  It demonstrates highly favorable safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles in preclin. and Phase 2 studies ongoing in patients with rheumatoid arthritis, lupus, and chronic spontaneous urticaria.  On the basis of its potency, selectivity, long target residence time, and noncovalent mode of inhibition, 29 has the potential to be a best-in-class Btk inhibitor for a wide range of immunol. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOUJgTOFJ-o7Vg90H21EOLACvtfcHk0liZnUNbWxy97A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCnt7c%253D&md5=eddbd31f387fe86827a7469e8be45430</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01712%26sid%3Dliteratum%253Aachs%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26aulast%3DBelmont%26aufirst%3DL.%2BD.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChoy%26aufirst%3DR.%26aulast%3DCoraggio%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DL.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DErickson%26aufirst%3DR.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DHau%26aufirst%3DJ.%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DSchutt%26aufirst%3DL.%26aulast%3DTay%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26atitle%3DDiscovery%2520of%2520GDC-0853%253A%2520A%2520Potent%252C%2520Selective%252C%2520and%2520Noncovalent%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitor%2520in%2520Early%2520Clinical%2520Development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2227%26epage%3D2245%26doi%3D10.1021%2Facs.jmedchem.7b01712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haselmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camps, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu-Bujalski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Mahony, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerli, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruns, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenningloh, R.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>202</i></span>,  <span class="NLM_fpage">2888</span>– <span class="NLM_lpage">2906</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1800583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.4049%2Fjimmunol.1800583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=30988116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvF2ntLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=202&publication_year=2019&pages=2888-2906&author=P.+Haselmayerauthor=M.+Campsauthor=L.+Liu-Bujalskiauthor=N.+Nguyenauthor=F.+Morandiauthor=J.+Headauthor=A.+O%E2%80%99Mahonyauthor=S.+C.+Zimmerliauthor=L.+Brunsauthor=A.+T.+Benderauthor=P.+Schroederauthor=R.+Grenningloh&title=Efficacy+and+Pharmacodynamic+Modeling+of+the+BTK+Inhibitor+Evobrutinib+in+Autoimmune+Disease+Models&doi=10.4049%2Fjimmunol.1800583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and pharmacodynamic modeling of the BTK inhibitor evobrutinib in autoimmune disease models</span></div><div class="casAuthors">Haselmayer, Philipp; Camps, Montserrat; Liu-Bujalski, Lesley; Nguyen, Ngan; Morandi, Federica; Head, Jared; O'Mahony, Alison; Zimmerli, Simone C.; Bruns, Lisa; Bender, Andrew T.; Schroeder, Patricia; Grenningloh, Roland</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">202</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2888-2906</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Because of its role in mediating both B cell and Fc receptor signaling, Bruton's tyrosine kinase (BTK) is a promising target for the treatment of autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).  Evobrutinib is a novel, highly selective, irreversible BTK inhibitor that potently inhibits BCR- and Fc receptor-mediated signaling and, thus, subsequent activation and function of human B cells and innate immune cells such as monocytes and basophils.  We evaluated evobrutinib in preclin. models of RA and SLE and characterized the relationship between BTK occupancy and inhibition of disease activity.  In mouse models of RA and SLE, orally administered evobrutinib displayed robust efficacy, as demonstrated by redn. of disease severity and histol. damage.  In the SLE model, evobrutinib inhibited B cell activation, reduced autoantibody prodn. and plasma cell nos., and normalized B and T cell subsets.  In the RA model, efficacy was achieved despite failure to reduce autoantibodies.  Pharmacokinetic/pharmacodynamic modeling showed that mean BTK occupancy in blood cells of 80% was linked to near-complete disease inhibition in both RA and SLE mouse models.  In addn., evobrutinib inhibited mast cell activation in a passive cutaneous anaphylaxis model.  Thus, evobrutinib achieves efficacy by acting both on B cells and innate immune cells.  Taken together, our data show that evobrutinib is a promising mol. for the chronic treatment of B cell-driven autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLVxS4palhvbVg90H21EOLACvtfcHk0ljeJMBUSdniJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvF2ntLg%253D&md5=9a339003f40e52527127ac12a2593ae9</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1800583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1800583%26sid%3Dliteratum%253Aachs%26aulast%3DHaselmayer%26aufirst%3DP.%26aulast%3DCamps%26aufirst%3DM.%26aulast%3DLiu-Bujalski%26aufirst%3DL.%26aulast%3DNguyen%26aufirst%3DN.%26aulast%3DMorandi%26aufirst%3DF.%26aulast%3DHead%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DZimmerli%26aufirst%3DS.%2BC.%26aulast%3DBruns%26aufirst%3DL.%26aulast%3DBender%26aufirst%3DA.%2BT.%26aulast%3DSchroeder%26aufirst%3DP.%26aulast%3DGrenningloh%26aufirst%3DR.%26atitle%3DEfficacy%2520and%2520Pharmacodynamic%2520Modeling%2520of%2520the%2520BTK%2520Inhibitor%2520Evobrutinib%2520in%2520Autoimmune%2520Disease%2520Models%26jtitle%3DJ.%2520Immunol.%26date%3D2019%26volume%3D202%26spage%3D2888%26epage%3D2906%26doi%3D10.4049%2Fjimmunol.1800583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kluge, A. F.</span></span> <span> </span><span class="NLM_article-title">Targeted Covalent Drugs of the Kinase Family</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">480</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2010.06.168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1016%2Fj.cbpa.2010.06.168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=20609616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=475-480&author=J.+Singhauthor=R.+C.+Petterauthor=A.+F.+Kluge&title=Targeted+Covalent+Drugs+of+the+Kinase+Family&doi=10.1016%2Fj.cbpa.2010.06.168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted covalent drugs of the kinase family</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Kluge, Arthur F.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">475-480</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In the past decade tremendous progress has been made toward a new class of therapeutics termed 'targeted covalent drugs', in which structure-based approaches are employed to create small mols. that inactivate their protein target through targeted covalent attachment to a specific cysteine.  In the kinase field, this approach is demonstrating promise in overcoming the potency, selectivity, and efficacy challenges currently faced by reversible kinase inhibitors, with several advancing into late stage clin. testing.  This design paradigm has been successfully applied to making drug candidates for epidermal growth factor receptor (EGFR), Her2, and Bruton's tyrosine kinase (Btk).  Here we review recent pre-clin. and clin. advances with targeted covalent kinase inhibitors, and the potential for broader application of the approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPQb40Eok-vbVg90H21EOLACvtfcHk0ljeJMBUSdniJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtr8%253D&md5=ee3b8b9e0c6ec317f975a426cf08428f</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2010.06.168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2010.06.168%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DKluge%26aufirst%3DA.%2BF.%26atitle%3DTargeted%2520Covalent%2520Drugs%2520of%2520the%2520Kinase%2520Family%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D14%26spage%3D475%26epage%3D480%26doi%3D10.1016%2Fj.cbpa.2010.06.168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span> <span> </span><span class="NLM_article-title">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6243</span>– <span class="NLM_lpage">6262</span>, <span class="refDoi"> DOI: 10.1021/jm3003203</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6243-6262&author=T.+Barfauthor=A.+Kaptein&title=Irreversible+Protein+Kinase+Inhibitors%3A+Balancing+the+Benefits+and+Risks&doi=10.1021%2Fjm3003203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span></div><div class="casAuthors">Barf, Tjeerd; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6243-6262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Not applicable for a Perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PLlisO0OVbVg90H21EOLACvtfcHk0ljeJMBUSdniJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D&md5=5d87850857d37faab02e6037ef8140a4</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm3003203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003203%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DIrreversible%2520Protein%2520Kinase%2520Inhibitors%253A%2520Balancing%2520the%2520Benefits%2520and%2520Risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6243%26epage%3D6262%26doi%3D10.1021%2Fjm3003203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitty, A.</span></span> <span> </span><span class="NLM_article-title">The Resurgence of Covalent Drugs</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1038/nrd3410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+Resurgence+of+Covalent+Drugs&doi=10.1038%2Fnrd3410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0liLmuana4mumQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520Resurgence%2520of%2520Covalent%2520Drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D307%26epage%3D317%26doi%3D10.1038%2Fnrd3410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D. K.</span></span> <span> </span><span class="NLM_article-title">Drug Discovery for a New Generation of Covalent Drugs</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.1517/17460441.2012.688744</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1517%2F17460441.2012.688744" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=22607458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC38XptFWmt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=561-581&author=A.+S.+Kalgutkarauthor=D.+K.+Dalvie&title=Drug+Discovery+for+a+New+Generation+of+Covalent+Drugs&doi=10.1517%2F17460441.2012.688744"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Drug discovery for a new generation of covalent drugs</span></div><div class="casAuthors">Kalgutkar, Amit S.; Dalvie, Deepak K.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">561-581</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The design of target-specific covalent inhibitors is conceptually attractive because of increased biochem. efficiency through covalency and increased duration of action that outlasts the pharmacokinetics of the agent.  Although many covalent inhibitors have been approved or are in advanced clin. trials to treat indications such as cancer and hepatitis C, there is a general tendency to avoid them as drug candidates because of concerns regarding immune-mediated toxicity that can arise from indiscriminate reactivity with off-target proteins.Areas covered: The review examines potential reason(s) for the excellent safety record of marketed covalent agents and advanced clin. candidates for emerging therapeutic targets.  A significant emphasis is placed on proteomic techniques and chem./biochem. reactivity assays that aim to provide a systematic rank ordering of pharmacol. selectivity relative to off-target protein reactivity of covalent inhibitors.Expert opinion: While tactics to examine selective covalent modification of the pharmacol. target are broadly applicable in drug discovery, it is unclear whether the output from such studies can prospectively predict idiosyncratic immune-mediated drug toxicity.  Opinions regarding an acceptable threshold of protein reactivity/body burden for a toxic electrophile and a non-toxic electrophilic covalent drug have not been defined.  Increasing confidence in proteomic and chem./biochem. reactivity screens will require a retrospective side-by-side profiling of marketed covalent drugs and electrophiles known to cause deleterious toxic effects via non-selective covalent binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowmXy20mDTPbVg90H21EOLACvtfcHk0liLmuana4mumQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptFWmt7k%253D&md5=b7fc8e60b263dda5765dd8380f52df17</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1517%2F17460441.2012.688744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2012.688744%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26atitle%3DDrug%2520Discovery%2520for%2520a%2520New%2520Generation%2520of%2520Covalent%2520Drugs%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2012%26volume%3D7%26spage%3D561%26epage%3D581%26doi%3D10.1517%2F17460441.2012.688744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norman, P.</span></span> <span> </span><span class="NLM_article-title">Investigational Bruton’s Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">891</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.1080/13543784.2016.1182499</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1080%2F13543784.2016.1182499" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=27148767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC28Xnslentb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=891-899&author=P.+Norman&title=Investigational+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitors+for+the+Treatment+of+Rheumatoid+Arthritis&doi=10.1080%2F13543784.2016.1182499"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Norman, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">891-899</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The Tec family of non-receptor tyrosine kinases comprises five members.  The cellular expression and function of these kinases has implicated them as potential drug targets for the treatment of both malignant and autoimmune diseases.  Most attention has focused on inhibitors of BTK kinase with ibrutinib already approved for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia.  Multiple BTK inhibitors are being developed for both oncol. and autoimmune disease indications.  BTK inhibitors being evaluated in rheumatoid arthritis are considered.  Both inhibitors which have progressed to early clin. development, and those demonstrating activity in rodent models of arthritis are reviewed.  These include both reversible and irreversible inhibitors of the kinase, most of which target the cysteine-481 residue of BTK.  The selectivity of these inhibitors for Tec family kinases is considered.  Developing inhibitors of any kinase to treat of rheumatoid arthritis has proved problematic with regard to both efficacy and selectivity.  It is anticipated that the more selective BTK inhibitors may prove more useful in treating arthritis, with the use of reversible inhibitors possibly offering a better strategy.  Chronic dosing may exacerbate the emergence of drug resistance, with resistant mutations already obsd. in ibrutinib-treated patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQsRSjuYxYa7Vg90H21EOLACvtfcHk0liLmuana4mumQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xnslentb0%253D&md5=037f60be680ad282725fe8f7619f1212</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1080%2F13543784.2016.1182499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2016.1182499%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DP.%26atitle%3DInvestigational%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Rheumatoid%2520Arthritis%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2016%26volume%3D25%26spage%3D891%26epage%3D899%26doi%3D10.1080%2F13543784.2016.1182499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lanning, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitby, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douhan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hett, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joslyn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niessen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnute, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulce, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteley, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">A Road Map to Evaluate the Proteome-Wide Selectivity of Covalent Kinase Inhibitors</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">767</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1038%2Fnchembio.1582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=25038787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFygs7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=760-767&author=B.+R.+Lanningauthor=L.+R.+Whitbyauthor=M.+M.+Dixauthor=J.+Douhanauthor=A.+M.+Gilbertauthor=E.+C.+Hettauthor=T.+O.+Johnsonauthor=C.+Joslynauthor=J.+C.+Kathauthor=S.+Niessenauthor=L.+R.+Robertsauthor=M.+E.+Schnuteauthor=C.+Wangauthor=J.+J.+Hulceauthor=B.+Weiauthor=L.+O.+Whiteleyauthor=M.+M.+Haywardauthor=B.+F.+Cravatt&title=A+Road+Map+to+Evaluate+the+Proteome-Wide+Selectivity+of+Covalent+Kinase+Inhibitors&doi=10.1038%2Fnchembio.1582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors</span></div><div class="casAuthors">Lanning, Bryan R.; Whitby, Landon R.; Dix, Melissa M.; Douhan, John; Gilbert, Adam M.; Hett, Erik C.; Johnson, Theodore O.; Joslyn, Chris; Kath, John C.; Niessen, Sherry; Roberts, Lee R.; Schnute, Mark E.; Wang, Chu; Hulce, Jonathan J.; Wei, Baoxian; Whiteley, Laurence O.; Hayward, Matthew M.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">760-767</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinases are principal components of signal transduction pathways and the focus of intense basic and drug discovery research.  Irreversible inhibitors that covalently modify non-catalytic cysteines in kinase active sites have emerged as valuable probes and approved drugs.  Many protein classes, however, have functional cysteines, and therefore understanding the proteome-wide selectivity of covalent kinase inhibitors is imperative.  Here, we accomplish this objective using activity-based protein profiling coupled with quant. MS to globally map the targets, both specific and nonspecific, of covalent kinase inhibitors in human cells.  Many of the specific off-targets represent nonkinase proteins that, notably, have conserved active site cysteines.  We define windows of selectivity for covalent kinase inhibitors and show that, when these windows are exceeded, rampant proteome-wide reactivity and kinase target-independent cell death conjointly occur.  Our findings, taken together, provide an exptl. road map to illuminate opportunities and surmount challenges for the development of covalent kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMAiUlEg9R5rVg90H21EOLACvtfcHk0liLmuana4mumQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFygs7nO&md5=6f17b0d1b00e088f37c511eea577d290</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1582%26sid%3Dliteratum%253Aachs%26aulast%3DLanning%26aufirst%3DB.%2BR.%26aulast%3DWhitby%26aufirst%3DL.%2BR.%26aulast%3DDix%26aufirst%3DM.%2BM.%26aulast%3DDouhan%26aufirst%3DJ.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DHett%26aufirst%3DE.%2BC.%26aulast%3DJohnson%26aufirst%3DT.%2BO.%26aulast%3DJoslyn%26aufirst%3DC.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DRoberts%26aufirst%3DL.%2BR.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHulce%26aufirst%3DJ.%2BJ.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWhiteley%26aufirst%3DL.%2BO.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DA%2520Road%2520Map%2520to%2520Evaluate%2520the%2520Proteome-Wide%2520Selectivity%2520of%2520Covalent%2520Kinase%2520Inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26spage%3D760%26epage%3D767%26doi%3D10.1038%2Fnchembio.1582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Médard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachl, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruprecht, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaeger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinzlmeir, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helm, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuehne, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dittmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuster, B.</span></span> <span> </span><span class="NLM_article-title">Optimized Chemical Proteomics Assay for Kinase Inhibitor Profiling</span>. <i>J. Proteome Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1574</span>– <span class="NLM_lpage">1586</span>, <span class="refDoi"> DOI: 10.1021/pr5012608</span> </span><div class="citationLinks">[<a href="/doi/10.1021/pr5012608" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit12ku7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=1574-1586&author=G.+M%C3%A9dardauthor=F.+Pachlauthor=B.+Ruprechtauthor=S.+Klaegerauthor=S.+Heinzlmeirauthor=D.+Helmauthor=H.+Qiaoauthor=X.+Kuauthor=M.+Wilhelmauthor=T.+Kuehneauthor=Z.+Wuauthor=A.+Dittmannauthor=C.+Hopfauthor=K.+Kramerauthor=B.+Kuster&title=Optimized+Chemical+Proteomics+Assay+for+Kinase+Inhibitor+Profiling&doi=10.1021%2Fpr5012608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Optimized Chemical Proteomics Assay for Kinase Inhibitor Profiling</span></div><div class="casAuthors">Medard, Guillaume; Pachl, Fiona; Ruprecht, Benjamin; Klaeger, Susan; Heinzlmeir, Stephanie; Helm, Dominic; Qiao, Huichao; Ku, Xin; Wilhelm, Mathias; Kuehne, Thomas; Wu, Zhixiang; Dittmann, Antje; Hopf, Carsten; Kramer, Karl; Kuster, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteome Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1574-1586</span>CODEN:
                <span class="NLM_cas:coden">JPROBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-3893</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Solid supported probes have proven to be an efficient tool for chem. proteomics.  The kinobeads technol. features kinase inhibitors covalently attached to Sepharose for affinity enrichment of kinomes from cell or tissue lysates.  This technol., combined with quant. mass spectrometry, is of particular interest for the profiling of kinase inhibitors.  It often leads to the identification of new targets for medicinal chem. campaigns where it allows a two-in-one binding and selectivity assay.  The assay can also uncover resistance mechanisms and mol. sources of toxicity.  Here we report on the optimization of the kinobead assay resulting in the combination of five chem. probes and four cell lines to cover half the human kinome in a single assay (∼260 kinases).  We show the utility and large-scale applicability of the new version of kinobeads by reprofiling the small mol. kinase inhibitors Alvocidib, Crizotinib, Dasatinib, Fasudil, Hydroxyfasudil, Nilotinib, Ibrutinib, Imatinib, and Sunitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2H1SXbNl9UrVg90H21EOLACvtfcHk0lgLB0ykV3lPAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit12ku7Y%253D&md5=8a6933cabc1f1189cb6a803b0183be1a</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fpr5012608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fpr5012608%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A9dard%26aufirst%3DG.%26aulast%3DPachl%26aufirst%3DF.%26aulast%3DRuprecht%26aufirst%3DB.%26aulast%3DKlaeger%26aufirst%3DS.%26aulast%3DHeinzlmeir%26aufirst%3DS.%26aulast%3DHelm%26aufirst%3DD.%26aulast%3DQiao%26aufirst%3DH.%26aulast%3DKu%26aufirst%3DX.%26aulast%3DWilhelm%26aufirst%3DM.%26aulast%3DKuehne%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DDittmann%26aufirst%3DA.%26aulast%3DHopf%26aufirst%3DC.%26aulast%3DKramer%26aufirst%3DK.%26aulast%3DKuster%26aufirst%3DB.%26atitle%3DOptimized%2520Chemical%2520Proteomics%2520Assay%2520for%2520Kinase%2520Inhibitor%2520Profiling%26jtitle%3DJ.%2520Proteome%2520Res.%26date%3D2015%26volume%3D14%26spage%3D1574%26epage%3D1586%26doi%3D10.1021%2Fpr5012608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molica, S.</span></span> <span> </span><span class="NLM_article-title">The Clinical Safety of Ibrutinib in Chronic Lymphocytic Leukemia</span>. <i>Expert Opin. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1621</span>– <span class="NLM_lpage">1629</span>, <span class="refDoi"> DOI: 10.1517/14740338.2015.1084286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1517%2F14740338.2015.1084286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=26359217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A280%3ADC%252BC283htFahtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=1621-1629&author=S.+Molica&title=The+Clinical+Safety+of+Ibrutinib+in+Chronic+Lymphocytic+Leukemia&doi=10.1517%2F14740338.2015.1084286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The clinical safety of ibrutinib in chronic lymphocytic leukemia</span></div><div class="casAuthors">Molica Stefano</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on drug safety</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1621-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Ibrutinib , a targeted inhibitor of B-cell receptor signaling, achieved impressive clinical results for patients with chronic lymphocytic leukemia (CLL).  These results allowed the approval of ibrutinib for the treatment of patients with CLL who have received at least one prior therapy and those with a 17p deletion regardless of line of therapy.  AREAS COVERED:  Comprehensive data from either Phase I-II or randomized Phase III studies are analyzed in this article.  In addition, we reviewed data on the prevalence and the clinical management of some peculiar toxicities ibrutinib related such as lymphocytosis, major bleeding and atrial fibrillation.  EXPERT OPINION:  Ibrutinib has radically changed the scenery of relapsed/refractory CLL treatment and established an important paradigm in the molecularly targeted approach of this disease.  Discontinuation of ibrutinib is rarely due to adverse events related to the drug.  Patients who discontinue treatment represent a challenge to the physicians because treatment options are very limited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQAcwMJAE2LJF1C8OJBvdfbfW6udTcc2ebaXBoXSshiK7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283htFahtA%253D%253D&md5=67e9920c0f81dd41b5f5ed21370c5c56</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1517%2F14740338.2015.1084286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740338.2015.1084286%26sid%3Dliteratum%253Aachs%26aulast%3DMolica%26aufirst%3DS.%26atitle%3DThe%2520Clinical%2520Safety%2520of%2520Ibrutinib%2520in%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2015%26volume%3D14%26spage%3D1621%26epage%3D1629%26doi%3D10.1517%2F14740338.2015.1084286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shatzel, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarty, O. J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danilov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLoughery, T. G.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib-Associated Bleeding: Pathogenesis, Management, and Risk Reduction Strategies</span>. <i>J. Thromb. Haemostasis</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">835</span>– <span class="NLM_lpage">847</span>, <span class="refDoi"> DOI: 10.1111/jth.13651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1111%2Fjth.13651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=28182323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvFenur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=835-847&author=J.+J.+Shatzelauthor=S.+R.+Olsonauthor=D.+L.+Taoauthor=O.+J.+T.+McCartyauthor=A.+V.+Danilovauthor=T.+G.+DeLoughery&title=Ibrutinib-Associated+Bleeding%3A+Pathogenesis%2C+Management%2C+and+Risk+Reduction+Strategies&doi=10.1111%2Fjth.13651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies</span></div><div class="casAuthors">Shatzel, J. J.; Olson, S. R.; Tao, D. L.; McCarty, O. J. T.; Danilov, A. V.; De Loughery, T. G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">835-847</span>CODEN:
                <span class="NLM_cas:coden">JTHOA5</span>;
        ISSN:<span class="NLM_cas:issn">1538-7933</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (Btk) that has proven to be an effective therapeutic agent for multiple B-cell-mediated lymphoproliferative disorders.  Ibrutinib, however, carries an increased bleeding risk compared with std. chemotherapy.  Bleeding events range from minor mucocutaneous bleeding to life-threatening hemorrhage, due in large part to the effects of ibrutinib on several distinct platelet signaling pathways.  There is currently a minimal amt. of data to guide clinicians regarding the use of ibrutinib in patients at high risk of bleeding or on anticoagulant or antiplatelet therapy.  In addn., the potential cardiovascular protective effects of ibrutinib monotherapy in patients at risk of vascular disease are unknown.  Patients should be cautioned against using non-steroidal anti-inflammatory drugs, fish oils, vitamin E and aspirin-contg. products, and consider replacing ibrutinib with a different agent if dual antiplatelet therapy is indicated.  Patients should not take vitamin K antagonists concurrently with ibrutinib; direct oral anticoagulants should be used if extended anticoagulation is strongly indicated.  In this review, we describe the pathophysiol. of ibrutinib-mediated bleeding and suggest risk redn. strategies for common clin. scenarios assocd. with ibrutinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7mVrIrFi1pLVg90H21EOLACvtfcHk0lgLB0ykV3lPAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvFenur0%253D&md5=9f3913a402960403a69b67249c870b87</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1111%2Fjth.13651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjth.13651%26sid%3Dliteratum%253Aachs%26aulast%3DShatzel%26aufirst%3DJ.%2BJ.%26aulast%3DOlson%26aufirst%3DS.%2BR.%26aulast%3DTao%26aufirst%3DD.%2BL.%26aulast%3DMcCarty%26aufirst%3DO.%2BJ.%2BT.%26aulast%3DDanilov%26aufirst%3DA.%2BV.%26aulast%3DDeLoughery%26aufirst%3DT.%2BG.%26atitle%3DIbrutinib-Associated%2520Bleeding%253A%2520Pathogenesis%252C%2520Management%252C%2520and%2520Risk%2520Reduction%2520Strategies%26jtitle%3DJ.%2520Thromb.%2520Haemostasis%26date%3D2017%26volume%3D15%26spage%3D835%26epage%3D847%26doi%3D10.1111%2Fjth.13651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. a</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. a</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. a</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N. a</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilotti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span> <span> </span><span class="NLM_article-title">Three-Year Follow-up of Treatment-Naive and Previously Treated Patients with CLL and SLL Receiving Single-Agent Ibrutinib</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">2497</span>– <span class="NLM_lpage">2506</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-10-606038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1182%2Fblood-2014-10-606038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=25700432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotV2hs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=2497-2506&author=J.+C.+Byrdauthor=R.+R.+Furmanauthor=S.+E.+Coutreauthor=J.+a+Burgerauthor=K.+a+Blumauthor=M.+Colemanauthor=W.+G.+Wierdaauthor=J.+a+Jonesauthor=W.+Zhaoauthor=N.+a+Heeremaauthor=A.+J.+Johnsonauthor=Y.+Shawauthor=E.+Bilottiauthor=C.+Zhouauthor=D.+F.+Jamesauthor=S.+O%E2%80%99Brien&title=Three-Year+Follow-up+of+Treatment-Naive+and+Previously+Treated+Patients+with+CLL+and+SLL+Receiving+Single-Agent+Ibrutinib&doi=10.1182%2Fblood-2014-10-606038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib</span></div><div class="casAuthors">Byrd, John C.; Furman, Richard R.; Coutre, Steven E.; Burger, Jan A.; Blum, Kristie A.; Coleman, Morton; Wierda, William G.; Jones, Jeffrey A.; Zhao, Weiqiang; Heerema, Nyla A.; Johnson, Amy J.; Shaw, Yun; Bilotti, Elizabeth; Zhou, Cathy; James, Danelle F.; O'Brien, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2497-2506</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Ibrutinib is an orally administered inhibitor of Bruton tyrosine kinase that antagonizes B-cell receptor, chemokine, and integrin-mediated signaling.  In early-phase studies, ibrutinib demonstrated high response rates and prolonged progression-free survival (PFS) in chronic lymphocytic leukemia (CLL).  The durable responses obsd. with ibrutinib relate in part to a modest toxicity profile that allows the majority of patients to receive continuous therapy for an extended period.  We report on median 3-yr follow-up of 132 patients with symptomatic treatment- naive and relapsed/refractory CLL or small lymphocytic lymphoma.  Longer treatment with ibrutinib was assocd. with improvement in response quality over time and durable remissions.  Toxicity with longer follow-up diminished with respect to occurrence of grade 3 or greater cytopenias, fatigue, and infections.  Progression remains uncommon, occurring primarily in some patients with relapsed del(17)(p13.1) and/or del(11)(q22.3) disease.  Treatment-related lymphocytosis remains largely asymptomatic even when persisting >1 yr and does not appear to alter longer-term PFS and overall survival compared with patients with partial response or better.  Collectively, these data provide evidence that ibrutinib controls CLL disease manifestations and is well tolerated for an extended period; this information can help direct potential treatment options for different subgroups to diminish the long-term risk of relapse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbUSbfHjGYebVg90H21EOLACvtfcHk0lhMfvYru-lQ5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotV2hs7c%253D&md5=1bedfb4e6798a3f51320d8b8054c13aa</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-10-606038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-10-606038%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DBurger%26aufirst%3DJ.%2Ba%26aulast%3DBlum%26aufirst%3DK.%2Ba%26aulast%3DColeman%26aufirst%3DM.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DJones%26aufirst%3DJ.%2Ba%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DHeerema%26aufirst%3DN.%2Ba%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DShaw%26aufirst%3DY.%26aulast%3DBilotti%26aufirst%3DE.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26atitle%3DThree-Year%2520Follow-up%2520of%2520Treatment-Naive%2520and%2520Previously%2520Treated%2520Patients%2520with%2520CLL%2520and%2520SLL%2520Receiving%2520Single-Agent%2520Ibrutinib%26jtitle%3DBlood%26date%3D2015%26volume%3D125%26spage%3D2497%26epage%3D2506%26doi%3D10.1182%2Fblood-2014-10-606038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurczak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romaguera, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stilgenbauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreyling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jedrzejczak, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spurgeon, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baher, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaupre, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rule, S.</span></span> <span> </span><span class="NLM_article-title">Long-Term Follow-up of MCL Patients Treated with Single-Agent Ibrutinib: Updated Safety and Efficacy Results</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">739</span>– <span class="NLM_lpage">745</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-03-635326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1182%2Fblood-2015-03-635326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=26059948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2ktLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2015&pages=739-745&author=M.+L.+Wangauthor=K.+A.+Blumauthor=P.+Martinauthor=A.+Goyauthor=R.+Auerauthor=B.+S.+Kahlauthor=W.+Jurczakauthor=R.+H.+Advaniauthor=J.+E.+Romagueraauthor=M.+E.+Williamsauthor=J.+C.+Barrientosauthor=E.+Chmielowskaauthor=J.+Radfordauthor=S.+Stilgenbauerauthor=M.+Dreylingauthor=W.+W.+Jedrzejczakauthor=P.+Johnsonauthor=S.+E.+Spurgeonauthor=L.+Zhangauthor=L.+Baherauthor=M.+Chengauthor=D.+Leeauthor=D.+M.+Beaupreauthor=S.+Rule&title=Long-Term+Follow-up+of+MCL+Patients+Treated+with+Single-Agent+Ibrutinib%3A+Updated+Safety+and+Efficacy+Results&doi=10.1182%2Fblood-2015-03-635326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results</span></div><div class="casAuthors">Wang, Michael L.; Blum, Kristie A.; Martin, Peter; Goy, Andre; Auer, Rebecca; Kahl, Brad S.; Jurczak, Wojciech; Advani, Ranjana H.; Romaguera, Jorge E.; Williams, Michael E.; Barrientos, Jacqueline C.; Chmielowska, Ewa; Radford, John; Stilgenbauer, Stephan; Dreyling, Martin; Jedrzejczak, Wieslaw Wiktor; Johnson, Peter; Spurgeon, Stephen E.; Zhang, Liang; Baher, Linda; Cheng, Mei; Lee, Dana; Beaupre, Darrin M.; Rule, Simon</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">739-745</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Ibrutinib, an oral inhibitor of Bruton tyrosine kinase, is approved for patients with mantle cell lymphoma (MCL) who have received one prior therapy.  We report the updated safety and efficacy results from the multicenter, open-label phase 2 registration trial of ibrutinib (median 26.7-mo follow-up).  Patients (N = 111) received oral ibrutinib 560 mg once daily, and those with stable disease or better could enter a long-term extension study.  The primary end point was overall response rate (ORR).  The median patient age was 68 years (range, 40-84), with a median of 3 prior therapies (range, 1-5).  The median treatment duration was 8.3 mo; 46% of patients were treated for >12 mo, and 22% were treated for ≥2 years.  The ORR was 67% (23% complete response), with a median duration of response of 17.5 mo.  The 24-mo progression-free survival and overall survival rates were 31% (95% confidence interval [CI], 22.3-40.4) and 47% (95% CI, 37.1-56.9), resp.  The most common adverse events (AEs) in >30% of patients included diarrhea (54%), fatigue (50%), nausea (33%), and dyspnea (32%).  The most frequent grade ≥3 infections included pneumonia (8%), urinary tract infection (4%), and cellulitis (3%).  Grade ≥3 bleeding events in ≥2% of patients were hematuria (2%) and subdural hematoma (2%).  Common all-grade hematol. AEs were thrombocytopenia (22%), neutropenia (19%), and anemia (18%).  The prevalence of infection, diarrhea, and bleeding was highest for the first 6 mo of therapy and less thereafter.  With longer follow-up, ibrutinib continues to demonstrate durable responses and favorable safety in relapsed/refractory MCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUEAHTEsAdqrVg90H21EOLACvtfcHk0lhMfvYru-lQ5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2ktLnJ&md5=42f321c41ad5605c0ccf27bc49477b4c</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-03-635326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-03-635326%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%2BL.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DAuer%26aufirst%3DR.%26aulast%3DKahl%26aufirst%3DB.%2BS.%26aulast%3DJurczak%26aufirst%3DW.%26aulast%3DAdvani%26aufirst%3DR.%2BH.%26aulast%3DRomaguera%26aufirst%3DJ.%2BE.%26aulast%3DWilliams%26aufirst%3DM.%2BE.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DChmielowska%26aufirst%3DE.%26aulast%3DRadford%26aufirst%3DJ.%26aulast%3DStilgenbauer%26aufirst%3DS.%26aulast%3DDreyling%26aufirst%3DM.%26aulast%3DJedrzejczak%26aufirst%3DW.%2BW.%26aulast%3DJohnson%26aufirst%3DP.%26aulast%3DSpurgeon%26aufirst%3DS.%2BE.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DBaher%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26aulast%3DRule%26aufirst%3DS.%26atitle%3DLong-Term%2520Follow-up%2520of%2520MCL%2520Patients%2520Treated%2520with%2520Single-Agent%2520Ibrutinib%253A%2520Updated%2520Safety%2520and%2520Efficacy%2520Results%26jtitle%3DBlood%26date%3D2015%26volume%3D126%26spage%3D739%26epage%3D745%26doi%3D10.1182%2Fblood-2015-03-635326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leong, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healey, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegal, D.</span></span> <span> </span><span class="NLM_article-title">The Risk of Atrial Fibrillation with Ibrutinib Use: A Systematic Review and Meta-Analysis</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">138</span>– <span class="NLM_lpage">140</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-05-712828</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1182%2Fblood-2016-05-712828" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=27247135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVymu7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=138-140&author=D.+P.+Leongauthor=F.+Caronauthor=C.+Hillisauthor=A.+Duanauthor=J.+S.+Healeyauthor=G.+Fraserauthor=D.+Siegal&title=The+Risk+of+Atrial+Fibrillation+with+Ibrutinib+Use%3A+A+Systematic+Review+and+Meta-Analysis&doi=10.1182%2Fblood-2016-05-712828"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis</span></div><div class="casAuthors">Leong, Darryl P.; Caron, Francois; Hillis, Christopher; Duan, Annie; Healey, Jeff S.; Fraser, Graeme; Siegal, Deborah</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">138-140</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Meta-anal. of ibrutinib recipients was undertaken to est. the magnitude of the increase in atrial fibrillation (AF) risk among ibrutinib recipients, as compared with alternative therapies and (2) quantify the frequency of AF reported among ibrutinib recipients.  This anal. suggests that ibrutinib consistently increases the risk of incident AF compared with alternative therapies.  The author suggested that patients treated with ibrutinib should be closely monitored for the development of AF, which is assocd. with a 5-fold increased risk of ischemic stroke, a leading cause of morbidity and mortality, in the general population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRmlExYguUALVg90H21EOLACvtfcHk0lj0_BYeqen4mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVymu7jP&md5=9e50bc64dad51e76c894d6ec5f098428</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-05-712828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-05-712828%26sid%3Dliteratum%253Aachs%26aulast%3DLeong%26aufirst%3DD.%2BP.%26aulast%3DCaron%26aufirst%3DF.%26aulast%3DHillis%26aufirst%3DC.%26aulast%3DDuan%26aufirst%3DA.%26aulast%3DHealey%26aufirst%3DJ.%2BS.%26aulast%3DFraser%26aufirst%3DG.%26aulast%3DSiegal%26aufirst%3DD.%26atitle%3DThe%2520Risk%2520of%2520Atrial%2520Fibrillation%2520with%2520Ibrutinib%2520Use%253A%2520A%2520Systematic%2520Review%2520and%2520Meta-Analysis%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26spage%3D138%26epage%3D140%26doi%3D10.1182%2Fblood-2016-05-712828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucchini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilotto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spada, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melisi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bria, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tortora, G.</span></span> <span> </span><span class="NLM_article-title">Targeting the Epidermal Growth Factor Receptor in Solid Tumors: Focus on Safety</span>. <i>Expert Opin. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">535</span>– <span class="NLM_lpage">549</span>, <span class="refDoi"> DOI: 10.1517/14740338.2014.904283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1517%2F14740338.2014.904283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=24684184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC2cXms1WrtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=535-549&author=E.+Lucchiniauthor=S.+Pilottoauthor=E.+Spadaauthor=D.+Melisiauthor=E.+Briaauthor=G.+Tortora&title=Targeting+the+Epidermal+Growth+Factor+Receptor+in+Solid+Tumors%3A+Focus+on+Safety&doi=10.1517%2F14740338.2014.904283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the epidermal growth factor receptor in solid tumors: focus on safety</span></div><div class="casAuthors">Lucchini, Eleonora; Pilotto, Sara; Spada, Elisa; Melisi, Davide; Bria, Emilio; Tortora, Giampaolo</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">535-549</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Inhibition of the EGFR has emerged as a promising anticancer strategy, offering improved efficacy and quality of life for patients affected by tumors.  The overall level of toxicity assocd. with EGFR inhibitors is low compared to other chemotherapy drugs, although they are commonly assocd. with skin and gastrointestinal adverse events.  Thus, patients' quality of life may be considerably affected both by a phys. and a psychosocial perspective.  Adverse events that lead to treatment interruption or cessation may significantly compromise their outcome.  Areas covered: This review summarizes the characteristics of the distinctive toxicities of drugs targeting EGFR, addressing their incidence, pathophysiol. and clin. presentation with a focus on the management of skin rash and other relevant adverse events, according to the available clin. evidence.  Data regarding the correlation between the development of skin rash and clin. outcome are also reported.  Expert opinion: Drugs targeting EGFR are assocd. with a lower overall incidence of systemic side effects compared to std. chemotherapeutic agents; nevertheless, an increased risk of distinct toxicities that may affect patient's quality of life and anticancer treatment compliance is obsd.  Thus, clin. training projects directed toward a more accurate knowledge of such adverse events are essential to maximize the progress of targeted therapies against cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVekRaAP41xbVg90H21EOLACvtfcHk0lj0_BYeqen4mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXms1WrtL0%253D&md5=9623fe732a5ebf47a628359097e382e2</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1517%2F14740338.2014.904283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740338.2014.904283%26sid%3Dliteratum%253Aachs%26aulast%3DLucchini%26aufirst%3DE.%26aulast%3DPilotto%26aufirst%3DS.%26aulast%3DSpada%26aufirst%3DE.%26aulast%3DMelisi%26aufirst%3DD.%26aulast%3DBria%26aufirst%3DE.%26aulast%3DTortora%26aufirst%3DG.%26atitle%3DTargeting%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520in%2520Solid%2520Tumors%253A%2520Focus%2520on%2520Safety%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2014%26volume%3D13%26spage%3D535%26epage%3D549%26doi%3D10.1517%2F14740338.2014.904283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quek, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, S. P.</span></span> <span> </span><span class="NLM_article-title">A Role for Bruton’s Tyrosine Kinase (Btk) in Platelet Activation by Collagen</span>. <i>Curr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1137</span>– <span class="NLM_lpage">1140</span>, <span class="refDoi"> DOI: 10.1016/S0960-9822(98)70471-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1016%2FS0960-9822%2898%2970471-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=9778529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADyaK1cXmslagsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=1137-1140&author=L.+S.+Quekauthor=J.+Bolenauthor=S.+P.+Watson&title=A+Role+for+Bruton%E2%80%99s+Tyrosine+Kinase+%28Btk%29+in+Platelet+Activation+by+Collagen&doi=10.1016%2FS0960-9822%2898%2970471-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen</span></div><div class="casAuthors">Quek, L. S.; Bolen, J.; Watson, S. P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1137-1140</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Current Biology Ltd.</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is essential for normal B-cell receptor signaling.  The lack of expression of functional Btk in humans leads to the B-cell deficiency X-linked agammaglobulinemia (XLA).  We report here that Btk is also important for signaling via the collagen receptor glycoprotein VI (GPVI) in platelets.  GPVI is coupled to the Fc receptor γ chain (FcRγ).  The FcRγ-chain contains a consensus sequence known as the immune-receptor tyrosine-based activation motif (ITAM).  Tyrosine phosphorylation of the ITAM upon GPVI stimulation is the initial step in the regulation of phospholipase C γ2 (PLCγ2) isoforms via the tyrosine kinase p72Syk (Syk) in platelets.  Here we show that collagen and a collagen-related peptide (CRP), which binds to GPVI but does not bind to the integrin α2β1, induced Btk tyrosine phosphorylation in platelets.  Aggregation, dense granule secretion and calcium mobilization were significantly diminished but not completely abolished in platelets from XLA patients in response to collagen and CRP.  These effects were assocd. with a redn. in tyrosine phosphorylation of PLCγ2.  In contrast, aggregation and secretion stimulated by thrombin in Btk-deficient platelets were not significantly altered.  Our results demonstrate that Btk is important for collagen signaling via GPVI, but is not essential for thrombin-mediated platelet activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIUgySXWpDX7Vg90H21EOLACvtfcHk0lj0_BYeqen4mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmslagsLk%253D&md5=182bde729153e994221edbc963d39065</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2FS0960-9822%2898%2970471-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-9822%252898%252970471-3%26sid%3Dliteratum%253Aachs%26aulast%3DQuek%26aufirst%3DL.%2BS.%26aulast%3DBolen%26aufirst%3DJ.%26aulast%3DWatson%26aufirst%3DS.%2BP.%26atitle%3DA%2520Role%2520for%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528Btk%2529%2520in%2520Platelet%2520Activation%2520by%2520Collagen%26jtitle%3DCurr.%2520Biol.%26date%3D1998%26volume%3D8%26spage%3D1137%26epage%3D1140%26doi%3D10.1016%2FS0960-9822%2898%2970471-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicolson, P. L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nock, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montague, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clifford, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huissoon, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malcor, J.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollitt, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlinson, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, S. P.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Btk by Btk-Specific Concentrations of Ibrutinib and Acalabrutinib Delays but Does Not Block Platelet Aggregation Mediated by Glycoprotein VI</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">2097</span>– <span class="NLM_lpage">2108</span>, <span class="refDoi"> DOI: 10.3324/haematol.2018.193391</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.3324%2Fhaematol.2018.193391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=30026342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFygu7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2018&pages=2097-2108&author=P.+L.+R.+Nicolsonauthor=C.+E.+Hughesauthor=S.+Watsonauthor=S.+H.+Nockauthor=A.+T.+Hardyauthor=C.+N.+Watsonauthor=S.+J.+Montagueauthor=H.+Cliffordauthor=A.+P.+Huissoonauthor=J.-D.+Malcorauthor=M.+R.+Thomasauthor=A.+Y.+Pollittauthor=M.+G.+Tomlinsonauthor=G.+Prattauthor=S.+P.+Watson&title=Inhibition+of+Btk+by+Btk-Specific+Concentrations+of+Ibrutinib+and+Acalabrutinib+Delays+but+Does+Not+Block+Platelet+Aggregation+Mediated+by+Glycoprotein+VI&doi=10.3324%2Fhaematol.2018.193391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI</span></div><div class="casAuthors">Nicolson, Phillip L. R.; Hughes, Craig E.; Watson, Stephanie; Nock, Sophie H.; Hardy, Alexander T.; Watson, Callum N.; Montague, Samantha J.; Clifford, Hayley; Huissoon, Aarnoud P.; Malcor, Jean-Daniel; Thomas, Mark R.; Pollitt, Alice Y.; Tomlinson, Michael G.; Pratt, Guy; Watson, Steve P.</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2097-2108</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">1592-8721</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">Ibrutinib and acalabrutinib are irreversible inhibitors of Bruton tyrosine kinase used in the treatment of B-cell malignancies.  They bind irreversibly to cysteine 481 of Bruton tyrosine kinase, blocking autophosphorylation on tyrosine 223 and phosphorylation of downstream substrates including phospholipase C-γ2.  In the present study, we demonstrate that concns. of ibrutinib and acalabrutinib that block Bruton tyrosine kinase activity, as shown by loss of phosphorylation at tyrosine 223 and phospholipase C-γ2, delay but do not block aggregation in response to a maximally-effective concn. of collagen-related peptide or collagen.  In contrast, 10- to 20-fold higher concns. of ibrutinib or acalabrutinib block platelet aggregation in response to glycoprotein VI agonists.  Ex vivo studies on patients treated with ibrutinib, but not acalabrutinib, showed a redn. of platelet aggregation in response to collagen-related peptide indicating that the clin. dose of ibrutinib but not acalabrutinib is supramaximal for Bruton tyrosine kinase blockade.  Unexpectedly, low concns. of ibrutinib inhibited aggregation in response to collagen-related peptide in patients deficient in Bruton tyrosine kinase.  The increased bleeding seen with ibrutinib over acalabrutinib is due to off-target actions of ibrutinib that occur because of unfavorable pharmacodynamics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonhmxALDChg7Vg90H21EOLACvtfcHk0lj0_BYeqen4mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFygu7vK&md5=2e78d1da663274f62fa00bbcacfaa9b4</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2018.193391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2018.193391%26sid%3Dliteratum%253Aachs%26aulast%3DNicolson%26aufirst%3DP.%2BL.%2BR.%26aulast%3DHughes%26aufirst%3DC.%2BE.%26aulast%3DWatson%26aufirst%3DS.%26aulast%3DNock%26aufirst%3DS.%2BH.%26aulast%3DHardy%26aufirst%3DA.%2BT.%26aulast%3DWatson%26aufirst%3DC.%2BN.%26aulast%3DMontague%26aufirst%3DS.%2BJ.%26aulast%3DClifford%26aufirst%3DH.%26aulast%3DHuissoon%26aufirst%3DA.%2BP.%26aulast%3DMalcor%26aufirst%3DJ.-D.%26aulast%3DThomas%26aufirst%3DM.%2BR.%26aulast%3DPollitt%26aufirst%3DA.%2BY.%26aulast%3DTomlinson%26aufirst%3DM.%2BG.%26aulast%3DPratt%26aufirst%3DG.%26aulast%3DWatson%26aufirst%3DS.%2BP.%26atitle%3DInhibition%2520of%2520Btk%2520by%2520Btk-Specific%2520Concentrations%2520of%2520Ibrutinib%2520and%2520Acalabrutinib%2520Delays%2520but%2520Does%2520Not%2520Block%2520Platelet%2520Aggregation%2520Mediated%2520by%2520Glycoprotein%2520VI%26jtitle%3DHaematologica%26date%3D2018%26volume%3D103%26spage%3D2097%26epage%3D2108%26doi%3D10.3324%2Fhaematol.2018.193391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Kar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulrajani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Lith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Hoek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Zwart, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demont, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkaik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krantz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">252</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.242909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1124%2Fjpet.117.242909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=28882879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtleltrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2017&pages=240-252&author=T.+Barfauthor=T.+Coveyauthor=R.+Izumiauthor=B.+van+de+Karauthor=M.+Gulrajaniauthor=B.+van+Lithauthor=M.+van+Hoekauthor=E.+de+Zwartauthor=D.+Mittagauthor=D.+Demontauthor=S.+Verkaikauthor=F.+Krantzauthor=P.+G.+Pearsonauthor=R.+Ulrichauthor=A.+Kaptein&title=Acalabrutinib+%28ACP-196%29%3A+A+Covalent+Bruton+Tyrosine+Kinase+Inhibitor+with+a+Differentiated+Selectivity+and+In+Vivo+Potency+Profile&doi=10.1124%2Fjpet.117.242909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile</span></div><div class="casAuthors">Barf, Tjeerd; Covey, Todd; Izumi, Raquel; van de Kar, Bas; Gulrajani, Michael; van Lith, Bart; van Hoek, Maaike; de Zwart, Edwin; Mittag, Diana; Demont, Dennis; Verkaik, Saskia; Krantz, Fanny; Pearson, Paul G.; Ulrich, Roger; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">240-252</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Several small-mol. Bruton tyrosine kinase (BTK) inhibitors are in development for B cell malignancies and autoimmune disorders, each characterized by distinct potency and selectivity patterns.  Herein we describe the pharmacol. characterization of BTK inhibitor acalabrutinib [compd. 1, ACP-196 (4-[8- amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin1-yl]-N-(2-pyridyl)benzamide)].  Acalabrutinib possesses a reactive butynamide group that binds covalently to Cys481 in BTK.  Relative to the other BTK inhibitors described here, the reduced intrinsic reactivity of acalabrutinib helps to limit inhibition of offtarget kinases having cysteine-mediated covalent binding potential.  Acalabrutinib demonstrated higher biochem. and cellular selectivity than ibrutinib and spebrutinib (compds. 2 and 3, resp.).  Importantly, off-target kinases, such as epidermal growth factor receptor (EGFR) and interleukin 2-inducible T cell kinase (ITK), were not inhibited.  Detn. of the inhibitory potential of anti-IgM-induced CD69 expression in human peripheral blood mononuclear cells and whole blood demonstrated that acalabrutinib is a potent functional BTK inhibitor.  In vivo evaluation in mice revealed that acalabrutinib is more potent than ibrutinib and spebrutinib.  Preclin. and clin. studies showed that the level and duration of BTK occupancy correlates with in vivo efficacy.  Evaluation of the pharmacokinetic properties of acalabrutinib in healthy adult volunteers demonstrated rapid absorption and fast elimination.  In these healthy individuals, a single oral dose of 100 mg showed approx. 99% median target coverage at 3 and 12 h and around 90% at 24 h in peripheral B cells.  In conclusion, acalabrutinib is a BTK inhibitor with key pharmacol. differentiators vs. ibrutinib and spebrutinib and is currently being evaluated in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol9xhDmwvup7Vg90H21EOLACvtfcHk0liJ-vDHyUw-0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtleltrnO&md5=73cbd3a87396abbf8cb20e4361f96f64</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.242909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.242909%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DCovey%26aufirst%3DT.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3Dvan%2Bde%2BKar%26aufirst%3DB.%26aulast%3DGulrajani%26aufirst%3DM.%26aulast%3Dvan%2BLith%26aufirst%3DB.%26aulast%3Dvan%2BHoek%26aufirst%3DM.%26aulast%3Dde%2BZwart%26aufirst%3DE.%26aulast%3DMittag%26aufirst%3DD.%26aulast%3DDemont%26aufirst%3DD.%26aulast%3DVerkaik%26aufirst%3DS.%26aulast%3DKrantz%26aufirst%3DF.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DUlrich%26aufirst%3DR.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DAcalabrutinib%2520%2528ACP-196%2529%253A%2520A%2520Covalent%2520Bruton%2520Tyrosine%2520Kinase%2520Inhibitor%2520with%2520a%2520Differentiated%2520Selectivity%2520and%2520In%2520Vivo%2520Potency%2520Profile%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D363%26spage%3D240%26epage%3D252%26doi%3D10.1124%2Fjpet.117.242909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gururaja, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukbuntherng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Versele, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span> <span> </span><span class="NLM_article-title">The Effect of Bruton’s Tyrosine Kinase (BTK) Inhibitors on Collagen-Induced Platelet Aggregation, BTK, and Tyrosine Kinase Expressed in Hepatocellular Carcinoma (TEC)</span>. <i>Eur. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">604</span>– <span class="NLM_lpage">612</span>, <span class="refDoi"> DOI: 10.1111/ejh.13148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1111%2Fejh.13148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVKgu73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2018&pages=604-612&author=J.+Chenauthor=T.+Kinoshitaauthor=T.+Gururajaauthor=J.+Sukbuntherngauthor=D.+Jamesauthor=D.+Luauthor=J.+Whangauthor=M.+Verseleauthor=B.+Y.+Chang&title=The+Effect+of+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29+Inhibitors+on+Collagen-Induced+Platelet+Aggregation%2C+BTK%2C+and+Tyrosine+Kinase+Expressed+in+Hepatocellular+Carcinoma+%28TEC%29&doi=10.1111%2Fejh.13148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC)</span></div><div class="casAuthors">Chen, Jun; Kinoshita, Taisei; Gururaja, Tarikere; Sukbuntherng, Juthamas; James, Danelle; Lu, Daniel; Whang, Jennifer; Versele, Matthias; Chang, Betty Y.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Haematology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">604-612</span>CODEN:
                <span class="NLM_cas:coden">EJHAEC</span>;
        ISSN:<span class="NLM_cas:issn">0902-4441</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Objectives : Bruton's tyrosine kinase (BTK) and tyrosine kinase expressed in hepatocellular carcinoma (TEC) are expressed by human platelets.  These kinases participate in platelet activation through the collagen receptor glycoprotein VI and may perform overlapping functions.  In clin. studies, BTK inhibitors (ibrutinib, acalabrutinib, tirabrutinib, zanubrutinib) have been assocd. with increased bleeding risk, which may result from inhibition of BTK alone or of both BTK and TEC, although the role of TEC in bleeding risk remains unclear.  Methods : Here, in vitro catalytic and binding activities of ibrutinib and acalabrutinib were detd. with four assay systems.  Platelet aggregation assays detd. inhibitor potency and its relationship to selectivity between BTK and TEC.  Results : Neither inhibitor was substantially more selective for BTK over TEC.  The potencies at which BTK inhibitors suppressed platelet aggregation correlated with the potencies in on-target BTK assays, including those in cells.  At clin. relevant plasma concn., ibrutinib, acalabrutinib, and tirabrutinib inhibited collagen-induced platelet aggregation to a similar extent, despite differing in vitro IC50s.  Conclusions : Our results suggest BTK inhibition is the primary driver for inhibition of platelet aggregation.  The subtle differences between these inhibitors suggest only randomized, double-blind, placebo-controlled clin. studies can fully address the bleeding risks of different BTK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-4t9KmFTj5LVg90H21EOLACvtfcHk0liJ-vDHyUw-0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVKgu73J&md5=ef4558e97d19f22350689e75088f1b34</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1111%2Fejh.13148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fejh.13148%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DKinoshita%26aufirst%3DT.%26aulast%3DGururaja%26aufirst%3DT.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DWhang%26aufirst%3DJ.%26aulast%3DVersele%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DB.%2BY.%26atitle%3DThe%2520Effect%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%2520Inhibitors%2520on%2520Collagen-Induced%2520Platelet%2520Aggregation%252C%2520BTK%252C%2520and%2520Tyrosine%2520Kinase%2520Expressed%2520in%2520Hepatocellular%2520Carcinoma%2520%2528TEC%2529%26jtitle%3DEur.%2520J.%2520Haematol.%26date%3D2018%26volume%3D101%26spage%3D604%26epage%3D612%26doi%3D10.1111%2Fejh.13148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dittus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muelbaier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span> <span> </span><span class="NLM_article-title">Differential Kinobeads Profiling for Target Identification of Irreversible Kinase Inhibitors</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2515</span>– <span class="NLM_lpage">2521</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00617</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00617" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVelu7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=2515-2521&author=L.+Dittusauthor=T.+Wernerauthor=M.+Muelbaierauthor=M.+Bantscheff&title=Differential+Kinobeads+Profiling+for+Target+Identification+of+Irreversible+Kinase+Inhibitors&doi=10.1021%2Facschembio.7b00617"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Differential Kinobeads Profiling for Target Identification of Irreversible Kinase Inhibitors</span></div><div class="casAuthors">Dittus, Lars; Werner, Thilo; Muelbaier, Marcel; Bantscheff, Marcus</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2515-2521</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chemoproteomics profiling of kinase inhibitors with kinobeads enables the assessment of inhibitor potency and selectivity for endogenously expressed protein kinases in cell lines and tissues.  Using a small panel of targeted covalent inhibitors, we demonstrate the importance of measuring covalent target binding in live cells.  We present a differential kinobeads profiling strategy for covalent kinase inhibitors where a compd. is added either to live cells or to a cell ext. that enables the comprehensive assessment of inhibitor selectivity for covalent and noncovalent targets.  We found that Acalabrutinib, CC-292, and Ibrutinib potently and covalently bind TEC family kinases, but only Ibrutinib also potently binds to BLK.  ZAK was identified as a submicromolar affinity Ibrutinib off-target due to covalent modification of Cys22.  In contrast to Ibrutinib, 5Z-7-Oxozeaenol reacted with Cys150 next to the DFG loop, demonstrating an alternative route to covalent inactivation of this kinase, e.g., to inhibit canonical TGF-β dependent processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdZpb3DpBXf7Vg90H21EOLACvtfcHk0lgC4Rmo8cDvnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVelu7zL&md5=cd7f70ef37de6afdec766bb9aa704b4a</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00617%26sid%3Dliteratum%253Aachs%26aulast%3DDittus%26aufirst%3DL.%26aulast%3DWerner%26aufirst%3DT.%26aulast%3DMuelbaier%26aufirst%3DM.%26aulast%3DBantscheff%26aufirst%3DM.%26atitle%3DDifferential%2520Kinobeads%2520Profiling%2520for%2520Target%2520Identification%2520of%2520Irreversible%2520Kinase%2520Inhibitors%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2017%26volume%3D12%26spage%3D2515%26epage%3D2521%26doi%3D10.1021%2Facschembio.7b00617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomgren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dambach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macaluso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sowell, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Potent and Selective Bruton’s Tyrosine Kinase Inhibitors: Discovery of GDC-0834</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1333</span>– <span class="NLM_lpage">1337</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.01.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1016%2Fj.bmcl.2015.01.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=25701252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVSit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1333-1337&author=W.+B.+Youngauthor=J.+Barbosaauthor=P.+Blomgrenauthor=M.+C.+Bremerauthor=J.+J.+Crawfordauthor=D.+Dambachauthor=S.+Gallionauthor=S.+Hymowitzauthor=J.+E.+Kropfauthor=S.+H.+Leeauthor=L.+Liuauthor=J.+Lubachauthor=J.+Macalusoauthor=P.+Maciejewskiauthor=B.+Maurerauthor=S.+A.+Mitchellauthor=D.+F.+Ortwineauthor=J.+Di+Paoloauthor=K.+Reifauthor=H.+Scheerensauthor=A.+Schmittauthor=C.+G.+Sowellauthor=X.+Wangauthor=H.+Wongauthor=J.-M.+Xiongauthor=J.+Xuauthor=Z.+Zhaoauthor=K.+S.+Currie&title=Potent+and+Selective+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitors%3A+Discovery+of+GDC-0834&doi=10.1016%2Fj.bmcl.2015.01.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective Bruton's tyrosine kinase inhibitors: Discovery of GDC-0834</span></div><div class="casAuthors">Young, Wendy B.; Barbosa, James; Blomgren, Peter; Bremer, Meire C.; Crawford, James J.; Dambach, Donna; Gallion, Steve; Hymowitz, Sarah G.; Kropf, Jeffrey E.; Lee, Seung H.; Liu, Lichuan; Lubach, Joseph W.; Macaluso, Jen; Maciejewski, Pat; Maurer, Brigitte; Mitchell, Scott A.; Ortwine, Daniel F.; Di Paolo, Julie; Reif, Karin; Scheerens, Heleen; Schmitt, Aaron; Sowell, C. Gregory; Wang, Xiaojing; Wong, Harvey; Xiong, Jin-Ming; Xu, Jianjun; Zhao, Zhongdong; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1333-1337</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">SAR studies focused on improving the pharmacokinetic (PK) properties of the previously reported potent and selective Btk inhibitor CGI-1746 resulted in the clin. candidate GDC-0834, which retained the potency and selectivity of CGI-1746, but with much improved PK in preclin. animal models.  Structure based design efforts drove this work as modifications to CGI-1746 were investigated at both the solvent exposed region as well as 'H3 binding pocket'.  However, in vitro metabolic evaluation of GDC-0834 revealed a non CYP-mediated metabolic process that was more prevalent in human than preclin. species (mouse, rat, dog, cyno), leading to a high-level of uncertainly in predicting human pharmacokinetics.  Due to its promising potency, selectivity, and preclin. efficacy, a single dose IND was filed and GDC-0834 was taken in to a single dose phase I trial in healthy volunteers to quickly evaluate the human pharmacokinetics.  In human, GDC-0834 was found to be highly labile at the exo-cyclic amide bond that links the tetrahydrobenzothiophene moiety to the central aniline ring, resulting in insufficient parent drug exposure.  This information informed the back-up program and discovery of improved inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhL04eYDiT3bVg90H21EOLACvtfcHk0lgC4Rmo8cDvnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVSit7w%253D&md5=fdebc0199c8222e093cfb9583244bce3</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.01.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.01.032%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DBremer%26aufirst%3DM.%2BC.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DDambach%26aufirst%3DD.%26aulast%3DGallion%26aufirst%3DS.%26aulast%3DHymowitz%26aufirst%3DS.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLubach%26aufirst%3DJ.%26aulast%3DMacaluso%26aufirst%3DJ.%26aulast%3DMaciejewski%26aufirst%3DP.%26aulast%3DMaurer%26aufirst%3DB.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DSchmitt%26aufirst%3DA.%26aulast%3DSowell%26aufirst%3DC.%2BG.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DXiong%26aufirst%3DJ.-M.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DPotent%2520and%2520Selective%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitors%253A%2520Discovery%2520of%2520GDC-0834%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1333%26epage%3D1337%26doi%3D10.1016%2Fj.bmcl.2015.01.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenningloh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haselmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu-Bujalski, L.</span></span> <span> </span><span class="NLM_article-title">Ability of Bruton’s Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but Not B-Cell Receptor Signaling</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">208</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1124/mol.116.107037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1124%2Fmol.116.107037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=28062735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpsFajtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2017&pages=208-219&author=A.+T.+Benderauthor=A.+Gardbergauthor=A.+Pereiraauthor=T.+Johnsonauthor=Y.+Wuauthor=R.+Grenninglohauthor=J.+Headauthor=F.+Morandiauthor=P.+Haselmayerauthor=L.+Liu-Bujalski&title=Ability+of+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitors+to+Sequester+Y551+and+Prevent+Phosphorylation+Determines+Potency+for+Inhibition+of+Fc+Receptor+but+Not+B-Cell+Receptor+Signaling&doi=10.1124%2Fmol.116.107037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Ability of Bruton's tyrosine kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of Fc receptor but not B-cell receptor signaling</span></div><div class="casAuthors">Bender, Andrew T.; Gardberg, Anna; Pereira, Albertina; Johnson, Theresa; Wu, Yin; Grenningloh, Roland; Head, Jared; Morandi, Federica; Haselmayer, Philipp; Liu-Bujalski, Lesley</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">208-219</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is expressed in a variety of hematopoietic cells.  Btk has been demonstrated to regulate signaling downstream of the B-cell receptor (BCR), Fc receptors (FcRs), and toll-like receptors.  It has become an attractive drug target because its inhibition may provide significant efficacy by simultaneously blocking multiple disease mechanisms.  Consequently, a large no. of Btk inhibitors have been developed.  These compds. have diverse binding modes, and both reversible and irreversible inhibitors have been developed.  Reported herein, we have tested nine Btk inhibitors and characterized on a mol. level how their interactions with Btk define their ability to block different signaling pathways.  By solving the crystal structures of Btk inhibitors bound to the enzyme, we discovered that the compds. can be classified by their ability to trigger sequestration of Btk residue Y551.  In cells, we found that sequestration of Y551 renders it inaccessible for phosphorylation.  The ability to sequester Y551 was an important determinant of potency against FcγR signaling as Y551 sequestering compds. were more potent for inhibiting basophils and mast cells.  This result was true for the inhibition of FcγR signaling as well.  In contrast, Y551 sequestration was less a factor in detg. potency against BCR signaling.  We also found that Btk activity is regulated differentially in basophils and B cells.  These results elucidate important determinants for Btk inhibitor potency against different signaling pathways and provide insight for designing new compds. with a broader inhibitory profile that will likely result in greater efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrN8F--ON3M7Vg90H21EOLACvtfcHk0lgC4Rmo8cDvnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpsFajtr8%253D&md5=f869d52d6bc1aabf352988787ff1cbcf</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1124%2Fmol.116.107037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.116.107037%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%2BT.%26aulast%3DGardberg%26aufirst%3DA.%26aulast%3DPereira%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DGrenningloh%26aufirst%3DR.%26aulast%3DHead%26aufirst%3DJ.%26aulast%3DMorandi%26aufirst%3DF.%26aulast%3DHaselmayer%26aufirst%3DP.%26aulast%3DLiu-Bujalski%26aufirst%3DL.%26atitle%3DAbility%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitors%2520to%2520Sequester%2520Y551%2520and%2520Prevent%2520Phosphorylation%2520Determines%2520Potency%2520for%2520Inhibition%2520of%2520Fc%2520Receptor%2520but%2520Not%2520B-Cell%2520Receptor%2520Signaling%26jtitle%3DMol.%2520Pharmacol.%26date%3D2017%26volume%3D91%26spage%3D208%26epage%3D219%26doi%3D10.1124%2Fmol.116.107037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pulz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angst, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gessier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersperger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinniger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janser, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Revesz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waelchli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerlin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cenni, B.</span></span> <span> </span><span class="NLM_article-title">Design of Potent and Selective Covalent Inhibitors of Bruton’s Tyrosine Kinase Targeting an Inactive Conformation</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1467</span>– <span class="NLM_lpage">1472</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00317</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00317" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslegt7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1467-1472&author=R.+Pulzauthor=D.+Angstauthor=J.+Dawsonauthor=F.+Gessierauthor=S.+Gutmannauthor=R.+Herspergerauthor=A.+Hinnigerauthor=P.+Janserauthor=G.+Kochauthor=L.+Reveszauthor=A.+Vulpettiauthor=R.+Waelchliauthor=A.+Zimmerlinauthor=B.+Cenni&title=Design+of+Potent+and+Selective+Covalent+Inhibitors+of+Bruton%E2%80%99s+Tyrosine+Kinase+Targeting+an+Inactive+Conformation&doi=10.1021%2Facsmedchemlett.9b00317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation</span></div><div class="casAuthors">Pulz, Robert; Angst, Daniela; Dawson, Janet; Gessier, Francois; Gutmann, Sascha; Hersperger, Rene; Hinniger, Alexandra; Janser, Philipp; Koch, Guido; Revesz, Laszlo; Vulpetti, Anna; Waelchli, Rudolf; Zimmerlin, Alfred; Cenni, Bruno</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1467-1472</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) is a member of the TEC kinase family and is selectively expressed in a subset of immune cells.  It is a key regulator of antigen receptor signaling in B cells and of Fc receptor signaling in mast cells and macrophages.  A BTK inhibitor will likely have a pos. impact on autoimmune diseases which are caused by autoreactive B cells and immune-complex driven inflammation.  We report the design, optimization, and characterization of potent and selective covalent BTK inhibitors.  Starting from the selective reversible inhibitor 3 binding to an inactive conformation of BTK, we designed covalent irreversible compds. by attaching an electrophilic warhead to reach Cys481.  The first prototype 4 covalently modified BTK and showed an excellent kinase selectivity including several Cys-contg. kinases, validating the design concept.  In addn., this compd. blocked FcγR-mediated hypersensitivity in vivo.  Optimization of whole blood potency and metabolic stability resulted in compds. such as 8, which maintained the excellent kinase selectivity and showed improved BTK occupancy in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtG6N4PXtS_bVg90H21EOLACvtfcHk0lhtm5cYYxj2Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslegt7zF&md5=1c05c5f592e5edf288855190d2b18391</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00317%26sid%3Dliteratum%253Aachs%26aulast%3DPulz%26aufirst%3DR.%26aulast%3DAngst%26aufirst%3DD.%26aulast%3DDawson%26aufirst%3DJ.%26aulast%3DGessier%26aufirst%3DF.%26aulast%3DGutmann%26aufirst%3DS.%26aulast%3DHersperger%26aufirst%3DR.%26aulast%3DHinniger%26aufirst%3DA.%26aulast%3DJanser%26aufirst%3DP.%26aulast%3DKoch%26aufirst%3DG.%26aulast%3DRevesz%26aufirst%3DL.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DWaelchli%26aufirst%3DR.%26aulast%3DZimmerlin%26aufirst%3DA.%26aulast%3DCenni%26aufirst%3DB.%26atitle%3DDesign%2520of%2520Potent%2520and%2520Selective%2520Covalent%2520Inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Targeting%2520an%2520Inactive%2520Conformation%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1467%26epage%3D1472%26doi%3D10.1021%2Facsmedchemlett.9b00317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-(3-(5-((3-Acrylamido-4-(Morpholine-4-Carbonyl)Phenyl)Amino)-1-Methyl-6-Oxo-1,6-Dihydropyridin-3-Yl)-2-Methylphenyl)-4-(Tert-Butyl)Benzamide (CHMFL-BTK-01) as a Highly Selective Irreversible Bruton’s Tyrosine Kinase (BTK) Inhibitor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1016%2Fj.ejmech.2017.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=28315597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC2sXksVOms7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2017&pages=107-125&author=Q.+Liangauthor=Y.+Chenauthor=K.+Yuauthor=C.+Chenauthor=S.+Zhangauthor=A.+Wangauthor=W.+Wangauthor=H.+Wuauthor=X.+Liuauthor=B.+Wangauthor=L.+Wangauthor=Z.+Huauthor=W.+Wangauthor=T.+Renauthor=S.+Zhangauthor=Q.+Liuauthor=C.-H.+Yunauthor=J.+Liu&title=Discovery+of+N-%283-%285-%28%283-Acrylamido-4-%28Morpholine-4-Carbonyl%29Phenyl%29Amino%29-1-Methyl-6-Oxo-1%2C6-Dihydropyridin-3-Yl%29-2-Methylphenyl%29-4-%28Tert-Butyl%29Benzamide+%28CHMFL-BTK-01%29+as+a+Highly+Selective+Irreversible+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29+Inhibitor&doi=10.1016%2Fj.ejmech.2017.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor</span></div><div class="casAuthors">Liang, Qianmao; Chen, Yongfei; Yu, Kailin; Chen, Cheng; Zhang, Shouxiang; Wang, Aoli; Wang, Wei; Wu, Hong; Liu, Xiaochuan; Wang, Beilei; Wang, Li; Hu, Zhenquan; Wang, Wenchao; Ren, Tao; Zhang, Shanchun; Liu, Qingsong; Yun, Cai-Hong; Liu, Jing</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">107-125</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Currently there are several irreversible BTK inhibitors targeting Cys 481 residue under preclin. or clin. development.  However, most of these inhibitors also targeted other kinases such as BMX, JAK3, and EGFR that bear the highly similar active cysteine residues.  Through a structure-based drug design approach, the authors discovered a highly potent (IC50: 7 nM) irreversible BTK inhibitor compd. 9 (CHMFL-BTK-01), which displayed a high selectivity profile in KINOMEscan (S score (35) = 0.00) among 468 kinases/mutants at the concn. of 1 μM.  Compd. 9 completely abolished BMX, JAK3 and EGFR's activity.  Both x-ray crystal structure and cysteine-serine mutation mediated rescue expt. confirmed 9's irreversible binding mode.  Compd. 9 also potently inhibited BTK Y223 auto-phosphorylation (EC50: <30 nM), arrested cell cycle in G0/G1 phase and induced apoptosis in U2932 and Pfeiffer cells.  The authors believe these features would make 9 a good pharmacol. tool to study the BTK related pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC1_3nnSrlpLVg90H21EOLACvtfcHk0lhtm5cYYxj2Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXksVOms7o%253D&md5=b9505b5c24a48cc61eff64a081b81a79</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DRen%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520N-%25283-%25285-%2528%25283-Acrylamido-4-%2528Morpholine-4-Carbonyl%2529Phenyl%2529Amino%2529-1-Methyl-6-Oxo-1%252C6-Dihydropyridin-3-Yl%2529-2-Methylphenyl%2529-4-%2528Tert-Butyl%2529Benzamide%2520%2528CHMFL-BTK-01%2529%2520as%2520a%2520Highly%2520Selective%2520Irreversible%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%2520Inhibitor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D131%26spage%3D107%26epage%3D125%26doi%3D10.1016%2Fj.ejmech.2017.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourne, P. E.</span></span> <span> </span><span class="NLM_article-title">Progress with Covalent Small-Molecule Kinase Inhibitors</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">735</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2018.01.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1016%2Fj.drudis.2018.01.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=29337202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslShurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=727-735&author=Z.+Zhaoauthor=P.+E.+Bourne&title=Progress+with+Covalent+Small-Molecule+Kinase+Inhibitors&doi=10.1016%2Fj.drudis.2018.01.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Progress with covalent small-molecule kinase inhibitors</span></div><div class="casAuthors">Zhao, Zheng; Bourne, Philip E.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">727-735</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">With reduced risk of toxicity and high selectivity, covalent small-mol. kinase inhibitors (CSKIs) have emerged rapidly.  Through the lens of structural system pharmacol., here we review this rapid progress by considering design strategies and the challenges and opportunities offered by current CSKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog6l6qMAopYLVg90H21EOLACvtfcHk0lhtm5cYYxj2Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslShurg%253D&md5=f97a19f53a72044812a778ee9351fe94</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2018.01.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2018.01.035%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DBourne%26aufirst%3DP.%2BE.%26atitle%3DProgress%2520with%2520Covalent%2520Small-Molecule%2520Kinase%2520Inhibitors%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2018%26volume%3D23%26spage%3D727%26epage%3D735%26doi%3D10.1016%2Fj.drudis.2018.01.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dalvit, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span> <span> </span><span class="NLM_article-title">Intermolecular and Intramolecular Hydrogen Bonds Involving Fluorine Atoms: Implications for Recognition, Selectivity, and Chemical Properties</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">262</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201100483</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1002%2Fcmdc.201100483" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=22262517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC38Xps1CisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=262-272&author=C.+Dalvitauthor=A.+Vulpetti&title=Intermolecular+and+Intramolecular+Hydrogen+Bonds+Involving+Fluorine+Atoms%3A+Implications+for+Recognition%2C+Selectivity%2C+and+Chemical+Properties&doi=10.1002%2Fcmdc.201100483"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Intermolecular and Intramolecular Hydrogen Bonds Involving Fluorine Atoms: Implications for Recognition, Selectivity, and Chemical Properties</span></div><div class="casAuthors">Dalvit, Claudio; Vulpetti, Anna</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">262-272</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A correlation between 19F NMR isotropic chem. shift and close intermol. F···H-X contacts (with X = N or O) has been identified upon anal. of the X-ray crystal structures of fluorinated mols. listed in the Cambridge Structural Database (CSD).  An optimal F···X distance involving primary and shielded secondary fluorine atoms in hydrogen-bond formation along with a correlation between F···H distance and F···H-X angle were also derived from the anal.  The hydrogen bonds involving fluorine are relevant, not only for the recognition mechanism and stabilization of a preferred conformation, but also for improvement in the permeability of the mols., as shown with examples taken from a proprietary database.  Results of an anal. of the small no. of fluorine-contg. natural products listed in the Protein Data Bank (PDB) appear to strengthen the derived correlation between 19F NMR isotropic chem. shift and interactions involving fluorine (also known as the "rule of shielding") and provides a hypothesis for the recognition mechanism and catalytic activity of specific enzymes.  Novel chem. scaffolds, based on the rule of shielding, have been designed for recognizing distinct structural motifs present in proteins.  It is envisaged that this approach could find useful applications in drug design for the efficient optimization of chem. fragments or promising compds. by increasing potency and selectivity against the desired biomol. target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDtfxYsmG4NrVg90H21EOLACvtfcHk0lhqTpEqhqjPjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xps1CisA%253D%253D&md5=21efccc023f44ed600725e2a834222ae</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201100483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201100483%26sid%3Dliteratum%253Aachs%26aulast%3DDalvit%26aufirst%3DC.%26aulast%3DVulpetti%26aufirst%3DA.%26atitle%3DIntermolecular%2520and%2520Intramolecular%2520Hydrogen%2520Bonds%2520Involving%2520Fluorine%2520Atoms%253A%2520Implications%2520for%2520Recognition%252C%2520Selectivity%252C%2520and%2520Chemical%2520Properties%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D262%26epage%3D272%26doi%3D10.1002%2Fcmdc.201100483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palkowitz, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, R. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Diverse N -Acryloyl Azetidines and Evaluation of Their Enhanced Thiol Reactivities</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2270</span>– <span class="NLM_lpage">2273</span>, <span class="refDoi"> DOI: 10.1021/acs.orglett.7b00788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.orglett.7b00788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt1KqtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=2270-2273&author=M.+D.+Palkowitzauthor=B.+Tanauthor=H.+Huauthor=K.+Rothauthor=R.+A.+Bauer&title=Synthesis+of+Diverse+N+-Acryloyl+Azetidines+and+Evaluation+of+Their+Enhanced+Thiol+Reactivities&doi=10.1021%2Facs.orglett.7b00788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Diverse N-Acryloyl Azetidines and Evaluation of Their Enhanced Thiol Reactivities</span></div><div class="casAuthors">Palkowitz, Maximilian D.; Tan, Bo; Hu, Haitao; Roth, Kenneth; Bauer, Renato A.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2270-2273</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Acyl azetidines exhibit nonplanar hybridization, leading to lower amide-like character of the corresponding (O)C-N bonds.  This impacts N-acryloyl azetidines by producing enhanced electrophilicy at appended Michael acceptors.  Herein, reactivity data are reported in the presence of glutathione (GSH) in phosphate buffer (pH 7.4) at 37 °C.  Wide reactivity ranges are obsd. by varying substitution at the Michael acceptor or by modulating the electron-withdrawing character of substituents at the C3 position of the azetidine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjUFdHgOWgc7Vg90H21EOLACvtfcHk0lhqTpEqhqjPjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt1KqtLw%253D&md5=d65414bda2976c07bc76cd0df6d4a38d</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Facs.orglett.7b00788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.orglett.7b00788%26sid%3Dliteratum%253Aachs%26aulast%3DPalkowitz%26aufirst%3DM.%2BD.%26aulast%3DTan%26aufirst%3DB.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DRoth%26aufirst%3DK.%26aulast%3DBauer%26aufirst%3DR.%2BA.%26atitle%3DSynthesis%2520of%2520Diverse%2520N%2520-Acryloyl%2520Azetidines%2520and%2520Evaluation%2520of%2520Their%2520Enhanced%2520Thiol%2520Reactivities%26jtitle%3DOrg.%2520Lett.%26date%3D2017%26volume%3D19%26spage%3D2270%26epage%3D2273%26doi%3D10.1021%2Facs.orglett.7b00788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span> <span> </span><span class="NLM_article-title">Evaluation of Enzyme Inhibitors in Drug Discovery. A Guide for Medicinal Chemists and Pharmacologists</span>. <i>Methods Biochem. Anal.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">265</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=16350889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A280%3ADC%252BD2MnmtlyjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2005&pages=1-265&author=R.+A.+Copeland&title=Evaluation+of+Enzyme+Inhibitors+in+Drug+Discovery.+A+Guide+for+Medicinal+Chemists+and+Pharmacologists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists</span></div><div class="casAuthors">Copeland Robert A</div><div class="citationInfo"><span class="NLM_cas:title">Methods of biochemical analysis</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-265</span>
        ISSN:<span class="NLM_cas:issn">0076-6941</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSR7_ubfiC0DK2q3xNe7a7QfW6udTcc2ebnPj31nunNPLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MnmtlyjsA%253D%253D&md5=4bb6759b5155aa6c2b6a462432afda7f</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26atitle%3DEvaluation%2520of%2520Enzyme%2520Inhibitors%2520in%2520Drug%2520Discovery.%2520A%2520Guide%2520for%2520Medicinal%2520Chemists%2520and%2520Pharmacologists%26jtitle%3DMethods%2520Biochem.%2520Anal.%26date%3D2005%26volume%3D46%26spage%3D1%26epage%3D265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paulini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diederich, F.</span></span> <span> </span><span class="NLM_article-title">Orthogonal Multipolar Interactions in Structural Chemistry and Biology</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1788</span>– <span class="NLM_lpage">1805</span>, <span class="refDoi"> DOI: 10.1002/anie.200462213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1002%2Fanie.200462213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BD2MXislWkt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2005&pages=1788-1805&author=R.+Pauliniauthor=K.+M%C3%BCllerauthor=F.+Diederich&title=Orthogonal+Multipolar+Interactions+in+Structural+Chemistry+and+Biology&doi=10.1002%2Fanie.200462213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Orthogonal multipolar interactions in structural chemistry and biology</span></div><div class="casAuthors">Paulini, Ralph; Mueller, Klaus; Diederich, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1788-1805</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The past few decades of mol. recognition studies have greatly enhanced our knowledge on apolar, ion-dipole, and hydrogen-bonding interactions.  However, much less attention has been given to the role that multipolar interactions, in particular those with orthogonal dipolar alignment, play in organizing a crystal lattice or stabilizing complexes involving biol. receptors.  By using results from database mining, this review attempts to give an overview of types and structural features of these previously rather overlooked interactions.  A no. of illustrative examples of these interactions found in X-ray crystal structures of small mols. and protein-ligand complexes demonstrate their propensity and thus potential importance for both, chem. and biol. mol. recognition processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTGHoutIq12LVg90H21EOLACvtfcHk0lhqTpEqhqjPjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXislWkt7s%253D&md5=6ad842547313b27fc1676e9c3a001909</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1002%2Fanie.200462213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200462213%26sid%3Dliteratum%253Aachs%26aulast%3DPaulini%26aufirst%3DR.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26aulast%3DDiederich%26aufirst%3DF.%26atitle%3DOrthogonal%2520Multipolar%2520Interactions%2520in%2520Structural%2520Chemistry%2520and%2520Biology%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2005%26volume%3D44%26spage%3D1788%26epage%3D1805%26doi%3D10.1002%2Fanie.200462213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggs, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azimioara, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzfeld, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lélias, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span> <span> </span><span class="NLM_article-title">A Small Molecule-Kinase Interaction Map for Clinical Kinase Inhibitors</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.-M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+Small+Molecule-Kinase+Interaction+Map+for+Clinical+Kinase+Inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0liB_GNaY2o0MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.-M.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520Small%2520Molecule-Kinase%2520Interaction%2520Map%2520for%2520Clinical%2520Kinase%2520Inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salerno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span> <span> </span><span class="NLM_article-title">Activation State-Dependent Binding of Small Molecule Kinase Inhibitors: Structural Insights from Biochemistry</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1241</span>– <span class="NLM_lpage">1249</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1016%2Fj.chembiol.2010.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=21095574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVGntrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=1241-1249&author=L.+M.+Wodickaauthor=P.+Ciceriauthor=M.+I.+Davisauthor=J.+P.+Huntauthor=M.+Floydauthor=S.+Salernoauthor=X.+H.+Huaauthor=J.+M.+Fordauthor=R.+C.+Armstrongauthor=P.+P.+Zarrinkarauthor=D.+K.+Treiber&title=Activation+State-Dependent+Binding+of+Small+Molecule+Kinase+Inhibitors%3A+Structural+Insights+from+Biochemistry&doi=10.1016%2Fj.chembiol.2010.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Activation state-dependent binding of small molecule kinase inhibitors: Structural insights from biochemistry</span></div><div class="casAuthors">Wodicka, Lisa M.; Ciceri, Pietro; Davis, Mindy I.; Hunt, Jeremy P.; Floyd, Mark; Salerno, Sara; Hua, Xuequn H.; Ford, Julia M.; Armstrong, Robert C.; Zarrinkar, Patrick P.; Treiber, Daniel K.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1241-1249</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Interactions between kinases and small mol. inhibitors can be activation state dependent.  A detailed understanding of inhibitor binding therefore requires characterizing interactions across multiple activation states.  We have systematically explored the effects of ABL1 activation loop phosphorylation and PDGFR family autoinhibitory juxtamembrane domain docking on inhibitor binding affinity.  For a diverse compd. set, the affinity patterns correctly classify inhibitors as having type I or type II binding modes, and we show that juxtamembrane domain docking can have dramatic neg. effects on inhibitor affinity.  The results have allowed us to assoc. ligand-induced conformational changes obsd. in cocrystal structures with specific energetic costs.  The approach we describe enables investigation of the complex relationship between kinase activation state and compd. binding affinity and should facilitate strategic inhibitor design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN9CBcWzoWcrVg90H21EOLACvtfcHk0liB_GNaY2o0MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVGntrfL&md5=d34c17fd4192eaa4ec0c2c84d5633d02</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DSalerno%26aufirst%3DS.%26aulast%3DHua%26aufirst%3DX.%2BH.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26atitle%3DActivation%2520State-Dependent%2520Binding%2520of%2520Small%2520Molecule%2520Kinase%2520Inhibitors%253A%2520Structural%2520Insights%2520from%2520Biochemistry%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D1241%26epage%3D1249%26doi%3D10.1016%2Fj.chembiol.2010.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berg, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melrose, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Privat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunkel, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span> <span> </span><span class="NLM_article-title">Chemical Target and Pathway Toxicity Mechanisms Defined in Primary Human Cell Systems</span>. <i>J. Pharmacol. Toxicol. Methods</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1016/j.vascn.2009.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1016%2Fj.vascn.2009.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=19879948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1WltbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2010&pages=3-15&author=E.+L.+Bergauthor=J.+Yangauthor=J.+Melroseauthor=D.+Nguyenauthor=S.+Privatauthor=E.+Roslerauthor=E.+J.+Kunkelauthor=S.+Ekins&title=Chemical+Target+and+Pathway+Toxicity+Mechanisms+Defined+in+Primary+Human+Cell+Systems&doi=10.1016%2Fj.vascn.2009.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical target and pathway toxicity mechanisms defined in primary human cell systems</span></div><div class="casAuthors">Berg, Ellen L.; Yang, Jian; Melrose, Jennifer; Nguyen, Dat; Privat, Sylvie; Rosler, Elen; Kunkel, Eric J.; Ekins, Sean</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-15</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The ability to predict the health effects resulting from drug or chem. exposure has been challenging due to the complexity of human biol.  Approaches that detect and discriminate a broad range of mechanisms in testing formats that are predictive and yet cost-effective are needed.  Here, the authors evaluated the performance of BioMAP systems, primary human cell-based disease models, as a platform for characterization of chem. toxicity mechanisms.  For this the authors tested a set of compds. with known or well-studied mechanisms in a panel of 8 BioMAP assays relevant to human respiratory, skin, immune and vascular exposure sites.  The authors evaluated the ability to detect and distinguish compds. based on mechanisms of action, comparing the BioMAP activity profiles generated in a reduced sample no. format to ref. database profiles derived from multiple expts.  The authors also studied the role of BioMAP assay panel size and concn. effects, both of which were found to contribute to the ability to discriminate chems. and mechanisms.  Compds. with diverse mechanisms, including modulators of the NFκB pathway, microtubule function and mitochondrial activity, could be discriminated and classified into target and pathway mechanisms in both assay formats.  Certain inhibitors of mitochondrial function, such as rotenone and sodium azide, but not others, were classified with inducers of endoplasmic reticulum stress, providing insight into the toxicity mechanisms of these agents.  This method may have utility in classifying novel agents with unknown modes of action according to their effects on toxicity pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojvjOxKr9mgLVg90H21EOLACvtfcHk0ljzZGrOfzEb3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1WltbnN&md5=7482b930574fe516d955e0b1f8625291</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2009.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2009.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DBerg%26aufirst%3DE.%2BL.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DMelrose%26aufirst%3DJ.%26aulast%3DNguyen%26aufirst%3DD.%26aulast%3DPrivat%26aufirst%3DS.%26aulast%3DRosler%26aufirst%3DE.%26aulast%3DKunkel%26aufirst%3DE.%2BJ.%26aulast%3DEkins%26aufirst%3DS.%26atitle%3DChemical%2520Target%2520and%2520Pathway%2520Toxicity%2520Mechanisms%2520Defined%2520in%2520Primary%2520Human%2520Cell%2520Systems%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2010%26volume%3D61%26spage%3D3%26epage%3D15%26doi%3D10.1016%2Fj.vascn.2009.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pompliano, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meek, T. D.</span></span> <span> </span><span class="NLM_article-title">Drug-Target Residence Time and Its Implications for Lead Optimization</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">730</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1038/nrd2082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1038%2Fnrd2082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=16888652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=730-739&author=R.+A.+Copelandauthor=D.+L.+Pomplianoauthor=T.+D.+Meek&title=Drug-Target+Residence+Time+and+Its+Implications+for+Lead+Optimization&doi=10.1038%2Fnrd2082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-target residence time and its implications for lead optimization</span></div><div class="casAuthors">Copeland, Robert A.; Pompliano, David L.; Meek, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">730-739</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromols. by low-mol.-mass drugs.  The binding of drugs to their macromol. targets is therefore seen as paramount for pharmacol. activity.  In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC50 or Kd.  This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex.  We describe the potential advantages of long residence time in terms of duration of pharmacol. effect and target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry6SJrMlrrTbVg90H21EOLACvtfcHk0ljzZGrOfzEb3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D&md5=60ede2301584b10ac4e8fa18e1e6d107</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fnrd2082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2082%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26atitle%3DDrug-Target%2520Residence%2520Time%2520and%2520Its%2520Implications%2520for%2520Lead%2520Optimization%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D730%26epage%3D739%26doi%3D10.1038%2Fnrd2082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tester, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labenski, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witowski, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lounsbury, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazdiyasni, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacht, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freed, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovskiy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W. F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>346</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.203489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1124%2Fjpet.113.203489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=23709115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2013&pages=219-228&author=E.+K.+Evansauthor=R.+Testerauthor=S.+Aslanianauthor=R.+Karpauthor=M.+Sheetsauthor=M.+T.+Labenskiauthor=S.+R.+Witowskiauthor=H.+Lounsburyauthor=P.+Chaturvediauthor=H.+Mazdiyasniauthor=Z.+Zhuauthor=M.+Nachtauthor=M.+I.+Freedauthor=R.+C.+Petterauthor=A.+Dubrovskiyauthor=J.+Singhauthor=W.+F.+Westlin&title=Inhibition+of+Btk+with+CC-292+Provides+Early+Pharmacodynamic+Assessment+of+Activity+in+Mice+and+Humans&doi=10.1124%2Fjpet.113.203489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans</span></div><div class="casAuthors">Evans, Erica K.; Tester, Richland; Aslanian, Sharon; Karp, Russell; Sheets, Michael; Labenski, Matthew T.; Witowski, Steven R.; Lounsbury, Heather; Chaturvedi, Prasoon; Mazdiyasni, Hormoz; Zhu, Zhendong; Nacht, Mariana; Freed, Martin I.; Petter, Russell C.; Dubrovskiy, Alex; Singh, Juswinder; Westlin, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-228</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Targeted therapies that suppress B cell receptor (BCR) signaling have emerged as promising agents in autoimmune disease and B cell malignancies.  Bruton's tyrosine kinase (Btk) plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity.  N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide (CC-292) is a highly selective, covalent Btk inhibitor and a sensitive and quant. assay that measures CC-292-Btk engagement has been developed.  This translational pharmacodynamic assay has accompanied CC-292 through each step of drug discovery and development.  These studies demonstrate the quantity of Btk bound by CC-292 correlates with the efficacy of CC-292 in vitro and in the collagen-induced arthritis model of autoimmune disease.  Recently, CC-292 has entered human clin. trials with a trial design that has provided rapid insight into safety, pharmacokinetics, and pharmacodynamics.  This first-in-human healthy volunteer trial has demonstrated that a single oral dose of 2 mg/kg CC-292 consistently engaged all circulating Btk protein and provides the basis for rational dose selection in future clin. trials.  This targeted covalent drug design approach has enabled the discovery and early clin. development of CC-292 and has provided support for Btk as a valuable drug target for B-cell mediated disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN2l8ZCVqCFLVg90H21EOLACvtfcHk0ljzZGrOfzEb3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM&md5=95fac997a246e59d943dd554af358a65</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.203489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.203489%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DE.%2BK.%26aulast%3DTester%26aufirst%3DR.%26aulast%3DAslanian%26aufirst%3DS.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DLabenski%26aufirst%3DM.%2BT.%26aulast%3DWitowski%26aufirst%3DS.%2BR.%26aulast%3DLounsbury%26aufirst%3DH.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DMazdiyasni%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DFreed%26aufirst%3DM.%2BI.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26atitle%3DInhibition%2520of%2520Btk%2520with%2520CC-292%2520Provides%2520Early%2520Pharmacodynamic%2520Assessment%2520of%2520Activity%2520in%2520Mice%2520and%2520Humans%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D346%26spage%3D219%26epage%3D228%26doi%3D10.1124%2Fjpet.113.203489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jerne, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordin, A. A.</span></span> <span> </span><span class="NLM_article-title">Plaque Formation in Agar by Single Antibody-Producing Cells</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1963</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">405</span>, <span class="refDoi"> DOI: 10.1126/science.140.3565.405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1126%2Fscience.140.3565.405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=13957684" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=1963&pages=405&author=N.+K.+Jerneauthor=A.+A.+Nordin&title=Plaque+Formation+in+Agar+by+Single+Antibody-Producing+Cells&doi=10.1126%2Fscience.140.3565.405"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1126%2Fscience.140.3565.405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.140.3565.405%26sid%3Dliteratum%253Aachs%26aulast%3DJerne%26aufirst%3DN.%2BK.%26aulast%3DNordin%26aufirst%3DA.%2BA.%26atitle%3DPlaque%2520Formation%2520in%2520Agar%2520by%2520Single%2520Antibody-Producing%2520Cells%26jtitle%3DScience%26date%3D1963%26volume%3D140%26spage%3D405%26doi%3D10.1126%2Fscience.140.3565.405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trentham, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townes, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, A. H.</span></span> <span> </span><span class="NLM_article-title">Autoimmunity to Type II Collagen an Experimental Model of Arthritis</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">857</span>– <span class="NLM_lpage">868</span>, <span class="refDoi"> DOI: 10.1084/jem.146.3.857</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1084%2Fjem.146.3.857" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=894190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A280%3ADyaE2s3ltFejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=1977&pages=857-868&author=D.+E.+Trenthamauthor=A.+S.+Townesauthor=A.+H.+Kang&title=Autoimmunity+to+Type+II+Collagen+an+Experimental+Model+of+Arthritis&doi=10.1084%2Fjem.146.3.857"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Autoimmunity to type II collagen an experimental model of arthritis</span></div><div class="casAuthors">Trentham D E; Townes A S; Kang A H</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of experimental medicine</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">857-68</span>
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    </div><div class="casAbstract">We have found that intradermal injection of native type II collagen extracted from human, chick or rat cartilage induces an inflammatory arthritis in approximately 40% of rats of several strains whether complete Freund's adjuvant or incomplete Freund's adjuvant is used.  Type I or III collagen extracted from skin, cartilage proteoglycans and alpha1(II) chains were incapable of eliciting arthritis, as was type II collagen injected without adjuvant.  The disease is a chronic proliferative synovitis, resembling adjuvant arthritis in rats and rheumatoid arthritis in humans.  Native type II co-lagen modified by limited pepsin digestion still produces arthritis, suggesting that type-specific determinants residing in the helical region of the molecule are responsible for the induction of disease.  Since homologous type II collagen emulsified in oil without bacterial preparations regularly causes the disease, this new animal model of arthritis represents a unique example of experimentally-inducible autoimmunity to a tissue component.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSQXNpzPUCAfUewzGPswiWOfW6udTcc2ebpwkv9sgi_Arntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE2s3ltFejtg%253D%253D&md5=022165ad1990f3c8398394f8624e4513</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1084%2Fjem.146.3.857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.146.3.857%26sid%3Dliteratum%253Aachs%26aulast%3DTrentham%26aufirst%3DD.%2BE.%26aulast%3DTownes%26aufirst%3DA.%2BS.%26aulast%3DKang%26aufirst%3DA.%2BH.%26atitle%3DAutoimmunity%2520to%2520Type%2520II%2520Collagen%2520an%2520Experimental%2520Model%2520of%2520Arthritis%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1977%26volume%3D146%26spage%3D857%26epage%3D868%26doi%3D10.1084%2Fjem.146.3.857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duris, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fava, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noelle, R. J.</span></span> <span> </span><span class="NLM_article-title">Collagen-Induced Arthritis as a Model of Rheumatoid Arthritis</span>. <i>Clin. Immunol. Immunopathol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1006/clin.1994.1164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1006%2Fclin.1994.1164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=7923907" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1994&pages=11-18&author=F.+H.+Durisauthor=R.+A.+Favaauthor=R.+J.+Noelle&title=Collagen-Induced+Arthritis+as+a+Model+of+Rheumatoid+Arthritis&doi=10.1006%2Fclin.1994.1164"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1006%2Fclin.1994.1164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fclin.1994.1164%26sid%3Dliteratum%253Aachs%26aulast%3DDuris%26aufirst%3DF.%2BH.%26aulast%3DFava%26aufirst%3DR.%2BA.%26aulast%3DNoelle%26aufirst%3DR.%2BJ.%26atitle%3DCollagen-Induced%2520Arthritis%2520as%2520a%2520Model%2520of%2520Rheumatoid%2520Arthritis%26jtitle%3DClin.%2520Immunol.%2520Immunopathol.%26date%3D1994%26volume%3D73%26spage%3D11%26epage%3D18%26doi%3D10.1006%2Fclin.1994.1164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. O.</span></span> <span> </span><span class="NLM_article-title">Collagen-Induced Arthritis in Mice: A Major Role for Tumor Necrosis Factor-α</span>. In  <i>Target Discovery and Validation Reviews and Protocols</i>; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">NJ</span>, <span class="NLM_year">2007</span>; Vol.  <span class="NLM_volume">361</span>, pp  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">284</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&pages=265-284&author=R.+O.+Williams&title=Target+Discovery+and+Validation+Reviews+and+Protocols"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DR.%2BO.%26atitle%3DCollagen-Induced%2520Arthritis%2520in%2520Mice%253A%2520A%2520Major%2520Role%2520for%2520Tumor%2520Necrosis%2520Factor-%25CE%25B1%26btitle%3DTarget%2520Discovery%2520and%2520Validation%2520Reviews%2520and%2520Protocols%26pub%3DHumana%2520Press%26date%3D2007%26volume%3D361%26spage%3D265%26epage%3D284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">End, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabanski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakab, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuhler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funhoff, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimanova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kistowska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinhikar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiolica, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuhr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cenni, B.</span></span> <span> </span><span class="NLM_article-title">LOU064: A highly selective and potent covalent oral BTK inhibitor with promising pharmacodynamic effects in skin</span>. <i>Allergy</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">376</span>, (Abstract LBPD1718) <span class="refDoi"> DOI: 10.1111/all.13960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1111%2Fall.13960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=31396969" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2019&pages=333-376&author=M.+Kaulauthor=J.+Storimauthor=P.+Endauthor=M.+Cabanskiauthor=A.+Jakabauthor=C.+Schuhlerauthor=E.+Funhoffauthor=F.+Schaeferauthor=E.+Dimanovaauthor=M.+Kistowskaauthor=A.+Kinhikarauthor=A.+Maiolicaauthor=A.+Sinnauthor=R.+Fuhrauthor=B.+Cenni&title=LOU064%3A+A+highly+selective+and+potent+covalent+oral+BTK+inhibitor+with+promising+pharmacodynamic+effects+in+skin&doi=10.1111%2Fall.13960"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1111%2Fall.13960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fall.13960%26sid%3Dliteratum%253Aachs%26aulast%3DKaul%26aufirst%3DM.%26aulast%3DStorim%26aufirst%3DJ.%26aulast%3DEnd%26aufirst%3DP.%26aulast%3DCabanski%26aufirst%3DM.%26aulast%3DJakab%26aufirst%3DA.%26aulast%3DSchuhler%26aufirst%3DC.%26aulast%3DFunhoff%26aufirst%3DE.%26aulast%3DSchaefer%26aufirst%3DF.%26aulast%3DDimanova%26aufirst%3DE.%26aulast%3DKistowska%26aufirst%3DM.%26aulast%3DKinhikar%26aufirst%3DA.%26aulast%3DMaiolica%26aufirst%3DA.%26aulast%3DSinn%26aufirst%3DA.%26aulast%3DFuhr%26aufirst%3DR.%26aulast%3DCenni%26aufirst%3DB.%26atitle%3DLOU064%253A%2520A%2520highly%2520selective%2520and%2520potent%2520covalent%2520oral%2520BTK%2520inhibitor%2520with%2520promising%2520pharmacodynamic%2520effects%2520in%2520skin%26jtitle%3DAllergy%26date%3D2019%26volume%3D74%26spage%3D333%26epage%3D376%26doi%3D10.1111%2Fall.13960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 22 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Mark S. Tichenor, John J. M. Wiener, Navin L. Rao, Charlotte Pooley Deckhut, J. Kent Barbay, Kevin D. Kreutter, Genesis M. Bacani, Jianmei Wei, Leon Chang, Heather E. Murrey, Weixue Wang, Kay Ahn, Michael Huber, Elizabeth Rex, Kevin J. Coe, JieJun Wu, Mark Seierstad, Scott D. Bembenek, Kristi A. Leonard, Alec D. Lebsack, Jennifer D. Venable, <span class="NLM_string-name hlFld-ContribAuthor">James P. Edwards</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Potent and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase with Oral Anti-Inflammatory Activity. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>12 </em>
                                    (5)
                                     , 782-790. <a href="https://doi.org/10.1021/acsmedchemlett.1c00044" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.1c00044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.1c00044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.1c00044%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252BPotent%252Band%252BSelective%252BCovalent%252BInhibitor%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252Bwith%252BOral%252BAnti-Inflammatory%252BActivity%26aulast%3DTichenor%26aufirst%3DMark%2BS.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D27012021%26date%3D28032021%26date%3D05042021%26volume%3D12%26issue%3D5%26spage%3D782%26epage%3D790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhijie Wang, Jiongheng Cai, Jie Cheng, Wenqianzi Yang, Yifan Zhu, Hongmei Li, Tao Lu, Yadong Chen, <span class="NLM_string-name hlFld-ContribAuthor">Shuai Lu</span>. </span><span class="cited-content_cbyCitation_article-title">FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (6)
                                     , 2878-2900. <a href="https://doi.org/10.1021/acs.jmedchem.0c01851" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01851</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01851%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFLT3%252BInhibitors%252Bin%252BAcute%252BMyeloid%252BLeukemia%25253A%252BChallenges%252Band%252BRecent%252BDevelopments%252Bin%252BOvercoming%252BResistance%26aulast%3DWang%26aufirst%3DZhijie%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D23102020%26date%3D10032021%26volume%3D64%26issue%3D6%26spage%3D2878%26epage%3D2900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhouling Xie, Xiaoxiao Yang, Yajun Duan, Jihong Han, <span class="NLM_string-name hlFld-ContribAuthor">Chenzhong Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1283-1345. <a href="https://doi.org/10.1021/acs.jmedchem.0c01511" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01511%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BNononcologic%252BDiseases%26aulast%3DXie%26aufirst%3DZhouling%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29082020%26date%3D22012021%26volume%3D64%26issue%3D3%26spage%3D1283%26epage%3D1345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Bin Ma, Tonika Bohnert, Kevin L. Otipoby, Eric Tien, Million Arefayene, Judy Bai, Bekim Bajrami, Eris Bame, Timothy R. Chan, Michael Humora, J. Michael MacPhee, Douglas Marcotte, Devangi Mehta, Claire M. Metrick, George Moniz, Evelyne Polack, Urjana Poreci, Annick Prefontaine, Sarah Sheikh, Patricia Schroeder, Karen Smirnakis, Lei Zhang, Fengmei Zheng, <span class="NLM_string-name hlFld-ContribAuthor">Brian T. Hopkins</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of BIIB068: A Selective, Potent, Reversible Bruton’s Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (21)
                                     , 12526-12541. <a href="https://doi.org/10.1021/acs.jmedchem.0c00702" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00702</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00702%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BBIIB068%25253A%252BA%252BSelective%25252C%252BPotent%25252C%252BReversible%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitor%252Bas%252Ban%252BOrally%252BEfficacious%252BAgent%252Bfor%252BAutoimmune%252BDiseases%26aulast%3DMa%26aufirst%3DBin%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27042020%26date%3D06082020%26date%3D22072020%26volume%3D63%26issue%3D21%26spage%3D12526%26epage%3D12541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Anurag S. Srivastava, Soo Ko, Scott H. Watterson, Mark A. Pattoli, Stacey Skala, Lihong Cheng, Mary T. Obermeier, Rodney Vickery, Lorell N. Discenza, Celia J. D’Arienzo, Kathleen M. Gillooly, Tracy L. Taylor, Claudine Pulicicchio, Kim W. McIntyre, Shiuhang Yip, Peng Li, Dawn Sun, Dauh-Rurng Wu, Jun Dai, Chunlei Wang, Yingru Zhang, Bei Wang, Joseph Pawluczyk, James Kempson, Rulin Zhao, Xiaoping Hou, Richard Rampulla, Arvind Mathur, Michael A. Galella, Luisa Salter-Cid, Joel C. Barrish, Percy H. Carter, Aberra Fura, James R. Burke, <span class="NLM_string-name hlFld-ContribAuthor">Joseph A. Tino</span>. </span><span class="cited-content_cbyCitation_article-title">Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (11)
                                     , 2195-2203. <a href="https://doi.org/10.1021/acsmedchemlett.0c00335" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00335</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00335%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDriving%252BPotency%252Bwith%252BRotationally%252BStable%252BAtropisomers%25253A%252BDiscovery%252Bof%252BPyridopyrimidinedione-Carbazole%252BInhibitors%252Bof%252BBTK%26aulast%3DSrivastava%26aufirst%3DAnurag%2BS.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D16062020%26date%3D16092020%26date%3D22092020%26date%3D16092020%26volume%3D11%26issue%3D11%26spage%3D2195%26epage%3D2203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Peter Ertl, Eva Altmann, <span class="NLM_string-name hlFld-ContribAuthor">Jeffrey M. McKenna</span>. </span><span class="cited-content_cbyCitation_article-title">The Most Common Functional Groups in Bioactive Molecules and How Their Popularity Has Evolved over Time. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (15)
                                     , 8408-8418. <a href="https://doi.org/10.1021/acs.jmedchem.0c00754" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00754</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00754%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BMost%252BCommon%252BFunctional%252BGroups%252Bin%252BBioactive%252BMolecules%252Band%252BHow%252BTheir%252BPopularity%252BHas%252BEvolved%252Bover%252BTime%26aulast%3DErtl%26aufirst%3DPeter%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D05052020%26date%3D29072020%26date%3D14072020%26volume%3D63%26issue%3D15%26spage%3D8408%26epage%3D8418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ronen Gabizon, <span class="NLM_string-name hlFld-ContribAuthor">Nir London</span>. </span><span class="cited-content_cbyCitation_article-title">A Fast and Clean BTK Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (10)
                                     , 5100-5101. <a href="https://doi.org/10.1021/acs.jmedchem.0c00597" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00597</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00597%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BFast%252Band%252BClean%252BBTK%252BInhibitor%26aulast%3DGabizon%26aufirst%3DRonen%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D10042020%26date%3D13052020%26volume%3D63%26issue%3D10%26spage%3D5100%26epage%3D5101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefan F. H.  Neys</span>, <span class="hlFld-ContribAuthor ">Rudi W.  Hendriks</span>, <span class="hlFld-ContribAuthor ">Odilia B. J.  Corneth</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fcell.2021.668131" title="DOI URL">https://doi.org/10.3389/fcell.2021.668131</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2021.668131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2021.668131%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DTargeting%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252Bin%252BInflammatory%252Band%252BAutoimmune%252BPathologies%26aulast%3DNeys%26aufirst%3DStefan%2BF.%2BH.%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hui  Qiu</span>, <span class="hlFld-ContribAuthor ">Zahid  Ali</span>, <span class="hlFld-ContribAuthor ">Andrew  Bender</span>, <span class="hlFld-ContribAuthor ">Richard  Caldwell</span>, <span class="hlFld-ContribAuthor ">Yi-Ying  Chen</span>, <span class="hlFld-ContribAuthor ">Zhizhou  Fang</span>, <span class="hlFld-ContribAuthor ">Anna  Gardberg</span>, <span class="hlFld-ContribAuthor ">Nina  Glaser</span>, <span class="hlFld-ContribAuthor ">Anja  Goettsche</span>, <span class="hlFld-ContribAuthor ">Andreas  Goutopoulos</span>, <span class="hlFld-ContribAuthor ">Roland  Grenningloh</span>, <span class="hlFld-ContribAuthor ">Bettina  Hanschke</span>, <span class="hlFld-ContribAuthor ">Jared  Head</span>, <span class="hlFld-ContribAuthor ">Theresa  Johnson</span>, <span class="hlFld-ContribAuthor ">Christopher  Jones</span>, <span class="hlFld-ContribAuthor ">Reinaldo  Jones</span>, <span class="hlFld-ContribAuthor ">Shashank  Kulkarni</span>, <span class="hlFld-ContribAuthor ">Christine  Maurer</span>, <span class="hlFld-ContribAuthor ">Federica  Morandi</span>, <span class="hlFld-ContribAuthor ">Constantin  Neagu</span>, <span class="hlFld-ContribAuthor ">Sven  Poetzsch</span>, <span class="hlFld-ContribAuthor ">Justin  Potnick</span>, <span class="hlFld-ContribAuthor ">Ralf  Schmidt</span>, <span class="hlFld-ContribAuthor ">Katherine  Roe</span>, <span class="hlFld-ContribAuthor ">Ariele  Viacava Follis</span>, <span class="hlFld-ContribAuthor ">Carolyn  Wing</span>, <span class="hlFld-ContribAuthor ">Xiaohua  Zhu</span>, <span class="hlFld-ContribAuthor ">Brian  Sherer</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of potent and selective reversible Bruton’s tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>40 </em>, 116163. <a href="https://doi.org/10.1016/j.bmc.2021.116163" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116163</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116163%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpotent%252Band%252Bselective%252Breversible%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DQiu%26aufirst%3DHui%26date%3D2021%26volume%3D40%26spage%3D116163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zahava  Vadasz</span>, <span class="hlFld-ContribAuthor ">Elias  Toubi</span>. </span><span class="cited-content_cbyCitation_article-title">New Biological Treatment Options in CSU. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.5772/intechopen.97647" title="DOI URL">https://doi.org/10.5772/intechopen.97647</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5772/intechopen.97647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5772%2Fintechopen.97647%26sid%3Dliteratum%253Aachs%26atitle%3DNew%252BBiological%252BTreatment%252BOptions%252Bin%252BCSU%26aulast%3DVadasz%26aufirst%3DZahava%26date%3D2021%26date%3D2021%26pub%3DIntechOpen%26atitle%3DUrticaria%252B-%252BDiagnosis%252Band%252BManagement%252B%25255BWorking%252BTitle%25255D%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthias R.  Bauer</span>, <span class="hlFld-ContribAuthor ">Paolo  Di Fruscia</span>, <span class="hlFld-ContribAuthor ">Simon C. C.  Lucas</span>, <span class="hlFld-ContribAuthor ">Iacovos N.  Michaelides</span>, <span class="hlFld-ContribAuthor ">Jennifer E.  Nelson</span>, <span class="hlFld-ContribAuthor ">R. Ian  Storer</span>, <span class="hlFld-ContribAuthor ">Benjamin C.  Whitehurst</span>. </span><span class="cited-content_cbyCitation_article-title">Put a ring on it: application of small aliphatic rings in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (4)
                                     , 448-471. <a href="https://doi.org/10.1039/D0MD00370K" title="DOI URL">https://doi.org/10.1039/D0MD00370K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00370K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00370K%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DPut%252Ba%252Bring%252Bon%252Bit%25253A%252Bapplication%252Bof%252Bsmall%252Baliphatic%252Brings%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DBauer%26aufirst%3DMatthias%2BR.%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D4%26spage%3D448%26epage%3D471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Melanie C.  Dispenza</span>. </span><span class="cited-content_cbyCitation_article-title">The Use of Bruton’s Tyrosine Kinase Inhibitors to Treat Allergic Disorders. </span><span class="cited-content_cbyCitation_journal-name">Current Treatment Options in Allergy</span><span> <strong>2021,</strong> <em>25 </em><a href="https://doi.org/10.1007/s40521-021-00286-y" title="DOI URL">https://doi.org/10.1007/s40521-021-00286-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40521-021-00286-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40521-021-00286-y%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Treatment%2520Options%2520in%2520Allergy%26atitle%3DThe%252BUse%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitors%252Bto%252BTreat%252BAllergic%252BDisorders%26aulast%3DDispenza%26aufirst%3DMelanie%2BC.%26date%3D2021%26date%3D2021%26volume%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martin  Kaul</span>, <span class="hlFld-ContribAuthor ">Peter  End</span>, <span class="hlFld-ContribAuthor ">Maciej  Cabanski</span>, <span class="hlFld-ContribAuthor ">Carole  Schuhler</span>, <span class="hlFld-ContribAuthor ">Annamaria  Jakab</span>, <span class="hlFld-ContribAuthor ">Magdalena  Kistowska</span>, <span class="hlFld-ContribAuthor ">Arvind  Kinhikar</span>, <span class="hlFld-ContribAuthor ">Alessio  Maiolica</span>, <span class="hlFld-ContribAuthor ">Angela  Sinn</span>, <span class="hlFld-ContribAuthor ">Rainard  Fuhr</span>, <span class="hlFld-ContribAuthor ">Bruno  Cenni</span>. </span><span class="cited-content_cbyCitation_article-title">Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. </span><span class="cited-content_cbyCitation_journal-name">Clinical and Translational Science</span><span> <strong>2021,</strong> <em>151 </em><a href="https://doi.org/10.1111/cts.13005" title="DOI URL">https://doi.org/10.1111/cts.13005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cts.13005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcts.13005%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520and%2520Translational%2520Science%26atitle%3DRemibrutinib%252B%252528LOU064%252529%25253A%252BA%252Bselective%252Bpotent%252Boral%252BBTK%252Binhibitor%252Bwith%252Bpromising%252Bclinical%252Bsafety%252Band%252Bpharmacodynamics%252Bin%252Ba%252Brandomized%252Bphase%252BI%252Btrial%26aulast%3DKaul%26aufirst%3DMartin%26date%3D2021%26date%3D2021%26volume%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Natalia I.  Ilyina</span>, <span class="hlFld-ContribAuthor ">Inna V.  Danilycheva</span>, <span class="hlFld-ContribAuthor ">Irina V.  Dorofeeva</span>, <span class="hlFld-ContribAuthor ">Olga G.  Elisyutina</span>, <span class="hlFld-ContribAuthor ">Oksana M.  Kurbacheva</span>, <span class="hlFld-ContribAuthor ">Elena A.  Latysheva</span>, <span class="hlFld-ContribAuthor ">Loliana S.  Litvin</span>, <span class="hlFld-ContribAuthor ">Irina A.  Manto</span>, <span class="hlFld-ContribAuthor ">Evgeniya V.  Nazarova</span>, <span class="hlFld-ContribAuthor ">Ksenia S.  Pavlova</span>, <span class="hlFld-ContribAuthor ">Anastasia S.  Primak</span>, <span class="hlFld-ContribAuthor ">Elena S.  Fedenko</span>, <span class="hlFld-ContribAuthor ">Rosalia V.  Schubelko</span>. </span><span class="cited-content_cbyCitation_article-title">Chronic urticaria in theory and practice. Experience of UCARE-centers for clinicians. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Allergy</span><span> <strong>2021,</strong> <em>18 </em>
                                    (1)
                                     , 79-96. <a href="https://doi.org/10.36691/RJA1425" title="DOI URL">https://doi.org/10.36691/RJA1425</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.36691/RJA1425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.36691%2FRJA1425%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Allergy%26atitle%3DChronic%252Burticaria%252Bin%252Btheory%252Band%252Bpractice.%252BExperience%252Bof%252BUCARE-centers%252Bfor%252Bclinicians%26aulast%3DIlyina%26aufirst%3DNatalia%2BI.%26date%3D2021%26date%3D2021%26volume%3D18%26issue%3D1%26spage%3D79%26epage%3D96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">H. Yesid  Estupiñán</span>, <span class="hlFld-ContribAuthor ">Anna  Berglöf</span>, <span class="hlFld-ContribAuthor ">Rula  Zain</span>, <span class="hlFld-ContribAuthor ">C. I. Edvard  Smith</span>. </span><span class="cited-content_cbyCitation_article-title">Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fcell.2021.630942" title="DOI URL">https://doi.org/10.3389/fcell.2021.630942</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2021.630942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2021.630942%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DComparative%252BAnalysis%252Bof%252BBTK%252BInhibitors%252Band%252BMechanisms%252BUnderlying%252BAdverse%252BEffects%26aulast%3DEstupi%25C3%25B1%25C3%25A1n%26aufirst%3DH.%2BYesid%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kam Lun  Hon</span>, <span class="hlFld-ContribAuthor ">Joyce T. S.  Li</span>, <span class="hlFld-ContribAuthor ">Alexander K.C.  Leung</span>, <span class="hlFld-ContribAuthor ">Vivian W. Y.  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Current and emerging pharmacotherapy for chronic spontaneous Urticaria: a focus on non-biological therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Pharmacotherapy</span><span> <strong>2021,</strong> <em>22 </em>
                                    (4)
                                     , 497-509. <a href="https://doi.org/10.1080/14656566.2020.1829593" title="DOI URL">https://doi.org/10.1080/14656566.2020.1829593</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14656566.2020.1829593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14656566.2020.1829593%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Pharmacotherapy%26atitle%3DCurrent%252Band%252Bemerging%252Bpharmacotherapy%252Bfor%252Bchronic%252Bspontaneous%252BUrticaria%25253A%252Ba%252Bfocus%252Bon%252Bnon-biological%252Btherapeutics%26aulast%3DHon%26aufirst%3DKam%2BLun%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D4%26spage%3D497%26epage%3D509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Philipp  von Hundelshausen</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Siess</span>. </span><span class="cited-content_cbyCitation_article-title">Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (5)
                                     , 1103. <a href="https://doi.org/10.3390/cancers13051103" title="DOI URL">https://doi.org/10.3390/cancers13051103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13051103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13051103%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DBleeding%252Bby%252BBruton%252BTyrosine%252BKinase-Inhibitors%25253A%252BDependency%252Bon%252BDrug%252BType%252Band%252BDisease%26aulast%3Dvon%2BHundelshausen%26aufirst%3DPhilipp%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D5%26spage%3D1103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Soňa  Krajčovičová</span>, <span class="hlFld-ContribAuthor ">Radek  Jorda</span>, <span class="hlFld-ContribAuthor ">David  Vanda</span>, <span class="hlFld-ContribAuthor ">Miroslav  Soural</span>, <span class="hlFld-ContribAuthor ">Vladimír  Kryštof</span>. </span><span class="cited-content_cbyCitation_article-title">1,4,6-Trisubstituted imidazo[4,5-c]pyridines as inhibitors of Bruton’s tyrosine kinase. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>211 </em>, 113094. <a href="https://doi.org/10.1016/j.ejmech.2020.113094" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113094</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113094%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D1%25252C4%25252C6-Trisubstituted%252Bimidazo%25255B4%25252C5-c%25255Dpyridines%252Bas%252Binhibitors%252Bof%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%26aulast%3DKraj%25C4%258Dovi%25C4%258Dov%25C3%25A1%26aufirst%3DSo%25C5%2588a%26date%3D2021%26volume%3D211%26spage%3D113094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maan H.  Harbi</span>, <span class="hlFld-ContribAuthor ">Christopher W.  Smith</span>, <span class="hlFld-ContribAuthor ">Phillip L. R.  Nicolson</span>, <span class="hlFld-ContribAuthor ">Steve P.  Watson</span>, <span class="hlFld-ContribAuthor ">Mark R.  Thomas</span>. </span><span class="cited-content_cbyCitation_article-title">Novel antiplatelet strategies targeting GPVI, CLEC-2 and tyrosine kinases. </span><span class="cited-content_cbyCitation_journal-name">Platelets</span><span> <strong>2021,</strong> <em>32 </em>
                                    (1)
                                     , 29-41. <a href="https://doi.org/10.1080/09537104.2020.1849600" title="DOI URL">https://doi.org/10.1080/09537104.2020.1849600</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/09537104.2020.1849600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F09537104.2020.1849600%26sid%3Dliteratum%253Aachs%26jtitle%3DPlatelets%26atitle%3DNovel%252Bantiplatelet%252Bstrategies%252Btargeting%252BGPVI%25252C%252BCLEC-2%252Band%252Btyrosine%252Bkinases%26aulast%3DHarbi%26aufirst%3DMaan%2BH.%26date%3D2021%26date%3D2020%26volume%3D32%26issue%3D1%26spage%3D29%26epage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonard  Sung</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent drugs in development for immune-mediated diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 33-74. <a href="https://doi.org/10.1016/bs.armc.2021.03.001" title="DOI URL">https://doi.org/10.1016/bs.armc.2021.03.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.armc.2021.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.armc.2021.03.001%26sid%3Dliteratum%253Aachs%26atitle%3DCovalent%252Bdrugs%252Bin%252Bdevelopment%252Bfor%252Bimmune-mediated%252Bdiseases%26aulast%3DSung%26aufirst%3DLeonard%26date%3D2021%26spage%3D33%26epage%3D74%26pub%3DElsevier%26atitle%3DThe%252BDesign%252Bof%252BCovalent-Based%252BInhibitors%26date%3D2021%26volume%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wolfgang  Siess</span>, <span class="hlFld-ContribAuthor ">Philipp Von  Hundelshausen</span>, <span class="hlFld-ContribAuthor ">Reinhard  Lorenz</span>. </span><span class="cited-content_cbyCitation_article-title">Selective inhibition of thromboinflammation in COVID-19 by Btk inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Platelets</span><span> <strong>2020,</strong> <em>31 </em>
                                    (8)
                                     , 989-992. <a href="https://doi.org/10.1080/09537104.2020.1809647" title="DOI URL">https://doi.org/10.1080/09537104.2020.1809647</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/09537104.2020.1809647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F09537104.2020.1809647%26sid%3Dliteratum%253Aachs%26jtitle%3DPlatelets%26atitle%3DSelective%252Binhibition%252Bof%252Bthromboinflammation%252Bin%252BCOVID-19%252Bby%252BBtk%252Binhibitors%26aulast%3DSiess%26aufirst%3DWolfgang%26date%3D2020%26date%3D2020%26volume%3D31%26issue%3D8%26spage%3D989%26epage%3D992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ana M.  Giménez-Arnau</span>, <span class="hlFld-ContribAuthor ">Andaç  Salman</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Therapy for Chronıc Spontaneous Urtıcarıa: Ratıonale and Recent Progress. </span><span class="cited-content_cbyCitation_journal-name">Drugs</span><span> <strong>2020,</strong> <em>80 </em>
                                    (16)
                                     , 1617-1634. <a href="https://doi.org/10.1007/s40265-020-01387-9" title="DOI URL">https://doi.org/10.1007/s40265-020-01387-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40265-020-01387-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40265-020-01387-9%26sid%3Dliteratum%253Aachs%26jtitle%3DDrugs%26atitle%3DTargeted%252BTherapy%252Bfor%252BChron%2525C4%2525B1c%252BSpontaneous%252BUrt%2525C4%2525B1car%2525C4%2525B1a%25253A%252BRat%2525C4%2525B1onale%252Band%252BRecent%252BProgress%26aulast%3DGim%25C3%25A9nez-Arnau%26aufirst%3DAna%2BM.%26date%3D2020%26date%3D2020%26volume%3D80%26issue%3D16%26spage%3D1617%26epage%3D1634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01916&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) Selected examples of covalent BTK inhibitors (<b>1</b>–<b>5</b>). (b) Structure of CGI-1746 (<b>6</b>), the first reported compound binding to an inactive BTK conformation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01916&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Morphing of the pyrrolopyrimidine scaffold to an aminopyrimidine scaffold, BTK enzyme inhibition in Caliper assay with IC<sub>50</sub> shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01916&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Crystal structure of <b>7</b> in complex with human BTK (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S90">6S90</a>; in cyan) overlaid with the binding model of compound <b>9</b> (in purple). H-bonds of the pyrrolopyrimidine and 6-aminopyrimidine scaffold to Met477 and a water molecule (red sphere) are highlighted (black dashed lines), as well as the hydrogen bond between the carbonyl of the amide of the ligand and Lys430 side chain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01916&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Rescue of BTK enzymatic activity by dilution. The increase of phosphorylated substrate peptide over time after the dilution step is indicated for the DMSO solvent control (black dash and triangles), for the reversible BTK inhibitor staurosporine (blue dash and triangles), for the noncovalent ethylamide analog <b>32</b> (red dash and empty circles), and for LOU064 (red line and filled circles).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01916&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Deconvoluted mass spectrum of covalent BTK kinase domain (encompassing amino acids 386–659) adduct with LOU064. The peak with a corresponding mass of 32 222.3 Da is indicative of the presence of one covalent adduct of LOU064 (507.5 Da) to the BTK kinase domain (31 714.5 Da).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01916&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. X-ray complex structure of BTK kinase domain bound to LOU064 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TFP">6TFP</a>, protein chain A with ligand chain L). The molecular surface of LOU064 is colored in orange, and key residues lining up the binding site are shown as labeled stick model. The main polar interactions between protein and inhibitor are indicated with dotted green lines. For improved clarity water molecules are omitted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01916&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Time- and concentration-dependent <i>in vitro</i> engagement of cellular BTK by LOU064 and related inhibitors in human blood. Left panel shows data for LOU064 from two independent experiments with different blood donors (solid lines show nonlinear one-phase association curve fits). Right panel shows the association kinetics for a concentration of 300 nM for each compound (solid lines show nonlinear one-phase association curve fits). Individual data are from two independent experiments with different blood donors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01916&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Spleen BTK occupancy relative to vehicle controls was measured 5 h after oral dosing in female rats combined from two separate studies (with 3 animals per each dose group). Open triangles show the BTK occupancy levels in the combined vehicle dosed animals. Filled circles show the BTK occupancy of LOU064 treated animals. The dotted line shows a dose–response curve fit.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01916&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. IgM response inhibition by LOU064 in the rat model of B cell response to SRBC immunization. Left panel: inhibition of anti-IgM response. Open triangles show vehicle (V), open circles cyclosporine A (CsA), and closed circles LOU064 treated animals. The group mean values are shown as the central bars, and the standard deviations are shown as whisker error bars. Statistical significance (ANOVA, followed by Dunnett’s test) is shown as ∗∗∗ for <i>p</i> < 0.001. Right panel: BTK occupancy in spleen 24 h after the last dose of LOU064. Open triangles show vehicle (V), open circles cyclosporine A (CsA), and closed circles LOU064 treated animals relative to the average of the vehicle group. Group mean values are shown as central bars and standard deviations as whisker error bars. Statistical significance (ANOVA, followed by Dunnett’s test) is shown as ∗∗∗ for <i>p</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01916&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Efficacy of LOU064 in the rat model of collagen-induced arthritis. Left panel: Paw swelling scores are shown as the mean ± SEM. LOU064 treatment is once daily with doses of 0.3, 3, 10, and 30 mg/kg from day 12 to 25 postimmunization. Statistical significance (ANOVA, followed by Dunnett’s test) is shown as ∗∗ for <i>p</i> < 0.01. Right panel: BTK occupancy in spleen 24 h after the last dose of LOU064. Triangles show vehicle (V), and circles represent LOU064 treated animals relative to the average of the vehicle group. Group mean values are shown as central bars and standard deviations as whiskers. Statistical significance (ANOVA, followed by Dunnett’s test) is shown as ∗∗∗ for <i>p</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01916&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Histopathological analysis of arthritis in rat CIA model. Left panel: Histology scores combined for the hind paws of each animal show inflammatory cell infiltrate, joint damage, and proteoglycan loss (average ± SEM of 6 animals per group, ANOVA, followed by Dunnett’s test with ∗∗ for <i>p</i> < 0.01). Right panel: Photomicrographs of paw sections stained with Giemsa (left column) and Safranin O (right column) illustrate joint tissue inflammation and preservation of joint cartilage, respectively. LOU064 significantly reduced joint inflammation and damage as well as proteoglycan loss at 3 and 10 mg/kg q.d. po.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01916&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Boronic Ester <b>38</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01916&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BISPIN, Pd(dppf)Cl<sub>2</sub>·DCM, KOAc, dioxane, 100 °C, 3.5 h, 92%; (b) H<sub>2</sub>, Pd/C, MeOH, RT, 7 h, 93%; (c) cyclopropylboronic acid, Pd(OAc)<sub>2</sub>, tricyclohexylphosphine, K<sub>3</sub>PO<sub>4</sub>, water, toluene, 100 °C, overnight, 99%; (d) <b>35</b>, NaHMDS (1 M in THF), THF, RT, 4 h, 76%.</p></p></figure><figure data-id="sch2" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/medium/jm9b01916_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of LOU064<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.9b01916/20200520/images/large/jm9b01916_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01916&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NH<sub>4</sub>OH, 2-propanol, 70 °C, 48 h, 94%; (b) BBr<sub>3</sub>, DCM, 40 °C, 3 h, 59%; (c) <i>N</i>-Boc-<i>N</i>-methyl-2-hydroxyethylamine, DIAD, Smopex-301, THF, 60 °C, 2 h, 53%; (d) <b>38</b>, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, aq Na<sub>2</sub>CO<sub>3</sub>, DME, water, microwave, 110 °C, 25 min, 74%; (e) TFA, DCM, RT, 12 h; (f) acrylic acid, DIPEA, T3P (50% in DMF), DMF, RT, 2 h, 45% over 2 steps.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i43">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61000" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61000" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 59 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Islam, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattsson, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohamed, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nore, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vihinen, M.</span></span> <span> </span><span class="NLM_article-title">The Tec Family of Cytoplasmic Tyrosine Kinases: Mammalian Btk, Bmx, Itk, Tec, Txk and Homologs in Other Species</span>. <i>BioEssays</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">436</span>– <span class="NLM_lpage">446</span>, <span class="refDoi"> DOI: 10.1002/bies.1062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1002%2Fbies.1062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=11340625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptVOjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2001&pages=436-446&author=C.+I.+E.+Smithauthor=T.+C.+Islamauthor=P.+T.+Mattssonauthor=A.+J.+Mohamedauthor=B.+F.+Noreauthor=M.+Vihinen&title=The+Tec+Family+of+Cytoplasmic+Tyrosine+Kinases%3A+Mammalian+Btk%2C+Bmx%2C+Itk%2C+Tec%2C+Txk+and+Homologs+in+Other+Species&doi=10.1002%2Fbies.1062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Tec family of cytoplasmic tyrosine kinases: Mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species</span></div><div class="casAuthors">Smith, C. I. Edvard; Islam, Tahmina C.; Mattsson, Pekka T.; Mohamed, Abdalla J.; Nore, Beston F.; Vihinen, Mauno</div><div class="citationInfo"><span class="NLM_cas:title">BioEssays</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">436-446</span>CODEN:
                <span class="NLM_cas:coden">BIOEEJ</span>;
        ISSN:<span class="NLM_cas:issn">0265-9247</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Cytoplasmic protein-tyrosine kinases (PTKs) are enzymes involved in transducing a vast no. of signals in metazoans.  The importance of the Tec family of kinases was immediately recognized when, in 1993, mutations in the gene encoding Bruton's tyrosine kinase (Btk) were reported to cause the human disease X-linked agammaglobulinemia (XLA).  Since then, addnl. kinases belonging to this family have been isolated, and the availability of full genome sequences allows identification of all members in selected species enabling phylogenetic considerations.  Tec kinases are endowed with Pleckstrin homol. (PH) and Tec homol. (TH) domains and are involved in diverse biol. processes related to the control of survival and differentiation fate.  Membrane translocation resulting in the activation of Tec kinases with subsequent Ca2+ release seems to be a general feature.  However, nuclear translocation may also be of importance.  The purpose of this essay is to characterize members of the Tec family and discuss their involvement in signaling.  The three-dimensional structure, expression pattern and evolutionary aspects will also be considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9ajt-jHfjH7Vg90H21EOLACvtfcHk0lhCRUVuXfmddA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptVOjtrc%253D&md5=1277b381019ee1e2e2371bb8a5282802</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fbies.1062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbies.1062%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26aulast%3DIslam%26aufirst%3DT.%2BC.%26aulast%3DMattsson%26aufirst%3DP.%2BT.%26aulast%3DMohamed%26aufirst%3DA.%2BJ.%26aulast%3DNore%26aufirst%3DB.%2BF.%26aulast%3DVihinen%26aufirst%3DM.%26atitle%3DThe%2520Tec%2520Family%2520of%2520Cytoplasmic%2520Tyrosine%2520Kinases%253A%2520Mammalian%2520Btk%252C%2520Bmx%252C%2520Itk%252C%2520Tec%252C%2520Txk%2520and%2520Homologs%2520in%2520Other%2520Species%26jtitle%3DBioEssays%26date%3D2001%26volume%3D23%26spage%3D436%26epage%3D446%26doi%3D10.1002%2Fbies.1062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, J. M.</span></span> <span> </span><span class="NLM_article-title">The Src, Syk, and Tec Family Kinases: Distinct Types of Molecular Switches</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1175</span>– <span class="NLM_lpage">1184</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2010.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1016%2Fj.cellsig.2010.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=20206686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtlyntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2010&pages=1175-1184&author=J.+M.+Bradshaw&title=The+Src%2C+Syk%2C+and+Tec+Family+Kinases%3A+Distinct+Types+of+Molecular+Switches&doi=10.1016%2Fj.cellsig.2010.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The Src, Syk, and Tec family kinases: Distinct types of molecular switches</span></div><div class="casAuthors">Bradshaw, J. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1175-1184</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The Src, Syk, and Tec family kinases are three of the most well characterized tyrosine kinase families found in the human genome.  Members of these kinase families function downstream of antigen and Fc receptors in hematopoietic cells and transduce signals leading to calcium mobilization, altered gene expression, cytokine prodn., and cell proliferation.  Over the last several years, structural and biochem. studies have begun to uncover the mol. mechanisms regulating activation of these kinases.  It appears that each kinase family functions as a distinct type of mol. switch.  This review discusses the activation of the Src, Syk, and Tec kinases from the perspective of structure, phosphorylation, allosteric regulation, and kinetics.  The multiple factors that regulate the Src, Syk, and Tec families illustrate the important role played by each of these kinases in immune cell signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_PA9QDCCGPLVg90H21EOLACvtfcHk0ligQR-5O4NS4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtlyntbw%253D&md5=7f562f792a04682d05aa32dc09a7cb6e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2010.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2010.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520Src%252C%2520Syk%252C%2520and%2520Tec%2520Family%2520Kinases%253A%2520Distinct%2520Types%2520of%2520Molecular%2520Switches%26jtitle%3DCell.%2520Signalling%26date%3D2010%26volume%3D22%26spage%3D1175%26epage%3D1184%26doi%3D10.1016%2Fj.cellsig.2010.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span> <span> </span><span class="NLM_article-title">Btk Function in B Cell Development and Response</span>. <i>Semin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">316</span>, <span class="refDoi"> DOI: 10.1006/smim.1998.0123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1006%2Fsmim.1998.0123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=9695187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADyaK1cXltlCiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1998&pages=309-316&author=A.+B.+Satterthwaiteauthor=Z.+Liauthor=O.+N.+Witte&title=Btk+Function+in+B+Cell+Development+and+Response&doi=10.1006%2Fsmim.1998.0123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Btk function in B cell development and response</span></div><div class="casAuthors">Satterthwaite, Anne B.; Li, Zuomei; Witte, Owen N.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-316</span>CODEN:
                <span class="NLM_cas:coden">SEIME2</span>;
        ISSN:<span class="NLM_cas:issn">1044-5323</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review with 85 refs.  Mutations in Bruton's tyrosine kinase (Btk) result in the B cell immunodeficiencies XLA (X-linked agammaglobulinemia) in humans and Xid (X-linked immunodeficiency) in mice.  Both the maintenance of peripheral B cell nos. and their response to B cell antigen receptor (BCR) crosslinking depend on Btk.  Btk integrates signals from multiple cell surface receptors, including BCR and G-protein coupled receptors.  These Btk dependent signals control B cell proliferation and survival by mediating Ca2+ flux, activating JNK and p38 and inducing cell cycle regulatory genes.  (c) 1998 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVrVOyUeT25bVg90H21EOLACvtfcHk0ligQR-5O4NS4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltlCiuro%253D&md5=f03605bc9f39d663d28794c7b7e40138</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1006%2Fsmim.1998.0123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fsmim.1998.0123%26sid%3Dliteratum%253Aachs%26aulast%3DSatterthwaite%26aufirst%3DA.%2BB.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DBtk%2520Function%2520in%2520B%2520Cell%2520Development%2520and%2520Response%26jtitle%3DSemin.%2520Immunol.%26date%3D1998%26volume%3D10%26spage%3D309%26epage%3D316%26doi%3D10.1006%2Fsmim.1998.0123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucheron, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellmeier, W.</span></span> <span> </span><span class="NLM_article-title">The Role of Tec Family Kinases in Myeloid Cells</span>. <i>Int. Arch. Allergy Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1159/000078339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1159%2F000078339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=15133303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktFKlsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2004&pages=65-78&author=U.+Schmidtauthor=N.+Boucheronauthor=B.+Ungerauthor=W.+Ellmeier&title=The+Role+of+Tec+Family+Kinases+in+Myeloid+Cells&doi=10.1159%2F000078339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Tec Family Kinases in Myeloid Cells</span></div><div class="casAuthors">Schmidt, Uwe; Boucheron, Nicole; Unger, Bernd; Ellmeier, Wilfried</div><div class="citationInfo"><span class="NLM_cas:title">International Archives of Allergy and Immunology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-78</span>CODEN:
                <span class="NLM_cas:coden">IAAIEG</span>;
        ISSN:<span class="NLM_cas:issn">1018-2438</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">A review.  Members of the Tec kinase family (Bmx, Btk, Itk, Rlk and Tec) are primarily expressed in the hematopoietic system and form, after the Src kinase family, the second largest class of non-receptor protein tyrosine kinases.  During lymphocyte development and activation Tec kinases have important functions in signaling pathways downstream of the antigen receptors.  Tec family kinases are also expressed in cells of the myeloid lineage.  However, with the exception of mast cells and platelets, their biol. role in the myeloid system is only poorly understood.  This review summarizes the current knowledge about the function of Tec family kinases in hematopoietic cells of the myeloid lineage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpewxKP7kBxe7Vg90H21EOLACvtfcHk0lh-C28fyn3odw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktFKlsr8%253D&md5=e6e88b9b59049d9e55e95b6621a27453</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1159%2F000078339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000078339%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DU.%26aulast%3DBoucheron%26aufirst%3DN.%26aulast%3DUnger%26aufirst%3DB.%26aulast%3DEllmeier%26aufirst%3DW.%26atitle%3DThe%2520Role%2520of%2520Tec%2520Family%2520Kinases%2520in%2520Myeloid%2520Cells%26jtitle%3DInt.%2520Arch.%2520Allergy%2520Immunol.%26date%3D2004%26volume%3D134%26spage%3D65%26epage%3D78%26doi%3D10.1159%2F000078339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, T.</span></span> <span> </span><span class="NLM_article-title">Bruton’s Tyrosine Kinase Is Involved in Innate and Adaptive Immunity</span>. <i>Histol. Histopathol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">945</span>– <span class="NLM_lpage">955</span>, <span class="refDoi"> DOI: 10.14670/HH-20.945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.14670%2FHH-20.945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=15944945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsFKjtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2005&pages=945-955&author=C.+Brunnerauthor=B.+M%C3%BCllerauthor=T.+Wirth&title=Bruton%E2%80%99s+Tyrosine+Kinase+Is+Involved+in+Innate+and+Adaptive+Immunity&doi=10.14670%2FHH-20.945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's Tyrosine Kinase is involved in innate and adaptive immunity</span></div><div class="casAuthors">Brunner, C.; Mueller, B.; Wirth, T.</div><div class="citationInfo"><span class="NLM_cas:title">Histology and Histopathology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">945-955</span>CODEN:
                <span class="NLM_cas:coden">HIHIES</span>;
        ISSN:<span class="NLM_cas:issn">0213-3911</span>.
    
            (<span class="NLM_cas:orgname">Jimenez Godoy, S.A.</span>)
        </div><div class="casAbstract">A review.  Btk is a cytoplasmic tyrosine kinase, which is mainly involved in B cell receptor signaling.  Gene targeting expts. revealed that Btk is important for B cell development and function.  However, Btk is not only expressed in B cells, but also in most other hematopoietic lineages except for T cells and plasma cells.  Recently we found that Btk is involved in Toll-like receptor signaling.  Toll-like receptors play an important role in innate immunity.  They are highly expressed on mast cells, macrophages and dendritic cells, which are essential for the recognition and consequently for the elimination of microbial pathogens.  Therefore Btk might play an important role for the function of immunocompetent cells of innate as well as adaptive immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQA-9NFdeNr7Vg90H21EOLACvtfcHk0liPwNRQAl-Rfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsFKjtL4%253D&md5=97cbcc5df2704d4b58933085ab8ff929</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.14670%2FHH-20.945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14670%252FHH-20.945%26sid%3Dliteratum%253Aachs%26aulast%3DBrunner%26aufirst%3DC.%26aulast%3DM%25C3%25BCller%26aufirst%3DB.%26aulast%3DWirth%26aufirst%3DT.%26atitle%3DBruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Is%2520Involved%2520in%2520Innate%2520and%2520Adaptive%2520Immunity%26jtitle%3DHistol.%2520Histopathol.%26date%3D2005%26volume%3D20%26spage%3D945%26epage%3D955%26doi%3D10.14670%2FHH-20.945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nyhoff, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barron, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonami, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kendall, P. L.</span></span> <span> </span><span class="NLM_article-title">Bruton’s Tyrosine Kinase Is Not Essential for B Cell Survival beyond Early Developmental Stages</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>200</i></span>,  <span class="NLM_fpage">2352</span>– <span class="NLM_lpage">2361</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1701489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.4049%2Fjimmunol.1701489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=29483358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFSltbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=200&publication_year=2018&pages=2352-2361&author=L.+E.+Nyhoffauthor=E.+S.+Clarkauthor=B.+L.+Barronauthor=R.+H.+Bonamiauthor=W.+N.+Khanauthor=P.+L.+Kendall&title=Bruton%E2%80%99s+Tyrosine+Kinase+Is+Not+Essential+for+B+Cell+Survival+beyond+Early+Developmental+Stages&doi=10.4049%2Fjimmunol.1701489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's Tyrosine Kinase Is Not Essential for B Cell Survival beyond Early Developmental Stages</span></div><div class="casAuthors">Nyhoff, Lindsay E.; Clark, Emily S.; Barron, Bridgette L.; Bonami, Rachel H.; Khan, Wasif N.; Kendall, Peggy L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">200</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2352-2361</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a crucial regulator of B cell signaling and is a therapeutic target for lymphoma and autoimmune disease.  BTK-deficient patients suffer from humoral immunodeficiency, as their B cells fail to progress beyond the bone marrow.  However, the role of Btk in fully developed, mature peripheral B cells is not well understood.  Anal. using BTK inhibitors is complicated by suboptimal inhibition, off-target effects, or failure to eliminate BTK's adaptor function.  Therefore a Btkflox/Cre-ERT2 mouse model was developed and used to excise Btk after B cell populations were established.  Mice lacking Btk from birth are known to have reduced follicular (FO) compartments, with expanded transitional populations, suggesting a block in development.  In adult Btkflox/Cre-ERT2 mice, Btk excision did not reduce FO B cells, which persisted for weeks.  Autoimmune-prone B1 cells also survived conditional Btk excision, contrasting their near absence in global Btk-deficient mice.  Therefore, Btk supports BCR signaling during selection into the FO and B1 compartments, but is not needed to maintain these cell populations.  B1-related natural IgM levels remained normal, contrasting global Btk deficiency, but B cell proliferation and T-independent type II immunization responses were blunted.  Thus, B cells have nuanced signaling responses that are differentially regulated by Btk for development, survival, and function.  These findings raise the possibility that Btk may also be expendable for survival of mature human B cells, therefore requiring prolonged dosing to be effective, and that success of BTK inhibitors may depend in part on off-target effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP6akmBuHl2bVg90H21EOLACvtfcHk0ljYZaLt_z1tbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFSltbo%253D&md5=c1e633a39d298ce08a70906db3ad577c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1701489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1701489%26sid%3Dliteratum%253Aachs%26aulast%3DNyhoff%26aufirst%3DL.%2BE.%26aulast%3DClark%26aufirst%3DE.%2BS.%26aulast%3DBarron%26aufirst%3DB.%2BL.%26aulast%3DBonami%26aufirst%3DR.%2BH.%26aulast%3DKhan%26aufirst%3DW.%2BN.%26aulast%3DKendall%26aufirst%3DP.%2BL.%26atitle%3DBruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Is%2520Not%2520Essential%2520for%2520B%2520Cell%2520Survival%2520beyond%2520Early%2520Developmental%2520Stages%26jtitle%3DJ.%2520Immunol.%26date%3D2018%26volume%3D200%26spage%3D2352%26epage%3D2361%26doi%3D10.4049%2Fjimmunol.1701489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conley, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobbs, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farmer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paris, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigoriadou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coustan-Smith, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campana, D.</span></span> <span> </span><span class="NLM_article-title">Primary B Cell Immunodeficiencies: Comparisons and Contrasts</span>. <i>Annu. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1146/annurev.immunol.021908.132649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1146%2Fannurev.immunol.021908.132649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=19302039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFSlsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=199-227&author=M.+E.+Conleyauthor=A.+K.+Dobbsauthor=D.+M.+Farmerauthor=S.+Kilicauthor=K.+Parisauthor=S.+Grigoriadouauthor=E.+Coustan-Smithauthor=V.+Howardauthor=D.+Campana&title=Primary+B+Cell+Immunodeficiencies%3A+Comparisons+and+Contrasts&doi=10.1146%2Fannurev.immunol.021908.132649"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Primary B cell immunodeficiencies: comparisons and contrasts</span></div><div class="casAuthors">Conley, Mary Ellen; Dobbs, A. Kerry; Farmer, Dana M.; Kilic, Sebnem; Paris, Kenneth; Grigoriadou, Sofia; Coustan-Smith, Elaine; Howard, Vanessa; Campana, Dario</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">199-227</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Sophisticated genetic tools have made possible the identification of the genes responsible for most well-described immunodeficiencies in the past 15 years.  Mutations in Btk, components of the pre-B cell and B cell receptor (λ5, Igα, Igβ), or the scaffold protein BLNK account for approx. 90% of patients with defects in early B cell development.  Hyper-IgM syndromes result from mutations in CD40 ligand, CD40, AID, or UNG in 70-80% of affected patients.  Rare defects in ICOS or CD19 can result in a clin. picture that is consistent with common variable immunodeficiency, and as many as 10% of patients with this disorder have heterozygous amino acid substitutions in TACI.  For all these disorders, there is considerable clin. heterogeneity in patients with the same mutation.  Identifying the genetic and environmental factors that influence the clin. phenotype may enhance patient care and the understanding of normal B cell development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_hgfd2bSrJ7Vg90H21EOLACvtfcHk0ljYZaLt_z1tbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFSlsbY%253D&md5=83216a7a297af38c2efdf9d3e79a1213</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1146%2Fannurev.immunol.021908.132649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.immunol.021908.132649%26sid%3Dliteratum%253Aachs%26aulast%3DConley%26aufirst%3DM.%2BE.%26aulast%3DDobbs%26aufirst%3DA.%2BK.%26aulast%3DFarmer%26aufirst%3DD.%2BM.%26aulast%3DKilic%26aufirst%3DS.%26aulast%3DParis%26aufirst%3DK.%26aulast%3DGrigoriadou%26aufirst%3DS.%26aulast%3DCoustan-Smith%26aufirst%3DE.%26aulast%3DHoward%26aufirst%3DV.%26aulast%3DCampana%26aufirst%3DD.%26atitle%3DPrimary%2520B%2520Cell%2520Immunodeficiencies%253A%2520Comparisons%2520and%2520Contrasts%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D2009%26volume%3D27%26spage%3D199%26epage%3D227%26doi%3D10.1146%2Fannurev.immunol.021908.132649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideras, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alt, F. W.</span></span> <span> </span><span class="NLM_article-title">The Role of Bruton’s Tyrosine Kinase in B-Cell Development and Function in Mice and Man</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>764</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.1995.tb55802.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1111%2Fj.1749-6632.1995.tb55802.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=7486535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADyaK28XkvFelsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=764&publication_year=1995&pages=27-38&author=W.+N.+Khanauthor=P.+Siderasauthor=F.+S.+Rosenauthor=F.+W.+Alt&title=The+Role+of+Bruton%E2%80%99s+Tyrosine+Kinase+in+B-Cell+Development+and+Function+in+Mice+and+Man&doi=10.1111%2Fj.1749-6632.1995.tb55802.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The role of Bruton's tyrosine kinase in B-cell development and function in mice and man</span></div><div class="casAuthors">Khan, Wasif N.; Sideras, Paschalis; Rosen, Fred S.; Alt, Frederick W.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">764</span>
        (<span class="NLM_cas:issue">Immunoglobulin Gene Expression in Development and Disease</span>),
    <span class="NLM_cas:pages">27-38</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">New York Academy of Sciences</span>)
        </div><div class="casAbstract">A review and discussion with 36 refs.  Both Btk (Bruton's tyrosine kinase) PH mutant chimeras and Btk kinase domain mutant mice lack expression of the btk protein.  The maturation and function of B cells are defective in both types of mutant mice and this defect is similar to that described for xid.  However, there appears to be a less stringent requirement for btk for early murine B cell development as compared to humans.  Possible explanations are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9njk8U5lZErVg90H21EOLACvtfcHk0licaGWSY-f5Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XkvFelsg%253D%253D&md5=73fe40ec20bad09a441ffac9556e7759</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.1995.tb55802.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.1995.tb55802.x%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DW.%2BN.%26aulast%3DSideras%26aufirst%3DP.%26aulast%3DRosen%26aufirst%3DF.%2BS.%26aulast%3DAlt%26aufirst%3DF.%2BW.%26atitle%3DThe%2520Role%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520in%2520B-Cell%2520Development%2520and%2520Function%2520in%2520Mice%2520and%2520Man%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D1995%26volume%3D764%26spage%3D27%26epage%3D38%26doi%3D10.1111%2Fj.1749-6632.1995.tb55802.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Howard, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pahwa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkelstein, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conley, M. E.</span></span> <span> </span><span class="NLM_article-title">The Health Status and Quality of Life of Adults with X-Linked Agammaglobulinemia</span>. <i>Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1016/j.clim.2005.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1016%2Fj.clim.2005.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=16377251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhtlars7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2006&pages=201-208&author=V.+Howardauthor=J.+M.+Greeneauthor=S.+Pahwaauthor=J.+A.+Winkelsteinauthor=J.+M.+Boyleauthor=M.+Kocakauthor=M.+E.+Conley&title=The+Health+Status+and+Quality+of+Life+of+Adults+with+X-Linked+Agammaglobulinemia&doi=10.1016%2Fj.clim.2005.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The health status and quality of life of adults with X-linked agammaglobulinemia</span></div><div class="casAuthors">Howard, Vanessa; Greene, Jeffrey M.; Pahwa, Savita; Winkelstein, Jerry A.; Boyle, John M.; Kocak, Mehmet; Conley, Mary Ellen</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Immunology (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">201-208</span>CODEN:
                <span class="NLM_cas:coden">CLIIFY</span>;
        ISSN:<span class="NLM_cas:issn">1521-6616</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Forty-one adults (mean age 33) with a definitive diagnosis of X-linked agammaglobulinemia (XLA) completed a questionnaire concerning current and past medical problems and quality of life.  Thirty-six of the 41 were working full time or were full time students; 18 had not missed any work or school due to infection in the previous year.  Their quality of life was equiv. to that of the general US male population.  Thirteen of the 41 reported that they had chronic lung disease, and 33 indicated that they had one or more episodes of sinusitis in the preceding year.  Arthritis, diarrhea and skin infections were common but not debilitating.  The 41 study subjects were more likely to have a prior family history of XLA, and they were more likely to have milder mutations in Btk, the gene responsible for XLA.  These results indicate that most adults with XLA are moderately healthy and lead productive lives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSok5lz2chVLVg90H21EOLACvtfcHk0lh3srFX0AIctQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhtlars7w%253D&md5=838bd23e504efab6a7c16d660d966faf</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.clim.2005.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clim.2005.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DHoward%26aufirst%3DV.%26aulast%3DGreene%26aufirst%3DJ.%2BM.%26aulast%3DPahwa%26aufirst%3DS.%26aulast%3DWinkelstein%26aufirst%3DJ.%2BA.%26aulast%3DBoyle%26aufirst%3DJ.%2BM.%26aulast%3DKocak%26aufirst%3DM.%26aulast%3DConley%26aufirst%3DM.%2BE.%26atitle%3DThe%2520Health%2520Status%2520and%2520Quality%2520of%2520Life%2520of%2520Adults%2520with%2520X-Linked%2520Agammaglobulinemia%26jtitle%3DClin.%2520Immunol.%26date%3D2006%26volume%3D118%26spage%3D201%26epage%3D208%26doi%3D10.1016%2Fj.clim.2005.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shillitoe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gennery, A.</span></span> <span> </span><span class="NLM_article-title">X-Linked Agammaglobulinaemia: Outcomes in the Modern Era</span>. <i>Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1016/j.clim.2017.07.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1016%2Fj.clim.2017.07.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=28729230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Giu7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2017&pages=54-62&author=B.+Shillitoeauthor=A.+Gennery&title=X-Linked+Agammaglobulinaemia%3A+Outcomes+in+the+Modern+Era&doi=10.1016%2Fj.clim.2017.07.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">X-Linked Agammaglobulinaemia: Outcomes in the modern era</span></div><div class="casAuthors">Shillitoe, Ben; Gennery, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Immunology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">54-62</span>CODEN:
                <span class="NLM_cas:coden">CLIIFY</span>;
        ISSN:<span class="NLM_cas:issn">1521-6616</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Colonel Ogden Bruton reported X-Linked Agammaglobulinemia in 1952 and treated the child with replacement Ig therapy.  Over 60 years later, the treatment for XLA has largely remained unchanged.  Replacement Ig lacks the isotypes IgA and IgM, leading to concerns that patients continue to experience recurrent sinopulmonary tract infections and be at increased risk of bronchiectasis.  There is potential hope of earlier diagnosis with newborn screening, and a potential cure for these patients, in the form of gene therapy.  However, it is first necessary to evaluate current management and outcomes to aid decisions regarding further research and clin. trials.  This article reviews current management and outcomes of XLA, while identifying gaps in our knowledge base that may need answering before we proceed with novel diagnostic methods and treatment for XLA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUnHekSivzvbVg90H21EOLACvtfcHk0lh3srFX0AIctQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Giu7fP&md5=5b02e84329c8ed351b680aa196e23ca4</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.clim.2017.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clim.2017.07.008%26sid%3Dliteratum%253Aachs%26aulast%3DShillitoe%26aufirst%3DB.%26aulast%3DGennery%26aufirst%3DA.%26atitle%3DX-Linked%2520Agammaglobulinaemia%253A%2520Outcomes%2520in%2520the%2520Modern%2520Era%26jtitle%3DClin.%2520Immunol.%26date%3D2017%26volume%3D183%26spage%3D54%26epage%3D62%26doi%3D10.1016%2Fj.clim.2017.07.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jansson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmdahl, R.</span></span> <span> </span><span class="NLM_article-title">Genes on the X Chromosome Affect Development of Collagen-Induced Arthritis in Mice</span>. <i>Clin. Exp. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">465</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2249.1993.tb08218.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1111%2Fj.1365-2249.1993.tb08218.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=8252807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADyaK2cXhtVCksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1993&pages=459-465&author=L.+Janssonauthor=R.+Holmdahl&title=Genes+on+the+X+Chromosome+Affect+Development+of+Collagen-Induced+Arthritis+in+Mice&doi=10.1111%2Fj.1365-2249.1993.tb08218.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Genes on the X chromosome affect development of collagen-induced arthritis in mice</span></div><div class="casAuthors">Jansson, Liselotte; Holmdahl, R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Immunology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">459-65</span>CODEN:
                <span class="NLM_cas:coden">CEXIAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    </div><div class="casAbstract">Susceptibility to collagen-induced arthritis (CIA) in mice is assocd. with a class II gene in MHC (Aq) but also with unknown genes outside MHC.  Investigated here is the influence of genes on the X chromosome as well as the role of the X-linked immunodeficiency (xid) mutation.  Reciprocal male F1 hybrids, bred to be heterozygous or homozygous for Aq, showed a genetic influence in their susceptibility to develop CIA.  Crosses were made between B10.G, B10.Q, DBA/1, SWR/J, C3H.Q and CBA/Ca, and all F1 mice were castrated to avoid sex hormone modulation of the susceptibility.  A differential timing of arthritis onset and severity were seen in the reciprocal F1 males.  An exception was the reciprocal F1 male offspring from SWR/J and DBA/1 crosses which differed only in disease severity late in the course of the disease.  The female F1 crosses did not show the same pattern of differential susceptibility to CIA as the F1 males.  To exclude the possible influence of the Y chromosome, F1 males of reciprocal crosses were back-crossed to the parental strains creating offspring with equal X chromosomes but divergent Y chromosomes.  No difference in development of arthritis was obsd. in these.  The influence of the xid mutation was investigated next.  The xid loci from the CBA/N mouse was bred into DBA/1 strain which is highly susceptible to CIA.  The resulting congenic DBA/1-xid strain was resistant to induction of CIA and did not develop an antibody response to type II collagen.  The authors concluded that polymorphic genes on the X chromosome modulate susceptibility to CIA.  The results from the expts. with mice carrying xid mutations confirm that such immune modulating genes exist on the sex chromosomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXuu6ocKN6h7Vg90H21EOLACvtfcHk0lh3srFX0AIctQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhtVCksL0%253D&md5=77777b6215fb6c1e839b5a68d555df3c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2249.1993.tb08218.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2249.1993.tb08218.x%26sid%3Dliteratum%253Aachs%26aulast%3DJansson%26aufirst%3DL.%26aulast%3DHolmdahl%26aufirst%3DR.%26atitle%3DGenes%2520on%2520the%2520X%2520Chromosome%2520Affect%2520Development%2520of%2520Collagen-Induced%2520Arthritis%2520in%2520Mice%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D1993%26volume%3D94%26spage%3D459%26epage%3D465%26doi%3D10.1111%2Fj.1365-2249.1993.tb08218.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smathers, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederiksen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, A. D.</span></span> <span> </span><span class="NLM_article-title">Ability of the Xid Gene to Prevent Autoimmunity in (NZB X NZW)F1 Mice during the Course of Their Natural History, after Polyclonal Stimulation, or Following Immunization with DNA</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">597</span>, <span class="refDoi"> DOI: 10.1172/JCI110651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1172%2FJCI110651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=6980900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A280%3ADyaL383ms1ejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1982&pages=587-597&author=B.+J.+Steinbergauthor=P.+A.+Smathersauthor=K.+Frederiksenauthor=A.+D.+Steinberg&title=Ability+of+the+Xid+Gene+to+Prevent+Autoimmunity+in+%28NZB+X+NZW%29F1+Mice+during+the+Course+of+Their+Natural+History%2C+after+Polyclonal+Stimulation%2C+or+Following+Immunization+with+DNA&doi=10.1172%2FJCI110651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Ability of the xid gene to prevent autoimmunity in (NZB X NZW)F1 mice during the course of their natural history, after polyclonal stimulation, or following immunization with DNA</span></div><div class="casAuthors">Steinberg B J; Smathers P A; Frederiksen K; Steinberg A D</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">587-97</span>
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    </div><div class="casAbstract">F1 hybrid offspring of New Zealand Black mothers and New Zealand White fathers [(NZB X NZW)F1] female mice develop antibodies to single-stranded (ss) and native DNA, immune complex glomerulonephritis, massive proteinuria, and premature death with renal failure.  By a series of matings, congenic (NZB X NZW)F1 . xid/xid mice were prepared.  These mice were different from (NZB X NZW)F1 mice in having the X chromosome-linked immune deficiency gene, xid, in homozygous form.  Such congenic (NZB X NZW)F1 . xid/xid females failed to develop antibodies to single-stranded or native DNA.  They also failed to develop fatal renal disease as measured by proteinuria, glomerular histology, glomerular immunofluorescence, and survival.  To control for unknown genetic factors, studies were performed with littermates that were derived by mating NZB . xid/+ females with NZW . xid/Y males such that the resulting offspring were either (NZB X NZW)F1 . xid/xid (and therefore "defective") or (NZB X NZW)F1 . xid/+ [phenotypically like (NZB X NZW)F1].  In these and in additional studies, mice were housed in the same cages and identified by ear tagging so as to avoid possible environmental variations from cage to cage.  In these studies, xid/xid mice failed to develop the characteristic signs of autoimmunity, whereas the controls did.  Similar results were also obtained with (NZW X NZB)F1 xid/xid mice compared with (NZW X NZB)F1 xid/+ mice.  The effect of xid/xid upon (NZB X NZW)F1 mice was further investigated by assessing responses to immunization and polyclonal B cell activation in vivo.  The xid/xid mice failed to produce anti-ssDNA following immunization with ssDNA complexed to a protein carrier in fluid form or even emulsified in adjuvant.  Finally, the xid/xid mice failed to produce antiDNA in response to multiple injections of the polyclonal activator, bacterial lipopolysaccharide (LPS), or the polyclonal activator, polyribose inosinic acid . polyribose cytidylic acid.  However, the xid/xid mice were neither generally hyporesponsive nor unable to recognize LPS because they made normal antibody responses following immunization with LPS to which multiple trinitrophenyl groups were chemically attached.  We conclude from these studies that xid/xid, which is known to cause the deletion of a B cell subset, has a profound affect upon (NZB X NZW)F1 mice, rendering them insusceptible to the naturally occurring autoimmune disease characteristic of (NZB X NZW)F1 mice, and preventing them from producing antibodies to DNA despite purposeful immunization and polyclonal B cell activation.  These results force a reevaluation of previous concepts regarding the mechanisms by which xid/xid might interfere with the development of autoimmunity, and a consideration of therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThDLn7032pYRBrI9DTGjC0fW6udTcc2eZRkZKKVvOyGLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL383ms1ejtg%253D%253D&md5=8608a4617f65a1c46ef46a6e5388f7a6</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1172%2FJCI110651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI110651%26sid%3Dliteratum%253Aachs%26aulast%3DSteinberg%26aufirst%3DB.%2BJ.%26aulast%3DSmathers%26aufirst%3DP.%2BA.%26aulast%3DFrederiksen%26aufirst%3DK.%26aulast%3DSteinberg%26aufirst%3DA.%2BD.%26atitle%3DAbility%2520of%2520the%2520Xid%2520Gene%2520to%2520Prevent%2520Autoimmunity%2520in%2520%2528NZB%2520X%2520NZW%2529F1%2520Mice%2520during%2520the%2520Course%2520of%2520Their%2520Natural%2520History%252C%2520after%2520Polyclonal%2520Stimulation%252C%2520or%2520Following%2520Immunization%2520with%2520DNA%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1982%26volume%3D70%26spage%3D587%26epage%3D597%26doi%3D10.1172%2FJCI110651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hata, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lantz, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda-Yamamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldfeld, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alt, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galli, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, T.</span></span> <span> </span><span class="NLM_article-title">Involvement of Bruton’s Tyrosine Kinase in FcεRI-Dependent Mast Cell Degranulation and Cytokine Production</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">1235</span>– <span class="NLM_lpage">1247</span>, <span class="refDoi"> DOI: 10.1084/jem.187.8.1235</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1084%2Fjem.187.8.1235" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=9547335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADyaK1cXis1Cru7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=1998&pages=1235-1247&author=D.+Hataauthor=Y.+Kawakamiauthor=N.+Inagakiauthor=C.+S.+Lantzauthor=T.+Kitamuraauthor=W.+N.+Khanauthor=M.+Maeda-Yamamotoauthor=T.+Miuraauthor=W.+Hanauthor=S.+E.+Hartmanauthor=L.+Yaoauthor=H.+Nagaiauthor=A.+E.+Goldfeldauthor=F.+W.+Altauthor=S.+J.+Galliauthor=O.+N.+Witteauthor=T.+Kawakami&title=Involvement+of+Bruton%E2%80%99s+Tyrosine+Kinase+in+Fc%CE%B5RI-Dependent+Mast+Cell+Degranulation+and+Cytokine+Production&doi=10.1084%2Fjem.187.8.1235"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of Bruton's tyrosine kinase in FcεRI-dependent mast cell degranulation and cytokine production</span></div><div class="casAuthors">Hata, Daisuke; Kawakami, Yuko; Inagaki, Naoki; Lantz, Chris S.; Kitamura, Toshio; Khan, Wasif N.; Maeda-Yamamoto, Mari; Miura, Toru; Han, Wei; Hartman, Stephen E.; Yao, Libo; Nagai, Hiroichi; Goldfeld, Anne E.; Alt, Frederick W.; Galli, Stephen J.; Witte, Owen N.; Kawakami, Toshiaki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1235-1247</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">The role of Bruton's tyrosine kinase (Btk) in FcεRI-dependent activation of mouse mast cells was investigated, using xid and btk null mutant mice.  Unlike B cell development, mast cell development is apparently normal in these btk mutant mice.  However, mast cells derived from these mice exhibited significant abnormalities in FcεRI-dependent function.  Xid mice primed with anti-dinitrophenyl monoclonal IgE antibody exhibited mildly diminished early-phase and severely blunted late-phase anaphylactic reactions in response to antigen challenge in vivo.  Consistent with this finding, cultured mast cells derived from the bone marrow cells of xid or btk null mice exhibited mild impairments in degranulation, and more profound defects in the prodn. of several cytokines, upon FcεRI crosslinking.  Moreover, the transcriptional activities of these cytokine genes were severely reduced in FcεRI-stimulated btk mutant mast cells.  The specificity of these effects of btk mutations was confirmed by the improvement in the ability of btk mutant mast cells to degranulate and to secrete cytokines after the retroviral transfer of wild-type btk cDNA, but not of vector or kinase-dead btk cDNA.  Retroviral transfer of Emt (= Itk/Tsk), Btk's closest relative, also partially improved the ability of btk mutant mast cells to secrete mediators.  These results demonstrate an important role for Btk in the full expression of FcεRI signal transduction in mast cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ3R8NlYi0F7Vg90H21EOLACvtfcHk0lgYMSafzabVkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXis1Cru7k%253D&md5=ca0908f7ddf320595c53c8ac7804bb1f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1084%2Fjem.187.8.1235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.187.8.1235%26sid%3Dliteratum%253Aachs%26aulast%3DHata%26aufirst%3DD.%26aulast%3DKawakami%26aufirst%3DY.%26aulast%3DInagaki%26aufirst%3DN.%26aulast%3DLantz%26aufirst%3DC.%2BS.%26aulast%3DKitamura%26aufirst%3DT.%26aulast%3DKhan%26aufirst%3DW.%2BN.%26aulast%3DMaeda-Yamamoto%26aufirst%3DM.%26aulast%3DMiura%26aufirst%3DT.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DHartman%26aufirst%3DS.%2BE.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DNagai%26aufirst%3DH.%26aulast%3DGoldfeld%26aufirst%3DA.%2BE.%26aulast%3DAlt%26aufirst%3DF.%2BW.%26aulast%3DGalli%26aufirst%3DS.%2BJ.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26aulast%3DKawakami%26aufirst%3DT.%26atitle%3DInvolvement%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520in%2520Fc%25CE%25B5RI-Dependent%2520Mast%2520Cell%2520Degranulation%2520and%2520Cytokine%2520Production%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1998%26volume%3D187%26spage%3D1235%26epage%3D1247%26doi%3D10.1084%2Fjem.187.8.1235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirisawad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loury, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thamm, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span> <span> </span><span class="NLM_article-title">The Bruton Tyrosine Kinase Inhibitor PCI-32765 Blocks B-Cell Activation and Is Efficacious in Models of Autoimmune Disease and B-Cell Malignancy</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">13075</span>– <span class="NLM_lpage">13080</span>, <span class="refDoi"> DOI: 10.1073/pnas.1004594107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1073%2Fpnas.1004594107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=20615965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=13075-13080&author=L.+A.+Honigbergauthor=A.+M.+Smithauthor=M.+Sirisawadauthor=E.+Vernerauthor=D.+Louryauthor=B.+Changauthor=S.+Liauthor=Z.+Panauthor=D.+H.+Thammauthor=R.+A.+Millerauthor=J.+J.+Buggy&title=The+Bruton+Tyrosine+Kinase+Inhibitor+PCI-32765+Blocks+B-Cell+Activation+and+Is+Efficacious+in+Models+of+Autoimmune+Disease+and+B-Cell+Malignancy&doi=10.1073%2Fpnas.1004594107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span></div><div class="casAuthors">Honigberg, Lee A.; Smith, Ashley M.; Sirisawad, Mint; Verner, Erik; Loury, David; Chang, Betty; Li, Shyr; Pan, Zhengying; Thamm, Douglas H.; Miller, Richard A.; Buggy, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">13075-13080, S13075/1-S13075/3</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Activation of the B-cell antigen receptor (BCR) signaling pathway contributes to the initiation and maintenance of B-cell malignancies and autoimmune diseases.  The Bruton tyrosine kinase (Btk) is specifically required for BCR signaling as demonstrated by human and mouse mutations that disrupt Btk function and prevent B-cell maturation at steps that require a functional BCR pathway.  Herein we describe a selective and irreversible Btk inhibitor, PCI-32765, that is currently under clin. development in patients with B-cell non-Hodgkin lymphoma.  We have used this inhibitor to investigate the biol. effects of Btk inhibition on mature B-cell function and the progression of B cell-assocd. diseases in vivo.  PCI-32765 blocked BCR signaling in human peripheral B cells at concns. that did not affect T cell receptor signaling.  In mice with collagen-induced arthritis, orally administered PCI-32765 reduced the level of circulating autoantibodies and completely suppressed disease.  PCI-32765 also inhibited autoantibody prodn. and the development of kidney disease in the MRL-Fas(lpr) lupus model.  Occupancy of the Btk active site by PCI-32765 was monitored in vitro and in vivo using a fluorescent affinity probe for Btk.  Active site occupancy of Btk was tightly correlated with the blockade of BCR signaling and in vivo efficacy.  Finally, PCI-32765 induced objective clin. responses in dogs with spontaneous B-cell non-Hodgkin lymphoma.  These findings support Btk inhibition as a therapeutic approach for the treatment of human diseases assocd. with activation of the BCR pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT4OQHme7oHLVg90H21EOLACvtfcHk0lj9S47Euo5bMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D&md5=196ce4a05bb9c622c49cb7e908682e63</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1004594107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1004594107%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DLoury%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DThamm%26aufirst%3DD.%2BH.%26aulast%3DMiller%26aufirst%3DR.%2BA.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Bruton%2520Tyrosine%2520Kinase%2520Inhibitor%2520PCI-32765%2520Blocks%2520B-Cell%2520Activation%2520and%2520Is%2520Efficacious%2520in%2520Models%2520of%2520Autoimmune%2520Disease%2520and%2520B-Cell%2520Malignancy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D13075%26epage%3D13080%26doi%3D10.1073%2Fpnas.1004594107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postelnek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, D.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pashine, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Mahony, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narula, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMartino, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fine, J. S.</span></span> <span> </span><span class="NLM_article-title">RN486, a Selective Bruton’s Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.187740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1124%2Fjpet.111.187740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=22228807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVagt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2012&pages=90-103&author=D.+Xuauthor=Y.+Kimauthor=J.+Postelnekauthor=M.+D.+Vuauthor=D.-Q.+Huauthor=C.+Liaoauthor=M.+Bradshawauthor=J.+Hsuauthor=J.+Zhangauthor=A.+Pashineauthor=D.+Srinivasanauthor=J.+Woodsauthor=A.+Levinauthor=A.+O%E2%80%99Mahonyauthor=T.+D.+Owensauthor=Y.+Louauthor=R.+J.+Hillauthor=S.+Narulaauthor=J.+DeMartinoauthor=J.+S.+Fine&title=RN486%2C+a+Selective+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitor%2C+Abrogates+Immune+Hypersensitivity+Responses+and+Arthritis+in+Rodents&doi=10.1124%2Fjpet.111.187740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents</span></div><div class="casAuthors">Xu, Daigen; Kim, Yong; Postelnek, Jennifer; Vu, Minh Diem; Hu, Dong-Qing; Liao, Cheng; Bradshaw, Mike; Hsu, Jonathan; Zhang, Jun; Pashine, Achal; Srinivasan, Dinesh; Woods, John; Levin, Anita; O'Mahony, Alison; Owens, Timothy D.; Lou, Yan; Hill, Ronald J.; Narula, Satwant; DeMartino, Julie; Fine, Jay S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">90-103</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Genetic mutation and pharmacol. inhibition of Bruton's tyrosine kinase (Btk) both have been shown to prevent the development of collagen-induced arthritis (CIA) in mice, providing a rationale for the development of Btk inhibitors for treating rheumatoid arthritis (RA).  In the present study, we characterized a novel Btk inhibitor, 6-cyclopropyl-8-fluoro-2-(2-hydroxymethyl-3-{1-methyl-5-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-2H-isoquinolin-1-one (RN486), in vitro and in rodent models of immune hypersensitivity and arthritis.  We demonstrated that RN486 not only potently and selectively inhibited the Btk enzyme, but also displayed functional activities in human cell-based assays in multiple cell types, blocking Fcε receptor crosslinking-induced degranulation in mast cells (IC50 = 2.9 nM), Fcγ receptor engagement-mediated tumor necrosis factor α prodn. in monocytes (IC50 = 7.0 nM), and B cell antigen receptor-induced expression of an activation marker, CD69, in B cells in whole blood (IC50 = 21.0 nM).  RN486 displayed similar functional activities in rodent models, effectively preventing type I and type III hypersensitivity responses.  More importantly, RN486 produced robust anti-inflammatory and bone-protective effects in mouse CIA and rat adjuvant-induced arthritis (AIA) models.  In the AIA model, RN486 inhibited both joint and systemic inflammation either alone or in combination with methotrexate, reducing both paw swelling and inflammatory markers in the blood.  Together, our findings not only demonstrate that Btk plays an essential and conserved role in regulating immunoreceptor-mediated immune responses in both humans and rodents, but also provide evidence and mechanistic insights to support the development of selective Btk inhibitors as small-mol. disease-modifying drugs for RA and potentially other autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXBTQENfl5RbVg90H21EOLACvtfcHk0ljMBF-3mEFDMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVagt7g%253D&md5=06be56a47afd2eb09e0871710c1d2b47</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.187740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.187740%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DPostelnek%26aufirst%3DJ.%26aulast%3DVu%26aufirst%3DM.%2BD.%26aulast%3DHu%26aufirst%3DD.-Q.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DBradshaw%26aufirst%3DM.%26aulast%3DHsu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPashine%26aufirst%3DA.%26aulast%3DSrinivasan%26aufirst%3DD.%26aulast%3DWoods%26aufirst%3DJ.%26aulast%3DLevin%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DNarula%26aufirst%3DS.%26aulast%3DDeMartino%26aufirst%3DJ.%26aulast%3DFine%26aufirst%3DJ.%2BS.%26atitle%3DRN486%252C%2520a%2520Selective%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitor%252C%2520Abrogates%2520Immune%2520Hypersensitivity%2520Responses%2520and%2520Arthritis%2520in%2520Rodents%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D341%26spage%3D90%26epage%3D103%26doi%3D10.1124%2Fjpet.111.187740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barck, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carano, R. A. D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForge, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrando, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staker, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Specific Btk Inhibition Suppresses B Cell- and Myeloid Cell-Mediated Arthritis</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1038/nchembio.481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1038%2Fnchembio.481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=21113169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=41-50&author=J.+A.+Di+Paoloauthor=T.+Huangauthor=M.+Balazsauthor=J.+Barbosaauthor=K.+H.+Barckauthor=B.+J.+Bravoauthor=R.+A.+D.+D.+Caranoauthor=J.+Darrowauthor=D.+R.+Daviesauthor=L.+E.+DeForgeauthor=L.+Diehlauthor=R.+Ferrandoauthor=S.+L.+Gallionauthor=A.+M.+Giannettiauthor=P.+Griblingauthor=V.+Hurezauthor=S.+G.+Hymowitzauthor=R.+Jonesauthor=J.+E.+Kropfauthor=W.+P.+Leeauthor=P.+M.+Maciejewskiauthor=S.+A.+Mitchellauthor=H.+Rongauthor=B.+L.+Stakerauthor=J.+A.+Whitneyauthor=S.+Yehauthor=W.+B.+Youngauthor=C.+Yuauthor=J.+Zhangauthor=K.+Reifauthor=K.+S.+Currie&title=Specific+Btk+Inhibition+Suppresses+B+Cell-+and+Myeloid+Cell-Mediated+Arthritis&doi=10.1038%2Fnchembio.481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span></div><div class="casAuthors">Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai H.; Bravo, Brandon J.; Carano, Richard A. D.; Darrow, James; Davies, Douglas R.; DeForge, Laura E.; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven L.; Giannetti, Anthony M.; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah G.; Jones, Randall; Kropf, Jeffrey E.; Lee, Wyne P.; Maciejewski, Patricia M.; Mitchell, Scott A.; Rong, Hong; Staker, Bart L.; Whitney, J. Andrew; Yeh, Sherry; Young, Wendy B.; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and mol. mechanisms by which Btk mediates inflammation are poorly understood.  Here we describe the discovery of CGI1746, a small-mol. Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.  CGI1746 has exquisite selectivity for Btk and inhibits both auto- and transphosphorylation steps necessary for enzyme activation.  Using CGI1746, we demonstrate that Btk regulates inflammatory arthritis by two distinct mechanisms.  CGI1746 blocks B cell receptor-dependent B cell proliferation and in prophylactic regimens reduces autoantibody levels in collagen-induced arthritis.  In macrophages, Btk inhibition abolishes FcγRIII-induced TNFα, IL-1β and IL-6 prodn.  Accordingly, in myeloid- and FcγR-dependent autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and ameliorates disease.  These results provide new understanding of the function of Btk in both B cell- or myeloid cell-driven disease processes and provide a compelling rationale for targeting Btk in rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoegiZYoitP57Vg90H21EOLACvtfcHk0ljMBF-3mEFDMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP&md5=99d925c71bc1b201191ebde0f1c0b50f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.481%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBarck%26aufirst%3DK.%2BH.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%2BD.%2BD.%26aulast%3DDarrow%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DFerrando%26aufirst%3DR.%26aulast%3DGallion%26aufirst%3DS.%2BL.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHurez%26aufirst%3DV.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DMaciejewski%26aufirst%3DP.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DSpecific%2520Btk%2520Inhibition%2520Suppresses%2520B%2520Cell-%2520and%2520Myeloid%2520Cell-Mediated%2520Arthritis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D41%26epage%3D50%26doi%3D10.1038%2Fnchembio.481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rankin, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreyeva, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, T. a</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmonds, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathialagan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoit, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyashiro, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaiah, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messing, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homer, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunussi-Joannopoulos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickerson-Nutter, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnute, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douhan, J.,  3rd</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">4540</span>– <span class="NLM_lpage">4550</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1301553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.4049%2Fjimmunol.1301553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=24068666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1eqs7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=4540-4550&author=A.+L.+Rankinauthor=N.+Sethauthor=S.+Keeganauthor=T.+Andreyevaauthor=T.+a+Cookauthor=J.+Edmondsauthor=N.+Mathialaganauthor=M.+J.+Bensonauthor=J.+Syedauthor=Y.+Zhanauthor=S.+E.+Benoitauthor=J.+S.+Miyashiroauthor=N.+Woodauthor=S.+Mohanauthor=E.+Peevaauthor=S.+K.+Ramaiahauthor=D.+Messingauthor=B.+L.+Homerauthor=K.+Dunussi-Joannopoulosauthor=C.+L.+Nickerson-Nutterauthor=M.+E.+Schnuteauthor=J.+Douhan&title=Selective+Inhibition+of+BTK+Prevents+Murine+Lupus+and+Antibody-Mediated+Glomerulonephritis&doi=10.4049%2Fjimmunol.1301553"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis</span></div><div class="casAuthors">Rankin, Andrew L.; Seth, Nilufer; Keegan, Sean; Andreyeva, Tatyana; Cook, Tim A.; Edmonds, Jason; Mathialagan, Nagappan; Benson, Micah J.; Syed, Jameel; Zhan, Yutian; Benoit, Stephen E.; Miyashiro, Joy S.; Wood, Nancy; Mohan, Shashi; Peeva, Elena; Ramaiah, Shashi K.; Messing, Dean; Homer, Bruce L.; Dunussi-Joannopoulos, Kyri; Nickerson-Nutter, Cheryl L.; Schnute, Mark E.; Douhan, John, III</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4540-4550</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Autoantibody prodn. and immune complex deposition within the kidney promote renal disease in patients with lupus nephritis.  Thus, therapeutics that inhibit these pathways may be efficacious in the treatment of systemic lupus erythematosus.  Bruton's tyrosine kinase (BTK) is a crit. signaling component of both BCR and FcR signaling.  We sought to assess the efficacy of inhibiting BTK in the development of lupus-like disease, and in this article describe (R)-5-amino-1-(1-cyanopiperidin-3-yl)-3-(4-[2,4-difluorophenoxy]phenyl)-1H-pyrazole-4-carboxamide (PF-06250112), a novel highly selective and potent BTK inhibitor.  We demonstrate in vitro that PF-06250112 inhibits both BCR-mediated signaling and proliferation, as well as FcR-mediated activation.  To assess the therapeutic impact of BTK inhibition, we treated aged NZBxWF1 mice with PF-06250112 and demonstrate that PF-06250112 significantly limits the spontaneous accumulation of splenic germinal center B cells and plasma cells.  Correspondingly, anti-dsDNA and autoantibody levels were reduced in a dose-dependent manner.  Moreover, administration of PF-06250112 prevented the development of proteinuria and improved glomerular pathol. scores in all treatment groups.  Strikingly, this therapeutic effect could occur with only a modest redn. obsd. in anti-dsDNA titers, implying a crit. role for BTK signaling in disease pathogenesis beyond inhibition of autoantibody prodn.  We subsequently demonstrate that PF-06250112 prevents proteinuria in an FcR-dependent, Ab-mediated model of glomerulonephritis.  Importantly, these results highlight that BTK inhibition potently limits the development of glomerulonephritis by impacting both cell- and effector mol.-mediated pathways.  These data provide support for evaluating the efficacy of BTK inhibition in systemic lupus erythematosus patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBldekay4INLVg90H21EOLACvtfcHk0liTjkB19UEZGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1eqs7zE&md5=7abfb074bf422aa3fb63aa0bc3d8cf58</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1301553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1301553%26sid%3Dliteratum%253Aachs%26aulast%3DRankin%26aufirst%3DA.%2BL.%26aulast%3DSeth%26aufirst%3DN.%26aulast%3DKeegan%26aufirst%3DS.%26aulast%3DAndreyeva%26aufirst%3DT.%26aulast%3DCook%26aufirst%3DT.%2Ba%26aulast%3DEdmonds%26aufirst%3DJ.%26aulast%3DMathialagan%26aufirst%3DN.%26aulast%3DBenson%26aufirst%3DM.%2BJ.%26aulast%3DSyed%26aufirst%3DJ.%26aulast%3DZhan%26aufirst%3DY.%26aulast%3DBenoit%26aufirst%3DS.%2BE.%26aulast%3DMiyashiro%26aufirst%3DJ.%2BS.%26aulast%3DWood%26aufirst%3DN.%26aulast%3DMohan%26aufirst%3DS.%26aulast%3DPeeva%26aufirst%3DE.%26aulast%3DRamaiah%26aufirst%3DS.%2BK.%26aulast%3DMessing%26aufirst%3DD.%26aulast%3DHomer%26aufirst%3DB.%2BL.%26aulast%3DDunussi-Joannopoulos%26aufirst%3DK.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%2BL.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DDouhan%26aufirst%3DJ.%26atitle%3DSelective%2520Inhibition%2520of%2520BTK%2520Prevents%2520Murine%2520Lupus%2520and%2520Antibody-Mediated%2520Glomerulonephritis%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D4540%26epage%3D4550%26doi%3D10.4049%2Fjimmunol.1301553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin
Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elzinga, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westhouse, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catlett, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pokross, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allentoff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3228</span>– <span class="NLM_lpage">3250</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00167</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00167" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC1MXls1aks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3228-3250&author=S.+H.+Wattersonauthor=Q.+Liuauthor=M.+Beaudoin%0ABertrandauthor=D.+G.+Battauthor=L.+Liauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=L.+Chengauthor=M.+T.+Obermeierauthor=R.+Mooreauthor=Z.+Yangauthor=R.+Vickeryauthor=P.+A.+Elzingaauthor=L.+Discenzaauthor=C.+D%E2%80%99Arienzoauthor=K.+M.+Gilloolyauthor=T.+L.+Taylorauthor=C.+Pulicicchioauthor=Y.+Zhangauthor=E.+Heimrichauthor=K.+W.+McIntyreauthor=Q.+Ruanauthor=R.+A.+Westhouseauthor=I.+M.+Catlettauthor=N.+Zhengauthor=C.+Chaudhryauthor=J.+Daiauthor=M.+A.+Galellaauthor=A.+J.+Tebbenauthor=M.+Pokrossauthor=J.+Liauthor=R.+Zhaoauthor=D.+Smithauthor=R.+Rampullaauthor=A.+Allentoffauthor=M.+A.+Wallaceauthor=A.+Mathurauthor=L.+Salter-Cidauthor=J.+E.+Macorauthor=P.+H.+Carterauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+A.+Tino&title=Discovery+of+Branebrutinib+%28BMS-986195%29%3A+A+Strategy+for+Identifying+a+Highly+Potent+and+Selective+Covalent+Inhibitor+Providing+Rapid+in+Vivo+Inactivation+of+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29&doi=10.1021%2Facs.jmedchem.9b00167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK)</span></div><div class="casAuthors">Watterson, Scott H.; Liu, Qingjie; Beaudoin Bertrand, Myra; Batt, Douglas G.; Li, Ling; Pattoli, Mark A.; Skala, Stacey; Cheng, Lihong; Obermeier, Mary T.; Moore, Robin; Yang, Zheng; Vickery, Rodney; Elzinga, Paul A.; Discenza, Lorell; D'Arienzo, Celia; Gillooly, Kathleen M.; Taylor, Tracy L.; Pulicicchio, Claudine; Zhang, Yifan; Heimrich, Elizabeth; McIntyre, Kim W.; Ruan, Qian; Westhouse, Richard A.; Catlett, Ian M.; Zheng, Naiyu; Chaudhry, Charu; Dai, Jun; Galella, Michael A.; Tebben, Andrew J.; Pokross, Matt; Li, Jianqing; Zhao, Rulin; Smith, Daniel; Rampulla, Richard; Allentoff, Alban; Wallace, Michael A.; Mathur, Arvind; Salter-Cid, Luisa; Macor, John E.; Carter, Percy H.; Fura, Aberra; Burke, James R.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3228-3250</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a non-receptor tyrosine kinase, is a member of the Tec family of kinases and is essential for B cell receptor (BCR) mediated signaling.  BTK also plays a crit. role in the downstream signaling pathways for the Fcγ receptor in monocytes, the Fcε receptor in granulocytes, and the RANK receptor in osteoclasts.  As a result, pharmacol. inhibition of BTK is anticipated to provide an effective strategy for the clin. treatment of autoimmune diseases such as rheumatoid arthritis and lupus.  This article will outline the evolution of our strategy to identify a covalent, irreversible inhibitor of BTK that has the intrinsic potency, selectivity, and pharmacokinetic properties necessary to provide a rapid rate of inactivation systemically following a very low dose.  With excellent in vivo efficacy and a very desirable tolerability profile, 5a (branebrutinib, BMS-986195) has advanced into clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGr5oQEoebirVg90H21EOLACvtfcHk0lirIC4vzkN2mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXls1aks7w%253D&md5=2d521ec7c06d503f940cb44d381af58d</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00167%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBeaudoin%2BBertrand%26aufirst%3DM.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DMoore%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DElzinga%26aufirst%3DP.%2BA.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DRuan%26aufirst%3DQ.%26aulast%3DWesthouse%26aufirst%3DR.%2BA.%26aulast%3DCatlett%26aufirst%3DI.%2BM.%26aulast%3DZheng%26aufirst%3DN.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DPokross%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DAllentoff%26aufirst%3DA.%26aulast%3DWallace%26aufirst%3DM.%2BA.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%2520Branebrutinib%2520%2528BMS-986195%2529%253A%2520A%2520Strategy%2520for%2520Identifying%2520a%2520Highly%2520Potent%2520and%2520Selective%2520Covalent%2520Inhibitor%2520Providing%2520Rapid%2520in%2520Vivo%2520Inactivation%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3228%26epage%3D3250%26doi%3D10.1021%2Facs.jmedchem.9b00167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lucca, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langevine, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin
Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traeger, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-Fluoro-1-Methyl-2,4-Dioxo-1,2-Dihydroquinazolin-3(4H)-Yl)-2-Methylphenyl)-2-(S)-(2-Hydroxypropan-2-Yl)-2,3,4,9-Tetrahydro-1H-Carbazole-8-Carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine (BTK) Conformationally Constrained by Two Locked Atropisomers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9173</span>– <span class="NLM_lpage">9200</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01088</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01088" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKjsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9173-9200&author=S.+H.+Wattersonauthor=G.+V.+De+Luccaauthor=Q.+Shiauthor=C.+M.+Langevineauthor=Q.+Liuauthor=D.+G.+Battauthor=M.+Beaudoin%0ABertrandauthor=H.+Gongauthor=J.+Daiauthor=S.+Yipauthor=P.+Liauthor=D.+Sunauthor=D.-R.+Wuauthor=C.+Wangauthor=Y.+Zhangauthor=S.+C.+Traegerauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=L.+Chengauthor=M.+T.+Obermeierauthor=R.+Vickeryauthor=L.+N.+Discenzaauthor=C.+J.+D%E2%80%99Arienzoauthor=Y.+Zhangauthor=E.+Heimrichauthor=K.+M.+Gilloolyauthor=T.+L.+Taylorauthor=C.+Pulicicchioauthor=K.+W.+McIntyreauthor=M.+A.+Galellaauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=C.+Changauthor=R.+Rampullaauthor=A.+Mathurauthor=L.+Salter-Cidauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+A.+Tino&title=Discovery+of+6-Fluoro-5-%28R%29-%283-%28S%29-%288-Fluoro-1-Methyl-2%2C4-Dioxo-1%2C2-Dihydroquinazolin-3%284H%29-Yl%29-2-Methylphenyl%29-2-%28S%29-%282-Hydroxypropan-2-Yl%29-2%2C3%2C4%2C9-Tetrahydro-1H-Carbazole-8-Carboxamide+%28BMS-986142%29%3A+A+Reversible+Inhibitor+of+Bruton%E2%80%99s+Tyrosine+%28BTK%29+Conformationally+Constrained+by+Two+Locked+Atropisomers&doi=10.1021%2Facs.jmedchem.6b01088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers</span></div><div class="casAuthors">Watterson, Scott H.; De Lucca, George V.; Shi, Qing; Langevine, Charles M.; Liu, Qingjie; Batt, Douglas G.; Beaudoin Bertrand, Myra; Gong, Hua; Dai, Jun; Yip, Shiuhang; Li, Peng; Sun, Dawn; Wu, Dauh-Rurng; Wang, Chunlei; Zhang, Yingru; Traeger, Sarah C.; Pattoli, Mark A.; Skala, Stacey; Cheng, Lihong; Obermeier, Mary T.; Vickery, Rodney; Discenza, Lorell N.; D'Arienzo, Celia J.; Zhang, Yifan; Heimrich, Elizabeth; Gillooly, Kathleen M.; Taylor, Tracy L.; Pulicicchio, Claudine; McIntyre, Kim W.; Galella, Michael A.; Tebben, Andy J.; Muckelbauer, Jodi K.; Chang, ChiehYing; Rampulla, Richard; Mathur, Arvind; Salter-Cid, Luisa; Barrish, Joel C.; Carter, Percy H.; Fura, Aberra; Burke, James R.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9173-9200</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a member of the Tec family of kinases.  BTK plays an essential role in B cell receptor (BCR)-mediated signaling as well as Fcγ receptor signaling in monocytes and Fcε receptor signaling in mast cells and basophils, all of which have been implicated in the pathophysiol. of autoimmune disease.  As a result, inhibition of BTK is anticipated to provide an effective strategy for the clin. treatment of autoimmune diseases such as lupus and rheumatoid arthritis.  This article details the structure-activity relationships (SAR) leading to a novel series of highly potent and selective carbazole and tetrahydrocarbazole based, reversible inhibitors of BTK.  Of particular interest is that two atropisomeric centers were rotationally locked to provide a single, stable atropisomer, resulting in enhanced potency and selectivity as well as a redn. in safety liabilities.  With significantly enhanced potency and selectivity, excellent in vivo properties and efficacy, and a very desirable tolerability and safety profile, 14f (BMS-986142) was advanced into clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmpBAygRAsYrVg90H21EOLACvtfcHk0lgM_K9CJxHjSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKjsrfF&md5=91098abc802521b9ad91563d20ac5893</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01088%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DLangevine%26aufirst%3DC.%2BM.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DBeaudoin%2BBertrand%26aufirst%3DM.%26aulast%3DGong%26aufirst%3DH.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DYip%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DD.-R.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTraeger%26aufirst%3DS.%2BC.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DDiscenza%26aufirst%3DL.%2BN.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25206-Fluoro-5-%2528R%2529-%25283-%2528S%2529-%25288-Fluoro-1-Methyl-2%252C4-Dioxo-1%252C2-Dihydroquinazolin-3%25284H%2529-Yl%2529-2-Methylphenyl%2529-2-%2528S%2529-%25282-Hydroxypropan-2-Yl%2529-2%252C3%252C4%252C9-Tetrahydro-1H-Carbazole-8-Carboxamide%2520%2528BMS-986142%2529%253A%2520A%2520Reversible%2520Inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520%2528BTK%2529%2520Conformationally%2520Constrained%2520by%2520Two%2520Locked%2520Atropisomers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9173%26epage%3D9200%26doi%3D10.1021%2Facs.jmedchem.6b01088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukral, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudhgaonkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span> <span> </span><span class="NLM_article-title">Bruton’s Tyrosine Kinase Inhibitor BMS-986142 in Experimental Models of Rheumatoid Arthritis Enhances Efficacy of Agents Representing Clinical Standard-of-Care</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e0181782</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0181782</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1371%2Fjournal.pone.0181782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=28742141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVSntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&author=K.+M.+Gilloolyauthor=C.+Pulicicchioauthor=M.+A.+Pattoliauthor=L.+Chengauthor=S.+Skalaauthor=E.+M.+Heimrichauthor=K.+W.+McIntyreauthor=T.+L.+Taylorauthor=D.+W.+Kukralauthor=S.+Dudhgaonkarauthor=J.+Nagarauthor=D.+Banasauthor=S.+H.+Wattersonauthor=J.+A.+Tinoauthor=A.+Furaauthor=J.+R.+Burke&title=Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitor+BMS-986142+in+Experimental+Models+of+Rheumatoid+Arthritis+Enhances+Efficacy+of+Agents+Representing+Clinical+Standard-of-Care&doi=10.1371%2Fjournal.pone.0181782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care</span></div><div class="casAuthors">Gillooly, Kathleen M.; Pulicicchio, Claudine; Pattoli, Mark A.; Cheng, Lihong; Skala, Stacey; Heimrich, Elizabeth M.; McIntyre, Kim W.; Taylor, Tracy L.; Kukral, Daniel W.; Dudhgaonkar, Shailesh; Nagar, Jignesh; Banas, Dana; Watterson, Scott H.; Tino, Joseph A.; Fura, Aberra; Burke, James R.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e0181782/1-e0181782/20</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) regulates crit. signal transduction pathways involved in the pathobiol. of rheumatoid arthritis (RA) and other autoimmune disorders.  BMS-986142 is a potent and highly selective reversible small mol. inhibitor of BTK currently being investigated in clin. trials for the treatment of both RA and primary Sj.ovrddot.ogren's syndrome.  In the present report, we detail the in vitro and in vivo pharmacol. of BMS-986142 and show this agent provides potent and selective inhibition of BTK (IC50 = 0.5 nM), blocks antigen receptor-dependent signaling and functional endpoints (cytokine prodn., co-stimulatory mol. expression, and proliferation) in human B cells (IC50 ≤ 5 nM), inhibits Fcγ receptor-dependent cytokine prodn. from peripheral blood mononuclear cells, and blocks RANK-L-induced osteoclastogenesis.  Through the benefits of impacting these important drivers of autoimmunity, BMS-986142 demonstrated robust efficacy in murine models of rheumatoid arthritis (RA), including collagen-induced arthritis (CIA) and collagen antibody-induced arthritis (CAIA).  In both models, robust efficacy was obsd. without continuous, complete inhibition of BTK.  When a suboptimal dose of BMS-986142 was combined with other agents representing the current std. of care for RA (e.g., methotrexate, the TNFα antagonist etanercept, or the murine form of CTLA4-Ig) in the CIA model, improved efficacy compared to either agent alone was obsd.  The results suggest BMS-986142 represents a potential therapeutic for clin. investigation in RA, as monotherapy or co-administered with agents with complementary mechanisms of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg22LhZ5lc9rVg90H21EOLACvtfcHk0lgM_K9CJxHjSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVSntbs%253D&md5=144039a2425c898869da3d9c263d7321</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0181782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0181782%26sid%3Dliteratum%253Aachs%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DHeimrich%26aufirst%3DE.%2BM.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DKukral%26aufirst%3DD.%2BW.%26aulast%3DDudhgaonkar%26aufirst%3DS.%26aulast%3DNagar%26aufirst%3DJ.%26aulast%3DBanas%26aufirst%3DD.%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26atitle%3DBruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitor%2520BMS-986142%2520in%2520Experimental%2520Models%2520of%2520Rheumatoid%2520Arthritis%2520Enhances%2520Efficacy%2520of%2520Agents%2520Representing%2520Clinical%2520Standard-of-Care%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26doi%3D10.1371%2Fjournal.pone.0181782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmont, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coraggio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2227</span>– <span class="NLM_lpage">2245</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01712</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01712" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCnt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2227-2245&author=J.+J.+Crawfordauthor=A.+R.+Johnsonauthor=D.+L.+Misnerauthor=L.+D.+Belmontauthor=G.+Castanedoauthor=R.+Choyauthor=M.+Coraggioauthor=L.+Dongauthor=C.+Eigenbrotauthor=R.+Ericksonauthor=N.+Ghilardiauthor=J.+Hauauthor=A.+Katewaauthor=P.+B.+Kohliauthor=W.+Leeauthor=J.+W.+Lubachauthor=B.+S.+McKenzieauthor=D.+F.+Ortwineauthor=L.+Schuttauthor=S.+Tayauthor=B.+Weiauthor=K.+Reifauthor=L.+Liuauthor=H.+Wongauthor=W.+B.+Young&title=Discovery+of+GDC-0853%3A+A+Potent%2C+Selective%2C+and+Noncovalent+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitor+in+Early+Clinical+Development&doi=10.1021%2Facs.jmedchem.7b01712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development</span></div><div class="casAuthors">Crawford, James J.; Johnson, Adam R.; Misner, Dinah L.; Belmont, Lisa D.; Castanedo, Georgette; Choy, Regina; Coraggio, Melis; Dong, Liming; Eigenbrot, Charles; Erickson, Rebecca; Ghilardi, Nico; Hau, Jonathan; Katewa, Arna; Kohli, Pawan Bir; Lee, Wendy; Lubach, Joseph W.; McKenzie, Brent S.; Ortwine, Daniel F.; Schutt, Leah; Tay, Suzanne; Wei, BinQing; Reif, Karin; Liu, Lichuan; Wong, Harvey; Young, Wendy B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2227-2245</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a nonreceptor cytoplasmic tyrosine kinase involved in B-cell and myeloid cell activation, downstream of B-cell and Fcγ receptors, resp.  Preclin. studies have indicated that inhibition of Btk activity might offer a potential therapy in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.  Here we disclose the discovery and preclin. characterization of a potent, selective, and noncovalent Btk inhibitor currently in clin. development.  GDC-0853 (29) suppresses B cell- and myeloid cell-mediated components of disease and demonstrates dose-dependent activity in an in vivo rat model of inflammatory arthritis.  It demonstrates highly favorable safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles in preclin. and Phase 2 studies ongoing in patients with rheumatoid arthritis, lupus, and chronic spontaneous urticaria.  On the basis of its potency, selectivity, long target residence time, and noncovalent mode of inhibition, 29 has the potential to be a best-in-class Btk inhibitor for a wide range of immunol. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOUJgTOFJ-o7Vg90H21EOLACvtfcHk0lh2ws8h4fDazA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCnt7c%253D&md5=eddbd31f387fe86827a7469e8be45430</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01712%26sid%3Dliteratum%253Aachs%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26aulast%3DBelmont%26aufirst%3DL.%2BD.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChoy%26aufirst%3DR.%26aulast%3DCoraggio%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DL.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DErickson%26aufirst%3DR.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DHau%26aufirst%3DJ.%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DSchutt%26aufirst%3DL.%26aulast%3DTay%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26atitle%3DDiscovery%2520of%2520GDC-0853%253A%2520A%2520Potent%252C%2520Selective%252C%2520and%2520Noncovalent%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitor%2520in%2520Early%2520Clinical%2520Development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2227%26epage%3D2245%26doi%3D10.1021%2Facs.jmedchem.7b01712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haselmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camps, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu-Bujalski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Mahony, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerli, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruns, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenningloh, R.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>202</i></span>,  <span class="NLM_fpage">2888</span>– <span class="NLM_lpage">2906</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1800583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.4049%2Fjimmunol.1800583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=30988116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvF2ntLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=202&publication_year=2019&pages=2888-2906&author=P.+Haselmayerauthor=M.+Campsauthor=L.+Liu-Bujalskiauthor=N.+Nguyenauthor=F.+Morandiauthor=J.+Headauthor=A.+O%E2%80%99Mahonyauthor=S.+C.+Zimmerliauthor=L.+Brunsauthor=A.+T.+Benderauthor=P.+Schroederauthor=R.+Grenningloh&title=Efficacy+and+Pharmacodynamic+Modeling+of+the+BTK+Inhibitor+Evobrutinib+in+Autoimmune+Disease+Models&doi=10.4049%2Fjimmunol.1800583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and pharmacodynamic modeling of the BTK inhibitor evobrutinib in autoimmune disease models</span></div><div class="casAuthors">Haselmayer, Philipp; Camps, Montserrat; Liu-Bujalski, Lesley; Nguyen, Ngan; Morandi, Federica; Head, Jared; O'Mahony, Alison; Zimmerli, Simone C.; Bruns, Lisa; Bender, Andrew T.; Schroeder, Patricia; Grenningloh, Roland</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">202</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2888-2906</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Because of its role in mediating both B cell and Fc receptor signaling, Bruton's tyrosine kinase (BTK) is a promising target for the treatment of autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).  Evobrutinib is a novel, highly selective, irreversible BTK inhibitor that potently inhibits BCR- and Fc receptor-mediated signaling and, thus, subsequent activation and function of human B cells and innate immune cells such as monocytes and basophils.  We evaluated evobrutinib in preclin. models of RA and SLE and characterized the relationship between BTK occupancy and inhibition of disease activity.  In mouse models of RA and SLE, orally administered evobrutinib displayed robust efficacy, as demonstrated by redn. of disease severity and histol. damage.  In the SLE model, evobrutinib inhibited B cell activation, reduced autoantibody prodn. and plasma cell nos., and normalized B and T cell subsets.  In the RA model, efficacy was achieved despite failure to reduce autoantibodies.  Pharmacokinetic/pharmacodynamic modeling showed that mean BTK occupancy in blood cells of 80% was linked to near-complete disease inhibition in both RA and SLE mouse models.  In addn., evobrutinib inhibited mast cell activation in a passive cutaneous anaphylaxis model.  Thus, evobrutinib achieves efficacy by acting both on B cells and innate immune cells.  Taken together, our data show that evobrutinib is a promising mol. for the chronic treatment of B cell-driven autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLVxS4palhvbVg90H21EOLACvtfcHk0lh2ws8h4fDazA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvF2ntLg%253D&md5=9a339003f40e52527127ac12a2593ae9</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1800583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1800583%26sid%3Dliteratum%253Aachs%26aulast%3DHaselmayer%26aufirst%3DP.%26aulast%3DCamps%26aufirst%3DM.%26aulast%3DLiu-Bujalski%26aufirst%3DL.%26aulast%3DNguyen%26aufirst%3DN.%26aulast%3DMorandi%26aufirst%3DF.%26aulast%3DHead%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DZimmerli%26aufirst%3DS.%2BC.%26aulast%3DBruns%26aufirst%3DL.%26aulast%3DBender%26aufirst%3DA.%2BT.%26aulast%3DSchroeder%26aufirst%3DP.%26aulast%3DGrenningloh%26aufirst%3DR.%26atitle%3DEfficacy%2520and%2520Pharmacodynamic%2520Modeling%2520of%2520the%2520BTK%2520Inhibitor%2520Evobrutinib%2520in%2520Autoimmune%2520Disease%2520Models%26jtitle%3DJ.%2520Immunol.%26date%3D2019%26volume%3D202%26spage%3D2888%26epage%3D2906%26doi%3D10.4049%2Fjimmunol.1800583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kluge, A. F.</span></span> <span> </span><span class="NLM_article-title">Targeted Covalent Drugs of the Kinase Family</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">480</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2010.06.168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1016%2Fj.cbpa.2010.06.168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=20609616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=475-480&author=J.+Singhauthor=R.+C.+Petterauthor=A.+F.+Kluge&title=Targeted+Covalent+Drugs+of+the+Kinase+Family&doi=10.1016%2Fj.cbpa.2010.06.168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted covalent drugs of the kinase family</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Kluge, Arthur F.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">475-480</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In the past decade tremendous progress has been made toward a new class of therapeutics termed 'targeted covalent drugs', in which structure-based approaches are employed to create small mols. that inactivate their protein target through targeted covalent attachment to a specific cysteine.  In the kinase field, this approach is demonstrating promise in overcoming the potency, selectivity, and efficacy challenges currently faced by reversible kinase inhibitors, with several advancing into late stage clin. testing.  This design paradigm has been successfully applied to making drug candidates for epidermal growth factor receptor (EGFR), Her2, and Bruton's tyrosine kinase (Btk).  Here we review recent pre-clin. and clin. advances with targeted covalent kinase inhibitors, and the potential for broader application of the approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPQb40Eok-vbVg90H21EOLACvtfcHk0lgYwWVbryn-Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtr8%253D&md5=ee3b8b9e0c6ec317f975a426cf08428f</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2010.06.168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2010.06.168%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DKluge%26aufirst%3DA.%2BF.%26atitle%3DTargeted%2520Covalent%2520Drugs%2520of%2520the%2520Kinase%2520Family%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D14%26spage%3D475%26epage%3D480%26doi%3D10.1016%2Fj.cbpa.2010.06.168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span> <span> </span><span class="NLM_article-title">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6243</span>– <span class="NLM_lpage">6262</span>, <span class="refDoi"> DOI: 10.1021/jm3003203</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6243-6262&author=T.+Barfauthor=A.+Kaptein&title=Irreversible+Protein+Kinase+Inhibitors%3A+Balancing+the+Benefits+and+Risks&doi=10.1021%2Fjm3003203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span></div><div class="casAuthors">Barf, Tjeerd; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6243-6262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Not applicable for a Perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PLlisO0OVbVg90H21EOLACvtfcHk0lgYwWVbryn-Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D&md5=5d87850857d37faab02e6037ef8140a4</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm3003203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003203%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DIrreversible%2520Protein%2520Kinase%2520Inhibitors%253A%2520Balancing%2520the%2520Benefits%2520and%2520Risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6243%26epage%3D6262%26doi%3D10.1021%2Fjm3003203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitty, A.</span></span> <span> </span><span class="NLM_article-title">The Resurgence of Covalent Drugs</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1038/nrd3410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+Resurgence+of+Covalent+Drugs&doi=10.1038%2Fnrd3410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0lgpGKXr_Fe08Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520Resurgence%2520of%2520Covalent%2520Drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D307%26epage%3D317%26doi%3D10.1038%2Fnrd3410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D. K.</span></span> <span> </span><span class="NLM_article-title">Drug Discovery for a New Generation of Covalent Drugs</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.1517/17460441.2012.688744</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1517%2F17460441.2012.688744" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=22607458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC38XptFWmt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=561-581&author=A.+S.+Kalgutkarauthor=D.+K.+Dalvie&title=Drug+Discovery+for+a+New+Generation+of+Covalent+Drugs&doi=10.1517%2F17460441.2012.688744"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Drug discovery for a new generation of covalent drugs</span></div><div class="casAuthors">Kalgutkar, Amit S.; Dalvie, Deepak K.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">561-581</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The design of target-specific covalent inhibitors is conceptually attractive because of increased biochem. efficiency through covalency and increased duration of action that outlasts the pharmacokinetics of the agent.  Although many covalent inhibitors have been approved or are in advanced clin. trials to treat indications such as cancer and hepatitis C, there is a general tendency to avoid them as drug candidates because of concerns regarding immune-mediated toxicity that can arise from indiscriminate reactivity with off-target proteins.Areas covered: The review examines potential reason(s) for the excellent safety record of marketed covalent agents and advanced clin. candidates for emerging therapeutic targets.  A significant emphasis is placed on proteomic techniques and chem./biochem. reactivity assays that aim to provide a systematic rank ordering of pharmacol. selectivity relative to off-target protein reactivity of covalent inhibitors.Expert opinion: While tactics to examine selective covalent modification of the pharmacol. target are broadly applicable in drug discovery, it is unclear whether the output from such studies can prospectively predict idiosyncratic immune-mediated drug toxicity.  Opinions regarding an acceptable threshold of protein reactivity/body burden for a toxic electrophile and a non-toxic electrophilic covalent drug have not been defined.  Increasing confidence in proteomic and chem./biochem. reactivity screens will require a retrospective side-by-side profiling of marketed covalent drugs and electrophiles known to cause deleterious toxic effects via non-selective covalent binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowmXy20mDTPbVg90H21EOLACvtfcHk0lgpGKXr_Fe08Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptFWmt7k%253D&md5=b7fc8e60b263dda5765dd8380f52df17</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1517%2F17460441.2012.688744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2012.688744%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26atitle%3DDrug%2520Discovery%2520for%2520a%2520New%2520Generation%2520of%2520Covalent%2520Drugs%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2012%26volume%3D7%26spage%3D561%26epage%3D581%26doi%3D10.1517%2F17460441.2012.688744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norman, P.</span></span> <span> </span><span class="NLM_article-title">Investigational Bruton’s Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">891</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.1080/13543784.2016.1182499</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1080%2F13543784.2016.1182499" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=27148767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC28Xnslentb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=891-899&author=P.+Norman&title=Investigational+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitors+for+the+Treatment+of+Rheumatoid+Arthritis&doi=10.1080%2F13543784.2016.1182499"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Norman, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">891-899</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The Tec family of non-receptor tyrosine kinases comprises five members.  The cellular expression and function of these kinases has implicated them as potential drug targets for the treatment of both malignant and autoimmune diseases.  Most attention has focused on inhibitors of BTK kinase with ibrutinib already approved for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia.  Multiple BTK inhibitors are being developed for both oncol. and autoimmune disease indications.  BTK inhibitors being evaluated in rheumatoid arthritis are considered.  Both inhibitors which have progressed to early clin. development, and those demonstrating activity in rodent models of arthritis are reviewed.  These include both reversible and irreversible inhibitors of the kinase, most of which target the cysteine-481 residue of BTK.  The selectivity of these inhibitors for Tec family kinases is considered.  Developing inhibitors of any kinase to treat of rheumatoid arthritis has proved problematic with regard to both efficacy and selectivity.  It is anticipated that the more selective BTK inhibitors may prove more useful in treating arthritis, with the use of reversible inhibitors possibly offering a better strategy.  Chronic dosing may exacerbate the emergence of drug resistance, with resistant mutations already obsd. in ibrutinib-treated patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQsRSjuYxYa7Vg90H21EOLACvtfcHk0lgpGKXr_Fe08Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xnslentb0%253D&md5=037f60be680ad282725fe8f7619f1212</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1080%2F13543784.2016.1182499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2016.1182499%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DP.%26atitle%3DInvestigational%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Rheumatoid%2520Arthritis%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2016%26volume%3D25%26spage%3D891%26epage%3D899%26doi%3D10.1080%2F13543784.2016.1182499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lanning, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitby, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douhan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hett, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joslyn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niessen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnute, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulce, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteley, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">A Road Map to Evaluate the Proteome-Wide Selectivity of Covalent Kinase Inhibitors</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">767</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1038%2Fnchembio.1582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=25038787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFygs7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=760-767&author=B.+R.+Lanningauthor=L.+R.+Whitbyauthor=M.+M.+Dixauthor=J.+Douhanauthor=A.+M.+Gilbertauthor=E.+C.+Hettauthor=T.+O.+Johnsonauthor=C.+Joslynauthor=J.+C.+Kathauthor=S.+Niessenauthor=L.+R.+Robertsauthor=M.+E.+Schnuteauthor=C.+Wangauthor=J.+J.+Hulceauthor=B.+Weiauthor=L.+O.+Whiteleyauthor=M.+M.+Haywardauthor=B.+F.+Cravatt&title=A+Road+Map+to+Evaluate+the+Proteome-Wide+Selectivity+of+Covalent+Kinase+Inhibitors&doi=10.1038%2Fnchembio.1582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors</span></div><div class="casAuthors">Lanning, Bryan R.; Whitby, Landon R.; Dix, Melissa M.; Douhan, John; Gilbert, Adam M.; Hett, Erik C.; Johnson, Theodore O.; Joslyn, Chris; Kath, John C.; Niessen, Sherry; Roberts, Lee R.; Schnute, Mark E.; Wang, Chu; Hulce, Jonathan J.; Wei, Baoxian; Whiteley, Laurence O.; Hayward, Matthew M.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">760-767</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinases are principal components of signal transduction pathways and the focus of intense basic and drug discovery research.  Irreversible inhibitors that covalently modify non-catalytic cysteines in kinase active sites have emerged as valuable probes and approved drugs.  Many protein classes, however, have functional cysteines, and therefore understanding the proteome-wide selectivity of covalent kinase inhibitors is imperative.  Here, we accomplish this objective using activity-based protein profiling coupled with quant. MS to globally map the targets, both specific and nonspecific, of covalent kinase inhibitors in human cells.  Many of the specific off-targets represent nonkinase proteins that, notably, have conserved active site cysteines.  We define windows of selectivity for covalent kinase inhibitors and show that, when these windows are exceeded, rampant proteome-wide reactivity and kinase target-independent cell death conjointly occur.  Our findings, taken together, provide an exptl. road map to illuminate opportunities and surmount challenges for the development of covalent kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMAiUlEg9R5rVg90H21EOLACvtfcHk0ligOxjqEftJ0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFygs7nO&md5=6f17b0d1b00e088f37c511eea577d290</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1582%26sid%3Dliteratum%253Aachs%26aulast%3DLanning%26aufirst%3DB.%2BR.%26aulast%3DWhitby%26aufirst%3DL.%2BR.%26aulast%3DDix%26aufirst%3DM.%2BM.%26aulast%3DDouhan%26aufirst%3DJ.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DHett%26aufirst%3DE.%2BC.%26aulast%3DJohnson%26aufirst%3DT.%2BO.%26aulast%3DJoslyn%26aufirst%3DC.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DRoberts%26aufirst%3DL.%2BR.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHulce%26aufirst%3DJ.%2BJ.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWhiteley%26aufirst%3DL.%2BO.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DA%2520Road%2520Map%2520to%2520Evaluate%2520the%2520Proteome-Wide%2520Selectivity%2520of%2520Covalent%2520Kinase%2520Inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26spage%3D760%26epage%3D767%26doi%3D10.1038%2Fnchembio.1582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Médard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachl, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruprecht, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaeger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinzlmeir, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helm, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuehne, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dittmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuster, B.</span></span> <span> </span><span class="NLM_article-title">Optimized Chemical Proteomics Assay for Kinase Inhibitor Profiling</span>. <i>J. Proteome Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1574</span>– <span class="NLM_lpage">1586</span>, <span class="refDoi"> DOI: 10.1021/pr5012608</span> </span><div class="citationLinks">[<a href="/doi/10.1021/pr5012608" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit12ku7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=1574-1586&author=G.+M%C3%A9dardauthor=F.+Pachlauthor=B.+Ruprechtauthor=S.+Klaegerauthor=S.+Heinzlmeirauthor=D.+Helmauthor=H.+Qiaoauthor=X.+Kuauthor=M.+Wilhelmauthor=T.+Kuehneauthor=Z.+Wuauthor=A.+Dittmannauthor=C.+Hopfauthor=K.+Kramerauthor=B.+Kuster&title=Optimized+Chemical+Proteomics+Assay+for+Kinase+Inhibitor+Profiling&doi=10.1021%2Fpr5012608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Optimized Chemical Proteomics Assay for Kinase Inhibitor Profiling</span></div><div class="casAuthors">Medard, Guillaume; Pachl, Fiona; Ruprecht, Benjamin; Klaeger, Susan; Heinzlmeir, Stephanie; Helm, Dominic; Qiao, Huichao; Ku, Xin; Wilhelm, Mathias; Kuehne, Thomas; Wu, Zhixiang; Dittmann, Antje; Hopf, Carsten; Kramer, Karl; Kuster, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteome Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1574-1586</span>CODEN:
                <span class="NLM_cas:coden">JPROBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-3893</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Solid supported probes have proven to be an efficient tool for chem. proteomics.  The kinobeads technol. features kinase inhibitors covalently attached to Sepharose for affinity enrichment of kinomes from cell or tissue lysates.  This technol., combined with quant. mass spectrometry, is of particular interest for the profiling of kinase inhibitors.  It often leads to the identification of new targets for medicinal chem. campaigns where it allows a two-in-one binding and selectivity assay.  The assay can also uncover resistance mechanisms and mol. sources of toxicity.  Here we report on the optimization of the kinobead assay resulting in the combination of five chem. probes and four cell lines to cover half the human kinome in a single assay (∼260 kinases).  We show the utility and large-scale applicability of the new version of kinobeads by reprofiling the small mol. kinase inhibitors Alvocidib, Crizotinib, Dasatinib, Fasudil, Hydroxyfasudil, Nilotinib, Ibrutinib, Imatinib, and Sunitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2H1SXbNl9UrVg90H21EOLACvtfcHk0ligOxjqEftJ0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit12ku7Y%253D&md5=8a6933cabc1f1189cb6a803b0183be1a</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fpr5012608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fpr5012608%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A9dard%26aufirst%3DG.%26aulast%3DPachl%26aufirst%3DF.%26aulast%3DRuprecht%26aufirst%3DB.%26aulast%3DKlaeger%26aufirst%3DS.%26aulast%3DHeinzlmeir%26aufirst%3DS.%26aulast%3DHelm%26aufirst%3DD.%26aulast%3DQiao%26aufirst%3DH.%26aulast%3DKu%26aufirst%3DX.%26aulast%3DWilhelm%26aufirst%3DM.%26aulast%3DKuehne%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DDittmann%26aufirst%3DA.%26aulast%3DHopf%26aufirst%3DC.%26aulast%3DKramer%26aufirst%3DK.%26aulast%3DKuster%26aufirst%3DB.%26atitle%3DOptimized%2520Chemical%2520Proteomics%2520Assay%2520for%2520Kinase%2520Inhibitor%2520Profiling%26jtitle%3DJ.%2520Proteome%2520Res.%26date%3D2015%26volume%3D14%26spage%3D1574%26epage%3D1586%26doi%3D10.1021%2Fpr5012608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molica, S.</span></span> <span> </span><span class="NLM_article-title">The Clinical Safety of Ibrutinib in Chronic Lymphocytic Leukemia</span>. <i>Expert Opin. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1621</span>– <span class="NLM_lpage">1629</span>, <span class="refDoi"> DOI: 10.1517/14740338.2015.1084286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1517%2F14740338.2015.1084286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=26359217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A280%3ADC%252BC283htFahtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=1621-1629&author=S.+Molica&title=The+Clinical+Safety+of+Ibrutinib+in+Chronic+Lymphocytic+Leukemia&doi=10.1517%2F14740338.2015.1084286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The clinical safety of ibrutinib in chronic lymphocytic leukemia</span></div><div class="casAuthors">Molica Stefano</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on drug safety</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1621-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Ibrutinib , a targeted inhibitor of B-cell receptor signaling, achieved impressive clinical results for patients with chronic lymphocytic leukemia (CLL).  These results allowed the approval of ibrutinib for the treatment of patients with CLL who have received at least one prior therapy and those with a 17p deletion regardless of line of therapy.  AREAS COVERED:  Comprehensive data from either Phase I-II or randomized Phase III studies are analyzed in this article.  In addition, we reviewed data on the prevalence and the clinical management of some peculiar toxicities ibrutinib related such as lymphocytosis, major bleeding and atrial fibrillation.  EXPERT OPINION:  Ibrutinib has radically changed the scenery of relapsed/refractory CLL treatment and established an important paradigm in the molecularly targeted approach of this disease.  Discontinuation of ibrutinib is rarely due to adverse events related to the drug.  Patients who discontinue treatment represent a challenge to the physicians because treatment options are very limited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQAcwMJAE2LJF1C8OJBvdfbfW6udTcc2ebAgmMjkGKTb7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283htFahtA%253D%253D&md5=67e9920c0f81dd41b5f5ed21370c5c56</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1517%2F14740338.2015.1084286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740338.2015.1084286%26sid%3Dliteratum%253Aachs%26aulast%3DMolica%26aufirst%3DS.%26atitle%3DThe%2520Clinical%2520Safety%2520of%2520Ibrutinib%2520in%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2015%26volume%3D14%26spage%3D1621%26epage%3D1629%26doi%3D10.1517%2F14740338.2015.1084286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shatzel, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarty, O. J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danilov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLoughery, T. G.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib-Associated Bleeding: Pathogenesis, Management, and Risk Reduction Strategies</span>. <i>J. Thromb. Haemostasis</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">835</span>– <span class="NLM_lpage">847</span>, <span class="refDoi"> DOI: 10.1111/jth.13651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1111%2Fjth.13651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=28182323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvFenur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=835-847&author=J.+J.+Shatzelauthor=S.+R.+Olsonauthor=D.+L.+Taoauthor=O.+J.+T.+McCartyauthor=A.+V.+Danilovauthor=T.+G.+DeLoughery&title=Ibrutinib-Associated+Bleeding%3A+Pathogenesis%2C+Management%2C+and+Risk+Reduction+Strategies&doi=10.1111%2Fjth.13651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies</span></div><div class="casAuthors">Shatzel, J. J.; Olson, S. R.; Tao, D. L.; McCarty, O. J. T.; Danilov, A. V.; De Loughery, T. G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">835-847</span>CODEN:
                <span class="NLM_cas:coden">JTHOA5</span>;
        ISSN:<span class="NLM_cas:issn">1538-7933</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (Btk) that has proven to be an effective therapeutic agent for multiple B-cell-mediated lymphoproliferative disorders.  Ibrutinib, however, carries an increased bleeding risk compared with std. chemotherapy.  Bleeding events range from minor mucocutaneous bleeding to life-threatening hemorrhage, due in large part to the effects of ibrutinib on several distinct platelet signaling pathways.  There is currently a minimal amt. of data to guide clinicians regarding the use of ibrutinib in patients at high risk of bleeding or on anticoagulant or antiplatelet therapy.  In addn., the potential cardiovascular protective effects of ibrutinib monotherapy in patients at risk of vascular disease are unknown.  Patients should be cautioned against using non-steroidal anti-inflammatory drugs, fish oils, vitamin E and aspirin-contg. products, and consider replacing ibrutinib with a different agent if dual antiplatelet therapy is indicated.  Patients should not take vitamin K antagonists concurrently with ibrutinib; direct oral anticoagulants should be used if extended anticoagulation is strongly indicated.  In this review, we describe the pathophysiol. of ibrutinib-mediated bleeding and suggest risk redn. strategies for common clin. scenarios assocd. with ibrutinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7mVrIrFi1pLVg90H21EOLACvtfcHk0lhszMh6gAfivg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvFenur0%253D&md5=9f3913a402960403a69b67249c870b87</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1111%2Fjth.13651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjth.13651%26sid%3Dliteratum%253Aachs%26aulast%3DShatzel%26aufirst%3DJ.%2BJ.%26aulast%3DOlson%26aufirst%3DS.%2BR.%26aulast%3DTao%26aufirst%3DD.%2BL.%26aulast%3DMcCarty%26aufirst%3DO.%2BJ.%2BT.%26aulast%3DDanilov%26aufirst%3DA.%2BV.%26aulast%3DDeLoughery%26aufirst%3DT.%2BG.%26atitle%3DIbrutinib-Associated%2520Bleeding%253A%2520Pathogenesis%252C%2520Management%252C%2520and%2520Risk%2520Reduction%2520Strategies%26jtitle%3DJ.%2520Thromb.%2520Haemostasis%26date%3D2017%26volume%3D15%26spage%3D835%26epage%3D847%26doi%3D10.1111%2Fjth.13651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. a</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. a</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. a</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N. a</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilotti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span> <span> </span><span class="NLM_article-title">Three-Year Follow-up of Treatment-Naive and Previously Treated Patients with CLL and SLL Receiving Single-Agent Ibrutinib</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">2497</span>– <span class="NLM_lpage">2506</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-10-606038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1182%2Fblood-2014-10-606038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=25700432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotV2hs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=2497-2506&author=J.+C.+Byrdauthor=R.+R.+Furmanauthor=S.+E.+Coutreauthor=J.+a+Burgerauthor=K.+a+Blumauthor=M.+Colemanauthor=W.+G.+Wierdaauthor=J.+a+Jonesauthor=W.+Zhaoauthor=N.+a+Heeremaauthor=A.+J.+Johnsonauthor=Y.+Shawauthor=E.+Bilottiauthor=C.+Zhouauthor=D.+F.+Jamesauthor=S.+O%E2%80%99Brien&title=Three-Year+Follow-up+of+Treatment-Naive+and+Previously+Treated+Patients+with+CLL+and+SLL+Receiving+Single-Agent+Ibrutinib&doi=10.1182%2Fblood-2014-10-606038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib</span></div><div class="casAuthors">Byrd, John C.; Furman, Richard R.; Coutre, Steven E.; Burger, Jan A.; Blum, Kristie A.; Coleman, Morton; Wierda, William G.; Jones, Jeffrey A.; Zhao, Weiqiang; Heerema, Nyla A.; Johnson, Amy J.; Shaw, Yun; Bilotti, Elizabeth; Zhou, Cathy; James, Danelle F.; O'Brien, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2497-2506</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Ibrutinib is an orally administered inhibitor of Bruton tyrosine kinase that antagonizes B-cell receptor, chemokine, and integrin-mediated signaling.  In early-phase studies, ibrutinib demonstrated high response rates and prolonged progression-free survival (PFS) in chronic lymphocytic leukemia (CLL).  The durable responses obsd. with ibrutinib relate in part to a modest toxicity profile that allows the majority of patients to receive continuous therapy for an extended period.  We report on median 3-yr follow-up of 132 patients with symptomatic treatment- naive and relapsed/refractory CLL or small lymphocytic lymphoma.  Longer treatment with ibrutinib was assocd. with improvement in response quality over time and durable remissions.  Toxicity with longer follow-up diminished with respect to occurrence of grade 3 or greater cytopenias, fatigue, and infections.  Progression remains uncommon, occurring primarily in some patients with relapsed del(17)(p13.1) and/or del(11)(q22.3) disease.  Treatment-related lymphocytosis remains largely asymptomatic even when persisting >1 yr and does not appear to alter longer-term PFS and overall survival compared with patients with partial response or better.  Collectively, these data provide evidence that ibrutinib controls CLL disease manifestations and is well tolerated for an extended period; this information can help direct potential treatment options for different subgroups to diminish the long-term risk of relapse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbUSbfHjGYebVg90H21EOLACvtfcHk0lhszMh6gAfivg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotV2hs7c%253D&md5=1bedfb4e6798a3f51320d8b8054c13aa</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-10-606038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-10-606038%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DBurger%26aufirst%3DJ.%2Ba%26aulast%3DBlum%26aufirst%3DK.%2Ba%26aulast%3DColeman%26aufirst%3DM.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DJones%26aufirst%3DJ.%2Ba%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DHeerema%26aufirst%3DN.%2Ba%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DShaw%26aufirst%3DY.%26aulast%3DBilotti%26aufirst%3DE.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26atitle%3DThree-Year%2520Follow-up%2520of%2520Treatment-Naive%2520and%2520Previously%2520Treated%2520Patients%2520with%2520CLL%2520and%2520SLL%2520Receiving%2520Single-Agent%2520Ibrutinib%26jtitle%3DBlood%26date%3D2015%26volume%3D125%26spage%3D2497%26epage%3D2506%26doi%3D10.1182%2Fblood-2014-10-606038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurczak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romaguera, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stilgenbauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreyling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jedrzejczak, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spurgeon, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baher, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaupre, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rule, S.</span></span> <span> </span><span class="NLM_article-title">Long-Term Follow-up of MCL Patients Treated with Single-Agent Ibrutinib: Updated Safety and Efficacy Results</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">739</span>– <span class="NLM_lpage">745</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-03-635326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1182%2Fblood-2015-03-635326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=26059948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2ktLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2015&pages=739-745&author=M.+L.+Wangauthor=K.+A.+Blumauthor=P.+Martinauthor=A.+Goyauthor=R.+Auerauthor=B.+S.+Kahlauthor=W.+Jurczakauthor=R.+H.+Advaniauthor=J.+E.+Romagueraauthor=M.+E.+Williamsauthor=J.+C.+Barrientosauthor=E.+Chmielowskaauthor=J.+Radfordauthor=S.+Stilgenbauerauthor=M.+Dreylingauthor=W.+W.+Jedrzejczakauthor=P.+Johnsonauthor=S.+E.+Spurgeonauthor=L.+Zhangauthor=L.+Baherauthor=M.+Chengauthor=D.+Leeauthor=D.+M.+Beaupreauthor=S.+Rule&title=Long-Term+Follow-up+of+MCL+Patients+Treated+with+Single-Agent+Ibrutinib%3A+Updated+Safety+and+Efficacy+Results&doi=10.1182%2Fblood-2015-03-635326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results</span></div><div class="casAuthors">Wang, Michael L.; Blum, Kristie A.; Martin, Peter; Goy, Andre; Auer, Rebecca; Kahl, Brad S.; Jurczak, Wojciech; Advani, Ranjana H.; Romaguera, Jorge E.; Williams, Michael E.; Barrientos, Jacqueline C.; Chmielowska, Ewa; Radford, John; Stilgenbauer, Stephan; Dreyling, Martin; Jedrzejczak, Wieslaw Wiktor; Johnson, Peter; Spurgeon, Stephen E.; Zhang, Liang; Baher, Linda; Cheng, Mei; Lee, Dana; Beaupre, Darrin M.; Rule, Simon</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">739-745</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Ibrutinib, an oral inhibitor of Bruton tyrosine kinase, is approved for patients with mantle cell lymphoma (MCL) who have received one prior therapy.  We report the updated safety and efficacy results from the multicenter, open-label phase 2 registration trial of ibrutinib (median 26.7-mo follow-up).  Patients (N = 111) received oral ibrutinib 560 mg once daily, and those with stable disease or better could enter a long-term extension study.  The primary end point was overall response rate (ORR).  The median patient age was 68 years (range, 40-84), with a median of 3 prior therapies (range, 1-5).  The median treatment duration was 8.3 mo; 46% of patients were treated for >12 mo, and 22% were treated for ≥2 years.  The ORR was 67% (23% complete response), with a median duration of response of 17.5 mo.  The 24-mo progression-free survival and overall survival rates were 31% (95% confidence interval [CI], 22.3-40.4) and 47% (95% CI, 37.1-56.9), resp.  The most common adverse events (AEs) in >30% of patients included diarrhea (54%), fatigue (50%), nausea (33%), and dyspnea (32%).  The most frequent grade ≥3 infections included pneumonia (8%), urinary tract infection (4%), and cellulitis (3%).  Grade ≥3 bleeding events in ≥2% of patients were hematuria (2%) and subdural hematoma (2%).  Common all-grade hematol. AEs were thrombocytopenia (22%), neutropenia (19%), and anemia (18%).  The prevalence of infection, diarrhea, and bleeding was highest for the first 6 mo of therapy and less thereafter.  With longer follow-up, ibrutinib continues to demonstrate durable responses and favorable safety in relapsed/refractory MCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUEAHTEsAdqrVg90H21EOLACvtfcHk0lhszMh6gAfivg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2ktLnJ&md5=42f321c41ad5605c0ccf27bc49477b4c</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-03-635326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-03-635326%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%2BL.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DAuer%26aufirst%3DR.%26aulast%3DKahl%26aufirst%3DB.%2BS.%26aulast%3DJurczak%26aufirst%3DW.%26aulast%3DAdvani%26aufirst%3DR.%2BH.%26aulast%3DRomaguera%26aufirst%3DJ.%2BE.%26aulast%3DWilliams%26aufirst%3DM.%2BE.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DChmielowska%26aufirst%3DE.%26aulast%3DRadford%26aufirst%3DJ.%26aulast%3DStilgenbauer%26aufirst%3DS.%26aulast%3DDreyling%26aufirst%3DM.%26aulast%3DJedrzejczak%26aufirst%3DW.%2BW.%26aulast%3DJohnson%26aufirst%3DP.%26aulast%3DSpurgeon%26aufirst%3DS.%2BE.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DBaher%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26aulast%3DRule%26aufirst%3DS.%26atitle%3DLong-Term%2520Follow-up%2520of%2520MCL%2520Patients%2520Treated%2520with%2520Single-Agent%2520Ibrutinib%253A%2520Updated%2520Safety%2520and%2520Efficacy%2520Results%26jtitle%3DBlood%26date%3D2015%26volume%3D126%26spage%3D739%26epage%3D745%26doi%3D10.1182%2Fblood-2015-03-635326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leong, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healey, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegal, D.</span></span> <span> </span><span class="NLM_article-title">The Risk of Atrial Fibrillation with Ibrutinib Use: A Systematic Review and Meta-Analysis</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">138</span>– <span class="NLM_lpage">140</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-05-712828</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1182%2Fblood-2016-05-712828" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=27247135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVymu7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=138-140&author=D.+P.+Leongauthor=F.+Caronauthor=C.+Hillisauthor=A.+Duanauthor=J.+S.+Healeyauthor=G.+Fraserauthor=D.+Siegal&title=The+Risk+of+Atrial+Fibrillation+with+Ibrutinib+Use%3A+A+Systematic+Review+and+Meta-Analysis&doi=10.1182%2Fblood-2016-05-712828"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis</span></div><div class="casAuthors">Leong, Darryl P.; Caron, Francois; Hillis, Christopher; Duan, Annie; Healey, Jeff S.; Fraser, Graeme; Siegal, Deborah</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">138-140</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Meta-anal. of ibrutinib recipients was undertaken to est. the magnitude of the increase in atrial fibrillation (AF) risk among ibrutinib recipients, as compared with alternative therapies and (2) quantify the frequency of AF reported among ibrutinib recipients.  This anal. suggests that ibrutinib consistently increases the risk of incident AF compared with alternative therapies.  The author suggested that patients treated with ibrutinib should be closely monitored for the development of AF, which is assocd. with a 5-fold increased risk of ischemic stroke, a leading cause of morbidity and mortality, in the general population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRmlExYguUALVg90H21EOLACvtfcHk0ljEUyeNGidIfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVymu7jP&md5=9e50bc64dad51e76c894d6ec5f098428</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-05-712828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-05-712828%26sid%3Dliteratum%253Aachs%26aulast%3DLeong%26aufirst%3DD.%2BP.%26aulast%3DCaron%26aufirst%3DF.%26aulast%3DHillis%26aufirst%3DC.%26aulast%3DDuan%26aufirst%3DA.%26aulast%3DHealey%26aufirst%3DJ.%2BS.%26aulast%3DFraser%26aufirst%3DG.%26aulast%3DSiegal%26aufirst%3DD.%26atitle%3DThe%2520Risk%2520of%2520Atrial%2520Fibrillation%2520with%2520Ibrutinib%2520Use%253A%2520A%2520Systematic%2520Review%2520and%2520Meta-Analysis%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26spage%3D138%26epage%3D140%26doi%3D10.1182%2Fblood-2016-05-712828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucchini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilotto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spada, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melisi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bria, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tortora, G.</span></span> <span> </span><span class="NLM_article-title">Targeting the Epidermal Growth Factor Receptor in Solid Tumors: Focus on Safety</span>. <i>Expert Opin. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">535</span>– <span class="NLM_lpage">549</span>, <span class="refDoi"> DOI: 10.1517/14740338.2014.904283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1517%2F14740338.2014.904283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=24684184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC2cXms1WrtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=535-549&author=E.+Lucchiniauthor=S.+Pilottoauthor=E.+Spadaauthor=D.+Melisiauthor=E.+Briaauthor=G.+Tortora&title=Targeting+the+Epidermal+Growth+Factor+Receptor+in+Solid+Tumors%3A+Focus+on+Safety&doi=10.1517%2F14740338.2014.904283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the epidermal growth factor receptor in solid tumors: focus on safety</span></div><div class="casAuthors">Lucchini, Eleonora; Pilotto, Sara; Spada, Elisa; Melisi, Davide; Bria, Emilio; Tortora, Giampaolo</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">535-549</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Inhibition of the EGFR has emerged as a promising anticancer strategy, offering improved efficacy and quality of life for patients affected by tumors.  The overall level of toxicity assocd. with EGFR inhibitors is low compared to other chemotherapy drugs, although they are commonly assocd. with skin and gastrointestinal adverse events.  Thus, patients' quality of life may be considerably affected both by a phys. and a psychosocial perspective.  Adverse events that lead to treatment interruption or cessation may significantly compromise their outcome.  Areas covered: This review summarizes the characteristics of the distinctive toxicities of drugs targeting EGFR, addressing their incidence, pathophysiol. and clin. presentation with a focus on the management of skin rash and other relevant adverse events, according to the available clin. evidence.  Data regarding the correlation between the development of skin rash and clin. outcome are also reported.  Expert opinion: Drugs targeting EGFR are assocd. with a lower overall incidence of systemic side effects compared to std. chemotherapeutic agents; nevertheless, an increased risk of distinct toxicities that may affect patient's quality of life and anticancer treatment compliance is obsd.  Thus, clin. training projects directed toward a more accurate knowledge of such adverse events are essential to maximize the progress of targeted therapies against cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVekRaAP41xbVg90H21EOLACvtfcHk0ljEUyeNGidIfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXms1WrtL0%253D&md5=9623fe732a5ebf47a628359097e382e2</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1517%2F14740338.2014.904283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740338.2014.904283%26sid%3Dliteratum%253Aachs%26aulast%3DLucchini%26aufirst%3DE.%26aulast%3DPilotto%26aufirst%3DS.%26aulast%3DSpada%26aufirst%3DE.%26aulast%3DMelisi%26aufirst%3DD.%26aulast%3DBria%26aufirst%3DE.%26aulast%3DTortora%26aufirst%3DG.%26atitle%3DTargeting%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520in%2520Solid%2520Tumors%253A%2520Focus%2520on%2520Safety%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2014%26volume%3D13%26spage%3D535%26epage%3D549%26doi%3D10.1517%2F14740338.2014.904283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quek, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, S. P.</span></span> <span> </span><span class="NLM_article-title">A Role for Bruton’s Tyrosine Kinase (Btk) in Platelet Activation by Collagen</span>. <i>Curr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1137</span>– <span class="NLM_lpage">1140</span>, <span class="refDoi"> DOI: 10.1016/S0960-9822(98)70471-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1016%2FS0960-9822%2898%2970471-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=9778529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADyaK1cXmslagsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=1137-1140&author=L.+S.+Quekauthor=J.+Bolenauthor=S.+P.+Watson&title=A+Role+for+Bruton%E2%80%99s+Tyrosine+Kinase+%28Btk%29+in+Platelet+Activation+by+Collagen&doi=10.1016%2FS0960-9822%2898%2970471-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen</span></div><div class="casAuthors">Quek, L. S.; Bolen, J.; Watson, S. P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1137-1140</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Current Biology Ltd.</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is essential for normal B-cell receptor signaling.  The lack of expression of functional Btk in humans leads to the B-cell deficiency X-linked agammaglobulinemia (XLA).  We report here that Btk is also important for signaling via the collagen receptor glycoprotein VI (GPVI) in platelets.  GPVI is coupled to the Fc receptor γ chain (FcRγ).  The FcRγ-chain contains a consensus sequence known as the immune-receptor tyrosine-based activation motif (ITAM).  Tyrosine phosphorylation of the ITAM upon GPVI stimulation is the initial step in the regulation of phospholipase C γ2 (PLCγ2) isoforms via the tyrosine kinase p72Syk (Syk) in platelets.  Here we show that collagen and a collagen-related peptide (CRP), which binds to GPVI but does not bind to the integrin α2β1, induced Btk tyrosine phosphorylation in platelets.  Aggregation, dense granule secretion and calcium mobilization were significantly diminished but not completely abolished in platelets from XLA patients in response to collagen and CRP.  These effects were assocd. with a redn. in tyrosine phosphorylation of PLCγ2.  In contrast, aggregation and secretion stimulated by thrombin in Btk-deficient platelets were not significantly altered.  Our results demonstrate that Btk is important for collagen signaling via GPVI, but is not essential for thrombin-mediated platelet activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIUgySXWpDX7Vg90H21EOLACvtfcHk0ljEUyeNGidIfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmslagsLk%253D&md5=182bde729153e994221edbc963d39065</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2FS0960-9822%2898%2970471-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-9822%252898%252970471-3%26sid%3Dliteratum%253Aachs%26aulast%3DQuek%26aufirst%3DL.%2BS.%26aulast%3DBolen%26aufirst%3DJ.%26aulast%3DWatson%26aufirst%3DS.%2BP.%26atitle%3DA%2520Role%2520for%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528Btk%2529%2520in%2520Platelet%2520Activation%2520by%2520Collagen%26jtitle%3DCurr.%2520Biol.%26date%3D1998%26volume%3D8%26spage%3D1137%26epage%3D1140%26doi%3D10.1016%2FS0960-9822%2898%2970471-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicolson, P. L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nock, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montague, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clifford, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huissoon, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malcor, J.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollitt, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlinson, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, S. P.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Btk by Btk-Specific Concentrations of Ibrutinib and Acalabrutinib Delays but Does Not Block Platelet Aggregation Mediated by Glycoprotein VI</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">2097</span>– <span class="NLM_lpage">2108</span>, <span class="refDoi"> DOI: 10.3324/haematol.2018.193391</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.3324%2Fhaematol.2018.193391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=30026342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFygu7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2018&pages=2097-2108&author=P.+L.+R.+Nicolsonauthor=C.+E.+Hughesauthor=S.+Watsonauthor=S.+H.+Nockauthor=A.+T.+Hardyauthor=C.+N.+Watsonauthor=S.+J.+Montagueauthor=H.+Cliffordauthor=A.+P.+Huissoonauthor=J.-D.+Malcorauthor=M.+R.+Thomasauthor=A.+Y.+Pollittauthor=M.+G.+Tomlinsonauthor=G.+Prattauthor=S.+P.+Watson&title=Inhibition+of+Btk+by+Btk-Specific+Concentrations+of+Ibrutinib+and+Acalabrutinib+Delays+but+Does+Not+Block+Platelet+Aggregation+Mediated+by+Glycoprotein+VI&doi=10.3324%2Fhaematol.2018.193391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI</span></div><div class="casAuthors">Nicolson, Phillip L. R.; Hughes, Craig E.; Watson, Stephanie; Nock, Sophie H.; Hardy, Alexander T.; Watson, Callum N.; Montague, Samantha J.; Clifford, Hayley; Huissoon, Aarnoud P.; Malcor, Jean-Daniel; Thomas, Mark R.; Pollitt, Alice Y.; Tomlinson, Michael G.; Pratt, Guy; Watson, Steve P.</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2097-2108</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">1592-8721</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">Ibrutinib and acalabrutinib are irreversible inhibitors of Bruton tyrosine kinase used in the treatment of B-cell malignancies.  They bind irreversibly to cysteine 481 of Bruton tyrosine kinase, blocking autophosphorylation on tyrosine 223 and phosphorylation of downstream substrates including phospholipase C-γ2.  In the present study, we demonstrate that concns. of ibrutinib and acalabrutinib that block Bruton tyrosine kinase activity, as shown by loss of phosphorylation at tyrosine 223 and phospholipase C-γ2, delay but do not block aggregation in response to a maximally-effective concn. of collagen-related peptide or collagen.  In contrast, 10- to 20-fold higher concns. of ibrutinib or acalabrutinib block platelet aggregation in response to glycoprotein VI agonists.  Ex vivo studies on patients treated with ibrutinib, but not acalabrutinib, showed a redn. of platelet aggregation in response to collagen-related peptide indicating that the clin. dose of ibrutinib but not acalabrutinib is supramaximal for Bruton tyrosine kinase blockade.  Unexpectedly, low concns. of ibrutinib inhibited aggregation in response to collagen-related peptide in patients deficient in Bruton tyrosine kinase.  The increased bleeding seen with ibrutinib over acalabrutinib is due to off-target actions of ibrutinib that occur because of unfavorable pharmacodynamics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonhmxALDChg7Vg90H21EOLACvtfcHk0lgh6k8blXk9ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFygu7vK&md5=2e78d1da663274f62fa00bbcacfaa9b4</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2018.193391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2018.193391%26sid%3Dliteratum%253Aachs%26aulast%3DNicolson%26aufirst%3DP.%2BL.%2BR.%26aulast%3DHughes%26aufirst%3DC.%2BE.%26aulast%3DWatson%26aufirst%3DS.%26aulast%3DNock%26aufirst%3DS.%2BH.%26aulast%3DHardy%26aufirst%3DA.%2BT.%26aulast%3DWatson%26aufirst%3DC.%2BN.%26aulast%3DMontague%26aufirst%3DS.%2BJ.%26aulast%3DClifford%26aufirst%3DH.%26aulast%3DHuissoon%26aufirst%3DA.%2BP.%26aulast%3DMalcor%26aufirst%3DJ.-D.%26aulast%3DThomas%26aufirst%3DM.%2BR.%26aulast%3DPollitt%26aufirst%3DA.%2BY.%26aulast%3DTomlinson%26aufirst%3DM.%2BG.%26aulast%3DPratt%26aufirst%3DG.%26aulast%3DWatson%26aufirst%3DS.%2BP.%26atitle%3DInhibition%2520of%2520Btk%2520by%2520Btk-Specific%2520Concentrations%2520of%2520Ibrutinib%2520and%2520Acalabrutinib%2520Delays%2520but%2520Does%2520Not%2520Block%2520Platelet%2520Aggregation%2520Mediated%2520by%2520Glycoprotein%2520VI%26jtitle%3DHaematologica%26date%3D2018%26volume%3D103%26spage%3D2097%26epage%3D2108%26doi%3D10.3324%2Fhaematol.2018.193391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Kar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulrajani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Lith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Hoek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Zwart, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demont, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkaik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krantz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">252</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.242909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1124%2Fjpet.117.242909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=28882879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtleltrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2017&pages=240-252&author=T.+Barfauthor=T.+Coveyauthor=R.+Izumiauthor=B.+van+de+Karauthor=M.+Gulrajaniauthor=B.+van+Lithauthor=M.+van+Hoekauthor=E.+de+Zwartauthor=D.+Mittagauthor=D.+Demontauthor=S.+Verkaikauthor=F.+Krantzauthor=P.+G.+Pearsonauthor=R.+Ulrichauthor=A.+Kaptein&title=Acalabrutinib+%28ACP-196%29%3A+A+Covalent+Bruton+Tyrosine+Kinase+Inhibitor+with+a+Differentiated+Selectivity+and+In+Vivo+Potency+Profile&doi=10.1124%2Fjpet.117.242909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile</span></div><div class="casAuthors">Barf, Tjeerd; Covey, Todd; Izumi, Raquel; van de Kar, Bas; Gulrajani, Michael; van Lith, Bart; van Hoek, Maaike; de Zwart, Edwin; Mittag, Diana; Demont, Dennis; Verkaik, Saskia; Krantz, Fanny; Pearson, Paul G.; Ulrich, Roger; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">240-252</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Several small-mol. Bruton tyrosine kinase (BTK) inhibitors are in development for B cell malignancies and autoimmune disorders, each characterized by distinct potency and selectivity patterns.  Herein we describe the pharmacol. characterization of BTK inhibitor acalabrutinib [compd. 1, ACP-196 (4-[8- amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin1-yl]-N-(2-pyridyl)benzamide)].  Acalabrutinib possesses a reactive butynamide group that binds covalently to Cys481 in BTK.  Relative to the other BTK inhibitors described here, the reduced intrinsic reactivity of acalabrutinib helps to limit inhibition of offtarget kinases having cysteine-mediated covalent binding potential.  Acalabrutinib demonstrated higher biochem. and cellular selectivity than ibrutinib and spebrutinib (compds. 2 and 3, resp.).  Importantly, off-target kinases, such as epidermal growth factor receptor (EGFR) and interleukin 2-inducible T cell kinase (ITK), were not inhibited.  Detn. of the inhibitory potential of anti-IgM-induced CD69 expression in human peripheral blood mononuclear cells and whole blood demonstrated that acalabrutinib is a potent functional BTK inhibitor.  In vivo evaluation in mice revealed that acalabrutinib is more potent than ibrutinib and spebrutinib.  Preclin. and clin. studies showed that the level and duration of BTK occupancy correlates with in vivo efficacy.  Evaluation of the pharmacokinetic properties of acalabrutinib in healthy adult volunteers demonstrated rapid absorption and fast elimination.  In these healthy individuals, a single oral dose of 100 mg showed approx. 99% median target coverage at 3 and 12 h and around 90% at 24 h in peripheral B cells.  In conclusion, acalabrutinib is a BTK inhibitor with key pharmacol. differentiators vs. ibrutinib and spebrutinib and is currently being evaluated in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol9xhDmwvup7Vg90H21EOLACvtfcHk0lgh6k8blXk9ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtleltrnO&md5=73cbd3a87396abbf8cb20e4361f96f64</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.242909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.242909%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DCovey%26aufirst%3DT.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3Dvan%2Bde%2BKar%26aufirst%3DB.%26aulast%3DGulrajani%26aufirst%3DM.%26aulast%3Dvan%2BLith%26aufirst%3DB.%26aulast%3Dvan%2BHoek%26aufirst%3DM.%26aulast%3Dde%2BZwart%26aufirst%3DE.%26aulast%3DMittag%26aufirst%3DD.%26aulast%3DDemont%26aufirst%3DD.%26aulast%3DVerkaik%26aufirst%3DS.%26aulast%3DKrantz%26aufirst%3DF.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DUlrich%26aufirst%3DR.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DAcalabrutinib%2520%2528ACP-196%2529%253A%2520A%2520Covalent%2520Bruton%2520Tyrosine%2520Kinase%2520Inhibitor%2520with%2520a%2520Differentiated%2520Selectivity%2520and%2520In%2520Vivo%2520Potency%2520Profile%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D363%26spage%3D240%26epage%3D252%26doi%3D10.1124%2Fjpet.117.242909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gururaja, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukbuntherng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Versele, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span> <span> </span><span class="NLM_article-title">The Effect of Bruton’s Tyrosine Kinase (BTK) Inhibitors on Collagen-Induced Platelet Aggregation, BTK, and Tyrosine Kinase Expressed in Hepatocellular Carcinoma (TEC)</span>. <i>Eur. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">604</span>– <span class="NLM_lpage">612</span>, <span class="refDoi"> DOI: 10.1111/ejh.13148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1111%2Fejh.13148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVKgu73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2018&pages=604-612&author=J.+Chenauthor=T.+Kinoshitaauthor=T.+Gururajaauthor=J.+Sukbuntherngauthor=D.+Jamesauthor=D.+Luauthor=J.+Whangauthor=M.+Verseleauthor=B.+Y.+Chang&title=The+Effect+of+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29+Inhibitors+on+Collagen-Induced+Platelet+Aggregation%2C+BTK%2C+and+Tyrosine+Kinase+Expressed+in+Hepatocellular+Carcinoma+%28TEC%29&doi=10.1111%2Fejh.13148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC)</span></div><div class="casAuthors">Chen, Jun; Kinoshita, Taisei; Gururaja, Tarikere; Sukbuntherng, Juthamas; James, Danelle; Lu, Daniel; Whang, Jennifer; Versele, Matthias; Chang, Betty Y.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Haematology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">604-612</span>CODEN:
                <span class="NLM_cas:coden">EJHAEC</span>;
        ISSN:<span class="NLM_cas:issn">0902-4441</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Objectives : Bruton's tyrosine kinase (BTK) and tyrosine kinase expressed in hepatocellular carcinoma (TEC) are expressed by human platelets.  These kinases participate in platelet activation through the collagen receptor glycoprotein VI and may perform overlapping functions.  In clin. studies, BTK inhibitors (ibrutinib, acalabrutinib, tirabrutinib, zanubrutinib) have been assocd. with increased bleeding risk, which may result from inhibition of BTK alone or of both BTK and TEC, although the role of TEC in bleeding risk remains unclear.  Methods : Here, in vitro catalytic and binding activities of ibrutinib and acalabrutinib were detd. with four assay systems.  Platelet aggregation assays detd. inhibitor potency and its relationship to selectivity between BTK and TEC.  Results : Neither inhibitor was substantially more selective for BTK over TEC.  The potencies at which BTK inhibitors suppressed platelet aggregation correlated with the potencies in on-target BTK assays, including those in cells.  At clin. relevant plasma concn., ibrutinib, acalabrutinib, and tirabrutinib inhibited collagen-induced platelet aggregation to a similar extent, despite differing in vitro IC50s.  Conclusions : Our results suggest BTK inhibition is the primary driver for inhibition of platelet aggregation.  The subtle differences between these inhibitors suggest only randomized, double-blind, placebo-controlled clin. studies can fully address the bleeding risks of different BTK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-4t9KmFTj5LVg90H21EOLACvtfcHk0lgh6k8blXk9ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVKgu73J&md5=ef4558e97d19f22350689e75088f1b34</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1111%2Fejh.13148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fejh.13148%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DKinoshita%26aufirst%3DT.%26aulast%3DGururaja%26aufirst%3DT.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DWhang%26aufirst%3DJ.%26aulast%3DVersele%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DB.%2BY.%26atitle%3DThe%2520Effect%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%2520Inhibitors%2520on%2520Collagen-Induced%2520Platelet%2520Aggregation%252C%2520BTK%252C%2520and%2520Tyrosine%2520Kinase%2520Expressed%2520in%2520Hepatocellular%2520Carcinoma%2520%2528TEC%2529%26jtitle%3DEur.%2520J.%2520Haematol.%26date%3D2018%26volume%3D101%26spage%3D604%26epage%3D612%26doi%3D10.1111%2Fejh.13148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dittus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muelbaier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span> <span> </span><span class="NLM_article-title">Differential Kinobeads Profiling for Target Identification of Irreversible Kinase Inhibitors</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2515</span>– <span class="NLM_lpage">2521</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00617</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00617" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVelu7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=2515-2521&author=L.+Dittusauthor=T.+Wernerauthor=M.+Muelbaierauthor=M.+Bantscheff&title=Differential+Kinobeads+Profiling+for+Target+Identification+of+Irreversible+Kinase+Inhibitors&doi=10.1021%2Facschembio.7b00617"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Differential Kinobeads Profiling for Target Identification of Irreversible Kinase Inhibitors</span></div><div class="casAuthors">Dittus, Lars; Werner, Thilo; Muelbaier, Marcel; Bantscheff, Marcus</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2515-2521</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chemoproteomics profiling of kinase inhibitors with kinobeads enables the assessment of inhibitor potency and selectivity for endogenously expressed protein kinases in cell lines and tissues.  Using a small panel of targeted covalent inhibitors, we demonstrate the importance of measuring covalent target binding in live cells.  We present a differential kinobeads profiling strategy for covalent kinase inhibitors where a compd. is added either to live cells or to a cell ext. that enables the comprehensive assessment of inhibitor selectivity for covalent and noncovalent targets.  We found that Acalabrutinib, CC-292, and Ibrutinib potently and covalently bind TEC family kinases, but only Ibrutinib also potently binds to BLK.  ZAK was identified as a submicromolar affinity Ibrutinib off-target due to covalent modification of Cys22.  In contrast to Ibrutinib, 5Z-7-Oxozeaenol reacted with Cys150 next to the DFG loop, demonstrating an alternative route to covalent inactivation of this kinase, e.g., to inhibit canonical TGF-β dependent processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdZpb3DpBXf7Vg90H21EOLACvtfcHk0liEQsY2xrfdMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVelu7zL&md5=cd7f70ef37de6afdec766bb9aa704b4a</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00617%26sid%3Dliteratum%253Aachs%26aulast%3DDittus%26aufirst%3DL.%26aulast%3DWerner%26aufirst%3DT.%26aulast%3DMuelbaier%26aufirst%3DM.%26aulast%3DBantscheff%26aufirst%3DM.%26atitle%3DDifferential%2520Kinobeads%2520Profiling%2520for%2520Target%2520Identification%2520of%2520Irreversible%2520Kinase%2520Inhibitors%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2017%26volume%3D12%26spage%3D2515%26epage%3D2521%26doi%3D10.1021%2Facschembio.7b00617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomgren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dambach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macaluso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sowell, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Potent and Selective Bruton’s Tyrosine Kinase Inhibitors: Discovery of GDC-0834</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1333</span>– <span class="NLM_lpage">1337</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.01.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1016%2Fj.bmcl.2015.01.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=25701252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVSit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1333-1337&author=W.+B.+Youngauthor=J.+Barbosaauthor=P.+Blomgrenauthor=M.+C.+Bremerauthor=J.+J.+Crawfordauthor=D.+Dambachauthor=S.+Gallionauthor=S.+Hymowitzauthor=J.+E.+Kropfauthor=S.+H.+Leeauthor=L.+Liuauthor=J.+Lubachauthor=J.+Macalusoauthor=P.+Maciejewskiauthor=B.+Maurerauthor=S.+A.+Mitchellauthor=D.+F.+Ortwineauthor=J.+Di+Paoloauthor=K.+Reifauthor=H.+Scheerensauthor=A.+Schmittauthor=C.+G.+Sowellauthor=X.+Wangauthor=H.+Wongauthor=J.-M.+Xiongauthor=J.+Xuauthor=Z.+Zhaoauthor=K.+S.+Currie&title=Potent+and+Selective+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitors%3A+Discovery+of+GDC-0834&doi=10.1016%2Fj.bmcl.2015.01.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective Bruton's tyrosine kinase inhibitors: Discovery of GDC-0834</span></div><div class="casAuthors">Young, Wendy B.; Barbosa, James; Blomgren, Peter; Bremer, Meire C.; Crawford, James J.; Dambach, Donna; Gallion, Steve; Hymowitz, Sarah G.; Kropf, Jeffrey E.; Lee, Seung H.; Liu, Lichuan; Lubach, Joseph W.; Macaluso, Jen; Maciejewski, Pat; Maurer, Brigitte; Mitchell, Scott A.; Ortwine, Daniel F.; Di Paolo, Julie; Reif, Karin; Scheerens, Heleen; Schmitt, Aaron; Sowell, C. Gregory; Wang, Xiaojing; Wong, Harvey; Xiong, Jin-Ming; Xu, Jianjun; Zhao, Zhongdong; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1333-1337</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">SAR studies focused on improving the pharmacokinetic (PK) properties of the previously reported potent and selective Btk inhibitor CGI-1746 resulted in the clin. candidate GDC-0834, which retained the potency and selectivity of CGI-1746, but with much improved PK in preclin. animal models.  Structure based design efforts drove this work as modifications to CGI-1746 were investigated at both the solvent exposed region as well as 'H3 binding pocket'.  However, in vitro metabolic evaluation of GDC-0834 revealed a non CYP-mediated metabolic process that was more prevalent in human than preclin. species (mouse, rat, dog, cyno), leading to a high-level of uncertainly in predicting human pharmacokinetics.  Due to its promising potency, selectivity, and preclin. efficacy, a single dose IND was filed and GDC-0834 was taken in to a single dose phase I trial in healthy volunteers to quickly evaluate the human pharmacokinetics.  In human, GDC-0834 was found to be highly labile at the exo-cyclic amide bond that links the tetrahydrobenzothiophene moiety to the central aniline ring, resulting in insufficient parent drug exposure.  This information informed the back-up program and discovery of improved inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhL04eYDiT3bVg90H21EOLACvtfcHk0liEQsY2xrfdMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVSit7w%253D&md5=fdebc0199c8222e093cfb9583244bce3</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.01.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.01.032%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DBremer%26aufirst%3DM.%2BC.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DDambach%26aufirst%3DD.%26aulast%3DGallion%26aufirst%3DS.%26aulast%3DHymowitz%26aufirst%3DS.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLubach%26aufirst%3DJ.%26aulast%3DMacaluso%26aufirst%3DJ.%26aulast%3DMaciejewski%26aufirst%3DP.%26aulast%3DMaurer%26aufirst%3DB.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DSchmitt%26aufirst%3DA.%26aulast%3DSowell%26aufirst%3DC.%2BG.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DXiong%26aufirst%3DJ.-M.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DPotent%2520and%2520Selective%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitors%253A%2520Discovery%2520of%2520GDC-0834%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1333%26epage%3D1337%26doi%3D10.1016%2Fj.bmcl.2015.01.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenningloh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haselmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu-Bujalski, L.</span></span> <span> </span><span class="NLM_article-title">Ability of Bruton’s Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but Not B-Cell Receptor Signaling</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">208</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1124/mol.116.107037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1124%2Fmol.116.107037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=28062735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpsFajtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2017&pages=208-219&author=A.+T.+Benderauthor=A.+Gardbergauthor=A.+Pereiraauthor=T.+Johnsonauthor=Y.+Wuauthor=R.+Grenninglohauthor=J.+Headauthor=F.+Morandiauthor=P.+Haselmayerauthor=L.+Liu-Bujalski&title=Ability+of+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitors+to+Sequester+Y551+and+Prevent+Phosphorylation+Determines+Potency+for+Inhibition+of+Fc+Receptor+but+Not+B-Cell+Receptor+Signaling&doi=10.1124%2Fmol.116.107037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Ability of Bruton's tyrosine kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of Fc receptor but not B-cell receptor signaling</span></div><div class="casAuthors">Bender, Andrew T.; Gardberg, Anna; Pereira, Albertina; Johnson, Theresa; Wu, Yin; Grenningloh, Roland; Head, Jared; Morandi, Federica; Haselmayer, Philipp; Liu-Bujalski, Lesley</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">208-219</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is expressed in a variety of hematopoietic cells.  Btk has been demonstrated to regulate signaling downstream of the B-cell receptor (BCR), Fc receptors (FcRs), and toll-like receptors.  It has become an attractive drug target because its inhibition may provide significant efficacy by simultaneously blocking multiple disease mechanisms.  Consequently, a large no. of Btk inhibitors have been developed.  These compds. have diverse binding modes, and both reversible and irreversible inhibitors have been developed.  Reported herein, we have tested nine Btk inhibitors and characterized on a mol. level how their interactions with Btk define their ability to block different signaling pathways.  By solving the crystal structures of Btk inhibitors bound to the enzyme, we discovered that the compds. can be classified by their ability to trigger sequestration of Btk residue Y551.  In cells, we found that sequestration of Y551 renders it inaccessible for phosphorylation.  The ability to sequester Y551 was an important determinant of potency against FcγR signaling as Y551 sequestering compds. were more potent for inhibiting basophils and mast cells.  This result was true for the inhibition of FcγR signaling as well.  In contrast, Y551 sequestration was less a factor in detg. potency against BCR signaling.  We also found that Btk activity is regulated differentially in basophils and B cells.  These results elucidate important determinants for Btk inhibitor potency against different signaling pathways and provide insight for designing new compds. with a broader inhibitory profile that will likely result in greater efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrN8F--ON3M7Vg90H21EOLACvtfcHk0liEQsY2xrfdMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpsFajtr8%253D&md5=f869d52d6bc1aabf352988787ff1cbcf</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1124%2Fmol.116.107037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.116.107037%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%2BT.%26aulast%3DGardberg%26aufirst%3DA.%26aulast%3DPereira%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DGrenningloh%26aufirst%3DR.%26aulast%3DHead%26aufirst%3DJ.%26aulast%3DMorandi%26aufirst%3DF.%26aulast%3DHaselmayer%26aufirst%3DP.%26aulast%3DLiu-Bujalski%26aufirst%3DL.%26atitle%3DAbility%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitors%2520to%2520Sequester%2520Y551%2520and%2520Prevent%2520Phosphorylation%2520Determines%2520Potency%2520for%2520Inhibition%2520of%2520Fc%2520Receptor%2520but%2520Not%2520B-Cell%2520Receptor%2520Signaling%26jtitle%3DMol.%2520Pharmacol.%26date%3D2017%26volume%3D91%26spage%3D208%26epage%3D219%26doi%3D10.1124%2Fmol.116.107037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pulz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angst, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gessier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersperger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinniger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janser, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Revesz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waelchli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerlin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cenni, B.</span></span> <span> </span><span class="NLM_article-title">Design of Potent and Selective Covalent Inhibitors of Bruton’s Tyrosine Kinase Targeting an Inactive Conformation</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1467</span>– <span class="NLM_lpage">1472</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00317</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00317" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslegt7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1467-1472&author=R.+Pulzauthor=D.+Angstauthor=J.+Dawsonauthor=F.+Gessierauthor=S.+Gutmannauthor=R.+Herspergerauthor=A.+Hinnigerauthor=P.+Janserauthor=G.+Kochauthor=L.+Reveszauthor=A.+Vulpettiauthor=R.+Waelchliauthor=A.+Zimmerlinauthor=B.+Cenni&title=Design+of+Potent+and+Selective+Covalent+Inhibitors+of+Bruton%E2%80%99s+Tyrosine+Kinase+Targeting+an+Inactive+Conformation&doi=10.1021%2Facsmedchemlett.9b00317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation</span></div><div class="casAuthors">Pulz, Robert; Angst, Daniela; Dawson, Janet; Gessier, Francois; Gutmann, Sascha; Hersperger, Rene; Hinniger, Alexandra; Janser, Philipp; Koch, Guido; Revesz, Laszlo; Vulpetti, Anna; Waelchli, Rudolf; Zimmerlin, Alfred; Cenni, Bruno</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1467-1472</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) is a member of the TEC kinase family and is selectively expressed in a subset of immune cells.  It is a key regulator of antigen receptor signaling in B cells and of Fc receptor signaling in mast cells and macrophages.  A BTK inhibitor will likely have a pos. impact on autoimmune diseases which are caused by autoreactive B cells and immune-complex driven inflammation.  We report the design, optimization, and characterization of potent and selective covalent BTK inhibitors.  Starting from the selective reversible inhibitor 3 binding to an inactive conformation of BTK, we designed covalent irreversible compds. by attaching an electrophilic warhead to reach Cys481.  The first prototype 4 covalently modified BTK and showed an excellent kinase selectivity including several Cys-contg. kinases, validating the design concept.  In addn., this compd. blocked FcγR-mediated hypersensitivity in vivo.  Optimization of whole blood potency and metabolic stability resulted in compds. such as 8, which maintained the excellent kinase selectivity and showed improved BTK occupancy in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtG6N4PXtS_bVg90H21EOLACvtfcHk0lhsaYD29G6MTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslegt7zF&md5=1c05c5f592e5edf288855190d2b18391</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00317%26sid%3Dliteratum%253Aachs%26aulast%3DPulz%26aufirst%3DR.%26aulast%3DAngst%26aufirst%3DD.%26aulast%3DDawson%26aufirst%3DJ.%26aulast%3DGessier%26aufirst%3DF.%26aulast%3DGutmann%26aufirst%3DS.%26aulast%3DHersperger%26aufirst%3DR.%26aulast%3DHinniger%26aufirst%3DA.%26aulast%3DJanser%26aufirst%3DP.%26aulast%3DKoch%26aufirst%3DG.%26aulast%3DRevesz%26aufirst%3DL.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DWaelchli%26aufirst%3DR.%26aulast%3DZimmerlin%26aufirst%3DA.%26aulast%3DCenni%26aufirst%3DB.%26atitle%3DDesign%2520of%2520Potent%2520and%2520Selective%2520Covalent%2520Inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Targeting%2520an%2520Inactive%2520Conformation%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1467%26epage%3D1472%26doi%3D10.1021%2Facsmedchemlett.9b00317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-(3-(5-((3-Acrylamido-4-(Morpholine-4-Carbonyl)Phenyl)Amino)-1-Methyl-6-Oxo-1,6-Dihydropyridin-3-Yl)-2-Methylphenyl)-4-(Tert-Butyl)Benzamide (CHMFL-BTK-01) as a Highly Selective Irreversible Bruton’s Tyrosine Kinase (BTK) Inhibitor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1016%2Fj.ejmech.2017.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=28315597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC2sXksVOms7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2017&pages=107-125&author=Q.+Liangauthor=Y.+Chenauthor=K.+Yuauthor=C.+Chenauthor=S.+Zhangauthor=A.+Wangauthor=W.+Wangauthor=H.+Wuauthor=X.+Liuauthor=B.+Wangauthor=L.+Wangauthor=Z.+Huauthor=W.+Wangauthor=T.+Renauthor=S.+Zhangauthor=Q.+Liuauthor=C.-H.+Yunauthor=J.+Liu&title=Discovery+of+N-%283-%285-%28%283-Acrylamido-4-%28Morpholine-4-Carbonyl%29Phenyl%29Amino%29-1-Methyl-6-Oxo-1%2C6-Dihydropyridin-3-Yl%29-2-Methylphenyl%29-4-%28Tert-Butyl%29Benzamide+%28CHMFL-BTK-01%29+as+a+Highly+Selective+Irreversible+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29+Inhibitor&doi=10.1016%2Fj.ejmech.2017.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor</span></div><div class="casAuthors">Liang, Qianmao; Chen, Yongfei; Yu, Kailin; Chen, Cheng; Zhang, Shouxiang; Wang, Aoli; Wang, Wei; Wu, Hong; Liu, Xiaochuan; Wang, Beilei; Wang, Li; Hu, Zhenquan; Wang, Wenchao; Ren, Tao; Zhang, Shanchun; Liu, Qingsong; Yun, Cai-Hong; Liu, Jing</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">107-125</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Currently there are several irreversible BTK inhibitors targeting Cys 481 residue under preclin. or clin. development.  However, most of these inhibitors also targeted other kinases such as BMX, JAK3, and EGFR that bear the highly similar active cysteine residues.  Through a structure-based drug design approach, the authors discovered a highly potent (IC50: 7 nM) irreversible BTK inhibitor compd. 9 (CHMFL-BTK-01), which displayed a high selectivity profile in KINOMEscan (S score (35) = 0.00) among 468 kinases/mutants at the concn. of 1 μM.  Compd. 9 completely abolished BMX, JAK3 and EGFR's activity.  Both x-ray crystal structure and cysteine-serine mutation mediated rescue expt. confirmed 9's irreversible binding mode.  Compd. 9 also potently inhibited BTK Y223 auto-phosphorylation (EC50: <30 nM), arrested cell cycle in G0/G1 phase and induced apoptosis in U2932 and Pfeiffer cells.  The authors believe these features would make 9 a good pharmacol. tool to study the BTK related pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC1_3nnSrlpLVg90H21EOLACvtfcHk0lhsaYD29G6MTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXksVOms7o%253D&md5=b9505b5c24a48cc61eff64a081b81a79</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DRen%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520N-%25283-%25285-%2528%25283-Acrylamido-4-%2528Morpholine-4-Carbonyl%2529Phenyl%2529Amino%2529-1-Methyl-6-Oxo-1%252C6-Dihydropyridin-3-Yl%2529-2-Methylphenyl%2529-4-%2528Tert-Butyl%2529Benzamide%2520%2528CHMFL-BTK-01%2529%2520as%2520a%2520Highly%2520Selective%2520Irreversible%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%2520Inhibitor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D131%26spage%3D107%26epage%3D125%26doi%3D10.1016%2Fj.ejmech.2017.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourne, P. E.</span></span> <span> </span><span class="NLM_article-title">Progress with Covalent Small-Molecule Kinase Inhibitors</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">735</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2018.01.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1016%2Fj.drudis.2018.01.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=29337202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslShurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=727-735&author=Z.+Zhaoauthor=P.+E.+Bourne&title=Progress+with+Covalent+Small-Molecule+Kinase+Inhibitors&doi=10.1016%2Fj.drudis.2018.01.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Progress with covalent small-molecule kinase inhibitors</span></div><div class="casAuthors">Zhao, Zheng; Bourne, Philip E.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">727-735</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">With reduced risk of toxicity and high selectivity, covalent small-mol. kinase inhibitors (CSKIs) have emerged rapidly.  Through the lens of structural system pharmacol., here we review this rapid progress by considering design strategies and the challenges and opportunities offered by current CSKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog6l6qMAopYLVg90H21EOLACvtfcHk0lhsaYD29G6MTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslShurg%253D&md5=f97a19f53a72044812a778ee9351fe94</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2018.01.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2018.01.035%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DBourne%26aufirst%3DP.%2BE.%26atitle%3DProgress%2520with%2520Covalent%2520Small-Molecule%2520Kinase%2520Inhibitors%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2018%26volume%3D23%26spage%3D727%26epage%3D735%26doi%3D10.1016%2Fj.drudis.2018.01.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dalvit, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span> <span> </span><span class="NLM_article-title">Intermolecular and Intramolecular Hydrogen Bonds Involving Fluorine Atoms: Implications for Recognition, Selectivity, and Chemical Properties</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">262</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201100483</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1002%2Fcmdc.201100483" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=22262517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC38Xps1CisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=262-272&author=C.+Dalvitauthor=A.+Vulpetti&title=Intermolecular+and+Intramolecular+Hydrogen+Bonds+Involving+Fluorine+Atoms%3A+Implications+for+Recognition%2C+Selectivity%2C+and+Chemical+Properties&doi=10.1002%2Fcmdc.201100483"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Intermolecular and Intramolecular Hydrogen Bonds Involving Fluorine Atoms: Implications for Recognition, Selectivity, and Chemical Properties</span></div><div class="casAuthors">Dalvit, Claudio; Vulpetti, Anna</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">262-272</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A correlation between 19F NMR isotropic chem. shift and close intermol. F···H-X contacts (with X = N or O) has been identified upon anal. of the X-ray crystal structures of fluorinated mols. listed in the Cambridge Structural Database (CSD).  An optimal F···X distance involving primary and shielded secondary fluorine atoms in hydrogen-bond formation along with a correlation between F···H distance and F···H-X angle were also derived from the anal.  The hydrogen bonds involving fluorine are relevant, not only for the recognition mechanism and stabilization of a preferred conformation, but also for improvement in the permeability of the mols., as shown with examples taken from a proprietary database.  Results of an anal. of the small no. of fluorine-contg. natural products listed in the Protein Data Bank (PDB) appear to strengthen the derived correlation between 19F NMR isotropic chem. shift and interactions involving fluorine (also known as the "rule of shielding") and provides a hypothesis for the recognition mechanism and catalytic activity of specific enzymes.  Novel chem. scaffolds, based on the rule of shielding, have been designed for recognizing distinct structural motifs present in proteins.  It is envisaged that this approach could find useful applications in drug design for the efficient optimization of chem. fragments or promising compds. by increasing potency and selectivity against the desired biomol. target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDtfxYsmG4NrVg90H21EOLACvtfcHk0lgzvKej8uJW-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xps1CisA%253D%253D&md5=21efccc023f44ed600725e2a834222ae</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201100483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201100483%26sid%3Dliteratum%253Aachs%26aulast%3DDalvit%26aufirst%3DC.%26aulast%3DVulpetti%26aufirst%3DA.%26atitle%3DIntermolecular%2520and%2520Intramolecular%2520Hydrogen%2520Bonds%2520Involving%2520Fluorine%2520Atoms%253A%2520Implications%2520for%2520Recognition%252C%2520Selectivity%252C%2520and%2520Chemical%2520Properties%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D262%26epage%3D272%26doi%3D10.1002%2Fcmdc.201100483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palkowitz, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, R. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Diverse N -Acryloyl Azetidines and Evaluation of Their Enhanced Thiol Reactivities</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2270</span>– <span class="NLM_lpage">2273</span>, <span class="refDoi"> DOI: 10.1021/acs.orglett.7b00788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.orglett.7b00788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt1KqtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=2270-2273&author=M.+D.+Palkowitzauthor=B.+Tanauthor=H.+Huauthor=K.+Rothauthor=R.+A.+Bauer&title=Synthesis+of+Diverse+N+-Acryloyl+Azetidines+and+Evaluation+of+Their+Enhanced+Thiol+Reactivities&doi=10.1021%2Facs.orglett.7b00788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Diverse N-Acryloyl Azetidines and Evaluation of Their Enhanced Thiol Reactivities</span></div><div class="casAuthors">Palkowitz, Maximilian D.; Tan, Bo; Hu, Haitao; Roth, Kenneth; Bauer, Renato A.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2270-2273</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Acyl azetidines exhibit nonplanar hybridization, leading to lower amide-like character of the corresponding (O)C-N bonds.  This impacts N-acryloyl azetidines by producing enhanced electrophilicy at appended Michael acceptors.  Herein, reactivity data are reported in the presence of glutathione (GSH) in phosphate buffer (pH 7.4) at 37 °C.  Wide reactivity ranges are obsd. by varying substitution at the Michael acceptor or by modulating the electron-withdrawing character of substituents at the C3 position of the azetidine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjUFdHgOWgc7Vg90H21EOLACvtfcHk0lgzvKej8uJW-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt1KqtLw%253D&md5=d65414bda2976c07bc76cd0df6d4a38d</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Facs.orglett.7b00788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.orglett.7b00788%26sid%3Dliteratum%253Aachs%26aulast%3DPalkowitz%26aufirst%3DM.%2BD.%26aulast%3DTan%26aufirst%3DB.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DRoth%26aufirst%3DK.%26aulast%3DBauer%26aufirst%3DR.%2BA.%26atitle%3DSynthesis%2520of%2520Diverse%2520N%2520-Acryloyl%2520Azetidines%2520and%2520Evaluation%2520of%2520Their%2520Enhanced%2520Thiol%2520Reactivities%26jtitle%3DOrg.%2520Lett.%26date%3D2017%26volume%3D19%26spage%3D2270%26epage%3D2273%26doi%3D10.1021%2Facs.orglett.7b00788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span> <span> </span><span class="NLM_article-title">Evaluation of Enzyme Inhibitors in Drug Discovery. A Guide for Medicinal Chemists and Pharmacologists</span>. <i>Methods Biochem. Anal.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">265</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=16350889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A280%3ADC%252BD2MnmtlyjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2005&pages=1-265&author=R.+A.+Copeland&title=Evaluation+of+Enzyme+Inhibitors+in+Drug+Discovery.+A+Guide+for+Medicinal+Chemists+and+Pharmacologists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists</span></div><div class="casAuthors">Copeland Robert A</div><div class="citationInfo"><span class="NLM_cas:title">Methods of biochemical analysis</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-265</span>
        ISSN:<span class="NLM_cas:issn">0076-6941</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSR7_ubfiC0DK2q3xNe7a7QfW6udTcc2eZOYjeADtjDvbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MnmtlyjsA%253D%253D&md5=4bb6759b5155aa6c2b6a462432afda7f</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26atitle%3DEvaluation%2520of%2520Enzyme%2520Inhibitors%2520in%2520Drug%2520Discovery.%2520A%2520Guide%2520for%2520Medicinal%2520Chemists%2520and%2520Pharmacologists%26jtitle%3DMethods%2520Biochem.%2520Anal.%26date%3D2005%26volume%3D46%26spage%3D1%26epage%3D265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paulini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diederich, F.</span></span> <span> </span><span class="NLM_article-title">Orthogonal Multipolar Interactions in Structural Chemistry and Biology</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1788</span>– <span class="NLM_lpage">1805</span>, <span class="refDoi"> DOI: 10.1002/anie.200462213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1002%2Fanie.200462213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BD2MXislWkt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2005&pages=1788-1805&author=R.+Pauliniauthor=K.+M%C3%BCllerauthor=F.+Diederich&title=Orthogonal+Multipolar+Interactions+in+Structural+Chemistry+and+Biology&doi=10.1002%2Fanie.200462213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Orthogonal multipolar interactions in structural chemistry and biology</span></div><div class="casAuthors">Paulini, Ralph; Mueller, Klaus; Diederich, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1788-1805</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The past few decades of mol. recognition studies have greatly enhanced our knowledge on apolar, ion-dipole, and hydrogen-bonding interactions.  However, much less attention has been given to the role that multipolar interactions, in particular those with orthogonal dipolar alignment, play in organizing a crystal lattice or stabilizing complexes involving biol. receptors.  By using results from database mining, this review attempts to give an overview of types and structural features of these previously rather overlooked interactions.  A no. of illustrative examples of these interactions found in X-ray crystal structures of small mols. and protein-ligand complexes demonstrate their propensity and thus potential importance for both, chem. and biol. mol. recognition processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTGHoutIq12LVg90H21EOLACvtfcHk0ljWtnahICTOEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXislWkt7s%253D&md5=6ad842547313b27fc1676e9c3a001909</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1002%2Fanie.200462213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200462213%26sid%3Dliteratum%253Aachs%26aulast%3DPaulini%26aufirst%3DR.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26aulast%3DDiederich%26aufirst%3DF.%26atitle%3DOrthogonal%2520Multipolar%2520Interactions%2520in%2520Structural%2520Chemistry%2520and%2520Biology%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2005%26volume%3D44%26spage%3D1788%26epage%3D1805%26doi%3D10.1002%2Fanie.200462213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggs, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azimioara, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzfeld, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lélias, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span> <span> </span><span class="NLM_article-title">A Small Molecule-Kinase Interaction Map for Clinical Kinase Inhibitors</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.-M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+Small+Molecule-Kinase+Interaction+Map+for+Clinical+Kinase+Inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0ljWtnahICTOEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.-M.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520Small%2520Molecule-Kinase%2520Interaction%2520Map%2520for%2520Clinical%2520Kinase%2520Inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salerno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span> <span> </span><span class="NLM_article-title">Activation State-Dependent Binding of Small Molecule Kinase Inhibitors: Structural Insights from Biochemistry</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1241</span>– <span class="NLM_lpage">1249</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1016%2Fj.chembiol.2010.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=21095574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVGntrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=1241-1249&author=L.+M.+Wodickaauthor=P.+Ciceriauthor=M.+I.+Davisauthor=J.+P.+Huntauthor=M.+Floydauthor=S.+Salernoauthor=X.+H.+Huaauthor=J.+M.+Fordauthor=R.+C.+Armstrongauthor=P.+P.+Zarrinkarauthor=D.+K.+Treiber&title=Activation+State-Dependent+Binding+of+Small+Molecule+Kinase+Inhibitors%3A+Structural+Insights+from+Biochemistry&doi=10.1016%2Fj.chembiol.2010.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Activation state-dependent binding of small molecule kinase inhibitors: Structural insights from biochemistry</span></div><div class="casAuthors">Wodicka, Lisa M.; Ciceri, Pietro; Davis, Mindy I.; Hunt, Jeremy P.; Floyd, Mark; Salerno, Sara; Hua, Xuequn H.; Ford, Julia M.; Armstrong, Robert C.; Zarrinkar, Patrick P.; Treiber, Daniel K.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1241-1249</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Interactions between kinases and small mol. inhibitors can be activation state dependent.  A detailed understanding of inhibitor binding therefore requires characterizing interactions across multiple activation states.  We have systematically explored the effects of ABL1 activation loop phosphorylation and PDGFR family autoinhibitory juxtamembrane domain docking on inhibitor binding affinity.  For a diverse compd. set, the affinity patterns correctly classify inhibitors as having type I or type II binding modes, and we show that juxtamembrane domain docking can have dramatic neg. effects on inhibitor affinity.  The results have allowed us to assoc. ligand-induced conformational changes obsd. in cocrystal structures with specific energetic costs.  The approach we describe enables investigation of the complex relationship between kinase activation state and compd. binding affinity and should facilitate strategic inhibitor design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN9CBcWzoWcrVg90H21EOLACvtfcHk0ljWtnahICTOEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVGntrfL&md5=d34c17fd4192eaa4ec0c2c84d5633d02</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DSalerno%26aufirst%3DS.%26aulast%3DHua%26aufirst%3DX.%2BH.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26atitle%3DActivation%2520State-Dependent%2520Binding%2520of%2520Small%2520Molecule%2520Kinase%2520Inhibitors%253A%2520Structural%2520Insights%2520from%2520Biochemistry%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D1241%26epage%3D1249%26doi%3D10.1016%2Fj.chembiol.2010.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berg, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melrose, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Privat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunkel, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span> <span> </span><span class="NLM_article-title">Chemical Target and Pathway Toxicity Mechanisms Defined in Primary Human Cell Systems</span>. <i>J. Pharmacol. Toxicol. Methods</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1016/j.vascn.2009.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1016%2Fj.vascn.2009.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=19879948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1WltbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2010&pages=3-15&author=E.+L.+Bergauthor=J.+Yangauthor=J.+Melroseauthor=D.+Nguyenauthor=S.+Privatauthor=E.+Roslerauthor=E.+J.+Kunkelauthor=S.+Ekins&title=Chemical+Target+and+Pathway+Toxicity+Mechanisms+Defined+in+Primary+Human+Cell+Systems&doi=10.1016%2Fj.vascn.2009.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical target and pathway toxicity mechanisms defined in primary human cell systems</span></div><div class="casAuthors">Berg, Ellen L.; Yang, Jian; Melrose, Jennifer; Nguyen, Dat; Privat, Sylvie; Rosler, Elen; Kunkel, Eric J.; Ekins, Sean</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-15</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The ability to predict the health effects resulting from drug or chem. exposure has been challenging due to the complexity of human biol.  Approaches that detect and discriminate a broad range of mechanisms in testing formats that are predictive and yet cost-effective are needed.  Here, the authors evaluated the performance of BioMAP systems, primary human cell-based disease models, as a platform for characterization of chem. toxicity mechanisms.  For this the authors tested a set of compds. with known or well-studied mechanisms in a panel of 8 BioMAP assays relevant to human respiratory, skin, immune and vascular exposure sites.  The authors evaluated the ability to detect and distinguish compds. based on mechanisms of action, comparing the BioMAP activity profiles generated in a reduced sample no. format to ref. database profiles derived from multiple expts.  The authors also studied the role of BioMAP assay panel size and concn. effects, both of which were found to contribute to the ability to discriminate chems. and mechanisms.  Compds. with diverse mechanisms, including modulators of the NFκB pathway, microtubule function and mitochondrial activity, could be discriminated and classified into target and pathway mechanisms in both assay formats.  Certain inhibitors of mitochondrial function, such as rotenone and sodium azide, but not others, were classified with inducers of endoplasmic reticulum stress, providing insight into the toxicity mechanisms of these agents.  This method may have utility in classifying novel agents with unknown modes of action according to their effects on toxicity pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojvjOxKr9mgLVg90H21EOLACvtfcHk0ljky6M7PBobpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1WltbnN&md5=7482b930574fe516d955e0b1f8625291</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2009.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2009.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DBerg%26aufirst%3DE.%2BL.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DMelrose%26aufirst%3DJ.%26aulast%3DNguyen%26aufirst%3DD.%26aulast%3DPrivat%26aufirst%3DS.%26aulast%3DRosler%26aufirst%3DE.%26aulast%3DKunkel%26aufirst%3DE.%2BJ.%26aulast%3DEkins%26aufirst%3DS.%26atitle%3DChemical%2520Target%2520and%2520Pathway%2520Toxicity%2520Mechanisms%2520Defined%2520in%2520Primary%2520Human%2520Cell%2520Systems%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2010%26volume%3D61%26spage%3D3%26epage%3D15%26doi%3D10.1016%2Fj.vascn.2009.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pompliano, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meek, T. D.</span></span> <span> </span><span class="NLM_article-title">Drug-Target Residence Time and Its Implications for Lead Optimization</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">730</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1038/nrd2082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1038%2Fnrd2082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=16888652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=730-739&author=R.+A.+Copelandauthor=D.+L.+Pomplianoauthor=T.+D.+Meek&title=Drug-Target+Residence+Time+and+Its+Implications+for+Lead+Optimization&doi=10.1038%2Fnrd2082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-target residence time and its implications for lead optimization</span></div><div class="casAuthors">Copeland, Robert A.; Pompliano, David L.; Meek, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">730-739</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromols. by low-mol.-mass drugs.  The binding of drugs to their macromol. targets is therefore seen as paramount for pharmacol. activity.  In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC50 or Kd.  This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex.  We describe the potential advantages of long residence time in terms of duration of pharmacol. effect and target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry6SJrMlrrTbVg90H21EOLACvtfcHk0ljky6M7PBobpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D&md5=60ede2301584b10ac4e8fa18e1e6d107</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fnrd2082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2082%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26atitle%3DDrug-Target%2520Residence%2520Time%2520and%2520Its%2520Implications%2520for%2520Lead%2520Optimization%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D730%26epage%3D739%26doi%3D10.1038%2Fnrd2082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tester, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labenski, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witowski, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lounsbury, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazdiyasni, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacht, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freed, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovskiy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W. F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>346</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.203489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1124%2Fjpet.113.203489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=23709115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2013&pages=219-228&author=E.+K.+Evansauthor=R.+Testerauthor=S.+Aslanianauthor=R.+Karpauthor=M.+Sheetsauthor=M.+T.+Labenskiauthor=S.+R.+Witowskiauthor=H.+Lounsburyauthor=P.+Chaturvediauthor=H.+Mazdiyasniauthor=Z.+Zhuauthor=M.+Nachtauthor=M.+I.+Freedauthor=R.+C.+Petterauthor=A.+Dubrovskiyauthor=J.+Singhauthor=W.+F.+Westlin&title=Inhibition+of+Btk+with+CC-292+Provides+Early+Pharmacodynamic+Assessment+of+Activity+in+Mice+and+Humans&doi=10.1124%2Fjpet.113.203489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans</span></div><div class="casAuthors">Evans, Erica K.; Tester, Richland; Aslanian, Sharon; Karp, Russell; Sheets, Michael; Labenski, Matthew T.; Witowski, Steven R.; Lounsbury, Heather; Chaturvedi, Prasoon; Mazdiyasni, Hormoz; Zhu, Zhendong; Nacht, Mariana; Freed, Martin I.; Petter, Russell C.; Dubrovskiy, Alex; Singh, Juswinder; Westlin, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-228</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Targeted therapies that suppress B cell receptor (BCR) signaling have emerged as promising agents in autoimmune disease and B cell malignancies.  Bruton's tyrosine kinase (Btk) plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity.  N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide (CC-292) is a highly selective, covalent Btk inhibitor and a sensitive and quant. assay that measures CC-292-Btk engagement has been developed.  This translational pharmacodynamic assay has accompanied CC-292 through each step of drug discovery and development.  These studies demonstrate the quantity of Btk bound by CC-292 correlates with the efficacy of CC-292 in vitro and in the collagen-induced arthritis model of autoimmune disease.  Recently, CC-292 has entered human clin. trials with a trial design that has provided rapid insight into safety, pharmacokinetics, and pharmacodynamics.  This first-in-human healthy volunteer trial has demonstrated that a single oral dose of 2 mg/kg CC-292 consistently engaged all circulating Btk protein and provides the basis for rational dose selection in future clin. trials.  This targeted covalent drug design approach has enabled the discovery and early clin. development of CC-292 and has provided support for Btk as a valuable drug target for B-cell mediated disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN2l8ZCVqCFLVg90H21EOLACvtfcHk0ljky6M7PBobpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM&md5=95fac997a246e59d943dd554af358a65</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.203489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.203489%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DE.%2BK.%26aulast%3DTester%26aufirst%3DR.%26aulast%3DAslanian%26aufirst%3DS.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DLabenski%26aufirst%3DM.%2BT.%26aulast%3DWitowski%26aufirst%3DS.%2BR.%26aulast%3DLounsbury%26aufirst%3DH.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DMazdiyasni%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DFreed%26aufirst%3DM.%2BI.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26atitle%3DInhibition%2520of%2520Btk%2520with%2520CC-292%2520Provides%2520Early%2520Pharmacodynamic%2520Assessment%2520of%2520Activity%2520in%2520Mice%2520and%2520Humans%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D346%26spage%3D219%26epage%3D228%26doi%3D10.1124%2Fjpet.113.203489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jerne, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordin, A. A.</span></span> <span> </span><span class="NLM_article-title">Plaque Formation in Agar by Single Antibody-Producing Cells</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1963</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">405</span>, <span class="refDoi"> DOI: 10.1126/science.140.3565.405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1126%2Fscience.140.3565.405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=13957684" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=1963&pages=405&author=N.+K.+Jerneauthor=A.+A.+Nordin&title=Plaque+Formation+in+Agar+by+Single+Antibody-Producing+Cells&doi=10.1126%2Fscience.140.3565.405"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1126%2Fscience.140.3565.405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.140.3565.405%26sid%3Dliteratum%253Aachs%26aulast%3DJerne%26aufirst%3DN.%2BK.%26aulast%3DNordin%26aufirst%3DA.%2BA.%26atitle%3DPlaque%2520Formation%2520in%2520Agar%2520by%2520Single%2520Antibody-Producing%2520Cells%26jtitle%3DScience%26date%3D1963%26volume%3D140%26spage%3D405%26doi%3D10.1126%2Fscience.140.3565.405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trentham, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townes, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, A. H.</span></span> <span> </span><span class="NLM_article-title">Autoimmunity to Type II Collagen an Experimental Model of Arthritis</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">857</span>– <span class="NLM_lpage">868</span>, <span class="refDoi"> DOI: 10.1084/jem.146.3.857</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1084%2Fjem.146.3.857" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=894190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=1%3ACAS%3A280%3ADyaE2s3ltFejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=1977&pages=857-868&author=D.+E.+Trenthamauthor=A.+S.+Townesauthor=A.+H.+Kang&title=Autoimmunity+to+Type+II+Collagen+an+Experimental+Model+of+Arthritis&doi=10.1084%2Fjem.146.3.857"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Autoimmunity to type II collagen an experimental model of arthritis</span></div><div class="casAuthors">Trentham D E; Townes A S; Kang A H</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of experimental medicine</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">857-68</span>
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    </div><div class="casAbstract">We have found that intradermal injection of native type II collagen extracted from human, chick or rat cartilage induces an inflammatory arthritis in approximately 40% of rats of several strains whether complete Freund's adjuvant or incomplete Freund's adjuvant is used.  Type I or III collagen extracted from skin, cartilage proteoglycans and alpha1(II) chains were incapable of eliciting arthritis, as was type II collagen injected without adjuvant.  The disease is a chronic proliferative synovitis, resembling adjuvant arthritis in rats and rheumatoid arthritis in humans.  Native type II co-lagen modified by limited pepsin digestion still produces arthritis, suggesting that type-specific determinants residing in the helical region of the molecule are responsible for the induction of disease.  Since homologous type II collagen emulsified in oil without bacterial preparations regularly causes the disease, this new animal model of arthritis represents a unique example of experimentally-inducible autoimmunity to a tissue component.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSQXNpzPUCAfUewzGPswiWOfW6udTcc2eZvRN7OfRgQDbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE2s3ltFejtg%253D%253D&md5=022165ad1990f3c8398394f8624e4513</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1084%2Fjem.146.3.857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.146.3.857%26sid%3Dliteratum%253Aachs%26aulast%3DTrentham%26aufirst%3DD.%2BE.%26aulast%3DTownes%26aufirst%3DA.%2BS.%26aulast%3DKang%26aufirst%3DA.%2BH.%26atitle%3DAutoimmunity%2520to%2520Type%2520II%2520Collagen%2520an%2520Experimental%2520Model%2520of%2520Arthritis%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1977%26volume%3D146%26spage%3D857%26epage%3D868%26doi%3D10.1084%2Fjem.146.3.857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duris, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fava, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noelle, R. J.</span></span> <span> </span><span class="NLM_article-title">Collagen-Induced Arthritis as a Model of Rheumatoid Arthritis</span>. <i>Clin. Immunol. Immunopathol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1006/clin.1994.1164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1006%2Fclin.1994.1164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=7923907" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1994&pages=11-18&author=F.+H.+Durisauthor=R.+A.+Favaauthor=R.+J.+Noelle&title=Collagen-Induced+Arthritis+as+a+Model+of+Rheumatoid+Arthritis&doi=10.1006%2Fclin.1994.1164"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1006%2Fclin.1994.1164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fclin.1994.1164%26sid%3Dliteratum%253Aachs%26aulast%3DDuris%26aufirst%3DF.%2BH.%26aulast%3DFava%26aufirst%3DR.%2BA.%26aulast%3DNoelle%26aufirst%3DR.%2BJ.%26atitle%3DCollagen-Induced%2520Arthritis%2520as%2520a%2520Model%2520of%2520Rheumatoid%2520Arthritis%26jtitle%3DClin.%2520Immunol.%2520Immunopathol.%26date%3D1994%26volume%3D73%26spage%3D11%26epage%3D18%26doi%3D10.1006%2Fclin.1994.1164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. O.</span></span> <span> </span><span class="NLM_article-title">Collagen-Induced Arthritis in Mice: A Major Role for Tumor Necrosis Factor-α</span>. In  <i>Target Discovery and Validation Reviews and Protocols</i>; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">NJ</span>, <span class="NLM_year">2007</span>; Vol.  <span class="NLM_volume">361</span>, pp  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">284</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&pages=265-284&author=R.+O.+Williams&title=Target+Discovery+and+Validation+Reviews+and+Protocols"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DR.%2BO.%26atitle%3DCollagen-Induced%2520Arthritis%2520in%2520Mice%253A%2520A%2520Major%2520Role%2520for%2520Tumor%2520Necrosis%2520Factor-%25CE%25B1%26btitle%3DTarget%2520Discovery%2520and%2520Validation%2520Reviews%2520and%2520Protocols%26pub%3DHumana%2520Press%26date%3D2007%26volume%3D361%26spage%3D265%26epage%3D284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">End, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabanski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakab, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuhler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funhoff, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimanova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kistowska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinhikar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiolica, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuhr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cenni, B.</span></span> <span> </span><span class="NLM_article-title">LOU064: A highly selective and potent covalent oral BTK inhibitor with promising pharmacodynamic effects in skin</span>. <i>Allergy</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">376</span>, (Abstract LBPD1718) <span class="refDoi"> DOI: 10.1111/all.13960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=10.1111%2Fall.13960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;key=31396969" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2019&pages=333-376&author=M.+Kaulauthor=J.+Storimauthor=P.+Endauthor=M.+Cabanskiauthor=A.+Jakabauthor=C.+Schuhlerauthor=E.+Funhoffauthor=F.+Schaeferauthor=E.+Dimanovaauthor=M.+Kistowskaauthor=A.+Kinhikarauthor=A.+Maiolicaauthor=A.+Sinnauthor=R.+Fuhrauthor=B.+Cenni&title=LOU064%3A+A+highly+selective+and+potent+covalent+oral+BTK+inhibitor+with+promising+pharmacodynamic+effects+in+skin&doi=10.1111%2Fall.13960"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1111%2Fall.13960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fall.13960%26sid%3Dliteratum%253Aachs%26aulast%3DKaul%26aufirst%3DM.%26aulast%3DStorim%26aufirst%3DJ.%26aulast%3DEnd%26aufirst%3DP.%26aulast%3DCabanski%26aufirst%3DM.%26aulast%3DJakab%26aufirst%3DA.%26aulast%3DSchuhler%26aufirst%3DC.%26aulast%3DFunhoff%26aufirst%3DE.%26aulast%3DSchaefer%26aufirst%3DF.%26aulast%3DDimanova%26aufirst%3DE.%26aulast%3DKistowska%26aufirst%3DM.%26aulast%3DKinhikar%26aufirst%3DA.%26aulast%3DMaiolica%26aufirst%3DA.%26aulast%3DSinn%26aufirst%3DA.%26aulast%3DFuhr%26aufirst%3DR.%26aulast%3DCenni%26aufirst%3DB.%26atitle%3DLOU064%253A%2520A%2520highly%2520selective%2520and%2520potent%2520covalent%2520oral%2520BTK%2520inhibitor%2520with%2520promising%2520pharmacodynamic%2520effects%2520in%2520skin%26jtitle%3DAllergy%26date%3D2019%26volume%3D74%26spage%3D333%26epage%3D376%26doi%3D10.1111%2Fall.13960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S90" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S90','PDB','6S90'); return false;">PDB: 6S90</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TFP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TFP','PDB','6TFP'); return false;">PDB: 6TFP</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i39"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01916">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_16060"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b01916?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01916</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Synthesis of compounds <b>9</b>–<b>24</b> and <b>26</b>–<b>32</b>; structural biology data; <i>in vitro</i> ADME profile of LOU064; biology data; animal studies; references (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01916/suppl_file/jm9b01916_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01916/suppl_file/jm9b01916_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01916/suppl_file/jm9b01916_si_001.pdf">jm9b01916_si_001.pdf (1.3 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01916/suppl_file/jm9b01916_si_002.csv">jm9b01916_si_002.csv (2.65 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB accession codes are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S90">6S90</a> (BTK kinase domain bound to <b>7</b>) and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TFP">6TFP</a> (BTK kinase domain bound to LOU064). Authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01916%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-10" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01916" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                8MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677abf58795925a5","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
